Details of Disease

General Information of Disease (ID: DIS1RRCY)

• Disease Name: Melanoma
• Synonyms: melanoma, malignant; melanoma; malignant melanoma; Naevocarcinoma; melanoma (disease)
• Disease Class: 2C30: Melanoma
• Definition: A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.
• Disease Hierarchy:
  DISOXEAY: Melanocytic neoplasm
  DIS1RRCY: Melanoma
• ICD Code:
  ICD-11: ICD-11: 2C30
  ICD-9: ICD-9: 172
  Expand ICD-9: 172
• Disease Identifiers:
  MONDO ID: MONDO_0005105
  MESH ID: D008545
  UMLS CUI: C0025202
  MedGen ID: 9944
  HPO ID: HP:0002861
  Orphanet ID: 411533
  SNOMED CT ID: 1162635006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 39 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
99mTc-depreotide	DMM4DV4	Approved	NA	[1]
ARRY-162	DM1P6FR	Approved	Small molecular drug	[2]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[3]
Avelumab	DMSZLJR	Approved	Monoclonal antibody	[4]
Bavencio	DMU9C8F	Approved	Monoclonal antibody	[3]
Dabrafenib	DMX6OE3	Approved	Small molecular drug	[5]
Dacarbazine	DMNPZL4	Approved	Small molecular drug	[6]
Durvalumab	DM4PVDY	Approved	Monoclonal antibody	[4]
HybriCell	DMCV6X9	Approved	NA	[1]
Hydroxyurea	DMOQVU9	Approved	Small molecular drug	[7]
Imiquimod	DM1TMA3	Approved	Small molecular drug	[8]
Ingenol mebutate	DMK1CZJ	Approved	Small molecular drug	[9]
Interferon Alfa-2b	DMWCQP4	Approved	Small molecular drug	[1]
Ipilimumab	DMJTIYK	Approved	Monoclonal antibody	[10]
Isoproterenol	DMK7MEY	Approved	Small molecular drug	[11]
Lapatinib	DM3BH1Y	Approved	Small molecular drug	[12]
Lenvatinib	DMB1IU4	Approved	Small molecular drug	[13]
LGX818	DMNQXV8	Approved	Small molecular drug	[2]
Lovastatin	DM9OZWQ	Approved	Small molecular drug	[14]
Melacine	DMXC544	Approved	NA	[1]
MK-3475	DMBYNW0	Approved	Monoclonal antibody	[15]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[16]
Omaveloxolone	DMLMNFX	Approved	Small molecular drug	[3]
Osimertinib	DMRJLAT	Approved	Small molecular drug	[17]
Palladium Pd 103	DMN3A34	Approved	Small molecular drug	[1]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[5]
Romidepsin	DMT5GNL	Approved	Small molecular drug	[19]
Talimogene Laherparepvec	DMKBW5C	Approved	Vaccine	[1]
Tc-99m tilmanocept	DMH3SSE	Approved	NA	[20]
Tebentafusp	DMUJ1WV	Approved	Monoclonal antibody	[21]
Temozolomide	DMKECZD	Approved	Small molecular drug	[22]
Teplizumab	DMZ3P6C	Approved	Antibody	[23]
Thymalfasin	DMADCYE	Approved	Small molecular drug	[24]
Toripalimab	DMSGA6Z	Approved in China	Monoclonal antibody	[25]
Trametinib	DM2JGQ3	Approved	Small molecular drug	[26]
Treosulfan	DMDIOAR	Approved	Small molecular drug	[27]
Vemurafenib	DM62UG5	Approved	Small molecular drug	[28]
Vindesine	DMVR628	Approved	Small molecular drug	[29]
HBI-8000	DMDWYUN	Registered	Small molecular drug	[4]

This Disease is Treated as An Indication in 1 Approved

Drug Name	Drug ID	Highest Status	Drug Type	REF
Relatlimab	DM28AZV	Approved	NA	[18]

This Disease is Treated as An Indication in 161 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MPL-containing Pollinex allergy desensitization vaccine	DM4W8QM	Preregistration	NA	[30]
OncoVAX	DMMPRAX	Preregistration	NA	[31]
177Lu-DOTA-octreotate	DMP5L8S	Phase 3	NA	[32]
ABT-888	DM4HYMS	Phase 3	Small molecular drug	[13]
AMD-070	DMVOY6B	Phase 3	Small molecular drug	[4]
BMS-986205	DM3MAYQ	Phase 3	NA	[4]
Canvaxin	DM90TDD	Phase 3	NA	[33]
Cotellic	DMF9M57	Phase 3	Small molecular drug	[3]
Daromun	DMC4O8L	Phase 3	NA	[4]
GMK	DM55ZM1	Phase 3	Small molecular drug	[34]
IMO-2125	DM735FA	Phase 3	NA	[4]
INCB24360	DMIJGT9	Phase 3	Small molecular drug	[4]
Javelin	DMCNF7E	Phase 3	NA	[35]
MAGE-A3 immunotherapeutic	DMI0GZT	Phase 3	NA	[36]
Melanoma vaccine	DMQEC6Z	Phase 3	Vaccine	[37]
Melanoma vaccine, University of Virginia	DMIPXTV	Phase 3	NA	[9]
Melapuldencel-T	DMNKG6L	Phase 3	NA	[38]
Mitumomab	DMY6VPA	Phase 3	Monoclonal antibody	[39]
MPDL-3280A	DM9K3LM	Phase 3	Monoclonal antibody	[40]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Phase 3	Vaccine	[37]
NKTR 214	DM376WT	Phase 3	NA	[41]
NKTR-214	DMACYW6	Phase 3	Recombinant protein	[42]
Oblimersen	DM7KI4E	Phase 3	NA	[43]
PDR001	DM53J6B	Phase 3	Antibody	[44]
Pegargiminase	DMQKFWX	Phase 3	Recombinant protein	[13]
PV-10	DM95UYC	Phase 3	Small molecular drug	[45]
QS-21	DMWHLMD	Phase 3	NA	[46]
RemuneX	DMCJUL5	Phase 3	NA	[47]
SD-101	DMAMTGI	Phase 3	Oligonucleotide	[4]
Selumetinib	DMC7W6R	Phase 3	Small molecular drug	[48]
Seviprotimut-L	DMQW6B6	Phase 3	NA	[49]
SNDX-275	DMH7W9X	Phase 3	Small molecular drug	[4]
Spartalizumab	DM4TOEQ	Phase 3	Monoclonal antibody	[50]
Tesetaxel	DM9LFYN	Phase 3	Small molecular drug	[51]
Tilsotolimod	DMGYK2N	Phase 3	Oligonucleotide	[52]
Velimogene aliplasmid	DMJBU9V	Phase 3	NA	[53]
FX005	DMG59CB	Phase 2/3	Small molecular drug	[54]
Imprime PGG	DMIUA3M	Phase 2/3	NA	[4]
NLG8189	DM0798Z	Phase 2/3	Small molecular drug	[4]
OT-101	DMCTRLN	Phase 2/3	Antisense oligonucleotide	[3]
ABX-IL8	DMCZFMS	Phase 2	Antibody	[55]
Ad-RTS-hIL-12	DMCNTFW	Phase 2	Gene therapy	[56]
AG140699	DMA9FKY	Phase 2	NA	[57]
Anti-CD3 activated vaccine-primed lymphocytes	DMNH84A	Phase 2	NA	[58]
Antigen-pulsed dendritic cell vaccine	DMMYHSV	Phase 2	NA	[59]
APN-301	DM32YTJ	Phase 2	NA	[60]
APX005M	DMX2P5G	Phase 2	Antibody	[61]
ARC-100	DMF6GK1	Phase 2	Small molecular drug	[62]
Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes	DMXQSWW	Phase 2	NA	[63]
BNT111	DMBTGNN	Phase 2	Vaccine	[64]
BVD-523	DMNB4XK	Phase 2	NA	[65]
Cancer vaccine	DM03BGT	Phase 2	NA	[66]
CB-10-01	DM2IFYZ	Phase 2	Vaccine	[67]
Coxsackievirus A21	DM2K5VP	Phase 2	NA	[68]
CYT-004-MelQbG10	DM6WG6C	Phase 2	NA	[69]
Dorgenmeltucel-L	DMUUVAA	Phase 2	NA	[70]
E7016	DMAHGKE	Phase 2	Small molecular drug	[71]
EDP-1503	DMLB64C	Phase 2	Live biotherapeutic product	[72]
FANG vaccine	DM0OV22	Phase 2	Vaccine	[49]
GCAN 101	DMESDH4	Phase 2	NA	[73]
Gp100:209-217(210M) peptide vaccine	DM38ARE	Phase 2	Vaccine	[74]
GR-MD-02	DM9QF65	Phase 2	Protein	[75]
GRN 1201	DMEF5UT	Phase 2	Vaccine	[76]
GRN-1201	DMXOYIH	Phase 2	NA	[68]
GSK-2302025A	DMTXR77	Phase 2	NA	[77]
GSK3377794	DMQ4RWW	Phase 2	NA	[4]
HF10	DMG5146	Phase 2	Oncolytic virus therapy	[4]
Hi-8 PrimeBoost therapeutic melanoma vaccine	DM2T2E8	Phase 2	NA	[78]
Hi8 melanoma vaccine	DMHGPZ8	Phase 2	NA	[79]
Interleukin-12 gene therapy	DMPO5IC	Phase 2	NA	[80]
IPI-549	DMG5Q7F	Phase 2	NA	[4]
ITIL-168	DMO3WV0	Phase 2	Cell therapy	[81]
Leuvectin	DM5LQEI	Phase 2	NA	[82]
Lifileucel	DM240TX	Phase 2	Cell therapy	[83]
LN-144	DMQ55RL	Phase 2	NA	[68]
MAGE-3-transduced autologous T-cell vaccine	DMFPSXI	Phase 2	NA	[84]
MGCD-0103	DM726HX	Phase 2	Small molecular drug	[3]
MKC-1106-MT	DMXKOW6	Phase 2	NA	[85]
MLN2480	DMBR8NF	Phase 2	Small molecular drug	[86]
MORAb-004	DMGK1JE	Phase 2	NA	[87]
mRNA-4157	DMVTTBZ	Phase 2	Vaccine	[88]
MSB0010445	DMICG0N	Phase 2	NA	[89]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Phase 2	Vaccine	[90]
Ontuxizumab	DM0FJIE	Phase 2	Antibody	[68]
PF-4878691	DM24I0N	Phase 2	NA	[91]
PLX8394	DMRTD7I	Phase 2	NA	[92]
Polynoma-1	DM3QDA6	Phase 2	Vaccine	[93]
PVSRIPO	DM3ZLTB	Phase 2	Vaccine	[94]
RAF265	DMC56T4	Phase 2	Small molecular drug	[95]
Resimmune	DMT5QSD	Phase 2	NA	[96]
SentoClone	DMHBGI0	Phase 2	NA	[97]
Stage IV melanoma vaccine	DMUXTV9	Phase 2	NA	[98]
Tavokinogene telseplasmid	DMZX0VF	Phase 2	Gene therapy	[4]
Telomelysin	DMNNDMA	Phase 2	NA	[68]
TH-302	DMFU0JY	Phase 2	Small molecular drug	[4]
TLPLDC	DMYENTG	Phase 2	NA	[99]
Tumor infiltrating lymphocyte	DM2MQ1P	Phase 2	NA	[100]
Urelumab	DM6RTVG	Phase 2	NA	[101]
V937	DMHITIP	Phase 2	Vaccine	[102]
Voyager-V1	DMNUDO0	Phase 2	Oncolytic virus therapy	[103]
Ad-IL-12 DNA therapeutic	DMB19IO	Phase 1/2	NA	[104]
Antigen-specific melanoma vaccine	DMLFYBB	Phase 1/2	NA	[105]
AU-011	DMAT7SD	Phase 1/2	NA	[4]
Delolimogene mupadenorepvec	DM4RCZ7	Phase 1/2	Oncolytic virus	[106]
ENB003	DMK2B3S	Phase 1/2	Small molecule	[107]
HL-085	DMJDVCW	Phase 1/2	NA	[108]
IMCnyeso	DMWVI0O	Phase 1/2	NA	[3]
ImmuFact IMP321	DMRKISI	Phase 1/2	NA	[109]
ImmunoVEX-timelan	DMQWEJ5	Phase 1/2	NA	[110]
LAG525	DMQX5SN	Phase 1/2	NA	[4]
LXS196	DM65MEL	Phase 1/2	NA	[4]
MAGE-A10 TCR	DM6H3YS	Phase 1/2	NA	[3]
NCI-4650	DM04U2E	Phase 1/2	NA	[3]
NKTR-262	DMYR8LF	Phase 1/2	NA	[3]
NY-ESO-TCR	DMS0L6J	Phase 1/2	NA	[68]
ONCOS-102	DMACFVN	Phase 1/2	Oncolytic virus therapy	[68]
SCIB-1	DMJQVB4	Phase 1/2	NA	[111]
TRX-518	DMQS5DY	Phase 1/2	Antibody	[112]
Adoptive T-cell therapy	DMCJHES	Phase 1	NA	[113]
ADP-A2M10	DM8BOFB	Phase 1	CAR-T cell therapy	[114]
AE-08	DM7X2HK	Phase 1	Vaccine	[115]
AEB701	DM8I4G0	Phase 1	NA	[116]
AMEP	DMFELMQ	Phase 1	Small molecular drug	[117]
AT13387	DM2B9E0	Phase 1	Small molecular drug	[118]
Autologous T Cells Expressing MET scFv CAR	DMZ763A	Phase 1	CAR T Cell Therapy	[119]
AV-MEL-1	DMIM8UD	Phase 1	Vaccine	[120]
BETULINIC ACID	DMBUI2A	Phase 1	Small molecular drug	[121]
CAR-T cells recognizing EpCAM	DMC7Y5F	Phase 1	CAR T Cell Therapy	[122]
CDX-1140	DMUGN0J	Phase 1	Antibody	[123]
CMP-001	DMGMI8P	Phase 1	NA	[3]
CV8102	DMYD37G	Phase 1	NA	[124]
DC-IL-12 DNA therapeutic	DMTBBHN	Phase 1	NA	[125]
DEDN-6526A	DMRJMDG	Phase 1	NA	[126]
Dendritic cancer cell vaccine	DMP7JBR	Phase 1	NA	[127]
Flanvotumab	DM2SALJ	Phase 1	Antibody	[128]
GEN-011	DMNELKW	Phase 1	Cell therapy	[129]
GPA-TriMAR-T cells	DM2MILF	Phase 1	CAR T Cell Therapy	[130]
GSK-2241658A	DM5VS7B	Phase 1	Vaccine	[131]
ICON-1	DM5JCNQ	Phase 1	NA	[68]
IL-2 pDNA	DM9Y9TT	Phase 1	NA	[132]
INCAGN2385	DMDSZNC	Phase 1	Antibody	[133]
INXN 2001	DMCJ2NW	Phase 1	NA	[134]
Ioflubenzamide (131I)	DM1DVXB	Phase 1	NA	[135]
Lipovaxin-MM	DM3WOFK	Phase 1	NA	[136]
LV305	DMP0TQA	Phase 1	NA	[137]
Melanoma DNA vaccine	DMR570I	Phase 1	NA	[138]
Multipeptide vaccine combination	DM11P6J	Phase 1	NA	[139]
NEO-PV-01	DM1C6CO	Phase 1	NA	[3]
PF-07284890	DMK7XYH	Phase 1	Small molecule	[140]
PRAME antigen-specific cancer immunotherapeutic	DMXRJ1N	Phase 1	NA	[141]
PRT1419	DMIKE0O	Phase 1	Small molecular drug	[142]
PTI-188	DMVK5W5	Phase 1	NA	[143]
SAM-6	DMDHQYA	Phase 1	Antibody	[144]
SB 11285	DMZ9YWG	Phase 1	NA	[145]
SX-682	DMHMG6X	Phase 1	Small molecular drug	[146]
TAK-202	DMVYEFZ	Phase 1	NA	[68]
TBX-3400	DMKH7QV	Phase 1	Cell therapy	[147]
TTI-621	DMDNPAV	Phase 1	Recombinant protein	[3]
Vaccimel	DM1QGVS	Phase 1	NA	[148]
VCL-1M01	DMS9EKG	Phase 1	NA	[149]
XmAb20717	DMJIH83	Phase 1	Antibody	[150]

This Disease is Treated as An Indication in 20 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Nuleusin	DMMDY27	Discontinued in Phase 3	NA	[151]
AN-9	DMGL0Q2	Discontinued in Phase 2	Small molecular drug	[152]
BIWB-1	DMQ6CYE	Discontinued in Phase 2	Vaccine	[153]
Ecromeximab	DM1N060	Discontinued in Phase 2	Monoclonal antibody	[154]
IDD-3	DMR6CTG	Discontinued in Phase 2	NA	[155]
Melanoma vaccine (ALVAC)	DM3HIQY	Discontinued in Phase 2	Vaccine	[156]
Melaxin	DM79LN9	Discontinued in Phase 2	NA	[157]
TriGem	DMAAITM	Discontinued in Phase 2	NA	[158]
XomaZyme-Mel	DMQ3EUK	Discontinued in Phase 2	NA	[159]
Zeniplatin	DMT48CI	Discontinued in Phase 2	Small molecular drug	[160]
ODC-0501	DMO3G2M	Discontinued in Phase 1/2	NA	[161]
ABX-MA1	DMZYVPB	Discontinued in Phase 1	Antibody	[162]
F-50040	DMMG6W5	Discontinued in Phase 1	NA	[163]
RG-7256	DM0LXBW	Discontinued in Phase 1	NA	[164]
RG7636	DMJ2TSR	Discontinued in Phase 1	NA	[165]
DISC GM-CSF	DMNQDTH	Terminated	NA	[167]
Novovac-M1	DM7L3AR	Terminated	NA	[168]
RAAV vaccine	DM6FSJG	Terminated	NA	[169]
SBP-002	DM9F7R0	Terminated	NA	[170]
Withaferin A	DMGHLG5	Terminated	Small molecular drug	[171]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ANAVEX 1007	DM2U16Z	Preclinical	NA	[166]

This Disease is Treated as An Indication in 28 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
1,3-bis(1,3-benzothiazol-2-ylthio)acetone	DMP86R3	Investigative	Small molecular drug	[172]
111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide (melanoma), NuView/University of New Mexico	DMH1R1B	Investigative	NA	[173]
20D75	DMTFJ1L	Investigative	NA	[173]
3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile	DMWLIK1	Investigative	NA	[172]
5-fluoro-1H-indole-2-carboxylic acid	DM9U1HV	Investigative	Small molecular drug	[172]
ADS-NPTMZ-1	DM79MNG	Investigative	NA	[173]
AEZS-120	DMF44MM	Investigative	NA	[173]
BCL-005	DML84IX	Investigative	NA	[173]
Box-5	DMSCA66	Investigative	NA	[173]
CGEN-791	DMMJ3Q5	Investigative	NA	[173]
Ektomun	DM63S8J	Investigative	NA	[173]
IMX-MEL1	DMPWYPZ	Investigative	NA	[173]
LG-723	DM6E1LB	Investigative	NA	[173]
Lm Melanoma	DMLD5HR	Investigative	NA	[173]
Lovaxin M	DME54PW	Investigative	NA	[173]
LY-1-100	DMT8R84	Investigative	NA	[173]
MT-062	DM5PD0G	Investigative	NA	[174]
MTI-SAM3	DMZUMSG	Investigative	NA	[173]
Narciclasine	DMI7A6R	Investigative	Small molecular drug	[175]
NVX-412	DM4QUDK	Investigative	NA	[173]
OP-03	DMXFJZ4	Investigative	NA	[173]
PDS-0102	DMICOMO	Investigative	NA	[173]
PRAME-SLP	DM2IS39	Investigative	NA	[173]
SMT-C2100	DMH8CEP	Investigative	NA	[173]
TOCA-621	DMFXRSI	Investigative	NA	[173]
TriMixDC	DML3OYH	Investigative	Vaccine	[176]
VitiGam	DMWK5O6	Investigative	NA	[173]
VLD-631	DMZ4OB2	Investigative	NA	[173]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 864 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCA1	TTJW1GN	Limited	Biomarker	[180]
ABCC1	TTOI92F	Limited	Altered Expression	[181]
ABCG1	TTMWDGU	Limited	Biomarker	[182]
ACVRL1	TTGYPTC	Limited	Biomarker	[183]
ADAM9	TTTYQNS	Limited	Genetic Variation	[184]
ADH7	TT3LE7P	Limited	Biomarker	[185]
ADRA1D	TT34BHT	Limited	Biomarker	[186]
ADRB3	TTMXGCW	Limited	Biomarker	[187]
ALOX15	TTN9T81	Limited	Biomarker	[188]
ALPI	TTHYMUV	Limited	Biomarker	[189]
ANGPTL4	TTWALY5	Limited	Biomarker	[190]
ANXA5	TT2Z83I	Limited	Altered Expression	[191]
AQP1	TTSF1KH	Limited	Biomarker	[192]
AQP9	TTQEI32	Limited	Altered Expression	[193]
ARSB	TTESQTG	Limited	Altered Expression	[194]
ATF4	TTQCKWT	Limited	Altered Expression	[195]
ATR	TT8ZYBQ	Limited	Genetic Variation	[196]
BAGE	TTS5GLJ	Limited	Biomarker	[197]
BCL2L1	TTRE6AX	Limited	Altered Expression	[198]
BCL2L2	TTQ79W8	Limited	Biomarker	[199]
BGN	TT0JPVF	Limited	Biomarker	[200]
BMP1	TT0L58T	Limited	Biomarker	[201]
BMPR2	TTGKF90	Limited	Altered Expression	[202]
CA9	TT2LVK8	Limited	Biomarker	[203]
CALR	TTUZ7OA	Limited	Biomarker	[204]
CASP1	TTCQIBE	Limited	Altered Expression	[205]
CASP4	TT6KIOT	Limited	Biomarker	[206]
CASP8	TT6SZNG	Limited	Genetic Variation	[207]
CCL21	TTLZK1U	Limited	Biomarker	[208]
CCN1	TTPK79J	Limited	Biomarker	[209]
CCNB1	TT9P6OW	Limited	Biomarker	[210]
CCND3	TT1JXNR	Limited	Altered Expression	[211]
CCR4	TT7HQD0	Limited	Biomarker	[212]
CCR5	TTJIH8Q	Limited	Altered Expression	[213]
CCR7	TT2GIDQ	Limited	Altered Expression	[214]
CD19	TTW640A	Limited	Biomarker	[215]
CD22	TTM6QSK	Limited	Biomarker	[216]
CD24	TTCTYNP	Limited	Biomarker	[217]
CD27	TTDO1MV	Limited	Biomarker	[218]
CD40LG	TTIJP3Q	Limited	Biomarker	[219]
CD6	TTMF6KC	Limited	Genetic Variation	[220]
CD74	TTCMYP9	Limited	Altered Expression	[221]
CD83	TTT9MRQ	Limited	Altered Expression	[222]
CD9	TTZEIBV	Limited	Altered Expression	[223]
CDH5	TTXLCFO	Limited	Altered Expression	[224]
CDK1	TTH6V3D	Limited	Biomarker	[225]
CDK7	TTQYF7G	Limited	Altered Expression	[226]
CDKL1	TTBTI6P	Limited	Altered Expression	[227]
CEACAM5	TTY6DTE	Limited	Biomarker	[228]
CFLAR	TTJZQYH	Limited	Biomarker	[229]
CHRM3	TTQ13Z5	Limited	Biomarker	[230]
CMA1	TT8VUE0	Limited	Biomarker	[231]
COASY	TT4YO0Z	Limited	Biomarker	[232]
COL18A1	TT63DI9	Limited	Biomarker	[233]
COL1A2	TTUABC1	Limited	Altered Expression	[234]
CRYZ	TTP6UO8	Limited	Altered Expression	[235]
CSF1	TT0IQER	Limited	Biomarker	[236]
CTSB	TTF2LRI	Limited	Biomarker	[237]
CTSD	TTPT2QI	Limited	Biomarker	[238]
CTSK	TTDZN01	Limited	Altered Expression	[239]
CTSL	TT36ETB	Limited	Biomarker	[238]
CXCR1	TTMWT8Z	Limited	Biomarker	[240]
CXCR2	TT30C9G	Limited	Altered Expression	[241]
CYSLTR2	TT0PZR5	Limited	Genetic Variation	[242]
DHFR	TTYZVDJ	Limited	Biomarker	[243]
DHODH	TTLVP78	Limited	Biomarker	[244]
DKK1	TTE3RAC	Limited	Biomarker	[245]
DLK1	TTF4AVB	Limited	Altered Expression	[246]
DOT1L	TTSZ8T1	Limited	Genetic Variation	[247]
DPP4	TTDIGC1	Limited	Biomarker	[248]
DTL	TT8396I	Limited	Biomarker	[249]
DUSP1	TTG8HIM	Limited	Altered Expression	[250]
EIF2AK3	TT79U1M	Limited	Genetic Variation	[251]
EIF2AK4	TT9U4EP	Limited	Biomarker	[252]
ELAVL1	TTPC9D0	Limited	Altered Expression	[253]
ENPEP	TT9PBIL	Limited	Biomarker	[254]
EPAS1	TTWPA54	Limited	Biomarker	[255]
EPHA3	TTHS2LR	Limited	Biomarker	[256]
EPO	TTQG4NR	Limited	Biomarker	[257]
ERN1	TTKIAT3	Limited	Biomarker	[258]
ESRRA	TTPNQAC	Limited	Biomarker	[259]
EZR	TTE47YC	Limited	Biomarker	[260]
F2RL2	TTVSEBF	Limited	Biomarker	[261]
FANCA	TTV5HJS	Limited	Biomarker	[262]
FASN	TT7AOUD	Limited	Biomarker	[263]
FBXW7	TT29KY7	Limited	Biomarker	[264]
FES	TTLBY21	Limited	Biomarker	[265]
FFAR1	TTB8FUC	Limited	Biomarker	[266]
FFAR4	TT08JVB	Limited	Altered Expression	[267]
FGF1	TTMY81X	Limited	Biomarker	[268]
FOSL1	TTY8LZG	Limited	Altered Expression	[269]
FOXQ1	TTEJZOL	Limited	Biomarker	[270]
FPR1	TT5Y4EM	Limited	Biomarker	[271]
FSCN1	TTTRS9B	Limited	Biomarker	[272]
FZD7	TTUQMO5	Limited	Biomarker	[273]
GH1	TTT3YKH	Limited	Biomarker	[274]
GHR	TTHJWYD	Limited	Biomarker	[274]
GLB1	TTNGJPH	Limited	Altered Expression	[275]
GNA11	TTSRXJW	Limited	Genetic Variation	[276]
GNRH1	TT0ID4A	Limited	Altered Expression	[277]
GOT1	TTU507L	Limited	Biomarker	[278]
GPC3	TTJTSX4	Limited	Altered Expression	[279]
GPNMB	TT7315J	Limited	Altered Expression	[280]
GRN	TT0LWE3	Limited	Biomarker	[281]
GSN	TTUH7OM	Limited	Biomarker	[282]
GSR	TTEP6RV	Limited	Biomarker	[283]
GZMB	TTKEPHX	Limited	Altered Expression	[284]
HDAC2	TTSHTOI	Limited	Biomarker	[285]
HDAC3	TT4YWTO	Limited	Biomarker	[286]
HDC	TTV9GOF	Limited	Biomarker	[287]
HEXIM1	TTFOKAH	Limited	Altered Expression	[288]
HLA-DQA1	TTU2I3J	Limited	Biomarker	[289]
HRAS	TT28ZON	Limited	Genetic Variation	[290]
HSD11B1	TTN7BL9	Limited	Biomarker	[291]
HSD11B2	TT9H85R	Limited	Biomarker	[292]
HSF1	TTN6STZ	Limited	Biomarker	[293]
HSPA8	TTMQL3K	Limited	Altered Expression	[294]
HSPA9	TTMTPG3	Limited	Altered Expression	[295]
HSPB3	TTLH8WG	Limited	Biomarker	[296]
HSPB8	TTY0OJN	Limited	Biomarker	[297]
HSPG2	TT5UM29	Limited	Biomarker	[298]
IAPP	TTHN8EM	Limited	Biomarker	[189]
ICOS	TTE5VP6	Limited	Altered Expression	[299]
ID1	TTBXVDE	Limited	Altered Expression	[300]
IDUA	TT0IUKX	Limited	Biomarker	[301]
IFNAR1	TTSYFMA	Limited	Biomarker	[302]
IFNL1	TTM624L	Limited	Biomarker	[303]
IGFBP3	TTZHNQA	Limited	Biomarker	[304]
IGFBP7	TTUQ01B	Limited	Altered Expression	[269]
IKBKB	TTJ3E9X	Limited	Biomarker	[305]
IL13RA2	TTMPZ7V	Limited	Biomarker	[306]
IL2RB	TT9721Y	Limited	Biomarker	[307]
IL32	TTD4G7L	Limited	Biomarker	[308]
IL4R	TTDWHC3	Limited	Biomarker	[309]
IL9	TT0JTFD	Limited	Biomarker	[310]
INHBA	TTVB30D	Limited	Altered Expression	[311]
IRF1	TT4TU3L	Limited	Altered Expression	[312]
IRF3	TTYR7OH	Limited	Altered Expression	[313]
ITGA4	TTJMF9P	Limited	Biomarker	[314]
ITGA6	TT165T3	Limited	Genetic Variation	[315]
ITGAE	TTH0Z37	Limited	Biomarker	[316]
ITGB2	TTIJWR7	Limited	Biomarker	[317]
JAK1	TT6DM01	Limited	Biomarker	[318]
KCNN3	TT9JH25	Limited	Biomarker	[319]
KDM5C	TT94UCF	Limited	Biomarker	[320]
KDM6B	TTDIJUQ	Limited	Altered Expression	[321]
KEAP1	TT3Z6Y9	Limited	Biomarker	[322]
KHDRBS1	TTAT6C7	Limited	Biomarker	[323]
KLK3	TTS78AZ	Limited	Altered Expression	[324]
KLK7	TTE6GTB	Limited	Biomarker	[325]
KLRC1	TTC4IMS	Limited	Biomarker	[326]
KMT5A	TTGC95K	Limited	Biomarker	[249]
LAG3	TTNVXAW	Limited	Biomarker	[327]
LAMB3	TT2WOUQ	Limited	Biomarker	[184]
LCK	TT860QF	Limited	Biomarker	[328]
LGMN	TTPTWV5	Limited	Altered Expression	[329]
LIF	TTGZ5WN	Limited	Biomarker	[330]
LIPA	TTS8T1M	Limited	Biomarker	[331]
LPAR3	TTE2YJR	Limited	Altered Expression	[332]
LPAR5	TTABCJ6	Limited	Altered Expression	[333]
LTF	TTSZDQU	Limited	Altered Expression	[334]
MAGEA10	TT1VNVM	Limited	Biomarker	[335]
MAGEA4	TT9EQUY	Limited	Biomarker	[335]
MAGEA6	TTJIWMO	Limited	Biomarker	[336]
MAGEC2	TTKGUEB	Limited	Biomarker	[337]
MALT1	TTCI81G	Limited	Biomarker	[338]
MAP2K1	TTIDAPM	Limited	Genetic Variation	[339]
MAP3K14	TT4LIAC	Limited	Biomarker	[340]
MAP3K7	TTJQT60	Limited	Altered Expression	[341]
MAP3K8	TTGECUM	Limited	Genetic Variation	[342]
MARK2	TTAJ45Y	Limited	Biomarker	[343]
MBTPS1	TTNSM2I	Limited	Biomarker	[344]
MDK	TTV8UE7	Limited	Biomarker	[345]
MELK	TTBZOTY	Limited	Biomarker	[346]
MERTK	TTO7LKR	Limited	Biomarker	[347]
MGLL	TTZ963I	Limited	Altered Expression	[348]
MRC1	TTKV8W5	Limited	Altered Expression	[349]
MTA1	TTO4HUS	Limited	Biomarker	[350]
MTDH	TTH6SA5	Limited	Biomarker	[351]
MYH2	TTBIL13	Limited	Altered Expression	[352]
NACC1	TT4AQ5F	Limited	Altered Expression	[353]
NCOA3	TT124R0	Limited	Biomarker	[354]
NCR1	TTQNRJM	Limited	Biomarker	[355]
NEDD8	TTNDC4K	Limited	Biomarker	[356]
NEK2	TT3VZ24	Limited	Altered Expression	[357]
NFKB2	TTKLNRV	Limited	Biomarker	[358]
NLRP1	TTQX29T	Limited	Genetic Variation	[359]
NOTCH3	TTVX7IA	Limited	Biomarker	[360]
NPEPPS	TT371QC	Limited	Altered Expression	[324]
NR1H2	TTXA6PH	Limited	Biomarker	[361]
NRG1	TTEH395	Limited	Biomarker	[362]
NRN1	TTS05MJ	Limited	Biomarker	[363]
NTN1	TT0AH4L	Limited	Biomarker	[364]
NUF2	TTIXBFP	Limited	Biomarker	[365]
OGG1	TTRU01G	Limited	Genetic Variation	[366]
OR51E2	TTZRE3C	Limited	Biomarker	[367]
OSM	TTIVXSE	Limited	Altered Expression	[368]
P2RY13	TT1FE3L	Limited	Genetic Variation	[290]
P2RY4	TT24DGP	Limited	Biomarker	[361]
PAK1	TTFN95D	Limited	Altered Expression	[369]
PDE4A	TTZ97H5	Limited	Biomarker	[370]
PDE4D	TTSKMI8	Limited	Biomarker	[370]
PDGFC	TTOABM9	Limited	Biomarker	[371]
PDGFD	TTSN0GA	Limited	Altered Expression	[372]
PDGFRA	TT8FYO9	Limited	Biomarker	[373]
PDGFRB	TTI7421	Limited	Altered Expression	[374]
PDXP	TT9UYG4	Limited	Biomarker	[375]
PFKFB3	TTTHMQJ	Limited	Biomarker	[376]
PGF	TT48I1Y	Limited	Biomarker	[377]
PHGDH	TT8DRCK	Limited	Altered Expression	[378]
PIM1	TTTN5QW	Limited	Biomarker	[379]
PIM3	TTCGOIN	Limited	Biomarker	[380]
PIN1	TTJNTSI	Limited	Biomarker	[381]
PLG	TTP86E2	Limited	Biomarker	[382]
PPARGC1B	TTKSQ3W	Limited	Altered Expression	[280]
PRDX5	TTLPJWH	Limited	Biomarker	[375]
PRKCZ	TTBSN0L	Limited	Biomarker	[383]
PRKG1	TT7IZSA	Limited	Biomarker	[384]
PRMT1	TTVOJAI	Limited	Biomarker	[385]
PRMT5	TTR1D7X	Limited	Biomarker	[386]
PSEN2	TTWN3F4	Limited	Altered Expression	[387]
PSIP1	TTH9LDP	Limited	Biomarker	[307]
PSMB8	TTEAD9J	Limited	Biomarker	[388]
PTAFR	TTQL5VC	Limited	Biomarker	[389]
PTBP1	TTWMX0U	Limited	Biomarker	[390]
PTGES	TTYLQ8V	Limited	Biomarker	[391]
PTK7	TTXH2ZN	Limited	Biomarker	[392]
PTN	TTA9EJK	Limited	Altered Expression	[393]
PTP4A3	TT7YM8D	Limited	Altered Expression	[394]
RAB7A	TTF6WAQ	Limited	Biomarker	[395]
RAPGEF4	TTOS63B	Limited	Biomarker	[396]
RECK	TTRZBW7	Limited	Biomarker	[397]
RGS4	TTGTKX9	Limited	Biomarker	[398]
RICTOR	TT143WL	Limited	Altered Expression	[399]
RIPK1	TTVJHX8	Limited	Biomarker	[341]
RNASEL	TT7V0K4	Limited	Biomarker	[400]
ROCK1	TTZN7RP	Limited	Altered Expression	[401]
ROCK2	TTGWKQJ	Limited	Altered Expression	[402]
ROS1	TTSZ6Y3	Limited	Genetic Variation	[403]
RPS6KA1	TTIXKA4	Limited	Biomarker	[404]
RPS6KB1	TTG0U4H	Limited	Biomarker	[379]
RPSA	TTLUW5B	Limited	Biomarker	[405]
RRM1	TTWP0NS	Limited	Altered Expression	[406]
RTN4R	TTVRZUO	Limited	Biomarker	[407]
RUNX2	TTD6SZ8	Limited	Biomarker	[408]
S100A8	TT4AF6N	Limited	Biomarker	[409]
SDC2	TT5H2F0	Limited	Altered Expression	[410]
SDHD	TTVH9W8	Limited	Altered Expression	[411]
SELE	TT1PL7M	Limited	Altered Expression	[412]
SELPLG	TTS5K8U	Limited	Biomarker	[413]
SEMA4D	TT5UT28	Limited	Biomarker	[414]
SERPINB3	TT6QLPX	Limited	Genetic Variation	[415]
SERPINB5	TT1KW50	Limited	Altered Expression	[416]
SETD2	TTPC3H4	Limited	Biomarker	[417]
SLC16A1	TTN1J82	Limited	Genetic Variation	[418]
SLC1A5	TTF7WRM	Limited	Biomarker	[419]
SLC5A2	TTF8JAT	Limited	Biomarker	[420]
SMAD7	TT0J32Z	Limited	Biomarker	[421]
SOX5	TTXHSZK	Limited	Altered Expression	[422]
SQSTM1	TTOT2RY	Limited	Biomarker	[323]
STC1	TTDLUER	Limited	Biomarker	[321]
SUV39H1	TTUWQTK	Limited	Biomarker	[423]
TCF3	TTULOD8	Limited	Biomarker	[307]
TEK	TT9VGXW	Limited	Altered Expression	[424]
TFPI	TT068JH	Limited	Biomarker	[425]
TFRC	TT8MG4S	Limited	Biomarker	[426]
TGFA	TTTLQFR	Limited	Altered Expression	[427]
TLR8	TT8CWFK	Limited	Altered Expression	[428]
TMSB4X	TTMVAIU	Limited	Biomarker	[429]
TNFRSF1B	TT63WSF	Limited	Biomarker	[307]
TNFSF4	TTBW580	Limited	Altered Expression	[430]
TOP2A	TTCGY2K	Limited	Altered Expression	[406]
TPCN2	TTHQJ2Y	Limited	Biomarker	[431]
TPT1	TT3PTB6	Limited	Altered Expression	[432]
TRAF6	TTCDR6M	Limited	Biomarker	[433]
TREM2	TTQRMSJ	Limited	Altered Expression	[434]
TRPC3	TTNVC34	Limited	Altered Expression	[435]
TRPM8	TTXDKTO	Limited	Altered Expression	[436]
TYRO3	TTIEMFN	Limited	Biomarker	[437]
UCHL1	TTX9IFP	Limited	Altered Expression	[438]
USP13	TTVJIO2	Limited	Biomarker	[439]
USP5	TTGYTMA	Limited	Biomarker	[440]
USP7	TTXU3EQ	Limited	Biomarker	[441]
USP8	TT1J07C	Limited	Altered Expression	[442]
UTRN	TTNO1VA	Limited	Biomarker	[443]
VCP	TTHNLSB	Limited	Biomarker	[444]
VSIR	TT51SK8	Limited	Biomarker	[445]
XRCC5	TTCB9KW	Limited	Biomarker	[446]
ZEB2	TTT2WK4	Limited	Altered Expression	[447]
ADRB2	TTG8ZWP	Disputed	Altered Expression	[448]
AICDA	TTKRTP6	Disputed	Biomarker	[413]
ARAF	TT5TURO	Disputed	Biomarker	[449]
ATG7	TTLVB9Z	Disputed	Biomarker	[450]
BBC3	TT7JUKC	Disputed	Biomarker	[451]
BRS3	TTKYEPM	Disputed	Altered Expression	[452]
CD248	TTYJWT7	Disputed	Altered Expression	[453]
CD28	TTQ13FT	Disputed	Biomarker	[454]
CD40	TT1ERKL	Disputed	Biomarker	[455]
CD86	TT53XHB	Disputed	Altered Expression	[456]
CDK8	TTBJR4L	Disputed	Biomarker	[457]
CDKN2C	TTBRUGA	Disputed	Genetic Variation	[458]
CREB1	TTH4AN3	Disputed	Biomarker	[459]
CXCR3	TT1UCIJ	Disputed	Biomarker	[460]
DDX58	TTVB0O3	Disputed	Biomarker	[461]
DICER1	TTTEOPU	Disputed	Altered Expression	[462]
EPCAM	TTZ8WH4	Disputed	Biomarker	[463]
EPHB6	TTZEMUY	Disputed	Biomarker	[464]
FGF4	TTCEKVZ	Disputed	Biomarker	[465]
FOXM1	TTD3KOX	Disputed	Biomarker	[466]
FUT4	TTNV1KZ	Disputed	Biomarker	[467]
GEM	TTAZF9M	Disputed	Genetic Variation	[468]
HDAC1	TT6R7JZ	Disputed	Biomarker	[469]
HSP90B1	TTFPKXQ	Disputed	Altered Expression	[470]
KCNK9	TTL4FMB	Disputed	Altered Expression	[471]
LPAR2	TTB7Y8I	Disputed	Altered Expression	[452]
LRP1	TTF2V7I	Disputed	Biomarker	[472]
MMP13	TTHY57M	Disputed	Altered Expression	[473]
MYB	TT8V13P	Disputed	Biomarker	[474]
NOTCH4	TTXDIK2	Disputed	Biomarker	[475]
NUAK2	TTHVOTQ	Disputed	Altered Expression	[476]
PPARA	TTJ584C	Disputed	Biomarker	[477]
PTK2	TTON5IT	Disputed	Biomarker	[478]
RALBP1	TTVSRUA	Disputed	Biomarker	[479]
ROR1	TTDEJAU	Disputed	Altered Expression	[480]
ROR2	TTUDPCI	Disputed	Altered Expression	[480]
RUNX3	TTKCVO7	Disputed	Altered Expression	[481]
SIK1	TT1H6LC	Disputed	Altered Expression	[482]
SLC1A2	TT2F078	Disputed	Biomarker	[450]
SLC22A16	TTITAVR	Disputed	Altered Expression	[483]
SMPD1	TTJTM88	Disputed	Biomarker	[484]
SNCA	TT08OSU	Disputed	Biomarker	[485]
SOCS3	TTI0ME6	Disputed	Biomarker	[486]
SP1	TTZEP6S	Disputed	Genetic Variation	[487]
SSTR4	TTAE1BR	Disputed	Altered Expression	[452]
TERF1	TT1Y6J2	Disputed	Genetic Variation	[488]
TIE1	TTT4236	Disputed	Genetic Variation	[489]
TLR7	TTRJ1K4	Disputed	Biomarker	[490]
TNFRSF10A	TT5WLRX	Disputed	Altered Expression	[491]
TNFRSF10B	TTW20TU	Disputed	Biomarker	[492]
TPX2	TT0PHL4	Disputed	Biomarker	[493]
TRPM2	TTEBMN7	Disputed	Biomarker	[494]
TWIST1	TTX1MY7	Disputed	Altered Expression	[269]
ABCC2	TTFLHJV	moderate	Altered Expression	[495]
ADORA2A	TTM2AOE	moderate	Biomarker	[496]
ADORA2B	TTNE7KG	moderate	Altered Expression	[497]
AMACR	TTLN1AP	moderate	Biomarker	[498]
ANG	TTURHFP	moderate	Biomarker	[499]
CASP2	TT12VNG	moderate	Altered Expression	[500]
CBS	TTVZJ7G	moderate	Biomarker	[501]
CCL11	TTCF05Y	moderate	Biomarker	[502]
CCR9	TTIPS8B	moderate	Altered Expression	[503]
CD160	TTOFEAS	moderate	Altered Expression	[504]
CD200	TT0BE68	moderate	Altered Expression	[505]
CD59	TTBGTEJ	moderate	Altered Expression	[506]
CDH11	TTRGWZC	moderate	Posttranslational Modification	[507]
CDH3	TTARMD9	moderate	Altered Expression	[508]
CHUK	TT1F8OQ	moderate	Biomarker	[509]
CRTC1	TT4GO0F	moderate	Altered Expression	[510]
CSF3R	TTC70AJ	moderate	Biomarker	[511]
CSNK2A1	TTER6YH	moderate	Biomarker	[512]
DIABLO	TTN74LE	moderate	Biomarker	[513]
EIF2AK2	TTXEZJ4	moderate	Altered Expression	[514]
EIF5A2	TTH53G9	moderate	Altered Expression	[515]
EPHA1	TTLFZVU	moderate	Biomarker	[516]
F2RL3	TTD0652	moderate	Biomarker	[517]
F9	TTFEZ5Q	moderate	Genetic Variation	[518]
FAP	TTGPQ0F	moderate	Biomarker	[519]
FCGR2B	TT5RWKQ	moderate	Biomarker	[520]
FGFR4	TT1KX2S	moderate	Biomarker	[521]
FPR2	TTOJ1NF	moderate	Biomarker	[522]
GABRA3	TT37EDJ	moderate	Biomarker	[523]
GHRHR	TTG4R8V	moderate	Biomarker	[524]
GNRHR	TT8R70G	moderate	Biomarker	[525]
GRIK4	TTQV6BO	moderate	Biomarker	[526]
GSTO1	TTWO3SH	moderate	Altered Expression	[527]
HDAC11	TT8K17W	moderate	Altered Expression	[514]
HDGF	TTKGV26	moderate	Altered Expression	[528]
HGFAC	TTD96RW	moderate	Biomarker	[529]
HOXB13	TTZ6I58	moderate	Biomarker	[530]
HTRA1	TT8POQR	moderate	Altered Expression	[531]
IL23A	TTC1GLB	moderate	Biomarker	[532]
INPP5D	TTTP2Z1	moderate	Altered Expression	[533]
ISG15	TTVOH3T	moderate	Altered Expression	[534]
ITGA2	TTSJ542	moderate	Genetic Variation	[315]
ITGAL	TT48WR6	moderate	Biomarker	[317]
KCNH5	TTX8LQ0	moderate	Altered Expression	[535]
KDM4A	TTZHPB8	moderate	Biomarker	[536]
KDM4C	TTV8CRH	moderate	Biomarker	[536]
KIR2DL1	TT4UXPE	moderate	Genetic Variation	[468]
KIR2DL3	TTEX3SI	moderate	Biomarker	[468]
KISS1R	TT3KBZY	moderate	Biomarker	[537]
LASP1	TTZJA87	moderate	Altered Expression	[538]
LIFR	TTID542	moderate	Biomarker	[539]
LTA4H	TTXZEAJ	moderate	Altered Expression	[540]
MAP3K1	TTW8TJI	moderate	Altered Expression	[541]
MMP12	TTXZ0KQ	moderate	Altered Expression	[542]
MPL	TTIHYA4	moderate	Biomarker	[543]
MSMB	TTYH1ZK	moderate	Biomarker	[544]
MUTYH	TTNB0ZK	moderate	Genetic Variation	[545]
MYCN	TT9JBY5	moderate	Altered Expression	[546]
NELL1	TT7H4BF	moderate	Biomarker	[547]
NODAL	TTK2O1Q	moderate	Altered Expression	[548]
NR4A2	TT9HKN3	moderate	Biomarker	[549]
NR5A2	TTAU3SY	moderate	Genetic Variation	[550]
NUAK1	TT65FL0	moderate	Biomarker	[551]
ORAI1	TTE76YK	moderate	Biomarker	[552]
PAWR	TT3I4WV	moderate	Biomarker	[517]
PCSK9	TTNIZ2B	moderate	Biomarker	[553]
PDE1C	TTW2HRK	moderate	Genetic Variation	[554]
PDE2A	TTJGW1Z	moderate	Altered Expression	[555]
PDGFA	TTSM78N	moderate	Altered Expression	[556]
PLA2G2A	TTO8QRU	moderate	Altered Expression	[557]
PLAUR	TTNOSTX	moderate	Altered Expression	[558]
PLP2	TTK5OG6	moderate	Biomarker	[559]
PRKDC	TTK3PY9	moderate	Genetic Variation	[560]
PSMD10	TT2H4LN	moderate	Altered Expression	[527]
PTPN11	TT7WUAV	moderate	Biomarker	[561]
RARA	TTW38KT	moderate	Posttranslational Modification	[562]
RCVRN	TTDQTEY	moderate	Altered Expression	[563]
RRM2	TT1S4LJ	moderate	Genetic Variation	[564]
SEMA3A	TTVKD3S	moderate	Biomarker	[565]
SLC16A3	TTG6VD5	moderate	Altered Expression	[566]
SRPK1	TTU3WV6	moderate	Biomarker	[567]
TACR1	TTZPO1L	moderate	Altered Expression	[568]
TAGLN	TTDRZ9H	moderate	Biomarker	[451]
TGFBR1	TTP4520	moderate	Biomarker	[569]
THBD	TTAPV67	moderate	Altered Expression	[570]
TIAM1	TTNU6I5	moderate	Biomarker	[571]
TNFRSF12A	TTKPS7V	moderate	Biomarker	[572]
TNFRSF8	TT2GM5R	moderate	Biomarker	[573]
TNFSF14	TTKVENM	moderate	Altered Expression	[574]
TNS4	TT1K65C	moderate	Biomarker	[575]
TOP1	TTGTQHC	moderate	Biomarker	[576]
TRIM24	TT9Q7AE	moderate	Genetic Variation	[577]
TRIM27	TTTO3QN	moderate	Biomarker	[522]
TXNRD1	TTR7UJ3	moderate	Biomarker	[578]
VDAC1	TTAMKGB	moderate	Biomarker	[579]
XPA	TTGT87E	moderate	Biomarker	[580]
XPO1	TTCJUR4	moderate	Biomarker	[581]
ABL1	TT6B75U	Strong	Biomarker	[582]
ACKR3	TTRQJTC	Strong	Altered Expression	[452]
ACVR1	TTJNBQA	Strong	Genetic Variation	[583]
AGER	TTMO9HF	Strong	Biomarker	[584]
AGRP	TT4DE1O	Strong	Biomarker	[585]
AHR	TT037IE	Strong	Genetic Variation	[586]
AIMP2	TTXWHGF	Strong	Biomarker	[587]
AKT3	TTO6SGY	Strong	Biomarker	[588]
ALCAM	TT2AFT6	Strong	Biomarker	[589]
ALK	TTPMQSO	Strong	Genetic Variation	[590]
ALOX12	TT12ABZ	Strong	Biomarker	[591]
AOC3	TT7HC21	Strong	Altered Expression	[592]
APEX1	TTHGL48	Strong	Altered Expression	[593]
APOH	TT2OUI9	Strong	Biomarker	[594]
AQP3	TTLDNMQ	Strong	Biomarker	[595]
ARL2	TTIDSFT	Strong	Biomarker	[285]
ATM	TTKBM7V	Strong	Altered Expression	[596]
ATRAID	TTFLIKM	Strong	Biomarker	[597]
AURKA	TTPS3C0	Strong	Biomarker	[598]
AURKB	TT9RTBL	Strong	Altered Expression	[599]
AXL	TTZPY6J	Strong	Biomarker	[600]
B2M	TTY7FKA	Strong	Biomarker	[601]
BAK1	TTFM7V0	Strong	Biomarker	[602]
BCL6	TTC9YX5	Strong	Biomarker	[450]
BIRC2	TTQ5LRD	Strong	Biomarker	[603]
BIRC7	TTHZ8TA	Strong	Biomarker	[604]
BMP6	TT07RIB	Strong	Biomarker	[605]
BRIP1	TTZV7LJ	Strong	Genetic Variation	[606]
BST2	TT90BJT	Strong	Altered Expression	[607]
C1QB	TT8A9DM	Strong	Biomarker	[608]
C9orf72	TTA4SHR	Strong	Genetic Variation	[609]
CA13	TTQPHSR	Strong	Biomarker	[610]
CA2	TTANPDJ	Strong	Biomarker	[611]
CAPN1	TT1WBIJ	Strong	Biomarker	[612]
CASP10	TTX5HEK	Strong	Biomarker	[613]
CASP6	TTKW4ML	Strong	Biomarker	[614]
CASP7	TTM7Y45	Strong	Biomarker	[615]
CBX7	TTBN3HC	Strong	Altered Expression	[616]
CCKBR	TTVFO0U	Strong	Biomarker	[617]
CCL5	TT9DWLC	Strong	Altered Expression	[618]
CD163	TTTZ9DE	Strong	Altered Expression	[619]
CD44	TTWFBT7	Strong	Biomarker	[620]
CDC7	TTSMTDI	Strong	Altered Expression	[621]
CDCA8	TT04YCM	Strong	Altered Expression	[622]
CDH2	TT1WS0T	Strong	Altered Expression	[623]
CDK11B	TT5Q79O	Strong	Biomarker	[624]
CDK13	TTRIM0E	Strong	Biomarker	[625]
CDK6	TTO0FDJ	Strong	Biomarker	[626]
CDKN1C	TTBSUAR	Strong	Biomarker	[530]
CEACAM3	TTPX7I5	Strong	Biomarker	[228]
CFB	TTA0P7K	Strong	Biomarker	[627]
CGA	TTFC29G	Strong	Genetic Variation	[628]
CHEK1	TTTU902	Strong	Biomarker	[629]
CLN3	TTORF9W	Strong	Altered Expression	[630]
CLU	TTRL76H	Strong	Therapeutic	[631]
COL7A1	TTBCOKN	Strong	Biomarker	[632]
COPS5	TTSTNJR	Strong	Altered Expression	[633]
CR1	TTEA8OW	Strong	Altered Expression	[634]
CRK	TTFEUYR	Strong	Biomarker	[587]
CRY1	TT5MLZR	Strong	Biomarker	[635]
CSF2	TTNYZG2	Strong	Biomarker	[636]
CSK	TTX6F0Q	Strong	Genetic Variation	[637]
CSNK1A1	TTFQEMX	Strong	Biomarker	[638]
CSPG4	TT7MYXI	Strong	Biomarker	[639]
CTAG1A	TTE5ITK	Strong	Altered Expression	[640]
CTCFL	TTY0RZT	Strong	Altered Expression	[641]
CTH	TTLQUZS	Strong	Biomarker	[501]
CUBN	TT9YLCR	Strong	Biomarker	[285]
CUL3	TTPCU0Q	Strong	Biomarker	[642]
CXCL10	TTQOVYA	Strong	Biomarker	[643]
CXCL12	TT4UGTF	Strong	Biomarker	[644]
CXCL2	TTZF0K2	Strong	Biomarker	[645]
CXCR4	TTBID49	Strong	Biomarker	[646]
CXXC5	TTVS4C3	Strong	Altered Expression	[647]
CYP1B1	TTI84H7	Strong	Biomarker	[530]
DDC	TTN451K	Strong	Biomarker	[648]
DDR2	TTU98HG	Strong	Biomarker	[649]
DGKA	TTGL8F0	Strong	Biomarker	[650]
DHCR24	TTTK0NH	Strong	Altered Expression	[651]
DKK2	TTST5KX	Strong	Altered Expression	[652]
DLL1	TT9CFQD	Strong	Genetic Variation	[653]
DLL3	TT1C9K6	Strong	Biomarker	[654]
DNASE1	TTYWGOJ	Strong	Biomarker	[655]
DRD1	TTZFYLI	Strong	Altered Expression	[656]
DYRK1A	TTSBVFO	Strong	Biomarker	[657]
E2F1	TTASI04	Strong	Biomarker	[658]
EBP	TT4VQZX	Strong	Altered Expression	[659]
EGFL7	TT7WD0H	Strong	Altered Expression	[660]
EGLN2	TTMHFRY	Strong	Biomarker	[661]
EIF4E	TTZGCP6	Strong	Biomarker	[195]
ENPP1	TTZTIWS	Strong	Biomarker	[662]
ENTPD1	TTYM8DJ	Strong	Biomarker	[663]
EP300	TTGH73N	Strong	Altered Expression	[466]
EPHA4	TTG84D3	Strong	Altered Expression	[664]
EPHB2	TTKPV6O	Strong	Genetic Variation	[665]
EPOR	TTAUX24	Strong	Biomarker	[666]
ERAP1	TT60XFL	Strong	Biomarker	[667]
ETS1	TTTGPSD	Strong	Altered Expression	[668]
F10	TTCIHJA	Strong	Biomarker	[669]
F2R	TTL935N	Strong	Altered Expression	[670]
F2RL1	TTQR74A	Strong	Biomarker	[530]
F3	TT38MDJ	Strong	Altered Expression	[671]
FABP3	TT3TGLR	Strong	Altered Expression	[672]
FASLG	TTO7014	Strong	Genetic Variation	[673]
FAT1	TTGUJYV	Strong	Biomarker	[674]
FBXO11	TT6G10V	Strong	Altered Expression	[675]
FCGR3A	TTIFOC0	Strong	Biomarker	[676]
FDFT1	TTFQEO5	Strong	Biomarker	[677]
FGF18	TT6ICRA	Strong	Altered Expression	[678]
FOLR2	TTT54CI	Strong	Altered Expression	[679]
FOS	TTOM5AU	Strong	Biomarker	[680]
FOXC2	TTLBAP1	Strong	Altered Expression	[681]
FST	TTDNM9W	Strong	Altered Expression	[682]
GAPDH	TTUGSWA	Strong	Altered Expression	[683]
GAS6	TT69QD2	Strong	Altered Expression	[684]
GDF15	TT4MXVG	Strong	Biomarker	[685]
GDNF	TTF23ML	Strong	Altered Expression	[459]
GGT1	TTZVT7O	Strong	Altered Expression	[686]
GJB6	TTAU8SJ	Strong	Altered Expression	[687]
GLI1	TTJOMH6	Strong	Altered Expression	[688]
GLI2	TT045OH	Strong	Altered Expression	[689]
GLO1	TTV9A7R	Strong	Biomarker	[690]
GPRC6A	TTI1PRE	Strong	Biomarker	[691]
GRIN2A	TTKJEMQ	Strong	Genetic Variation	[692]
GRM3	TT8A9EF	Strong	Biomarker	[693]
GSK3A	TTQWAU1	Strong	Altered Expression	[694]
HAL	TTXQOZW	Strong	Biomarker	[695]
HAX1	TT21BYA	Strong	Altered Expression	[696]
HDAC6	TT5ZKDI	Strong	Biomarker	[697]
HMGB2	TTA78JQ	Strong	Biomarker	[698]
HOXA11	TTEX4ZA	Strong	Altered Expression	[699]
HPGDS	TTCYE56	Strong	Biomarker	[700]
HRH2	TTQHJ1K	Strong	Altered Expression	[701]
HSP90AA1	TT78R5H	Strong	Biomarker	[702]
HSP90AB1	TTH5YN2	Strong	Biomarker	[703]
HSPA5	TTW26OG	Strong	Biomarker	[704]
HTR2B	TT0K1SC	Strong	Altered Expression	[656]
ICOSLG	TTB9Z8R	Strong	Altered Expression	[705]
IDO1	TTZJYKH	Strong	Altered Expression	[706]
IFNA2	TTSIUJ9	Strong	Biomarker	[707]
IFNA5	TTLHGSF	Strong	Therapeutic	[708]
IFNB1	TT4TZ8J	Strong	Biomarker	[709]
IFNG	TT93WF5	Strong	Biomarker	[710]
IL12A	TTRTK6Y	Strong	Altered Expression	[711]
IL15	TTJFA35	Strong	Biomarker	[712]
IL15RA	TTGN89I	Strong	Biomarker	[712]
IL17D	TTC5LTG	Strong	Biomarker	[713]
IL19	TT87RWS	Strong	Biomarker	[714]
IL2	TTF89GD	Strong	Altered Expression	[715]
IL24	TT1EPXZ	Strong	Biomarker	[716]
IL25	TTVMO5W	Strong	Biomarker	[717]
IL2RA	TT10Y9E	Strong	Genetic Variation	[320]
IL7	TT8FRMO	Strong	Biomarker	[718]
IMP3	TTEJA2R	Strong	Altered Expression	[719]
IRAK1	TTXAJWN	Strong	Biomarker	[720]
IRF8	TTHUBNK	Strong	Biomarker	[721]
ITGA11	TTANXZ7	Strong	Altered Expression	[722]
ITGB1	TTBVIQC	Strong	Altered Expression	[723]
ITGB3	TTJA1ZO	Strong	Biomarker	[724]
ITK	TT3C80U	Strong	Biomarker	[725]
JUN	TTS7IR5	Strong	Biomarker	[726]
KCNMA1	TTE87WJ	Strong	Altered Expression	[727]
KDM1A	TTNR0UQ	Strong	Biomarker	[536]
KDM5B	TTCLI75	Strong	Biomarker	[728]
KLRK1	TTLRN4A	Strong	Genetic Variation	[729]
LONP1	TTM1VPZ	Strong	Altered Expression	[730]
LOX	TTQHNAM	Strong	Biomarker	[731]
LTBR	TTFO0PM	Strong	Biomarker	[732]
LYVE1	TTG8DNU	Strong	Altered Expression	[733]
M6PR	TT95ICL	Strong	Altered Expression	[734]
MAD1L1	TTNE9U7	Strong	Biomarker	[735]
MAG	TT9XFON	Strong	Biomarker	[736]
MAGEA2	TTOZT28	Strong	Biomarker	[737]
MAGEC1	TT9M6NA	Strong	Biomarker	[738]
MAP2K2	TT8H9GB	Strong	Biomarker	[739]
MAP3K5	TTOQCD8	Strong	Genetic Variation	[740]
MAP3K9	TTUNSIX	Strong	Biomarker	[741]
MAPK12	TTYT93M	Strong	Biomarker	[742]
MAPK14	TTQBR95	Strong	Biomarker	[587]
MAPK3	TT1MG9E	Strong	Altered Expression	[743]
MAPK8	TT0K6EO	Strong	Biomarker	[587]
MC4R	TTD0CIQ	Strong	Biomarker	[744]
MCHR1	TTX4RTB	Strong	Altered Expression	[745]
MCHR2	TTS17MG	Strong	Genetic Variation	[746]
MCL1	TTL53M6	Strong	Biomarker	[747]
MCM7	TT1RM3F	Strong	Biomarker	[748]
MCOLN1	TT9XBVO	Strong	Biomarker	[749]
MDM2	TT9TE0O	Strong	Biomarker	[750]
MDM4	TT9OUDQ	Strong	Biomarker	[386]
METAP2	TTZL0OI	Strong	Altered Expression	[751]
MFGE8	TT1GLAJ	Strong	Biomarker	[752]
MGMT	TTJ8DV7	Strong	Biomarker	[753]
MKNK1	TTEZAUX	Strong	Biomarker	[195]
MMP11	TTZW4MV	Strong	Altered Expression	[754]
MMP14	TTJ4QE7	Strong	Altered Expression	[397]
MMP8	TTGA1IV	Strong	Biomarker	[755]
MRGPRX1	TTIX6PK	Strong	Biomarker	[691]
MS4A1	TTUE541	Strong	Biomarker	[756]
MSI1	TTSM4BA	Strong	Altered Expression	[757]
MST1R	TTBQ3OC	Strong	Biomarker	[544]
MTAP	TTDBX7N	Strong	Genetic Variation	[758]
MTNR1B	TT32JK8	Strong	Altered Expression	[759]
MVD	TTE5J6X	Strong	Biomarker	[760]
MYD88	TTB6Q2O	Strong	Altered Expression	[477]
NCL	TTK1V5Q	Strong	Biomarker	[761]
NEDD4	TT1QU6G	Strong	Altered Expression	[762]
NEDD9	TT1UREA	Strong	Biomarker	[763]
NF2	TTZIK7P	Strong	Biomarker	[764]
NFKB1	TTUIZKC	Strong	Altered Expression	[477]
NGF	TTDN3LF	Strong	Genetic Variation	[765]
NQO2	TTJLP0R	Strong	Altered Expression	[766]
NR1I3	TTRANFM	Strong	Biomarker	[767]
NRP1	TTIPJCB	Strong	Altered Expression	[768]
NT5E	TTK0O6Y	Strong	Biomarker	[663]
NTF3	TTZHKV9	Strong	Biomarker	[769]
NTF4	TTIM2WO	Strong	Biomarker	[769]
NTRK1	TTTDVOJ	Strong	Biomarker	[770]
OSMR	TTAH0KM	Strong	Biomarker	[771]
OXER1	TT7WBSV	Strong	Biomarker	[691]
PAGE5	TTNWOIT	Strong	Altered Expression	[772]
PAM	TTF4ZPC	Strong	Biomarker	[773]
PARP1	TTVDSZ0	Strong	Biomarker	[774]
PCSK1	TTED9LZ	Strong	Biomarker	[662]
PCSK7	TTD30LY	Strong	Biomarker	[775]
PDE1A	TT73TEJ	Strong	Genetic Variation	[776]
PDE4C	TT6A59G	Strong	Biomarker	[777]
PDE8A	TTIS4OW	Strong	Biomarker	[778]
PDGFB	TTQA6SX	Strong	Biomarker	[779]
PDK1	TTCZOF2	Strong	Altered Expression	[446]
PDPK1	TTYMGWX	Strong	Altered Expression	[446]
PECAM1	TT4EZB2	Strong	Biomarker	[780]
PEPD	TTLZXI0	Strong	Altered Expression	[781]
PGC	TT7K6AD	Strong	Altered Expression	[782]
PIGU	TT2LHI6	Strong	Genetic Variation	[783]
PKMYT1	TTB4PAZ	Strong	Biomarker	[285]
PLD1	TT3T17P	Strong	Altered Expression	[784]
PLEKHA5	TTCDZMO	Strong	Biomarker	[785]
PMS1	TTX1ISF	Strong	Altered Expression	[786]
POMC	TT21AKM	Strong	Biomarker	[787]
POSTN	TT8ALTZ	Strong	Biomarker	[788]
PPARD	TT2JWF6	Strong	Genetic Variation	[789]
PRAME	TTPH7T0	Strong	Biomarker	[790]
PRKCA	TTFJ8Q1	Strong	Altered Expression	[791]
PRKCB	TTYPXQF	Strong	Altered Expression	[792]
PRKCD	TT7A1BO	Strong	Genetic Variation	[793]
PRKCE	TT57MT2	Strong	Biomarker	[794]
PRKCI	TTWJTHX	Strong	Biomarker	[795]
PRSS1	TT2WR1T	Strong	Biomarker	[796]
PSMB6	TT8EPLT	Strong	Genetic Variation	[653]
PTGS2	TTVKILB	Strong	Biomarker	[797]
PTPN6	TT369M5	Strong	Biomarker	[798]
PYGM	TTZHY6R	Strong	Genetic Variation	[799]
QPCT	TTJ7YTV	Strong	Biomarker	[530]
RAB22A	TTAJ746	Strong	Biomarker	[800]
RAB9A	TT958S6	Strong	Biomarker	[801]
RAC1	TT2M9CG	Strong	Altered Expression	[802]
RAD51	TTC0G1L	Strong	Biomarker	[469]
RAF1	TTAN5W2	Strong	Genetic Variation	[803]
REG3A	TTL4H8N	Strong	Biomarker	[804]
RET	TT4DXQT	Strong	Biomarker	[706]
RHAG	TTVHFE8	Strong	Biomarker	[805]
RHO	TTH0KSX	Strong	Altered Expression	[806]
RHOB	TT6LPFO	Strong	Biomarker	[807]
ROBO1	TTND1YP	Strong	Biomarker	[808]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[809]
RSF1	TTMP86V	Strong	Altered Expression	[810]
S100A9	TT0TMQG	Strong	Altered Expression	[811]
SCT	TTOBVIN	Strong	Biomarker	[691]
SELL	TT2IYXF	Strong	Altered Expression	[812]
SERPINF1	TTR59S1	Strong	Biomarker	[813]
SF3B1	TTL2WUI	Strong	Altered Expression	[814]
SHCBP1	TTZ9WGL	Strong	Biomarker	[773]
SIRT5	TTH0IOD	Strong	Genetic Variation	[815]
SIRT6	TTUXYWF	Strong	Biomarker	[816]
SKP2	TT5B2EO	Strong	Altered Expression	[817]
SLC15A2	TT27Q3A	Strong	Biomarker	[738]
SLC17A5	TTFSUIA	Strong	Biomarker	[393]
SLC33A1	TTL69WB	Strong	Altered Expression	[818]
SLC38A2	TTUSC27	Strong	Altered Expression	[819]
SLC39A6	TTZN1CF	Strong	Altered Expression	[820]
SLC52A2	TT6TKEN	Strong	Altered Expression	[821]
SLC5A5	TTW7HI9	Strong	Biomarker	[822]
SLC6A11	TT8RXO5	Strong	Biomarker	[823]
SLC7A11	TTBZMIO	Strong	Altered Expression	[824]
SLC9A1	TTGSEFH	Strong	Altered Expression	[825]
SOCS1	TT8COJM	Strong	Biomarker	[826]
SRC	TT6PKBN	Strong	Biomarker	[274]
SREBF1	TTER0UB	Strong	Genetic Variation	[827]
SYK	TT2HUPM	Strong	Biomarker	[828]
TDG	TTEXRQD	Strong	Biomarker	[829]
TDGF1	TTN7HMG	Strong	Altered Expression	[830]
TERT	TTQY2EJ	Strong	Biomarker	[831]
TF	TT8WXAV	Strong	Altered Expression	[832]
THRB	TTGER3L	Strong	Genetic Variation	[833]
TIGIT	TTWNL74	Strong	Altered Expression	[327]
TLR1	TTW14D0	Strong	Genetic Variation	[834]
TLR3	TTD24Y0	Strong	Biomarker	[835]
TLR4	TTISGCA	Strong	Biomarker	[477]
TNC	TTUCPMY	Strong	Altered Expression	[836]
TNF	TTF8CQI	Strong	Altered Expression	[477]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[837]
TNNC1	TT8RDXP	Strong	Biomarker	[838]
TRH	TT2Z39D	Strong	Biomarker	[839]
TRIM59	TT613U4	Strong	Biomarker	[840]
TRPC1	TTA76X0	Strong	Biomarker	[796]
TRPM7	TTFPVZO	Strong	Biomarker	[841]
TRPV2	TTBECWA	Strong	Altered Expression	[842]
TTK	TTP7EGM	Strong	Biomarker	[301]
TYMP	TTO0IB8	Strong	Biomarker	[843]
TYRP1	TTFRV98	Strong	Altered Expression	[844]
VEGFC	TT0QUFV	Strong	Altered Expression	[845]
VEGFD	TTOM5H4	Strong	Biomarker	[846]
WEE1	TTJFOAL	Strong	Altered Expression	[847]
WNT5A	TTKG7F8	Strong	Biomarker	[750]
WRN	TT2H5WQ	Strong	Genetic Variation	[848]
XIAP	TTK3WBU	Strong	Altered Expression	[849]
YAP1	TT8UN2D	Strong	Biomarker	[850]
ABCB1	TT3OT40	Definitive	Biomarker	[851]
ADA	TTLP57V	Definitive	Biomarker	[852]
ADAM17	TT6AZXG	Definitive	Biomarker	[853]
ADRA1A	TTNGILX	Definitive	Altered Expression	[452]
ADRA2B	TTWM4TY	Definitive	Altered Expression	[452]
AGTR1	TT8DBY3	Definitive	Biomarker	[854]
ANPEP	TTPHMWB	Definitive	Altered Expression	[855]
ARG1	TT7ZQEV	Definitive	Biomarker	[856]
BCL2A1	TTGT9C7	Definitive	Altered Expression	[747]
BDNF	TTSMLOH	Definitive	Genetic Variation	[765]
BIRC3	TTAIWZN	Definitive	Biomarker	[857]
BMI1	TTIPNSR	Definitive	Biomarker	[858]
BSG	TT5UJWD	Definitive	Biomarker	[433]
C5	TTKANGO	Definitive	Biomarker	[859]
C5AR1	TTHXFA1	Definitive	Biomarker	[859]
CAMP	TTULOB6	Definitive	Biomarker	[860]
CCL22	TTBTWI1	Definitive	Biomarker	[861]
CCL3	TT8I4WB	Definitive	Altered Expression	[862]
CD47	TT28S46	Definitive	Biomarker	[863]
CD80	TT89Z17	Definitive	Altered Expression	[456]
CDK9	TT1LVF2	Definitive	Altered Expression	[864]
CDKN1A	TT9GUW0	Definitive	Biomarker	[865]
CMKLR1	TT4UGZL	Definitive	Biomarker	[866]
CSF1R	TT7MRDV	Definitive	Biomarker	[455]
CTSS	TTUMQVO	Definitive	Biomarker	[238]
CXCL1	TTLK1RW	Definitive	Altered Expression	[867]
CXCR6	TT2BVUA	Definitive	Altered Expression	[452]
DDR1	TTI1FPZ	Definitive	Altered Expression	[226]
DEK	TT1NMGV	Definitive	Biomarker	[868]
DKK3	TTY2ZV6	Definitive	Biomarker	[869]
DNMT3B	TT6VZ78	Definitive	Biomarker	[870]
E2F3	TTWIJYH	Definitive	Biomarker	[871]
EDNRA	TTKRD0G	Definitive	Altered Expression	[452]
EGLN1	TT9ISBX	Definitive	Genetic Variation	[872]
EML4	TT92GY4	Definitive	Biomarker	[873]
ENG	TTB30LE	Definitive	Biomarker	[874]
EPHA2	TTRJB2G	Definitive	Altered Expression	[875]
EPHB4	TTI4ZX2	Definitive	Altered Expression	[876]
ERBB3	TTSINU2	Definitive	Genetic Variation	[877]
ESR1	TTZAYWL	Definitive	Genetic Variation	[210]
FDPS	TTIKWV4	Definitive	Biomarker	[878]
FKBP4	TTHY0FT	Definitive	Biomarker	[879]
FKBP5	TT0J5KQ	Definitive	Biomarker	[879]
FLT4	TTDCBX5	Definitive	Biomarker	[880]
FZD10	TTP1S2F	Definitive	Biomarker	[881]
HHAT	TT1VNCG	Definitive	Biomarker	[882]
HLA-A	TTHONFT	Definitive	Altered Expression	[883]
IGF2R	TTPNE41	Definitive	Genetic Variation	[884]
IGFBP2	TTU4QSN	Definitive	Altered Expression	[885]
IL1A	TTPM6HI	Definitive	Biomarker	[886]
IL4	TTLGTKB	Definitive	Biomarker	[887]
ITGA5	TTHIZP9	Definitive	Altered Expression	[888]
ITGAV	TTT1R2L	Definitive	Altered Expression	[889]
ITPR1	TT5HWAT	Definitive	Altered Expression	[890]
ITPR3	TTH1769	Definitive	Altered Expression	[890]
KISS1	TTU2O6T	Definitive	Altered Expression	[891]
KITLG	TTDJ51N	Definitive	Genetic Variation	[892]
KLF4	TTTI53X	Definitive	Biomarker	[893]
LAMP1	TTC214J	Definitive	Biomarker	[284]
LDHA	TTW76JE	Definitive	Biomarker	[894]
LRRC32	TT0FAYT	Definitive	Biomarker	[895]
MAPK7	TTU6FSC	Definitive	Biomarker	[896]
MAPK9	TT3IVG2	Definitive	Biomarker	[897]
MLH1	TTISG27	Definitive	Altered Expression	[898]
MSH2	TTCAWRT	Definitive	Biomarker	[898]
NAMPT	TTD1WIG	Definitive	Altered Expression	[899]
NEK9	TTM57AW	Definitive	Biomarker	[900]
NQO1	TT8XK6L	Definitive	Biomarker	[901]
NR4A1	TTMXE2Q	Definitive	Biomarker	[902]
NRP2	TTRXUVC	Definitive	Altered Expression	[903]
PAH	TTGSVH2	Definitive	Biomarker	[904]
PBK	TTMY6BZ	Definitive	Biomarker	[340]
PCNA	TTLG1PD	Definitive	Altered Expression	[905]
PDCD1LG2	TTW14O3	Definitive	Biomarker	[906]
PFKFB2	TTQYVKD	Definitive	Posttranslational Modification	[376]
PHB	TT6U071	Definitive	Altered Expression	[907]
PKD2L1	TTAHD89	Definitive	Biomarker	[880]
PKM	TT4LOT8	Definitive	Biomarker	[908]
PLK1	TTH4IP0	Definitive	Biomarker	[909]
PLK4	TTGPNZQ	Definitive	Biomarker	[910]
PNP	TTMCF1Y	Definitive	Biomarker	[911]
PPM1D	TTENJAB	Definitive	Biomarker	[912]
PROM1	TTXMZ81	Definitive	Biomarker	[913]
PRTN3	TT5MLC4	Definitive	Genetic Variation	[914]
PTPRJ	TTWMKXP	Definitive	Genetic Variation	[915]
RAPGEF3	TTOE7I0	Definitive	Biomarker	[396]
RASA1	TTPNZ1F	Definitive	Biomarker	[916]
RGS6	TTJ96M8	Definitive	Biomarker	[916]
RORA	TT1TYN7	Definitive	Altered Expression	[917]
RXRA	TT6PEUO	Definitive	Biomarker	[918]
SCARB1	TTRE324	Definitive	Biomarker	[919]
SDC1	TTYDSVG	Definitive	Altered Expression	[410]
SIRT2	TTLKF5M	Definitive	Biomarker	[920]
SLAMF6	TTSIYJ6	Definitive	Biomarker	[921]
SLC38A7	TTEARWC	Definitive	Altered Expression	[922]
SPARC	TTBQFM7	Definitive	Altered Expression	[923]
SPHK1	TTOHFIY	Definitive	Biomarker	[924]
STAT1	TTN7R6K	Definitive	Biomarker	[925]
STMN1	TT7W5OT	Definitive	Altered Expression	[926]
STS	TTHM0R1	Definitive	Biomarker	[439]
TBK1	TTMP03S	Definitive	Altered Expression	[724]
TFAP2A	TTDY4BS	Definitive	Biomarker	[927]
TKTL1	TTNQ1J3	Definitive	Biomarker	[928]
TNFRSF18	TTG6LA7	Definitive	Biomarker	[762]
TNFRSF4	TTL31H0	Definitive	Biomarker	[929]
TNFSF11	TT9E8HR	Definitive	Biomarker	[930]
TSPO	TTPTXIN	Definitive	Biomarker	[230]
USP14	TTVSYP9	Definitive	Biomarker	[931]

This Disease Is Related to 13 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ATP7A	DT0LT17	Limited	Biomarker	[932]
SLC24A5	DTAWCS9	Limited	Altered Expression	[933]
SLC39A12	DT1UIT5	Limited	Biomarker	[285]
ABCB8	DT0KQND	moderate	Altered Expression	[934]
SLC25A25	DTN7X5J	moderate	Biomarker	[935]
SLC25A3	DTCRIWV	moderate	Altered Expression	[936]
ABCA12	DT7LDG0	Strong	Genetic Variation	[937]
ABCB5	DTKVEXO	Strong	Biomarker	[639]
SLC25A16	DTNU9EW	Strong	Biomarker	[210]
SLC26A1	DTJ785O	Strong	Altered Expression	[819]
SLC27A1	DTKDTML	Strong	Biomarker	[938]
SLC52A1	DT7NOKR	Strong	Altered Expression	[821]
SLC2A3	DT9SQ3L	Definitive	Altered Expression	[939]

This Disease Is Related to 28 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ASNS	DEXISVQ	Limited	Altered Expression	[195]
CPA4	DEXKD7J	Limited	Biomarker	[940]
CRMP1	DE0EUXB	Limited	Biomarker	[443]
CYP27B1	DE3FYEM	Limited	Altered Expression	[941]
GGCT	DEKW6PB	Limited	Genetic Variation	[942]
GLS	DE3E0VT	Limited	Altered Expression	[943]
HINT1	DEWJATF	Limited	Biomarker	[944]
HK1	DEDMAGE	Limited	Genetic Variation	[376]
MAT2B	DEKF1OH	Limited	Altered Expression	[945]
MT1A	DE5ME8A	Limited	Posttranslational Modification	[946]
NAT10	DEZV4AP	Limited	Biomarker	[947]
NNMT	DECVGJ3	Limited	Altered Expression	[948]
NT5C2	DE1DOKJ	Limited	Biomarker	[949]
PSAT1	DEBS17P	Limited	Altered Expression	[324]
HPRT1	DEVXTP5	moderate	Biomarker	[950]
ACP5	DESITDW	Strong	Biomarker	[951]
AKR1B10	DEP6GT1	Strong	Biomarker	[823]
ALDH1A1	DE2JP1Y	Strong	Altered Expression	[952]
CMPK1	DEMPH4I	Strong	Genetic Variation	[953]
CYP2R1	DEBIHM3	Strong	Biomarker	[954]
HSD17B12	DE915QP	Strong	Genetic Variation	[955]
NDUFS7	DEIW03B	Strong	Genetic Variation	[956]
P3H2	DELB5PA	Strong	Posttranslational Modification	[957]
P4HA3	DE2L4RX	Strong	Altered Expression	[958]
PARK7	DEPOVCH	Strong	Altered Expression	[959]
SCLY	DEH4TD6	Strong	Altered Expression	[960]
UGT2B10	DEI8NGH	Strong	Biomarker	[823]
PTGDS	DER3H9C	Definitive	Altered Expression	[961]

This Disease Is Related to 1339 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AADAC	OT8VACT2	Limited	Biomarker	[962]
ACAD10	OTFAG3M0	Limited	Altered Expression	[963]
ACSL3	OT3MWER1	Limited	Biomarker	[964]
ACSS1	OT6C1WQD	Limited	Biomarker	[965]
ADAM15	OTZ7VLTP	Limited	Biomarker	[966]
ADAR	OTQNOHR8	Limited	Altered Expression	[967]
AFAP1L2	OTJBI0VN	Limited	Genetic Variation	[488]
AGAP3	OT8C6PKL	Limited	Biomarker	[968]
AHNAK	OT6KH1WG	Limited	Biomarker	[969]
AIM2	OT86QUI8	Limited	Biomarker	[970]
AKT1S1	OT4JHN4Y	Limited	Biomarker	[971]
ALPP	OTZU4G9W	Limited	Biomarker	[189]
AMIGO2	OTPAIT1O	Limited	Biomarker	[972]
APCDD1	OTV9AD0L	Limited	Biomarker	[973]
ARHGAP45	OTL86FEQ	Limited	Biomarker	[974]
ARHGEF5	OTUVGFT9	Limited	Biomarker	[975]
ARID2	OTIRJXWM	Limited	Biomarker	[976]
ARL5B	OTYYBIDG	Limited	Biomarker	[285]
ART3	OT68OFVT	Limited	Biomarker	[977]
ASAH1	OT1DNGXL	Limited	Altered Expression	[978]
ASXL1	OTX931AW	Limited	Biomarker	[979]
ATG10	OTVRPC5X	Limited	Biomarker	[980]
ATG16L1	OTEOYC5D	Limited	Altered Expression	[980]
ATN1	OTNZFLKY	Limited	Biomarker	[981]
ATP13A2	OTKWBUGK	Limited	Genetic Variation	[982]
ATP2B4	OTMWFDAC	Limited	Altered Expression	[983]
B4GALNT1	OTCY80HS	Limited	Altered Expression	[984]
BAD	OT63ERYM	Limited	Altered Expression	[877]
BASP1	OTF4VS5G	Limited	Altered Expression	[783]
BATF3	OTI61WXQ	Limited	Genetic Variation	[985]
BCAR1	OTKT2C2N	Limited	Biomarker	[986]
BHLHE40	OTITX14U	Limited	Biomarker	[987]
BIK	OTTH1T3D	Limited	Biomarker	[988]
BNIP3	OT4SO7J4	Limited	Biomarker	[989]
BPTF	OTD1RZAD	Limited	Altered Expression	[990]
BRMS1L	OTJIW47U	Limited	Biomarker	[991]
BTRC	OT2EZDGR	Limited	Genetic Variation	[992]
CACUL1	OT6P1ZVP	Limited	Altered Expression	[993]
CANX	OTYP1F6J	Limited	Biomarker	[426]
CAP2	OTC1WFNO	Limited	Altered Expression	[994]
CBLIF	OTNE20WU	Limited	Biomarker	[995]
CBLL2	OTB4AD3V	Limited	Biomarker	[993]
CCDC8	OTO295IH	Limited	Biomarker	[426]
CCL14	OT8QETQU	Limited	Biomarker	[996]
CCL27	OTUZYC61	Limited	Altered Expression	[997]
CCL4L2	OTDBSXOU	Limited	Altered Expression	[222]
CCN4	OT69BER9	Limited	Altered Expression	[998]
CCNF	OTJFVU43	Limited	Altered Expression	[999]
CD207	OTI9RUDN	Limited	Genetic Variation	[1000]
CD8A	OTDWQJXK	Limited	Biomarker	[1001]
CDC5L	OTTPFUU5	Limited	Altered Expression	[1002]
CDC6	OTX93FE7	Limited	Biomarker	[1003]
CDCA4	OT0AAXAC	Limited	Biomarker	[1004]
CDK16	OTUBXIIT	Limited	Altered Expression	[900]
CDK2AP2	OTR99SJ8	Limited	Biomarker	[1005]
CDT1	OTVY53VG	Limited	Biomarker	[1003]
CDX2	OTCG4TSY	Limited	Genetic Variation	[1006]
CELF1	OT6JQ5RS	Limited	Biomarker	[1007]
CEP350	OT5Q3AEA	Limited	Biomarker	[1008]
CERS6	OTOP4GV1	Limited	Biomarker	[1009]
CFDP1	OTXY7J96	Limited	Biomarker	[444]
CHL1	OT6E6E8P	Limited	Biomarker	[912]
CIB1	OT4BVCRU	Limited	Biomarker	[1010]
CIITA	OTRJNZFO	Limited	Altered Expression	[1011]
CITED1	OTUJQ3VL	Limited	Biomarker	[1012]
CKS1B	OTNUPLUJ	Limited	Altered Expression	[1013]
CLDN11	OTNN6UTL	Limited	Biomarker	[753]
CLEC14A	OT0UJQ4O	Limited	Altered Expression	[1014]
CNGB1	OTA5DE38	Limited	Biomarker	[895]
COL17A1	OTID5AH2	Limited	Biomarker	[1015]
COMP	OTS2FPMI	Limited	Biomarker	[1016]
CPA3	OTOK8M0V	Limited	Altered Expression	[940]
CPEB4	OTW1SCZW	Limited	Biomarker	[1017]
CPT1A	OTI862QH	Limited	Genetic Variation	[1018]
CSAD	OT3I2G0A	Limited	Biomarker	[1019]
CSDE1	OT15D7GH	Limited	Biomarker	[361]
CTAG2	OT8HISP4	Limited	Biomarker	[1020]
CTBP1	OTVYH2DH	Limited	Altered Expression	[1021]
CTCF	OT8ZB70U	Limited	Biomarker	[1022]
CTHRC1	OTV88X2G	Limited	Biomarker	[1023]
CTNND1	OTUMPSHR	Limited	Posttranslational Modification	[1024]
CUL1	OTXPE1UZ	Limited	Biomarker	[993]
CXCL16	OTD49T9R	Limited	Biomarker	[1025]
DAPK2	OTWODUQG	Limited	Biomarker	[443]
DCBLD1	OTA702JK	Limited	Biomarker	[285]
DCLRE1C	OTW3KB1I	Limited	Biomarker	[1026]
DCP1A	OT3NCON3	Limited	Altered Expression	[1027]
DCTN2	OTMB4IXD	Limited	Biomarker	[1028]
DCTN4	OTM7C943	Limited	Biomarker	[323]
DCTN5	OTESGJ1N	Limited	Biomarker	[1028]
DDB1	OTTR2L3Z	Limited	Altered Expression	[1029]
DDIT3	OTI8YKKE	Limited	Biomarker	[1030]
DDX3X	OTDO4TRX	Limited	Altered Expression	[1031]
DDX53	OTHK3EGZ	Limited	Biomarker	[1032]
DENR	OTXP9HOY	Limited	Biomarker	[443]
DGKI	OTDZ602D	Limited	Genetic Variation	[1033]
DLG2	OTQ3BD8U	Limited	Biomarker	[285]
DNAJB4	OTUD01BK	Limited	Altered Expression	[1034]
DSG2	OTJPB2TO	Limited	Altered Expression	[1035]
DST	OTHZBM4X	Limited	Biomarker	[1036]
DUSP6	OT4H6RKW	Limited	Biomarker	[1037]
EBF1	OTZ61YYH	Limited	Genetic Variation	[1038]
EBF3	OTB0IWLW	Limited	Altered Expression	[1039]
EDA	OTAKS5WS	Limited	Biomarker	[285]
EDEM1	OTWHN69S	Limited	Biomarker	[1040]
EDIL3	OTDVVNS0	Limited	Altered Expression	[1041]
EDN3	OTN7Q9BE	Limited	Altered Expression	[1042]
EIF1AX	OTWG2LAB	Limited	Genetic Variation	[1043]
EIF2B1	OT4NCVY1	Limited	Biomarker	[1044]
EIF2B2	OTQQMHM1	Limited	Biomarker	[1044]
EIF2B4	OTTM5SX1	Limited	Biomarker	[1044]
EIF2S2	OTXF0B09	Limited	Biomarker	[1044]
EIF3D	OTDOMP80	Limited	Biomarker	[1045]
EIF3I	OTE07WND	Limited	Biomarker	[1046]
EIF4A2	OT08H03R	Limited	Altered Expression	[1047]
EIF4G1	OT2CF1E6	Limited	Altered Expression	[1047]
EIF4G2	OTEO98CR	Limited	Biomarker	[444]
ELK4	OTVSSEOE	Limited	Altered Expression	[1048]
ERCC4	OTFIOPG1	Limited	Genetic Variation	[1049]
ERCC5	OTQAKFJM	Limited	Genetic Variation	[1050]
ERRFI1	OT7VZ2IZ	Limited	Altered Expression	[1014]
ESRP1	OTNCS4SL	Limited	Altered Expression	[1051]
ETFA	OTXX61VZ	Limited	Biomarker	[1052]
ETV1	OT6PMJIK	Limited	Altered Expression	[1053]
EXO1	OTI87RS5	Limited	Altered Expression	[1054]
EYA1	OTHU807A	Limited	Altered Expression	[1055]
FAH	OTGZA1YR	Limited	Biomarker	[1002]
FAM3C	OTBR6U9G	Limited	Biomarker	[1056]
FANCD2	OTVEB5LF	Limited	Biomarker	[469]
FBXW4	OTEGSZOX	Limited	Biomarker	[962]
FERMT2	OTZNPWWX	Limited	Biomarker	[323]
FERMT3	OTFQOT3C	Limited	Altered Expression	[1057]
FGF5	OTQXGHBY	Limited	Biomarker	[1058]
FHOD1	OTROM7N3	Limited	Altered Expression	[1059]
FIS1	OT2HL10J	Limited	Biomarker	[1060]
FLG	OTE9QDV6	Limited	Biomarker	[1036]
FLII	OT7G9JG6	Limited	Biomarker	[1061]
FLNB	OTPCOYL6	Limited	Biomarker	[711]
FMR1	OTWEV0T5	Limited	Altered Expression	[1062]
FNDC3B	OTBILGDR	Limited	Biomarker	[1063]
FOSB	OTW6C05J	Limited	Altered Expression	[1064]
FOXA2	OTJOCVOY	Limited	Biomarker	[1065]
FOXD3	OTXYV6GO	Limited	Biomarker	[1066]
FUNDC2	OTY3TQM5	Limited	Biomarker	[996]
FUT1	OTODG57A	Limited	Altered Expression	[1067]
FUT2	OTLXM6WI	Limited	Altered Expression	[1067]
FUT8	OTJJCVG1	Limited	Biomarker	[1068]
FXR1	OTEMQ1SR	Limited	Altered Expression	[1069]
GBE1	OTK2N05B	Limited	Biomarker	[1070]
GBP1	OTUM7RPJ	Limited	Biomarker	[1071]
GC	OTWS63BY	Limited	Genetic Variation	[1072]
GEMIN4	OTX7402E	Limited	Biomarker	[444]
GINS2	OT974IYI	Limited	Altered Expression	[1073]
GLIS3	OTBC960E	Limited	Biomarker	[1074]
GMPR	OTERWHYM	Limited	Biomarker	[1075]
GNA12	OT3IRZH3	Limited	Biomarker	[281]
GNA14	OTYZ1ZI0	Limited	Biomarker	[232]
GOLM1	OTOZSV6O	Limited	Biomarker	[1076]
GPC6	OTNJBESF	Limited	Biomarker	[1077]
GPHA2	OT3HY17B	Limited	Biomarker	[285]
GSTM2	OTG4WT05	Limited	Genetic Variation	[1078]
GYPA	OTABU4YV	Limited	Biomarker	[1079]
H2AZ1	OT3KJJNQ	Limited	Biomarker	[1080]
HCLS1	OTX7WGYN	Limited	Biomarker	[307]
HLA-DOA	OTZE5Q7R	Limited	Biomarker	[1081]
HLA-DQB1	OTVVI3UI	Limited	Biomarker	[1082]
HM13	OTGEO1LP	Limited	Altered Expression	[791]
HS2ST1	OTHOU8I2	Limited	Biomarker	[1083]
HSPA1A	OTKGIE76	Limited	Biomarker	[1084]
HSPB2	OTS01646	Limited	Biomarker	[296]
HSPH1	OTVRR73T	Limited	Biomarker	[1085]
ID4	OTPMJ39I	Limited	Biomarker	[1086]
IFI30	OT9DERT1	Limited	Altered Expression	[1087]
IFNA17	OTHXRYG3	Limited	Genetic Variation	[1088]
IGSF8	OTU22IKI	Limited	Biomarker	[1089]
IKBKG	OTNWJWSD	Limited	Genetic Variation	[1090]
IL17RB	OT0KDNSF	Limited	Biomarker	[249]
IL27	OTIS3OF8	Limited	Altered Expression	[527]
IL34	OTZ15VVK	Limited	Genetic Variation	[1091]
IL4I1	OTK54C63	Limited	Biomarker	[887]
ILF3	OTKMZ5K5	Limited	Altered Expression	[1092]
IMMP1L	OTA6LOLR	Limited	Altered Expression	[791]
INCENP	OT9HFRYK	Limited	Biomarker	[285]
ING1	OTEZBRKW	Limited	Altered Expression	[1093]
INO80	OTJBMS8T	Limited	Altered Expression	[1094]
INPP4B	OTLROA7G	Limited	Biomarker	[1095]
IQGAP1	OTZRWTGA	Limited	Biomarker	[1096]
IRF2	OTAZRUW3	Limited	Biomarker	[1097]
IRF6	OTKJ44EV	Limited	Altered Expression	[1098]
IRF7	OTC1A2PQ	Limited	Altered Expression	[1099]
IRF9	OTK4MYQJ	Limited	Altered Expression	[1099]
IRS4	OTTOL40K	Limited	Biomarker	[1100]
ITGA10	OTM0V5AO	Limited	Genetic Variation	[315]
ITGA9	OTHN1IKA	Limited	Altered Expression	[1101]
JUNB	OTG2JXV5	Limited	Altered Expression	[1064]
JUND	OTNKACJD	Limited	Altered Expression	[1064]
KARS1	OT0EU4SV	Limited	Biomarker	[944]
KDM6A	OTZM3MJJ	Limited	Genetic Variation	[320]
KHSRP	OTDHZARB	Limited	Biomarker	[1102]
LAMTOR2	OTHEDISB	Limited	Biomarker	[1005]
LARP6	OTUQ9QS9	Limited	Biomarker	[1103]
LIMD2	OTSIFTD8	Limited	Biomarker	[1104]
LMO1	OTB59SKB	Limited	Genetic Variation	[1105]
LOXL3	OTLLY1QI	Limited	Biomarker	[1106]
LRBA	OTOUZN9G	Limited	Biomarker	[1107]
LRIG1	OTY5HZN5	Limited	Biomarker	[1108]
LRPPRC	OTXSK5LP	Limited	Biomarker	[368]
LSAMP	OTYXVQX2	Limited	Biomarker	[1109]
LVRN	OTHBF42S	Limited	Biomarker	[193]
LXN	OTZQ2M6Y	Limited	Altered Expression	[269]
LYPLA1	OTENU47T	Limited	Biomarker	[1110]
MACC1	OTV3DLX0	Limited	Altered Expression	[1111]
MAGI1	OTMV4ASV	Limited	Genetic Variation	[1112]
MAGT1	OTQSAV5C	Limited	Biomarker	[189]
MAP1LC3B	OTUYHB84	Limited	Altered Expression	[748]
MAP2	OT6UYT3X	Limited	Altered Expression	[1113]
MAP3K12	OT5HODDD	Limited	Biomarker	[1114]
MAP3K13	OTS93BTX	Limited	Biomarker	[1114]
MAPK6	OTDDNF3Q	Limited	Altered Expression	[1115]
MAPK8IP2	OTDUHLN0	Limited	Biomarker	[1116]
MAVS	OTTQ0J64	Limited	Altered Expression	[313]
MB	OTYWYL2D	Limited	Biomarker	[1117]
MCAT	OTH07FIW	Limited	Biomarker	[231]
MCTS1	OT7SAOJP	Limited	Biomarker	[231]
MED19	OTT9RT5N	Limited	Altered Expression	[1118]
MED27	OT40PZ9R	Limited	Biomarker	[1119]
MEN1	OTN6U6V0	Limited	Biomarker	[1120]
MIA3	OTBVIZQD	Limited	Altered Expression	[1121]
MIB2	OTJCC3HS	Limited	Biomarker	[1122]
MINDY4	OTBZ2SZB	Limited	Biomarker	[192]
MMRN1	OT7ZNYHT	Limited	Genetic Variation	[1123]
MPC2	OT0GHXGG	Limited	Biomarker	[1124]
MPEG1	OT7DAO0F	Limited	Biomarker	[301]
MPPE1	OTINBJVE	Limited	Biomarker	[1125]
MRPL41	OTG5URO4	Limited	Biomarker	[402]
MRTFA	OTCVXASM	Limited	Altered Expression	[1126]
MSN	OTZJ4J6G	Limited	Biomarker	[1127]
MSX1	OT5U41ZP	Limited	Biomarker	[1128]
MUC13	OTWKS9MF	Limited	Biomarker	[1129]
MUL1	OT2JC9YR	Limited	Biomarker	[993]
MXD1	OTS5CTHX	Limited	Biomarker	[387]
MYH10	OTXN2WXS	Limited	Biomarker	[1130]
MYO10	OTHB78ZQ	Limited	Biomarker	[1130]
MYO5A	OTMWLP3E	Limited	Biomarker	[1131]
MYOF	OTRFC3IJ	Limited	Altered Expression	[1132]
MYSM1	OTO73N00	Limited	Biomarker	[1133]
NAV2	OTGAOL01	Limited	Posttranslational Modification	[1134]
NEO1	OTGJ1997	Limited	Altered Expression	[1135]
NFAT5	OTKIE59S	Limited	Biomarker	[1136]
NGLY1	OTZBQD5Q	Limited	Biomarker	[1137]
NHS	OTKE8QAT	Limited	Genetic Variation	[1138]
NLRC4	OTAIA3NA	Limited	Genetic Variation	[1139]
NME2	OTCYGLHV	Limited	Altered Expression	[1140]
NOLC1	OTKDZU0D	Limited	Genetic Variation	[1141]
NOX5	OTHTH59G	Limited	Altered Expression	[1142]
NPAS2	OTMRT2TS	Limited	Genetic Variation	[942]
NPNT	OTFZAO1G	Limited	Altered Expression	[1143]
NR2C2	OTDZWVOJ	Limited	Biomarker	[341]
NRCAM	OT80HHQ2	Limited	Biomarker	[1144]
NRF1	OTOXWNV8	Limited	Altered Expression	[1145]
NT5DC1	OTNI9MFH	Limited	Biomarker	[285]
NTN4	OTDRRMP3	Limited	Biomarker	[1074]
NUCB2	OTHO6JWN	Limited	Biomarker	[893]
NUDT1	OTZSES3W	Limited	Altered Expression	[817]
NUMB	OTMB586Q	Limited	Biomarker	[889]
NUP62	OTMN63DH	Limited	Biomarker	[323]
NUTM1	OTONYC08	Limited	Biomarker	[1146]
NXF1	OTEFHXG6	Limited	Biomarker	[711]
OCM	OTQRML29	Limited	Biomarker	[1147]
OLIG2	OTMCN6D3	Limited	Altered Expression	[1148]
OPN1LW	OTFNUZ7O	Limited	Biomarker	[1149]
OPRPN	OT6K1ZD6	Limited	Genetic Variation	[1150]
PAG1	OTFOJUIQ	Limited	Biomarker	[1149]
PANX1	OTXPEDOK	Limited	Altered Expression	[1151]
PARD3	OTH5BPLO	Limited	Biomarker	[261]
PCBP4	OTDLL4NB	Limited	Biomarker	[1149]
PCGF2	OTIY1J5L	Limited	Biomarker	[858]
PCK2	OTJ8LX4N	Limited	Altered Expression	[1152]
PDCD4	OTZ6NXUX	Limited	Biomarker	[785]
PDHB	OT2NHE5E	Limited	Biomarker	[1153]
PDPN	OTBUV19I	Limited	Biomarker	[1154]
PEG10	OTWD2278	Limited	Altered Expression	[1155]
PHIP	OTZY806Z	Limited	Biomarker	[1156]
PHLPP1	OTIFXW8D	Limited	Altered Expression	[1157]
PINK1	OT50NR57	Limited	Biomarker	[1158]
PITX1	OTA0UN4C	Limited	Altered Expression	[1159]
PLAG1	OTT9AJQY	Limited	Altered Expression	[324]
PLEC	OTU4XDEG	Limited	Biomarker	[1160]
PLIN2	OTRXJ9UN	Limited	Biomarker	[1161]
PLP1	OT8CM9CX	Limited	Biomarker	[375]
PLXNB1	OTCA7JIT	Limited	Biomarker	[414]
PMAIP1	OTXEE550	Limited	Genetic Variation	[1162]
PNPT1	OTBR2Q0F	Limited	Biomarker	[1163]
POLD1	OTWO4UCJ	Limited	Altered Expression	[227]
PPA1	OTHZK1QB	Limited	Biomarker	[1164]
PPARGC1A	OTHCDQ22	Limited	Biomarker	[1165]
PPIP5K1	OT06HYH8	Limited	Altered Expression	[313]
PPP1R14A	OTQODWZB	Limited	Biomarker	[1166]
PPP1R14B	OT9PTWAX	Limited	Biomarker	[285]
PPP1R1A	OTGTAGCV	Limited	Biomarker	[1167]
PPP2R3B	OT5Y53WZ	Limited	Biomarker	[1003]
PRDM16	OT0BGA27	Limited	Biomarker	[1168]
PRDX6	OTS8KC8A	Limited	Genetic Variation	[914]
PREX1	OTUTPVA9	Limited	Biomarker	[1169]
PRIMA1	OT9ITT3P	Limited	Genetic Variation	[1162]
PROS1	OTXQWNOI	Limited	Altered Expression	[324]
PSMD2	OT6HZHN7	Limited	Biomarker	[444]
PSME3	OTSTC4YY	Limited	Biomarker	[1170]
PTX3	OTPXHRKU	Limited	Biomarker	[1171]
PVR	OT3N91T7	Limited	Biomarker	[1172]
PXDN	OTFGGM9R	Limited	Biomarker	[1074]
PXN	OTVMMUOF	Limited	Altered Expression	[986]
PYCR2	OTS2HLGD	Limited	Biomarker	[1173]
RAB38	OTU0NZU0	Limited	Biomarker	[1174]
RAB3GAP1	OT4DQ8F2	Limited	Genetic Variation	[1141]
RAB5A	OTFR2KM4	Limited	Biomarker	[1175]
RAB7B	OT60A0E9	Limited	Biomarker	[395]
RABGEF1	OTWC3Z3R	Limited	Altered Expression	[587]
RAD51AP1	OTXM7UTD	Limited	Biomarker	[1176]
RANBP3	OTI8ESC3	Limited	Altered Expression	[1177]
RAP1A	OT5RH6TI	Limited	Altered Expression	[587]
RAP1GAP	OTC31ONQ	Limited	Altered Expression	[1178]
RARRES2	OT1BJE8K	Limited	Biomarker	[1179]
RASGRP3	OTEMEV3P	Limited	Biomarker	[1180]
RASSF10	OTGB7EBG	Limited	Biomarker	[1181]
RASSF2	OT2JHDO4	Limited	Altered Expression	[1181]
RBL2	OTBQSOE6	Limited	Genetic Variation	[1141]
REG1A	OTMHUH1D	Limited	Altered Expression	[1182]
RFX6	OT8H77DL	Limited	Biomarker	[285]
RGS5	OTUY0Q2I	Limited	Biomarker	[1183]
RHCE	OTS18IZ5	Limited	Genetic Variation	[1184]
RING1	OTCWTAX0	Limited	Biomarker	[1185]
RIPK3	OTL1D484	Limited	Biomarker	[1114]
RMC1	OT7K8MTJ	Limited	Biomarker	[1186]
RNF123	OTL59S8J	Limited	Altered Expression	[1187]
RNF44	OTGWL4U4	Limited	Altered Expression	[1188]
RPL17	OTTYMPS6	Limited	Biomarker	[485]
RPL22	OTVCN8K0	Limited	Biomarker	[254]
RPL36A	OT1LYV85	Limited	Altered Expression	[1014]
RPL5	OTM8EBRI	Limited	Genetic Variation	[1189]
RPP14	OT4OYFSK	Limited	Biomarker	[1005]
RPS19	OTBKGP48	Limited	Genetic Variation	[1190]
RPS27	OTFXKY7P	Limited	Biomarker	[301]
RPS6	OTT4D1LN	Limited	Genetic Variation	[1191]
RRAS	OTBBF28C	Limited	Altered Expression	[1192]
SARDH	OTQ49Q27	Limited	Biomarker	[1193]
SCIN	OT6U09OL	Limited	Biomarker	[1194]
SEC14L2	OTJST64D	Limited	Biomarker	[1195]
SEC16A	OTFNQ1ZU	Limited	Biomarker	[1196]
SEC23A	OTBRNIJ3	Limited	Biomarker	[1197]
SEM1	OTASLBM1	Limited	Altered Expression	[1198]
SEMA5A	OTUOIOJV	Limited	Altered Expression	[1199]
SERPINB4	OT88LHZ8	Limited	Genetic Variation	[415]
SF3B6	OTPRKS6S	Limited	Biomarker	[1005]
SFN	OTLJCZ1U	Limited	Biomarker	[1200]
SFPQ	OTLCIAPJ	Limited	Genetic Variation	[1201]
SFRP2	OT8GZ0CA	Limited	Biomarker	[1202]
SH3PXD2A	OTYRQJIH	Limited	Altered Expression	[1203]
SHARPIN	OTU1J2KH	Limited	Biomarker	[587]
SIAH2	OTKED2XN	Limited	Altered Expression	[1204]
SIGLEC1	OTNWSQA9	Limited	Biomarker	[1205]
SIGLEC7	OTNDLURR	Limited	Biomarker	[307]
SIX1	OT70YYWM	Limited	Altered Expression	[1206]
SKIL	OTNBXH32	Limited	Altered Expression	[1207]
SLC25A45	OTP7EAUM	Limited	Biomarker	[285]
SLC2A4RG	OTW3LX8D	Limited	Altered Expression	[1208]
SLITRK1	OT1QQ7FR	Limited	Biomarker	[1209]
SLN	OTERIU75	Limited	Biomarker	[1210]
SLURP1	OT89YD2E	Limited	Biomarker	[1211]
SMARCA2	OTSGJ8SV	Limited	Altered Expression	[1212]
SMARCB1	OT2LP7LJ	Limited	Altered Expression	[1213]
SMIM10L2B	OT04IG2N	Limited	Biomarker	[932]
SMR3B	OTL5HNM8	Limited	Biomarker	[394]
SMS	OT8JYKNH	Limited	Biomarker	[1214]
SNAI3	OTG9DI66	Limited	Altered Expression	[1215]
SOCS2	OTBPNKJQ	Limited	Altered Expression	[1216]
SPATA2	OTOA45GL	Limited	Biomarker	[485]
SPEN	OT37A2MD	Limited	Altered Expression	[1217]
SPIN1	OT69VAOX	Limited	Biomarker	[1218]
SPRED1	OTKX7P8G	Limited	Biomarker	[1219]
SRA1	OTYOGMTG	Limited	Biomarker	[1220]
SRL	OT7IEBWZ	Limited	Biomarker	[1193]
SS18L1	OT9ZEGV7	Limited	Biomarker	[1221]
SSR2	OTQJSL7M	Limited	Biomarker	[1222]
STAG3	OTEV0AOD	Limited	Biomarker	[1223]
STAP2	OTEB1VVI	Limited	Biomarker	[1224]
STK11	OT1YZSP3	Limited	Biomarker	[1225]
STK19	OTYM6437	Limited	Biomarker	[1226]
STK3	OTLNSCQD	Limited	Biomarker	[1227]
SULF1	OTJCNCO0	Limited	Altered Expression	[1228]
TAC4	OTYWPPM3	Limited	Biomarker	[504]
TAT	OT2CJ91O	Limited	Biomarker	[1229]
TBC1D16	OTPR3C6A	Limited	Biomarker	[1230]
TBC1D9	OTSSCTB5	Limited	Altered Expression	[1231]
TBPL1	OT4I143E	Limited	Biomarker	[1232]
TCHP	OTVDMHSY	Limited	Biomarker	[1233]
TEAD1	OTK6971C	Limited	Genetic Variation	[1234]
TEAD4	OTJS0T2B	Limited	Genetic Variation	[1234]
TFCP2	OTA246TE	Limited	Biomarker	[1235]
TFE3	OTM99ZWH	Limited	Altered Expression	[1236]
TFEB	OTJUJJQY	Limited	Altered Expression	[1236]
TFF3	OTJJDRTU	Limited	Biomarker	[425]
TFG	OT2KJENI	Limited	Genetic Variation	[1237]
TGFBI	OTR443C5	Limited	Altered Expression	[1238]
TIMELESS	OTD8DCBJ	Limited	Biomarker	[975]
TIMP2	OT8S1RRP	Limited	Biomarker	[1239]
TMEM178B	OTTQWHVU	Limited	Biomarker	[1033]
TMEM31	OTKDPZD4	Limited	Biomarker	[1240]
TMEM45B	OTVQCO8N	Limited	Altered Expression	[1241]
TNFAIP8	OT1G9297	Limited	Altered Expression	[1242]
TNFSF9	OTV9L89D	Limited	Altered Expression	[1243]
TP53I3	OTSCM68G	Limited	Biomarker	[402]
TP53INP2	OT0GTBXO	Limited	Altered Expression	[1244]
TPI1	OT14KP4B	Limited	Biomarker	[975]
TRIB3	OTG5OS7X	Limited	Altered Expression	[1245]
TRIM16	OTLRXYOZ	Limited	Biomarker	[1246]
TRIP13	OTFM3TI9	Limited	Biomarker	[964]
TSC22D3	OT03UM03	Limited	Biomarker	[1247]
TSPYL4	OTHCX9RH	Limited	Biomarker	[285]
AP2A1	OTEFZB21	Disputed	Biomarker	[1248]
APIP	OT8ZABOU	Disputed	Biomarker	[450]
ARHGEF2	OTBQTFRT	Disputed	Altered Expression	[1208]
B3GAT1	OTXFP98E	Disputed	Altered Expression	[504]
BCL2L11	OTNQQWFJ	Disputed	Biomarker	[1249]
BLM	OTEJOAJX	Disputed	Altered Expression	[1250]
CCDC88C	OTIU02BS	Disputed	Biomarker	[1251]
CCL18	OT7JYSK9	Disputed	Posttranslational Modification	[1252]
CDC42	OT5QBC5M	Disputed	Genetic Variation	[1253]
CDH13	OTD2CYM5	Disputed	Biomarker	[1254]
CEP85L	OTSHJFOT	Disputed	Biomarker	[450]
CLOCK	OTNEOJY7	Disputed	Genetic Variation	[942]
CLTC	OTBFASMA	Disputed	Biomarker	[450]
CMAS	OTFQJG3C	Disputed	Biomarker	[1255]
CRISP2	OT8HLTV5	Disputed	Biomarker	[1256]
CRYBA1	OT8617WJ	Disputed	Genetic Variation	[789]
DNLZ	OT48CG1W	Disputed	Biomarker	[1257]
FOXD1	OT80PRHS	Disputed	Altered Expression	[1258]
GADD45A	OTDRV63V	Disputed	Altered Expression	[1259]
GCNT2	OTRUIMC4	Disputed	Altered Expression	[1260]
GPX4	OTRAFFX2	Disputed	Biomarker	[639]
HOXA1	OTMSOJ7D	Disputed	Altered Expression	[1261]
IFI27	OTI2XGIT	Disputed	Biomarker	[1262]
IGFBP4	OT2HZRBD	Disputed	Altered Expression	[1263]
ING4	OT0VVG4V	Disputed	Biomarker	[1264]
ISG20	OTCWRJJW	Disputed	Biomarker	[1265]
KMT2B	OTMMAZQX	Disputed	Biomarker	[493]
LEF1	OTWS5I5H	Disputed	Biomarker	[1266]
LOXL4	OT6XY2JL	Disputed	Biomarker	[731]
LUM	OTSRC874	Disputed	Altered Expression	[1267]
MOK	OTQK7M9V	Disputed	Biomarker	[584]
MPG	OTAHW80B	Disputed	Biomarker	[1268]
NOP14	OTKPM0Z5	Disputed	Biomarker	[1269]
OSR1	OTB19LEQ	Disputed	Biomarker	[1270]
PEX3	OTGZ7ME2	Disputed	Altered Expression	[1271]
PFKFB4	OTQYEXL2	Disputed	Altered Expression	[417]
PIK3R3	OTXGJ8N1	Disputed	Biomarker	[1272]
PPP1R13L	OTNCPLWE	Disputed	Altered Expression	[1149]
PRKAA2	OTU1KZPV	Disputed	Biomarker	[1273]
PRKAB1	OT1OG4QZ	Disputed	Biomarker	[1273]
PRSS55	OTXXWI5Y	Disputed	Biomarker	[1256]
PSMD9	OT6Y5CC3	Disputed	Biomarker	[1262]
PTPA	OTRGFOI7	Disputed	Altered Expression	[1274]
PTPRD	OTZPJ3GX	Disputed	Biomarker	[1275]
PYCR1	OTQHB52T	Disputed	Altered Expression	[1276]
RAB27A	OT9SQRWY	Disputed	Biomarker	[1277]
RBM3	OTAJ7R31	Disputed	Altered Expression	[1278]
RBX1	OTYA1UIO	Disputed	Altered Expression	[993]
ROBO3	OTPVG40S	Disputed	Biomarker	[461]
RPE	OT0XT3JU	Disputed	Genetic Variation	[789]
SART3	OTC1AM7S	Disputed	Altered Expression	[1279]
SFRP5	OTLCVVSH	Disputed	Altered Expression	[1280]
SGK3	OTQ6QO99	Disputed	Biomarker	[1281]
SLAMF9	OTH1OGZW	Disputed	Altered Expression	[1282]
SLC12A9	OTR7VRAK	Disputed	Altered Expression	[1283]
SMCP	OTXKY794	Disputed	Biomarker	[639]
SOX4	OTSS40SS	Disputed	Altered Expression	[1284]
SPRY4	OT2VK9N0	Disputed	Biomarker	[703]
SPZ1	OTQH8HJ5	Disputed	Biomarker	[1256]
STAMBP	OTOT2OXM	Disputed	Altered Expression	[1285]
SYNE2	OTBUXGQ0	Disputed	Biomarker	[892]
TAP2	OTWSYFI7	Disputed	Biomarker	[1286]
TBX2	OTTOT7A9	Disputed	Biomarker	[1287]
TFAM	OTXXV5V7	Disputed	Biomarker	[1288]
TICAM2	OTK7GIJ5	Disputed	Biomarker	[1262]
TIMP3	OTDGQAD1	Disputed	Altered Expression	[1289]
TMED7	OTONO8E6	Disputed	Biomarker	[1262]
TNFRSF10C	OTVHOL9B	Disputed	Altered Expression	[1290]
TNFRSF10D	OTOSRDJT	Disputed	Posttranslational Modification	[1291]
A2M	OTFTX90K	moderate	Biomarker	[1292]
AANAT	OTUBJ7SX	moderate	Biomarker	[1293]
AATK	OTVHAX5N	moderate	Altered Expression	[1294]
ABI2	OT8GIIS5	moderate	Genetic Variation	[1295]
ACTRT1	OTHFKSIZ	moderate	Genetic Variation	[1295]
ADAM12	OTZKOTDB	moderate	Genetic Variation	[1296]
AEBP1	OTBI1RZ6	moderate	Altered Expression	[1297]
AGO2	OT4JY32Q	moderate	Altered Expression	[1298]
AIMP1	OTTA5C3U	moderate	Altered Expression	[1299]
AIRE	OTA7G1Y1	moderate	Genetic Variation	[1300]
ALDH18A1	OT6W40XU	moderate	Biomarker	[1301]
ANKK1	OT0OM1O0	moderate	Genetic Variation	[1302]
ANTXR1	OT5W1GPC	moderate	Biomarker	[1303]
APOBEC3B	OTHLNI51	moderate	Biomarker	[1304]
ARL6IP1	OT536XAV	moderate	Genetic Variation	[1295]
ASXL2	OTNG4E2M	moderate	Biomarker	[1305]
ASXL3	OTNDJWEZ	moderate	Biomarker	[1305]
ATF6	OTAFHAVI	moderate	Biomarker	[1306]
ATP2C1	OTQN51T3	moderate	Genetic Variation	[1307]
AXIN1	OTRGZGZ5	moderate	Genetic Variation	[1308]
BAG4	OTUPX3M2	moderate	Altered Expression	[1309]
BCAP31	OTKSACR4	moderate	Biomarker	[1310]
BCL3	OT1M5B95	moderate	Biomarker	[1311]
CACYBP	OTJMZD2T	moderate	Biomarker	[1312]
CAMLG	OTTSRY39	moderate	Altered Expression	[1313]
CAPN3	OTCHG3YK	moderate	Altered Expression	[1314]
CCDC6	OTXRQDYG	moderate	Genetic Variation	[518]
CCL8	OTCTWYN8	moderate	Altered Expression	[1315]
CCN3	OTOW5YL4	moderate	Biomarker	[1316]
CCNC	OTMVK4K4	moderate	Biomarker	[1317]
CD226	OT4UG0KB	moderate	Biomarker	[1318]
CD81	OTQFXNAZ	moderate	Biomarker	[1089]
CDH7	OTQEXCKU	moderate	Altered Expression	[1319]
CDK11A	OTN5TSGQ	moderate	Biomarker	[1320]
CDKN3	OTBE3H07	moderate	Genetic Variation	[1321]
CIC	OTFXCHNZ	moderate	Altered Expression	[1322]
CKAP4	OTDUC9ME	moderate	Altered Expression	[1323]
CLNS1A	OT1HL9L1	moderate	Biomarker	[285]
CLPTM1	OT14QP7N	moderate	Genetic Variation	[1324]
CLPTM1L	OTDJWQXI	moderate	Genetic Variation	[1325]
CNKSR3	OTXP4QH8	moderate	Biomarker	[1326]
CNN1	OTVPG39Z	moderate	Biomarker	[451]
CNOT9	OT1NIIQD	moderate	Genetic Variation	[1327]
CNTNAP5	OTF0AAJD	moderate	Biomarker	[494]
CNTRL	OTQI3VBA	moderate	Biomarker	[1328]
COL4A1	OTL6D1YE	moderate	Biomarker	[1329]
COL9A3	OTCUJOEK	moderate	Altered Expression	[1330]
COX5A	OTP0961M	moderate	Biomarker	[1331]
CP	OTM8JE4Y	moderate	Biomarker	[1332]
CPOX	OTIAY121	moderate	Biomarker	[1331]
CREM	OTJIJ5AL	moderate	Altered Expression	[1333]
CSMD2	OT541Z3W	moderate	Biomarker	[494]
CTC1	OTRJY7QD	moderate	Biomarker	[1334]
CTNNAL1	OTESJ6JD	moderate	Altered Expression	[1335]
CTTN	OTJRG4ES	moderate	Biomarker	[1336]
DAB2IP	OTF456VC	moderate	Genetic Variation	[1295]
DAXX	OTX6O7PL	moderate	Genetic Variation	[1337]
DBF4	OTBL7JHQ	moderate	Biomarker	[1338]
DDB2	OTO8HVVB	moderate	Biomarker	[1029]
DDX43	OTK1RYSK	moderate	Biomarker	[1339]
DGUOK	OT78HUZB	moderate	Altered Expression	[1340]
DIDO1	OT9PB547	moderate	Altered Expression	[1341]
DNALI1	OTTB3L8N	moderate	Altered Expression	[527]
DOCK3	OTF3YS2W	moderate	Biomarker	[1342]
DRG1	OTIFYMI3	moderate	Biomarker	[1343]
DUSP14	OTGODFCR	moderate	Genetic Variation	[1344]
ECM1	OT1K65VW	moderate	Altered Expression	[1345]
EHD1	OTDMEKLV	moderate	Genetic Variation	[1346]
EIF4A1	OTMTBX6N	moderate	Biomarker	[1347]
ERCC3	OTVAW3P1	moderate	Altered Expression	[226]
ESCO1	OTZ9P12A	moderate	Biomarker	[1348]
FBLN1	OT5MHHOP	moderate	Posttranslational Modification	[1349]
FBRSL1	OT4BPXGG	moderate	Genetic Variation	[1350]
FGF3	OT9PK2SI	moderate	Biomarker	[1351]
GAGE1	OT53E50E	moderate	Biomarker	[1352]
GAGE4	OTPB5C0O	moderate	Biomarker	[1352]
GAGE5	OTFI6OVS	moderate	Biomarker	[1352]
GHRH	OT94U6MO	moderate	Biomarker	[524]
GIPC2	OT68YFO1	moderate	Genetic Variation	[1353]
GIT1	OTHO92S5	moderate	Biomarker	[1354]
GNA13	OTVDL515	moderate	Altered Expression	[1355]
GNMT	OT0O2OQO	moderate	Biomarker	[1356]
GOSR1	OTX8TMVU	moderate	Altered Expression	[527]
GPAT2	OTZ8VP2Y	moderate	Altered Expression	[1357]
H2AX	OT18UX57	moderate	Altered Expression	[514]
HAS2	OTTD3PAL	moderate	Biomarker	[1358]
HAS3	OTPM8IL8	moderate	Altered Expression	[1359]
HLA-E	OTX1CTFB	moderate	Altered Expression	[1360]
HMGCL	OTRO9RII	moderate	Genetic Variation	[1361]
HOXB7	OTC7WYU8	moderate	Biomarker	[1362]
HS3ST5	OTOB6Z3F	moderate	Biomarker	[285]
IFIT2	OTI4EOAR	moderate	Altered Expression	[534]
IGF2BP3	OTB97VIK	moderate	Altered Expression	[719]
IL20RA	OTSIVBVS	moderate	Altered Expression	[1363]
IL20RB	OTHFXK95	moderate	Biomarker	[1363]
IL9R	OTILCLXA	moderate	Biomarker	[1364]
ILKAP	OT2A6FSA	moderate	Biomarker	[1365]
ING2	OT6H0EWF	moderate	Altered Expression	[1366]
INPP5E	OTJF2AZ9	moderate	Altered Expression	[533]
INPP5K	OTQFLQKA	moderate	Biomarker	[1367]
INTS2	OT2N5TCK	moderate	Biomarker	[1351]
KANK2	OT3SZIWM	moderate	Biomarker	[1312]
KAT5	OTL7257A	moderate	Biomarker	[1368]
KDM4B	OT5P1UPY	moderate	Biomarker	[536]
KIF23	OTY850JC	moderate	Biomarker	[1369]
KIF5B	OTT34MT8	moderate	Biomarker	[1370]
KIR3DL1	OTPOSXFX	moderate	Genetic Variation	[468]
KLHL1	OTAX6SAD	moderate	Altered Expression	[495]
LGALS7	OTMSVI7R	moderate	Altered Expression	[1371]
LLGL1	OTAIQSXZ	moderate	Biomarker	[1372]
LMLN	OTQF0JPY	moderate	Biomarker	[544]
LRAT	OTB7CJKY	moderate	Altered Expression	[1373]
MAGEB2	OTAGUVU5	moderate	Biomarker	[1300]
MAGED1	OT6EOLFC	moderate	Altered Expression	[1374]
MAGED2	OTMEWNSE	moderate	Biomarker	[1375]
MAGEH1	OTVE05K7	moderate	Biomarker	[307]
MAGI2	OTXDDKZS	moderate	Genetic Variation	[1295]
MAML1	OTQA4DDN	moderate	Altered Expression	[1376]
MAML2	OT1TSVAR	moderate	Biomarker	[1377]
MARK1	OTP7KL47	moderate	Biomarker	[1378]
MCM2	OTGGORIQ	moderate	Biomarker	[1379]
MGAT5	OTU4DD4G	moderate	Altered Expression	[1380]
MICAL1	OTJEDVWA	moderate	Altered Expression	[1381]
MICU1	OTS7N0LE	moderate	Biomarker	[1382]
MLKL	OTDSLC81	moderate	Biomarker	[1383]
MNT	OTPC4ANL	moderate	Biomarker	[1384]
MPST	OTCDPH5D	moderate	Biomarker	[501]
MSH3	OTD3YPVL	moderate	Altered Expression	[181]
MST1	OTOC4UNG	moderate	Biomarker	[544]
MTSS1	OT5DTDO2	moderate	Biomarker	[1385]
MX2	OT05NF37	moderate	Genetic Variation	[1386]
MYH6	OT3YNCH1	moderate	Biomarker	[1387]
MYO6	OTJQYRC7	moderate	Biomarker	[1387]
NCOA1	OTLIUJQD	moderate	Altered Expression	[1388]
NCR3LG1	OT15YWU7	moderate	Altered Expression	[1389]
NDN	OTYBYJ82	moderate	Biomarker	[1390]
NDUFS6	OT9IOONQ	moderate	Altered Expression	[1391]
NEDD4L	OT1B19RU	moderate	Biomarker	[1392]
NEU1	OTH9BY8Y	moderate	Biomarker	[1393]
NEURL1	OT2C4P70	moderate	Biomarker	[1393]
NFATC1	OT4TMERS	moderate	Biomarker	[1394]
NFKBIE	OTLAYEL9	moderate	Biomarker	[1395]
NPPA	OTMQNTNX	moderate	Therapeutic	[1396]
NRDE2	OTJ1V33O	moderate	Biomarker	[494]
NSMAF	OTYNVZ23	moderate	Biomarker	[1328]
NUS1	OT4DQ82L	moderate	Biomarker	[285]
ODAM	OTT666SJ	moderate	Biomarker	[1397]
PAPPA	OTTTG9PG	moderate	Biomarker	[1398]
PBX1	OTORABGO	moderate	Biomarker	[1399]
PBX2	OTEBYCAW	moderate	Biomarker	[1400]
PDCD6IP	OTS8T6A7	moderate	Genetic Variation	[1295]
PDIK1L	OTISF4KG	moderate	Biomarker	[1401]
PHF19	OTF6RUCR	moderate	Biomarker	[1402]
PHLDA1	OTFTWMIQ	moderate	Biomarker	[1403]
PIAS4	OTB7SVMZ	moderate	Altered Expression	[1404]
PIK3C3	OTLUM9L7	moderate	Biomarker	[1405]
PLAA	OTZ7NJGA	moderate	Genetic Variation	[1406]
PLEK	OTB73XXA	moderate	Posttranslational Modification	[1407]
PLEKHM2	OT4ZYV73	moderate	Biomarker	[1367]
PLXND1	OTNK9ALK	moderate	Altered Expression	[1408]
PNPLA2	OTR3ERMR	moderate	Biomarker	[813]
POLE	OTFM3MMU	moderate	Genetic Variation	[1409]
POLN	OTMHB3H8	moderate	Genetic Variation	[560]
POTEF	OTV3WXYE	moderate	Biomarker	[1410]
POU4F1	OTMHYGWQ	moderate	Altered Expression	[1220]
PPP1R3B	OTVCRXEZ	moderate	Biomarker	[1411]
PTPRF	OTH5KF2D	moderate	Altered Expression	[936]
PTPRU	OTHDO0QG	moderate	Altered Expression	[936]
RAB40B	OTCA9ZF5	moderate	Posttranslational Modification	[562]
RACGAP1	OTQE8IEH	moderate	Biomarker	[1412]
RAD51B	OTCJVRMY	moderate	Biomarker	[1413]
RASEF	OTGSAM2E	moderate	Altered Expression	[1414]
RASSF6	OT25GVWY	moderate	Biomarker	[1415]
RASSF8	OTXKGIB3	moderate	Biomarker	[1416]
RB1	OTQJUJMZ	Moderate	Autosomal dominant	[1417]
RBM14	OTO9GMBD	moderate	Biomarker	[1312]
RESF1	OTQIZIJF	moderate	Biomarker	[1418]
REST	OTLL92LQ	moderate	Biomarker	[1419]
RIT1	OTVNOGOH	moderate	Altered Expression	[1420]
RMDN1	OTE1NB6U	moderate	Biomarker	[1421]
RMDN3	OTKO7AUM	moderate	Biomarker	[1421]
RND3	OTXMXPIH	moderate	Biomarker	[1422]
RNF125	OTBD1Q3X	moderate	Altered Expression	[1423]
RNH1	OT6EC79B	moderate	Biomarker	[1424]
ROPN1B	OTPH2XLW	moderate	Altered Expression	[1330]
RRM2B	OTE8GBUR	moderate	Biomarker	[1425]
RYBP	OTZZ4P2Z	moderate	Biomarker	[1426]
S100A13	OT582SUS	moderate	Altered Expression	[1427]
S100A2	OTTGHJ1H	moderate	Biomarker	[1428]
SAGE1	OT4H6FFA	moderate	Biomarker	[1429]
SAT2	OT28QL7H	moderate	Altered Expression	[1430]
SBF1	OTW6I9RV	moderate	Biomarker	[1431]
SCG2	OTXWUQQL	moderate	Biomarker	[1432]
SEPTIN4	OTD16B30	moderate	Biomarker	[1433]
SET	OTGYYQJO	moderate	Altered Expression	[1274]
SHOC2	OTUNQ2CT	moderate	Biomarker	[1434]
SLC16A4	OT1YXBKC	moderate	Altered Expression	[566]
SNRPD1	OTWKZV4E	moderate	Biomarker	[1435]
SNW1	OTKWG3PS	moderate	Biomarker	[1367]
SOS1	OTTCWXC3	moderate	Genetic Variation	[583]
SOX11	OT4LG7LA	moderate	Biomarker	[1436]
SPANXA1	OTMK3QIS	moderate	Biomarker	[1437]
SPANXB1	OTLMGC9T	moderate	Biomarker	[1437]
SPANXC	OT1033B9	moderate	Biomarker	[1437]
SPHKAP	OT5RHUYJ	moderate	Biomarker	[1367]
SPINT2	OTQV7BKQ	moderate	Biomarker	[529]
SSX1	OTZ7NRCY	moderate	Biomarker	[1438]
SSX4	OT0E4H2D	moderate	Biomarker	[337]
ST6GALNAC2	OT9PBQVT	moderate	Biomarker	[1439]
STIM1	OT8CLQ1W	moderate	Biomarker	[552]
STIM2	OTYNXAW0	moderate	Biomarker	[1440]
STING1	OTDAP4G0	moderate	Biomarker	[1441]
SUZ12	OT655XF8	moderate	Genetic Variation	[1442]
SYBU	OT3FQV7N	moderate	Biomarker	[1421]
SYCE1L	OTXU44F3	moderate	Altered Expression	[495]
SYN1	OTMNPWC1	moderate	Altered Expression	[1443]
SYNE1	OTSBSLUH	moderate	Genetic Variation	[1444]
TAS2R38	OTX5MM36	moderate	Genetic Variation	[518]
TBP	OT6C0S52	moderate	Biomarker	[1445]
TCEA1	OTBFO594	moderate	Biomarker	[1312]
TCL1B	OT4CSO39	moderate	Altered Expression	[1443]
TES	OTL8PP6V	moderate	Biomarker	[1446]
TFAP2C	OTUDIW05	moderate	Biomarker	[1345]
THY1	OTVONVTB	moderate	Altered Expression	[1447]
TMED5	OT70W1J8	moderate	Altered Expression	[527]
TMPRSS13	OTMAOAP3	moderate	Biomarker	[544]
TP53INP1	OT2363Z9	moderate	Biomarker	[1312]
TRIB2	OTHSX3MX	moderate	Biomarker	[1448]
TSACC	OT3QW6PH	moderate	Biomarker	[1312]
TTC4	OTAPMYXU	moderate	Genetic Variation	[1449]
ACD	OTC54EPO	Strong	Genetic Variation	[1450]
ACER3	OTIVQBG5	Strong	Biomarker	[285]
ACTB	OT1MCP2F	Strong	Altered Expression	[683]
ADAMTS18	OTRMFI04	Strong	Genetic Variation	[1451]
ADAMTS20	OTU0EKLN	Strong	Biomarker	[1452]
AFM	OTPOR8IO	Strong	Biomarker	[1453]
AGFG2	OTXQZHCR	Strong	Genetic Variation	[1454]
AHSA1	OTC7AFHT	Strong	Biomarker	[587]
AIFM1	OTKPWB7Q	Strong	Genetic Variation	[1455]
ALDH1A3	OT1C9NKQ	Strong	Altered Expression	[952]
ALDH3A1	OTAYZZE6	Strong	Altered Expression	[1456]
ALDH7A1	OTV57BZD	Strong	Altered Expression	[1457]
ALLC	OTZE4XV7	Strong	Biomarker	[1458]
ALX1	OTZVARA5	Strong	Biomarker	[1459]
AMBRA1	OTY0YGT9	Strong	Altered Expression	[1460]
AMFR	OTQRX7LC	Strong	Altered Expression	[1461]
AMPH	OTWPGWZX	Strong	Biomarker	[1462]
ANGPTL1	OTXIN6V5	Strong	Biomarker	[1463]
ANGPTL2	OTB6JG41	Strong	Biomarker	[1464]
ANXA6	OT9KIQ0Y	Strong	Altered Expression	[1465]
ANXA9	OTKNYMU2	Strong	Genetic Variation	[1466]
APBB1IP	OTN02KUV	Strong	Biomarker	[1467]
APLF	OTYUR3AH	Strong	Biomarker	[1468]
ARHGAP22	OTXUQEFL	Strong	Posttranslational Modification	[1134]
ARHGAP35	OTJ8POG0	Strong	Biomarker	[1469]
ARHGEF17	OTUGS4FL	Strong	Genetic Variation	[1470]
ARHGEF7	OT9BPJCL	Strong	Altered Expression	[1471]
ARL11	OTF6UDDB	Strong	Genetic Variation	[1472]
ARMC9	OT0MZER2	Strong	Biomarker	[1473]
ARNT	OTMSIEZY	Strong	Altered Expression	[1474]
ARPC1B	OTYE3DN2	Strong	Biomarker	[1475]
ARR3	OTRZ00CH	Strong	Biomarker	[767]
ARTN	OTWIWGL6	Strong	Biomarker	[585]
ASAP1	OT4DLRYY	Strong	Altered Expression	[1476]
ASCC1	OTH4VAP9	Strong	Altered Expression	[1471]
ASF1A	OT4S44GP	Strong	Genetic Variation	[1477]
ASS1	OT4ZMG0Q	Strong	Altered Expression	[1478]
ATG5	OT4T5SMS	Strong	Biomarker	[1479]
ATP6V0D2	OTMOZJO0	Strong	Altered Expression	[1480]
AXIN2	OTRMGQNU	Strong	Genetic Variation	[1481]
BANP	OT1JMTBD	Strong	Altered Expression	[1482]
BATF2	OT4XBZC9	Strong	Biomarker	[1483]
BCL10	OT47MCLI	Strong	Biomarker	[1484]
BIRC6	OTCQJAB0	Strong	Genetic Variation	[1485]
BOP1	OTMZMQDO	Strong	Altered Expression	[1486]
BRMS1	OTV5A6LL	Strong	Biomarker	[991]
BUB1B	OT8KME51	Strong	Biomarker	[1487]
BZW1	OT4GUFIG	Strong	Biomarker	[285]
C11orf68	OTOKOGZ6	Strong	Biomarker	[285]
C16orf96	OTE0B1QV	Strong	Biomarker	[1488]
CAMK2B	OTS9YK3E	Strong	Altered Expression	[1489]
CASC3	OTLK3K4U	Strong	Altered Expression	[683]
CAST	OTBXZZGF	Strong	Altered Expression	[1490]
CCDC63	OTKDRXAE	Strong	Biomarker	[823]
CCL16	OTOOQI1F	Strong	Biomarker	[1491]
CCL25	OTLWJ8CJ	Strong	Altered Expression	[1492]
CCNH	OTKDU3SR	Strong	Altered Expression	[226]
CD151	OTF3UZS7	Strong	Biomarker	[1493]
CD163L1	OTZHN1XQ	Strong	Biomarker	[738]
CD1D	OT3ROU4J	Strong	Biomarker	[1494]
CD3D	OTRBLP0R	Strong	Biomarker	[1495]
CDCA2	OTX8UF9J	Strong	Altered Expression	[1496]
CDCP1	OTD7RRWK	Strong	Biomarker	[1497]
CDK5RAP1	OTDEJXD0	Strong	Biomarker	[1498]
CDKN2D	OT2TTZPZ	Strong	Genetic Variation	[1499]
CEACAM7	OTKFDTZY	Strong	Biomarker	[228]
CENPS	OTZ4J391	Strong	Altered Expression	[1500]
CERS2	OTRAHYYP	Strong	Genetic Variation	[1466]
CETN1	OTGQ8JOZ	Strong	Biomarker	[1501]
CH25H	OT9S2BSW	Strong	Biomarker	[1502]
CHD5	OTS5EVHH	Strong	Genetic Variation	[1503]
CHI3L1	OT2Z7VJH	Strong	Altered Expression	[1504]
CHST10	OTEDU5YC	Strong	Biomarker	[1505]
CISD3	OT0MM1MW	Strong	Biomarker	[1506]
CISH	OT8T5NYL	Strong	Altered Expression	[534]
CLEC1B	OTO38TRG	Strong	Biomarker	[1154]
CLTA	OTLHOXMQ	Strong	Altered Expression	[683]
CMPK2	OTOG90R0	Strong	Genetic Variation	[953]
CNNM1	OTHRSSGH	Strong	Biomarker	[1507]
COL2A1	OT5E59C8	Strong	Biomarker	[1507]
COX2	OTTMVBJJ	Strong	Biomarker	[1508]
COX6C	OT3V7JE5	Strong	Genetic Variation	[1509]
CPQ	OTTNZNLD	Strong	Biomarker	[1510]
CPT1C	OT8F1MBF	Strong	Biomarker	[1507]
CRABP2	OTY01V9G	Strong	Altered Expression	[1511]
CRACD	OTII2U6L	Strong	Biomarker	[1512]
CRYBG1	OTIPDI15	Strong	Biomarker	[1513]
CSGALNACT1	OTBML9D9	Strong	Altered Expression	[819]
CST6	OTZVHJTF	Strong	Biomarker	[329]
CST8	OTT2FRCJ	Strong	Biomarker	[1514]
CSTA	OT1K68KE	Strong	Biomarker	[1515]
CTAG1B	OTIQGW6U	Strong	Altered Expression	[640]
CTAGE1	OTWM7KSJ	Strong	Genetic Variation	[1516]
CTNNBIP1	OTX9SBJG	Strong	Biomarker	[1517]
CUX1	OTU1LCNJ	Strong	Altered Expression	[1518]
CXADR	OT9ZP02A	Strong	Biomarker	[767]
CXCL6	OTFTCQ4O	Strong	Biomarker	[1519]
CYTB	OTAHB98A	Strong	Biomarker	[1520]
DBT	OT4KZ5R9	Strong	Altered Expression	[1521]
DCC	OT2C1SHW	Strong	Biomarker	[738]
DCTN6	OTI8PIN9	Strong	Biomarker	[1028]
DDAH2	OT8Q40G2	Strong	Biomarker	[1522]
DDIT4L	OT26Z2KN	Strong	Biomarker	[1507]
DDX41	OT6KEIHP	Strong	Altered Expression	[1523]
DENND2D	OTXEFJWM	Strong	Genetic Variation	[1470]
DEPDC1B	OTMVFOT1	Strong	Altered Expression	[1524]
DERA	OT8SMO3N	Strong	Biomarker	[1525]
DIAPH1	OTZBYPLH	Strong	Altered Expression	[1526]
DKC1	OTX7DJR6	Strong	Genetic Variation	[1514]
DLEC1	OTMKKBUW	Strong	Biomarker	[1527]
DNAH8	OTGES2OU	Strong	Altered Expression	[1528]
DNAJB6	OTMHIIAN	Strong	Biomarker	[1529]
DNAJC1	OTCKFOZ0	Strong	Biomarker	[285]
DNAJC15	OTNDUKAA	Strong	Biomarker	[530]
DNAJC2	OT3JDA0R	Strong	Biomarker	[1530]
DNASE1L3	OTEUIMC2	Strong	Biomarker	[1531]
DOCK10	OTI3MBLV	Strong	Altered Expression	[1532]
DPH3	OT59Q6C4	Strong	Biomarker	[1533]
DRAP1	OTRWLF6D	Strong	Biomarker	[285]
DRG2	OTFYAWE5	Strong	Altered Expression	[1534]
DSC1	OTNII6GZ	Strong	Biomarker	[1535]
DSG1	OT11HC3A	Strong	Biomarker	[1536]
DSP	OTB2MOP8	Strong	Altered Expression	[936]
DSTN	OTMXO4YB	Strong	Biomarker	[1537]
DUSP4	OT6WAO12	Strong	Biomarker	[1538]
ECHDC1	OTMS00PY	Strong	Biomarker	[285]
EDAR	OT3W2UQS	Strong	Biomarker	[1539]
EEF1A1	OT00THXS	Strong	Biomarker	[1540]
EEF1E1	OTRA6XOB	Strong	Biomarker	[597]
EFNA1	OTU2NUA2	Strong	Biomarker	[1541]
EGR3	OTGPJIRA	Strong	Biomarker	[1542]
EIF1AD	OT3EXB6S	Strong	Biomarker	[285]
EIF3F	OTU20K6L	Strong	Genetic Variation	[1543]
ELOVL2	OTDAF6U3	Strong	Genetic Variation	[955]
ELP1	OTYEWBF7	Strong	Biomarker	[1544]
ELP5	OTW5R7YD	Strong	Biomarker	[1544]
ELP6	OT0T3BLP	Strong	Biomarker	[1544]
EPB41	OTGCFPV8	Strong	Biomarker	[530]
EPHX3	OTU7LW2F	Strong	Biomarker	[1507]
ETV5	OTE2OBM4	Strong	Altered Expression	[1545]
FABP7	OTRE2H4G	Strong	Altered Expression	[772]
FADD	OTV7GFHH	Strong	Altered Expression	[1546]
FAM20C	OTW5YZ7X	Strong	Biomarker	[1547]
FARP1	OTL1EBTM	Strong	Altered Expression	[1548]
FAT4	OT7QONNV	Strong	Altered Expression	[1549]
FBXO22	OTEJ5MO0	Strong	Biomarker	[1550]
FCRLA	OT6MK4M1	Strong	Biomarker	[1551]
FLI1	OT0EV3LX	Strong	Altered Expression	[1552]
FLOT2	OTZ0QR5L	Strong	Altered Expression	[1553]
FOXN3	OTOJYJZP	Strong	Genetic Variation	[1554]
FOXO3	OTHXQG4P	Strong	Altered Expression	[1555]
FOXO4	OT90X9LN	Strong	Genetic Variation	[1556]
FRS2	OTDMD800	Strong	Biomarker	[1557]
FRZB	OTTO3DPY	Strong	Posttranslational Modification	[1558]
FTL	OTYQA8A6	Strong	Biomarker	[1559]
FXYD5	OT81DIOD	Strong	Altered Expression	[1560]
FZD3	OTIWDN78	Strong	Altered Expression	[1561]
GAB1	OTQKE6V4	Strong	Biomarker	[1562]
GAB2	OTBFN705	Strong	Genetic Variation	[1563]
GAGE2A	OTRAJ80C	Strong	Altered Expression	[1564]
GALNT14	OT9BSDDQ	Strong	Altered Expression	[1565]
GAPDHS	OT7YUSA5	Strong	Biomarker	[1566]
GAS1	OTKJXG52	Strong	Biomarker	[1567]
GBP5	OTS4AO4A	Strong	Altered Expression	[1568]
GFRA1	OT3WBVYB	Strong	Biomarker	[1569]
GNS	OTNFKYGB	Strong	Biomarker	[1229]
GOLGA4	OTCMEHNJ	Strong	Genetic Variation	[1570]
GOPC	OTRBGH71	Strong	Biomarker	[285]
GPAM	OTR1XD9B	Strong	Biomarker	[285]
GPLD1	OTUUQOVY	Strong	Biomarker	[1571]
GPR143	OTWUA2AV	Strong	Altered Expression	[1572]
GPR151	OT7EACU6	Strong	Biomarker	[691]
GRAP2	OTS5NIZ3	Strong	Biomarker	[587]
GRK1	OT7MPSG7	Strong	Altered Expression	[806]
GRK7	OT083IH0	Strong	Altered Expression	[806]
GSDME	OT1ZWY32	Strong	Biomarker	[1573]
GTF2H2	OTK72L9I	Strong	Altered Expression	[226]
GTF2H3	OT87W5QJ	Strong	Altered Expression	[226]
GTF2H4	OTPD1DIU	Strong	Altered Expression	[226]
GTF2H5	OTRL219S	Strong	Altered Expression	[226]
HAND2	OTCXYW4Y	Strong	Biomarker	[401]
HCP5	OTV0YRI8	Strong	Altered Expression	[1574]
HERC2	OTNQYKOB	Strong	Genetic Variation	[1575]
HIKESHI	OTPKV3UZ	Strong	Biomarker	[285]
HLA-DRB4	OTNXIHQU	Strong	Biomarker	[1576]
HLA-F	OT76CM19	Strong	Biomarker	[1577]
HNRNPD	OT5UO1FA	Strong	Altered Expression	[1578]
HNRNPK	OTNPRM8U	Strong	Altered Expression	[1579]
HOXA9	OTKNK5H0	Strong	Biomarker	[1507]
HOXC11	OT8NMHM6	Strong	Altered Expression	[1388]
HOXD12	OTKRUPGV	Strong	Biomarker	[1507]
HOXD13	OTWSC8TF	Strong	Altered Expression	[1580]
HOXD3	OTBUZ35T	Strong	Biomarker	[1581]
HPR	OTXSC9UB	Strong	Biomarker	[1582]
HSF5	OT2IZ1CX	Strong	Biomarker	[1583]
HSPA4	OT5HR0AR	Strong	Biomarker	[1584]
HTRA2	OTC7616F	Strong	Biomarker	[1445]
ICMT	OT8CNKBO	Strong	Biomarker	[1585]
IDH2	OTTQA4PB	Strong	Biomarker	[1586]
IFITM3	OT2QP8D3	Strong	Posttranslational Modification	[1587]
IGF2BP1	OT9G360P	Strong	Biomarker	[390]
IL1RAPL1	OTW3T4B2	Strong	Biomarker	[1588]
IL27RA	OTSQBAKI	Strong	Altered Expression	[1589]
IL2RG	OTRZ3OMY	Strong	Biomarker	[1590]
ING3	OTDIJXFP	Strong	Altered Expression	[1591]
IQCH	OTEYWCIW	Strong	Biomarker	[285]
IRF5	OT8SIIAP	Strong	Genetic Variation	[1592]
ITGA2B	OT4Y17PY	Strong	Altered Expression	[1593]
ITGAX	OTOGIMHE	Strong	Altered Expression	[1594]
JAKMIP2	OT2H3MRD	Strong	Biomarker	[738]
JMJD6	OTILR7E4	Strong	Biomarker	[1595]
KCNH4	OTHJ8WTU	Strong	Biomarker	[1596]
KCNIP3	OTCQPEM4	Strong	Biomarker	[1597]
KCTD12	OTPYKT4Z	Strong	Biomarker	[1598]
KHDRBS2	OTEKL45T	Strong	Biomarker	[823]
KIDINS220	OTLBH2MA	Strong	Altered Expression	[1599]
KIF15	OTJRJEXL	Strong	Biomarker	[1600]
KIF18B	OTOBUDOE	Strong	Biomarker	[1601]
KIF20A	OTXOQHE0	Strong	Biomarker	[1602]
KIF7	OT1J6NAW	Strong	Altered Expression	[1603]
KIR2DS4	OT00N6UJ	Strong	Altered Expression	[1604]
KLF3	OTIIAC18	Strong	Biomarker	[1605]
KLF6	OTQY9S7F	Strong	Biomarker	[1606]
KLF9	OTBFEJRQ	Strong	Biomarker	[1607]
KLRB1	OTQ2959Y	Strong	Biomarker	[1608]
KNL1	OT4Q3LHV	Strong	Altered Expression	[1609]
KRT15	OTS6WLF7	Strong	Biomarker	[1610]
KRT16	OTGA0EQN	Strong	Biomarker	[662]
KRT18	OTVLQFIP	Strong	Genetic Variation	[1611]
LAMB2	OT71OI2Y	Strong	Biomarker	[1612]
LAMTOR1	OTIBJBW9	Strong	Biomarker	[597]
LCP1	OTK61F2A	Strong	Altered Expression	[1613]
LGR6	OTPZ1PWR	Strong	Biomarker	[691]
LIG4	OT40DNXU	Strong	Genetic Variation	[1614]
LRIT1	OTNEQPMZ	Strong	Biomarker	[773]
LRP1B	OT4YZG2N	Strong	Biomarker	[1535]
LRP8	OTZ71YV2	Strong	Biomarker	[1615]
LSP1	OTSPSIFO	Strong	Altered Expression	[1616]
LTBP2	OTS88GSD	Strong	Biomarker	[1617]
LTBP3	OTME98V7	Strong	Biomarker	[1617]
LTBP4	OTC8WL2V	Strong	Biomarker	[1618]
LYPD5	OTGP7UKA	Strong	Altered Expression	[1619]
LYPLA2	OT03UIYC	Strong	Biomarker	[1286]
LZTS1	OTXXL864	Strong	Altered Expression	[1620]
MAFK	OTZJUE4P	Strong	Biomarker	[597]
MAGEA12	OT8ULELL	Strong	Biomarker	[1621]
MAGEB1	OTN7G8V1	Strong	Altered Expression	[1622]
MAGEE1	OTOQQO2X	Strong	Altered Expression	[1623]
MAGEL2	OTXEL4R7	Strong	Altered Expression	[1390]
MATN1	OTBRTCTQ	Strong	Altered Expression	[1624]
MAU2	OTALDF8Q	Strong	Biomarker	[1625]
MCC	OTQVI1EM	Strong	Genetic Variation	[1626]
MCM3	OTOOHQPM	Strong	Altered Expression	[1627]
MDH2	OT7364GY	Strong	Biomarker	[1628]
MEIS1	OTH9DKAD	Strong	Biomarker	[1629]
METTL3	OTSXP1M3	Strong	Altered Expression	[1630]
METTL4	OT061H4E	Strong	Biomarker	[1631]
MFN1	OTCBXQZF	Strong	Biomarker	[1060]
MFN2	OTPYN8A3	Strong	Biomarker	[1060]
MFSD12	OT54Y9TN	Strong	Biomarker	[1632]
MGP	OTZWU3FU	Strong	Biomarker	[1514]
MGRN1	OTFZC41K	Strong	Altered Expression	[1633]
MICA	OTPEIEAR	Strong	Biomarker	[1634]
MICB	OTS2DVDW	Strong	Biomarker	[1634]
MLLT10	OTURMDV7	Strong	Biomarker	[285]
MMP25	OT3BG37V	Strong	Biomarker	[409]
MMP26	OT9O89KU	Strong	Altered Expression	[1635]
MOGS	OT99MBGB	Strong	Biomarker	[1636]
MOS	OTNMQPFJ	Strong	Biomarker	[1637]
MRGPRX3	OTRKCCDS	Strong	Biomarker	[691]
MRGPRX4	OTOBHZVA	Strong	Biomarker	[691]
MRPL19	OTRBKF6R	Strong	Altered Expression	[683]
MRPL40	OTB2QZDY	Strong	Altered Expression	[1638]
MRPL49	OTN5PNSP	Strong	Biomarker	[285]
MSX2	OT1WDKE1	Strong	Biomarker	[1639]
MT1E	OTXJKU4Y	Strong	Posttranslational Modification	[1640]
MTPAP	OT6HQ02S	Strong	Biomarker	[285]
MX1	OT6X8G5T	Strong	Biomarker	[863]
MYDGF	OT9HRPL6	Strong	Biomarker	[713]
MYH7B	OTCB2IJB	Strong	Genetic Variation	[783]
MYL9	OT6B22JB	Strong	Altered Expression	[1641]
MYO7A	OTBZSPEL	Strong	Biomarker	[865]
MZF1	OTMVZCPW	Strong	Biomarker	[1642]
NAT9	OT4ZKCRS	Strong	Biomarker	[1643]
NAV3	OT97M1TR	Strong	Genetic Variation	[1644]
NCAPG	OT1AI9EO	Strong	Altered Expression	[1645]
NCK2	OTUYPF55	Strong	Altered Expression	[1646]
NCOA6	OTOMIGTV	Strong	Genetic Variation	[550]
NDRG1	OTVO66BO	Strong	Altered Expression	[1647]
NEU3	OTQ5PQOW	Strong	Altered Expression	[1648]
NF1	OTC29NHH	Strong	Biomarker	[1167]
NLK	OT2LETFS	Strong	Altered Expression	[1649]
NMI	OTYVG3NM	Strong	Biomarker	[1650]
NMT1	OT42GQ3D	Strong	Altered Expression	[1190]
NONO	OTN36Q6U	Strong	Altered Expression	[1651]
NPAP1	OTECLRPR	Strong	Biomarker	[738]
NPC2	OTE9UEJC	Strong	Biomarker	[1514]
OAS1	OT8ZLOCY	Strong	Altered Expression	[534]
OCA2	OTDWIGBF	Strong	Biomarker	[1652]
OS9	OTB5B2TY	Strong	Genetic Variation	[1653]
OVOL1	OTFJ62UI	Strong	Biomarker	[1654]
OVOL2	OTFM1GKF	Strong	Biomarker	[1654]
PAEP	OTQA0NV4	Strong	Biomarker	[1655]
PAQR3	OTTKJ9Y4	Strong	Biomarker	[1656]
PAX2	OTKP1N8F	Strong	Altered Expression	[1657]
PAX6	OTOC9876	Strong	Biomarker	[1507]
PCDHB8	OTRF344J	Strong	Biomarker	[823]
PCLAF	OTMVIOUU	Strong	Biomarker	[459]
PDCD6	OT2YA5M8	Strong	Altered Expression	[1658]
PDIA3	OTHPQ0Q3	Strong	Altered Expression	[1659]
PDSS2	OTEOQBMX	Strong	Altered Expression	[1660]
PEG3	OTHQW98S	Strong	Biomarker	[1661]
PERP	OTP0YL53	Strong	Altered Expression	[1662]
PGK1	OT6V1ICH	Strong	Altered Expression	[1467]
PGLYRP1	OTBTPR2T	Strong	Biomarker	[1663]
PI3	OT47MTC3	Strong	Altered Expression	[1664]
PIAS2	OTJLSC3V	Strong	Biomarker	[1665]
PIDD1	OTWFM930	Strong	Biomarker	[1501]
PIP4K2A	OTO9JO9U	Strong	Biomarker	[285]
PIR	OT8ALXHU	Strong	Biomarker	[1666]
PKD1	OT5ALRZ5	Strong	Biomarker	[662]
PKP1	OT9HSQ8F	Strong	Altered Expression	[1667]
PKP3	OTPL1HRB	Strong	Biomarker	[1668]
PLAAT4	OTI66SAJ	Strong	Biomarker	[461]
PLCB2	OTPAHDGO	Strong	Biomarker	[1669]
PLCB4	OTPA0QHW	Strong	Genetic Variation	[1670]
PLEK2	OTUBWUUK	Strong	Biomarker	[608]
PMP2	OTKYV2NE	Strong	Biomarker	[1671]
PODXL	OTPNQXF3	Strong	Altered Expression	[1041]
POLDIP2	OT8SZSJ6	Strong	Biomarker	[587]
POU2F1	OTK7ELJ0	Strong	Biomarker	[1672]
POU3F2	OT30NFOC	Strong	Biomarker	[1673]
PPP1R15A	OTYG179K	Strong	Biomarker	[1674]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[1675]
PPP6C	OTR1STMJ	Strong	Genetic Variation	[1676]
PRDM2	OT8L7CGX	Strong	Genetic Variation	[1677]
PRDX2	OTLWCY9T	Strong	Biomarker	[1507]
PRKAA1	OT7TNF0L	Strong	Biomarker	[1273]
PRKD3	OT987HJI	Strong	Biomarker	[1678]
PRSS23	OT6DQAM1	Strong	Biomarker	[285]
PSD4	OTEFB87Z	Strong	Biomarker	[1679]
PSG2	OT2EIXAI	Strong	Biomarker	[228]
PSMC5	OTJOORMR	Strong	Altered Expression	[1680]
PSMD11	OT8KO67V	Strong	Biomarker	[979]
PSMD3	OT585WY8	Strong	Biomarker	[979]
PTBP2	OTF4S7NE	Strong	Altered Expression	[1681]
PTER	OTBYJHDG	Strong	Biomarker	[285]
PTPRK	OTAP5AT3	Strong	Biomarker	[285]
PTPRO	OTFLKWOY	Strong	Biomarker	[823]
PUDP	OTEPEJLX	Strong	Genetic Variation	[1682]
RAB8A	OTPB54Y3	Strong	Biomarker	[1683]
RABGAP1L	OT7QO47I	Strong	Biomarker	[771]
RAC2	OTAOHFNH	Strong	Biomarker	[1684]
RAG1	OTV131E4	Strong	Biomarker	[1685]
RAG2	OTG9UYTW	Strong	Biomarker	[1590]
RAI1	OTKLQU00	Strong	Biomarker	[285]
RALGDS	OTG36NI7	Strong	Biomarker	[1686]
RAP2B	OTD2NDQP	Strong	Altered Expression	[1687]
RAPGEF5	OT53VS75	Strong	Biomarker	[1688]
RASA2	OTL06RG2	Strong	Altered Expression	[1192]
RASD1	OT2BAJHK	Strong	Biomarker	[1175]
RASGRF1	OTNWJ7EN	Strong	Biomarker	[1689]
RASSF1	OTEZIPB7	Strong	Biomarker	[753]
RASSF7	OT0V4EIZ	Strong	Genetic Variation	[1690]
RAX	OTJ3YCE7	Strong	Biomarker	[1507]
RB1	OT9VMY7B	Strong	Posttranslational Modification	[423]
RBM45	OTWTHD77	Strong	Genetic Variation	[1691]
RBP1	OTRP1MFC	Strong	Altered Expression	[1692]
RBP2	OTR8QG5V	Strong	Altered Expression	[1511]
RCAN1	OT1MVXC7	Strong	Altered Expression	[1693]
REC8	OT6JAVXE	Strong	Biomarker	[1507]
RECQL4	OT59LSW7	Strong	Biomarker	[1694]
RGPD2	OTMUZ0HX	Strong	Genetic Variation	[1454]
RHEB	OTFLTSEC	Strong	Biomarker	[1695]
RHOC	OTOLE1FT	Strong	Altered Expression	[1696]
RIN1	OTPBROUD	Strong	Altered Expression	[1697]
RMDN2	OTK5WSFI	Strong	Genetic Variation	[783]
RMI1	OT1ZVTFL	Strong	Genetic Variation	[1698]
RNASE3	OTVE2XD1	Strong	Biomarker	[1699]
RNASE4	OTA5SZLC	Strong	Biomarker	[1700]
RNASET2	OTWY64L7	Strong	Biomarker	[1701]
RNF128	OTJO86CJ	Strong	Biomarker	[620]
RNF19A	OTKWCV80	Strong	Biomarker	[587]
RNF5	OTDQGI37	Strong	Altered Expression	[1702]
RPL8	OTHMZ1R9	Strong	Biomarker	[1703]
RPP38	OTOXHKTX	Strong	Biomarker	[285]
RPS2	OTSMTZVB	Strong	Altered Expression	[683]
RPS3	OT0K3TMH	Strong	Biomarker	[1382]
RREB1	OT62460U	Strong	Biomarker	[474]
RTL10	OTHGB81W	Strong	Biomarker	[1704]
RYR2	OT0PF19E	Strong	Biomarker	[1705]
S100A10	OTI71243	Strong	Altered Expression	[1706]
S100A7	OTJFVJRF	Strong	Biomarker	[1707]
SARS1	OTFKXQ1O	Strong	Altered Expression	[596]
SARS2	OTU4T99W	Strong	Altered Expression	[596]
SCAMP3	OTUNPYCE	Strong	Biomarker	[1708]
SCNN1D	OTTX2G9M	Strong	Altered Expression	[1709]
SCO2	OTJQQDRS	Strong	Biomarker	[843]
SCRT1	OTWTE24S	Strong	Altered Expression	[1710]
SDC4	OTKUVUGZ	Strong	Altered Expression	[1711]
SDCBP	OTS3NCC5	Strong	Biomarker	[1712]
SDF4	OTQ7WFYW	Strong	Biomarker	[1501]
SEMA3E	OTD4S36H	Strong	Altered Expression	[1713]
SEMA7A	OT0ZJK64	Strong	Biomarker	[1714]
SERPINA3	OT9BP2S0	Strong	Altered Expression	[1715]
SERPINB9	OTJ811IF	Strong	Altered Expression	[1716]
SESN2	OT889IXY	Strong	Altered Expression	[1717]
SETDB1	OTWVUA1B	Strong	Biomarker	[1718]
SETDB2	OTBVVP9Q	Strong	Biomarker	[1718]
SF1	OTLEDM2S	Strong	Biomarker	[285]
SGMS1	OTZQE7PW	Strong	Altered Expression	[1719]
SGSM3	OTIB1P8A	Strong	Biomarker	[1720]
SHB	OTF2HSC0	Strong	Biomarker	[1721]
SHC1	OT1J5IRN	Strong	Altered Expression	[1681]
SHC4	OTQ0H76H	Strong	Altered Expression	[1681]
SIAH1	OT29A838	Strong	Biomarker	[1204]
SIGLEC9	OTZC7SIM	Strong	Altered Expression	[1722]
SIPA1	OTXY5RXC	Strong	Biomarker	[285]
SKI	OT4KJ8F6	Strong	Altered Expression	[1723]
SLC35G2	OTFBVS0P	Strong	Biomarker	[1507]
SLFN5	OTT1AESL	Strong	Altered Expression	[1724]
SLIT3	OTU8MKEU	Strong	Altered Expression	[1725]
SMAD4	OTWQWCKG	Strong	Genetic Variation	[1726]
SMARCA1	OT0Y6PTU	Strong	Altered Expression	[1213]
SMIM10	OTISM8ZT	Strong	Biomarker	[1727]
SMUG1	OT2YIOCQ	Strong	Genetic Variation	[1728]
SNAI1	OTDPYAMC	Strong	Biomarker	[1729]
SNAI2	OT7Y8EJ2	Strong	Altered Expression	[1285]
SNIP1	OTL3RA91	Strong	Biomarker	[1730]
SOX10	OTF25ULQ	Strong	Biomarker	[1731]
SOX18	OTPUMHWA	Strong	Biomarker	[1732]
SOX6	OTT0W0LE	Strong	Biomarker	[1733]
SOX9	OTVDJFGN	Strong	Altered Expression	[763]
SPAM1	OTMPOB4E	Strong	Biomarker	[1734]
SPANXD	OTMM6ANB	Strong	Biomarker	[1437]
SPG7	OT8OY9ST	Strong	Biomarker	[767]
SPINT1	OT1CLR5L	Strong	Genetic Variation	[1735]
SPP2	OTX254AR	Strong	Genetic Variation	[1736]
SPPL2A	OTCVF6MM	Strong	Altered Expression	[719]
SPRY2	OTH0CRCZ	Strong	Altered Expression	[1737]
SRGAP2	OTUWFMCQ	Strong	Altered Expression	[1738]
SSX2	OT2Z6RLL	Strong	Altered Expression	[1739]
SSX5	OTNOHH4H	Strong	Genetic Variation	[1740]
ST13	OTNML6UP	Strong	Biomarker	[1514]
ST3GAL4	OTNENJZQ	Strong	Biomarker	[1741]
STAG2	OTR6X1Q7	Strong	Biomarker	[1223]
STAT2	OTO9G2RZ	Strong	Biomarker	[264]
STIP1	OT7TXLOX	Strong	Altered Expression	[1742]
STN1	OT8UWRA3	Strong	Genetic Variation	[892]
SUGCT	OTA8L0TN	Strong	Biomarker	[1743]
SYT4	OTA1D7VL	Strong	Biomarker	[1744]
TAS2R60	OTZRD883	Strong	Biomarker	[823]
TBX3	OTM64N7K	Strong	Altered Expression	[1745]
TCF21	OT393IMA	Strong	Biomarker	[1746]
TERF2IP	OT3M5P3G	Strong	Altered Expression	[587]
TET2	OTKKT03T	Strong	Biomarker	[1747]
TFPI2	OTZCRWOR	Strong	Biomarker	[1748]
THOC2	OTNXE5G2	Strong	Biomarker	[1749]
TIMM8A	OTDX9687	Strong	Biomarker	[1405]
TINAGL1	OTZZO56M	Strong	Biomarker	[1750]
TJP1	OTBDCUPK	Strong	Biomarker	[1751]
TLE1	OT50MRZ1	Strong	Altered Expression	[1752]
TLE3	OTR9PH95	Strong	Altered Expression	[1753]
TMEM132B	OTDSGT9O	Strong	Biomarker	[823]
TMEM30B	OTNSBH84	Strong	Biomarker	[1507]
TMSB10	OTLVZ13T	Strong	Biomarker	[1754]
TNFRSF19	OTTVT4MB	Strong	Biomarker	[1755]
TOP3A	OT3CKUI9	Strong	Genetic Variation	[1756]
TPD52	OTPKSK43	Strong	Biomarker	[662]
TPM1	OTD73X6R	Strong	Biomarker	[1757]
TPM3	OT5RU5G6	Strong	Biomarker	[1758]
TPPP2	OTI3WA6X	Strong	Biomarker	[597]
TRAF2	OT1MEZZN	Strong	Altered Expression	[1759]
TRAPPC2L	OT1LN60D	Strong	Biomarker	[1733]
TRIM13	OTQIUACB	Strong	Biomarker	[767]
TRIM44	OT0B1T2B	Strong	Biomarker	[1760]
TRIT1	OTCU9FS5	Strong	Biomarker	[1761]
TRRAP	OT68OI2Y	Strong	Biomarker	[823]
TSGA10	OTIF1O1T	Strong	Altered Expression	[1762]
TSHZ1	OTYQ9ECW	Strong	Genetic Variation	[628]
TSPAN8	OT1F68WQ	Strong	Biomarker	[1763]
TTC12	OTDB24YV	Strong	Biomarker	[1764]
ACKR2	OTWYY14H	Definitive	Biomarker	[1765]
ACP1	OTJ9CKLU	Definitive	Biomarker	[1766]
ACTN4	OTCNZAJ5	Definitive	Biomarker	[1767]
ADGRG1	OTQBB8NT	Definitive	Biomarker	[1768]
AGFG1	OTI8ZKC4	Definitive	Altered Expression	[1769]
AKAP9	OT7Z2YRP	Definitive	Genetic Variation	[1770]
ANKRD11	OTV0V70M	Definitive	Genetic Variation	[1771]
ANKRD36B	OT3MW415	Definitive	Biomarker	[1772]
ARF6	OTVV7KJO	Definitive	Biomarker	[1773]
ARHGDIB	OT9PD6CS	Definitive	Altered Expression	[865]
ARL6IP5	OTYZ6BEQ	Definitive	Altered Expression	[1774]
ATF1	OT251CI0	Definitive	Altered Expression	[459]
ATF2	OTNIZPEA	Definitive	Biomarker	[1775]
ATOX1	OT05LF59	Definitive	Biomarker	[1776]
AZIN2	OT8OB7CG	Definitive	Biomarker	[1777]
BAG1	OTRQNIA4	Definitive	Biomarker	[1778]
BID	OTOSHSHU	Definitive	Biomarker	[1779]
BPIFA3	OTCXD1HX	Definitive	Genetic Variation	[1780]
C5AR2	OTP1Q82J	Definitive	Biomarker	[859]
CADM1	OTRWG9QS	Definitive	Altered Expression	[1781]
CCDC80	OTOZSYEM	Definitive	Altered Expression	[1782]
CD63	OT2UGZA9	Definitive	Biomarker	[1783]
CD68	OTOYEY3J	Definitive	Biomarker	[619]
CD82	OTH8MC64	Definitive	Biomarker	[1784]
CDCA5	OTZLCQ5U	Definitive	Altered Expression	[1785]
CDH17	OT9EV2XK	Definitive	Biomarker	[1786]
CDK10	OTKP7TTR	Definitive	Genetic Variation	[783]
CDK15	OT8S67QS	Definitive	Biomarker	[340]
CDKAL1	OTA0SGNE	Definitive	Genetic Variation	[783]
CFL1	OTT6D5MH	Definitive	Biomarker	[1787]
CILK1	OTWOYEYP	Definitive	Biomarker	[340]
CIP2A	OTVS2GXA	Definitive	Biomarker	[426]
CLEC10A	OTD8HQT6	Definitive	Altered Expression	[1788]
COIL	OTP4I4DL	Definitive	Biomarker	[1789]
CXCL5	OTZOUPCA	Definitive	Altered Expression	[1790]
CYLD	OT37FKH0	Definitive	Biomarker	[1791]
DBNDD1	OTATKUA8	Definitive	Genetic Variation	[1771]
DCAF1	OT3ZDVOE	Definitive	Altered Expression	[1769]
DDX11	OT1WR3MD	Definitive	Biomarker	[912]
DEF8	OTS93PPZ	Definitive	Genetic Variation	[1466]
DNM1L	OTXK1Q1G	Definitive	Biomarker	[1060]
ELAVL2	OT6EJ8MQ	Definitive	Genetic Variation	[1792]
EMP2	OTPS2H0L	Definitive	Biomarker	[1793]
ESPN	OT7Z6LX2	Definitive	Altered Expression	[1794]
ETV4	OT8C98UZ	Definitive	Altered Expression	[409]
EWSR1	OT7SRHV3	Definitive	Genetic Variation	[1255]
FLACC1	OTZN9TZV	Definitive	Genetic Variation	[783]
FLT3LG	OTU0YGC4	Definitive	Biomarker	[1795]
FMNL2	OT9OVWCV	Definitive	Altered Expression	[1796]
FSTL1	OT6KEZUD	Definitive	Biomarker	[1797]
GADL1	OTJM4A0R	Definitive	Biomarker	[1777]
GALNT3	OT7M67WT	Definitive	Altered Expression	[447]
GCNT3	OTQ9ALTR	Definitive	Altered Expression	[1798]
GDF6	OTERXWJU	Definitive	Biomarker	[1221]
GGPS1	OTVEHG28	Definitive	Biomarker	[878]
GLT8D1	OTG14TPO	Definitive	Altered Expression	[1799]
GOLPH3	OTDLGYM3	Definitive	Altered Expression	[1800]
GORASP1	OTQS91S7	Definitive	Biomarker	[1801]
GPR42	OTEB0ROY	Definitive	Altered Expression	[452]
GPX3	OT6PK94R	Definitive	Altered Expression	[1802]
GTF2H1	OTCRXC6B	Definitive	Altered Expression	[226]
GTSE1	OTPP742Z	Definitive	Altered Expression	[1803]
HACE1	OTEZULKD	Definitive	Biomarker	[1804]
HADHB	OT4Y1I62	Definitive	Biomarker	[902]
HAVCR2	OTOL603T	Definitive	Altered Expression	[1805]
HELB	OT769EC5	Definitive	Biomarker	[1806]
HLA-C	OTV38BUJ	Definitive	Biomarker	[1807]
HOXB9	OTMVHQOU	Definitive	Biomarker	[1065]
IL3	OT0CQ35N	Definitive	Biomarker	[1808]
IL6ST	OT1N9C70	Definitive	Biomarker	[368]
IRF4	OT1DHQ1P	Definitive	Altered Expression	[1809]
ISYNA1	OT49ONSE	Definitive	Altered Expression	[313]
KAT8	OT5LPQTR	Definitive	Biomarker	[1810]
KL	OTD4VWU6	Definitive	Biomarker	[1811]
KLHDC2	OTBHH882	Definitive	Biomarker	[1812]
LAMP3	OTN0XL3W	Definitive	Biomarker	[1109]
LGALS9	OT7MF91K	Definitive	Biomarker	[214]
LIN28B	OTVWP0FN	Definitive	Altered Expression	[1813]
MAK16	OTD546E5	Definitive	Biomarker	[390]
MAP2K3	OTI2OREX	Definitive	Biomarker	[1814]
MARCHF1	OTI2EYO6	Definitive	Genetic Variation	[1815]
MED1	OTOO24C4	Definitive	Biomarker	[1816]
MFAP1	OTZN4FT3	Definitive	Altered Expression	[1817]
MIA2	OTOGTUTU	Definitive	Altered Expression	[1121]
MSC	OTBRPZL5	Definitive	Biomarker	[1818]
MVP	OTJGHJRB	Definitive	Biomarker	[405]
NCOA5	OTOGWTWB	Definitive	Genetic Variation	[1477]
NFATC2	OTK5T6HZ	Definitive	Biomarker	[1819]
NID1	OTKLBLS6	Definitive	Genetic Variation	[1820]
NOG	OTGRHHPG	Definitive	Biomarker	[1821]
NOVA1	OT6A9KHY	Definitive	Altered Expression	[1555]
NPM2	OT9JSU8L	Definitive	Biomarker	[1822]
OPN1MW	OTPJ7LX4	Definitive	Biomarker	[1823]
OTOR	OTA62UQB	Definitive	Altered Expression	[1121]
PARVA	OTLKEWRY	Definitive	Altered Expression	[1824]
PBX3	OT8WMVM4	Definitive	Biomarker	[1825]
PELI1	OTMLBCLC	Definitive	Altered Expression	[1826]
PHF20	OTCBVH5P	Definitive	Genetic Variation	[1827]
PHLPP2	OTXB1OUI	Definitive	Altered Expression	[1157]
PLA1A	OT2IXYNX	Definitive	Altered Expression	[1828]
PLXNC1	OTJ5XKYY	Definitive	Biomarker	[1829]
PNO1	OT010GIS	Definitive	Biomarker	[390]
POLR2A	OTHJQ1DZ	Definitive	Biomarker	[1830]
PREX2	OTYT1J6J	Definitive	Genetic Variation	[1831]
PRKACG	OTKOQYF8	Definitive	Biomarker	[340]
PRRT2	OTCJUBDO	Definitive	Altered Expression	[792]
PTHLH	OTI1JF13	Definitive	Biomarker	[375]
PTPRA	OTZA82J1	Definitive	Biomarker	[405]
PTTG1	OTIMYS4W	Definitive	Biomarker	[1832]
PYCARD	OT67RON3	Definitive	Biomarker	[439]
RALY	OT78NNWY	Definitive	Genetic Variation	[783]
RBMS3	OTFSC9MR	Definitive	Biomarker	[390]
RGS1	OTGXJYMG	Definitive	Biomarker	[916]
RGS7	OTDQA90X	Definitive	Biomarker	[1833]
RNF2	OTFPLOIN	Definitive	Altered Expression	[1834]
RPAIN	OTBMXAYK	Definitive	Altered Expression	[1769]
RRAD	OTW2O4GD	Definitive	Biomarker	[1835]
RTN3	OTGZ51QF	Definitive	Biomarker	[1778]
SAFB	OTGRV2LW	Definitive	Biomarker	[1778]
SCD5	OTSSUQ3Z	Definitive	Altered Expression	[1836]
SDHA	OTOJ8QFF	Definitive	Biomarker	[1837]
SELENOK	OTKM7N7P	Definitive	Biomarker	[1838]
SEMA6A	OTDQ7QAW	Definitive	Biomarker	[1839]
SIL1	OTDI85I5	Definitive	Altered Expression	[1840]
SNAPC5	OTNCB038	Definitive	CausalMutation	[1535]
SPATA33	OTU5TYJA	Definitive	Genetic Variation	[1771]
SRRM2	OTSIMMC9	Definitive	Biomarker	[390]
ST8SIA1	OTGND2YZ	Definitive	Biomarker	[1841]
STAT5B	OTZVPEBT	Definitive	Biomarker	[1842]
SYF2	OTY2ZW1H	Definitive	Genetic Variation	[914]
SYT1	OTVTPOI6	Definitive	Biomarker	[1801]
THBS2	OTXET551	Definitive	Biomarker	[1843]
TIMP1	OTOXC51H	Definitive	Altered Expression	[1844]
TLK1	OTICTXI8	Definitive	Biomarker	[340]
TMEM132D	OTV6I4Z0	Definitive	Biomarker	[1845]
TNMD	OTHLVA9G	Definitive	Biomarker	[1791]
TP53AIP1	OT1XVNDP	Definitive	Altered Expression	[1846]
TRAF3IP3	OTNG0L8X	Definitive	Biomarker	[1847]
TRIP4	OTA8OASA	Definitive	Biomarker	[1848]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075259.
• [7] Hydroxyurea FDA Label
• [8] Imiquimod FDA Label
• [9] ClinicalTrials.gov (NCT01546571) Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients. U.S. National Institutes of Health.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6888).
• [11] A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
• [12] Lapatinib FDA Label
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Lovastatin FDA Label
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7499).
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7335).
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7719).
• [18] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
• [19] Romidepsin FDA Label
• [20] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [21] ClinicalTrials.gov (NCT03070392) Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
• [22] Temozolomide FDA Label
• [23] ClinicalTrials.gov (NCT00920582) Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus. U.S. National Institutes of Health.
• [24] ClinicalTrials.gov (NCT01031966) A Pilot Study to Evaluate ZADAXIN's (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine. U.S. National Institutes of Health.
• [25] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6495).
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8281).
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5893).
• [29] Study of therapy resistance in cancer cells with functional proteome analysis. Clin Chem Lab Med. 2002 Mar;40(3):221-34.
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010983)
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011670)
• [32] ClinicalTrials.gov (NCT01578239) A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours. U.S. National Institutes of Health.
• [33] ClinicalTrials.gov (NCT00052130) Vaccine Therapy for Patients With Stage III Melanoma. U.S. National Institutes of Health.
• [34] GMK (Progenics Pharmaceuticals). Curr Opin Investig Drugs. 2002 Jan;3(1):159-64.
• [35] ClinicalTrials.gov (NCT02395172) Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200). U.S. National Institutes of Health.
• [36] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [37] ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health.
• [38] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035277)
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7981).
• [40] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7990).
• [41] ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
• [42] ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
• [43] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8269).
• [44] ClinicalTrials.gov (NCT02967692) A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i). U.S. National Institutes of Health.
• [45] ClinicalTrials.gov (NCT02288897) PV-10 Intralesional Injection vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma. U.S. National Institutes of Health.
• [46] ClinicalTrials.gov (NCT00005052) Vaccine Therapy in Treating Patients With Primary Stage II Melanoma. U.S. National Institutes of Health.
• [47] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019204)
• [48] ClinicalTrials.gov (NCT01933932) Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)
• [49] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [50] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [51] ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.
• [52] ClinicalTrials.gov (NCT03445533) A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) (ILLUMINATE-301). U.S. National Institutes of Health.
• [53] ClinicalTrials.gov (NCT00050388) Phase II Trial of Allovectin-7 for Head and Neck Cancer. U.S. National Institutes of Health.
• [54] ClinicalTrials.gov (NCT00791492) An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy. U.S. National Institutes of Health.
• [55] ClinicalTrials.gov (NCT00035828) A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD. U.S. National Institutes of Health.
• [56] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033476)
• [57] Critical Care Nephrology, Claudio Ronco,Rinaldo Bellomo,John A. Kellum. Page(444).
• [58] Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 2003 Mar 1;21(5):884-90.
• [59] Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. Med Oncol. 2012 Dec;29(4):2966-77.
• [60] ClinicalTrials.gov (NCT00590824) Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma. U.S. National Institutes of Health.
• [61] ClinicalTrials.gov (NCT04337931) A Study to Evaluate APX005M in Subjects With Unresectable or Metastatic Melanoma. U.S. National Institutes of Health.
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019429)
• [63] ClinicalTrials.gov (NCT00509496) Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes. U.S. National Institutes of Health.
• [64] ClinicalTrials.gov (NCT04526899) Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma. U.S.National Institutes of Health.
• [65] ClinicalTrials.gov (NCT03417739) A Phase II Study of BVD-523 in Metastatic Uveal Melanoma. U.S. National Institutes of Health.
• [66] Clinical pipeline report, company report or official report of AVAX Technologies.
• [67] ClinicalTrials.gov (NCT00925314) A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma. U.S. National Institutes of Health.
• [68] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [69] ClinicalTrials.gov (NCT00306553) Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients. U.S. National Institutes of Health.
• [70] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025020)
• [71] ClinicalTrials.gov (NCT01605162) Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT03595683) Pembrolizumab and EDP1503 in Advanced Melanoma. U.S. National Institutes of Health.
• [73] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022232)
• [74] ClinicalTrials.gov (NCT00003895) Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma. U.S. National Institutes of Health.
• [75] ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health.
• [76] ClinicalTrials.gov (NCT02696356) Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma. U.S. National Institutes of Health.
• [77] ClinicalTrials.gov (NCT01149343) Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer. U.S. National Institutes of Health.
• [78] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013884)
• [79] Phase I/II trial of Hi8 PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. Melanoma Research. 09/2006; 16(Supplement 1).
• [80] Clinical pipeline report, company report or official report of OncoSec Medical.
• [81] ClinicalTrials.gov (NCT05050006) A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1). U.S.National Institutes of Health.
• [82] ClinicalTrials.gov (NCT00004050) Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer. U.S. National Institutes of Health.
• [83] ClinicalTrials.gov (NCT02360579) Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144). U.S. National Institutes of Health.
• [84] Clinical pipeline report, company report or official report of MolMed.
• [85] ClinicalTrials.gov (NCT01026051) Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. U.S. National Institutes of Health.
• [86] ClinicalTrials.gov (NCT01425008) Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma. U.S. National Institutes of Health.
• [87] ClinicalTrials.gov (NCT01574716) Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE). U.S. National Institutes of Health.
• [88] ClinicalTrials.gov (NCT03897881) An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942). U.S. National Institutes of Health.
• [89] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026542)
• [90] ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
• [91] ClinicalTrials.gov (NCT00189332) Use of 852A in Metastatic Cutaneous Melanoma.. U.S. National Institutes of Health.
• [92] ClinicalTrials.gov (NCT02428712) A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors. U.S. National Institutes of Health.
• [93] An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
• [94] ClinicalTrials.gov (NCT04577807) LUMINOS-102: PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma. U.S. National Institutes of Health.
• [95] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5674).
• [96] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038158)
• [97] ClinicalTrials.gov (NCT00991250) SentoClone Compared to Reference Treatment in Advanced Malignant Melanoma. U.S. National Institutes of Health.
• [98] ClinicalTrials.gov (NCT00042783) Vaccine Therapy in Treating Patients With Stage IV Melanoma. U.S. National Institutes of Health.
• [99] ClinicalTrials.gov (NCT02301611) Phase IIB TL + YCWP + DC in Melanoma. U.S. National Institutes of Health.
• [100] Clinical pipeline report, company report or official report of Lion biotechnologies.
• [101] ClinicalTrials.gov (NCT00612664) Phase II, 2nd Line Melanoma - RAND Monotherapy. U.S. National Institutes of Health.
• [102] ClinicalTrials.gov (NCT04152863) Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011). U.S. National Institutes of Health.
• [103] ClinicalTrials.gov (NCT04291105) Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients. U.S. National Institutes of Health.
• [104] Clinical pipeline report, company report or official report of ZIOPHARM.
• [105] A Special Report on Gene Therapy, K. K. Jain. Page(138).
• [106] ClinicalTrials.gov (NCT04123470) A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma. U.S. National Institutes of Health.
• [107] ClinicalTrials.gov (NCT04205227) A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
• [108] ClinicalTrials.gov (NCT03973151) Study of HL-085 in NRAS Mutant Advanced Melanoma. U.S. National Institutes of Health.
• [109] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024121)
• [110] Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
• [111] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032104)
• [112] ClinicalTrials.gov (NCT01239134) Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors. U.S. National Institutes of Health.
• [113] Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007 June 1; 117(6): 1466-1476.
• [114] Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679.
• [115] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037366)
• [116] Nearly 800 Medicines and Vaccines in Clinical Testing For Cancer Offer New Hope to Patients. Pharmaceutical Research and Manufacturers of America report. 2014.
• [117] Pre-EMP-tive strike against GBM. SciBX 7(14); doi:10.1038/scibx.2014.389. April 10 2014
• [118] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [119] ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
• [120] ClinicalTrials.gov (NCT03743298) Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma. U.S. National Institutes of Health.
• [121] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3945).
• [122] ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
• [123] ClinicalTrials.gov (NCT03329950) A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [124] ClinicalTrials.gov (NCT03291002) Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC. U.S. National Institutes of Health.
• [125] ClinicalTrials.gov (NCT00815607) Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma. U.S. National Institutes of Health.
• [126] ClinicalTrials.gov (NCT01522664) A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma. U.S. National Institutes of Health.
• [127] Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015 May 15;348(6236):803-8.
• [128] ClinicalTrials.gov (NCT01137006) An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma. U.S. National Institutes of Health.
• [129] ClinicalTrials.gov (NCT04596033) TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy. U.S. National Institutes of Health.
• [130] ClinicalTrials.gov (NCT03649529) Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy
• [131] ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
• [132] Phase I trial of IL-2 plasmid DNA with electroporation in metastatic melanoma, Journal of Clinical Oncology, Vol 25, No 18S (June 20 Supplement), 2007: 8578.
• [133] ClinicalTrials.gov (NCT04370704) Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies. U.S. National Institutes of Health.
• [134] ClinicalTrials.gov (NCT01397708) Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma. U.S. National Institutes of Health.
• [135] ClinicalTrials.gov (NCT00747825) Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma. U.S. National Institutes of Health.
• [136] ClinicalTrials.gov (NCT01052142) Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma. U.S. National Institutes of Health.
• [137] ClinicalTrials.gov (NCT02122861) A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1. U.S. National Institutes of Health.
• [138] ClinicalTrials.gov (NCT00471133) Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation. U.S. National Institutes of Health.
• [139] Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1 Supplement), 2005: 7551.
• [140] ClinicalTrials.gov (NCT04543188) A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT. U.S.National Institutes of Health.
• [141] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [142] ClinicalTrials.gov (NCT04543305) A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies. U.S. National Institutes of Health.
• [143] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025308)
• [144] ClinicalTrials.gov (NCT01727778) Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [145] ClinicalTrials.gov (NCT04096638) Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [146] ClinicalTrials.gov (NCT03161431) SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab. U.S. National Institutes of Health.
• [147] ClinicalTrials.gov (NCT03385486) Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors. U.S. National Institutes of Health.
• [148] A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother. 2006 Jul-Aug;29(4):444-54.
• [149] ClinicalTrials.gov (NCT00223899) A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma. U.S. National Institutes of Health.
• [150] ClinicalTrials.gov (NCT03517488) A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2). U.S. National Institutes of Health.
• [151] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027551)
• [152] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004320)
• [153] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004906)
• [154] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013219)
• [155] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017393)
• [156] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014153)
• [157] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028388)
• [158] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010286)
• [159] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008660)
• [160] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001208)
• [161] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021775)
• [162] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016814)
• [163] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016041)
• [164] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022593)
• [165] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035865)
• [166] 2011 Pipeline of Anavex.
• [167] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008666)
• [168] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008898)
• [169] Clinical pipeline report, company report or official report of MediGene AG.
• [170] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022850)
• [171] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006527)
• [172] Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63.
• [173] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [174] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [175] Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J. 2010 Nov;24(11):4575-84.
• [176] Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.
• [177] Clinical pipeline report, company report or official report of novartis.
• [178] Clinical pipeline report, company report or official report of Roche.
• [179] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [180] Myeloid-specific genetic ablation of ATP-binding cassette transporter ABCA1 is protective against cancer.Oncotarget. 2017 Jun 27;8(42):71965-71980. doi: 10.18632/oncotarget.18666. eCollection 2017 Sep 22.
• [181] Combined effects of GSTP1 and MRP1 in melanoma drug resistance.Br J Cancer. 2005 Jul 25;93(2):216-23. doi: 10.1038/sj.bjc.6602681.
• [182] Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Horm Cancer. 2017 Jun;8(3):143-156. doi: 10.1007/s12672-017-0292-7. Epub 2017 Mar 14.
• [183] Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.Clin Cancer Res. 2016 Jan 1;22(1):96-106. doi: 10.1158/1078-0432.CCR-15-0743. Epub 2015 Sep 15.
• [184] Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis.Oncogene. 2017 Aug 31;36(35):5058-5067. doi: 10.1038/onc.2017.162. Epub 2017 May 29.
• [185] Differentiation-inducing and anti-proliferative activities of isoliquiritigenin and all-trans-retinoic acid on B16F0 melanoma cells: Mechanisms profiling by RNA-seq.Gene. 2016 Oct 30;592(1):86-98. doi: 10.1016/j.gene.2016.07.052. Epub 2016 Jul 25.
• [186] Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.Expert Opin Biol Ther. 2018 Jul;18(sup1):77-83. doi: 10.1080/14712598.2018.1494717.
• [187] 3-adrenoreceptor blockade reduces tumor growth and increases neuronal differentiation in neuroblastoma via SK2/S1P(2) modulation.Oncogene. 2020 Jan;39(2):368-384. doi: 10.1038/s41388-019-0993-1. Epub 2019 Sep 2.
• [188] Enhancement role of host 12/15-lipoxygenase in melanoma progression.Eur J Cancer. 2013 Aug;49(12):2747-59. doi: 10.1016/j.ejca.2013.03.030. Epub 2013 May 8.
• [189] Characterization of ML-IAP protein stability and physiological role in vivo.Biochem J. 2012 Nov 1;447(3):427-36. doi: 10.1042/BJ20121103.
• [190] ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis.Oncotarget. 2017 Jul 5;8(44):75778-75796. doi: 10.18632/oncotarget.19018. eCollection 2017 Sep 29.
• [191] Physico-chemical and Biological Evaluation of Flavonols: Fisetin, Quercetin and Kaempferol Alone and Incorporated in beta Cyclodextrins.Anticancer Agents Med Chem. 2017;17(4):615-626. doi: 10.2174/1871520616666160621105306.
• [192] Aquaporin-1 inhibition reduces metastatic formation in a mouse model of melanoma.J Cell Mol Med. 2018 Feb;22(2):904-912. doi: 10.1111/jcmm.13378. Epub 2017 Oct 17.
• [193] Aquaporins mediate the chemoresistance of human melanoma cells to arsenite.Mol Oncol. 2012 Feb;6(1):81-7. doi: 10.1016/j.molonc.2011.11.001. Epub 2011 Nov 13.
• [194] Decline in arylsulfatase B leads to increased invasiveness of melanoma cells.Oncotarget. 2017 Jan 17;8(3):4169-4180. doi: 10.18632/oncotarget.13751.
• [195] Translational reprogramming marks adaptation to asparagine restriction in cancer.Nat Cell Biol. 2019 Dec;21(12):1590-1603. doi: 10.1038/s41556-019-0415-1. Epub 2019 Nov 18.
• [196] ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.Cell Rep. 2017 Mar 7;18(10):2331-2342. doi: 10.1016/j.celrep.2017.02.040.
• [197] Cancer vaccines.Anticancer Drugs. 1997 Sep;8(8):727-33. doi: 10.1097/00001813-199709000-00001.
• [198] IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.J Invest Dermatol. 2008 Jun;128(6):1499-505. doi: 10.1038/sj.jid.5701185. Epub 2007 Dec 13.
• [199] Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.Oncotarget. 2016 Dec 20;7(51):84594-84607. doi: 10.18632/oncotarget.13141.
• [200] Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-1 expression.Oncotarget. 2017 Jun 27;8(26):42901-42916. doi: 10.18632/oncotarget.17160.
• [201] Interaction of Complement Defence Collagens C1q and Mannose-Binding Lectin with BMP-1/Tolloid-like Proteinases.Sci Rep. 2017 Dec 5;7(1):16958. doi: 10.1038/s41598-017-17318-w.
• [202] Hyaluronic acid-CD44 interactions promote BMP4/7-dependent Id1/3 expression in melanoma cells.Sci Rep. 2018 Oct 8;8(1):14913. doi: 10.1038/s41598-018-33337-7.
• [203] Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically.Cancer Immunol Res. 2019 Jul;7(7):1064-1078. doi: 10.1158/2326-6066.CIR-18-0657. Epub 2019 May 14.
• [204] Ecto-Calreticulin is essential for an efficient immunogenic cell death stimulation in mouse melanoma.Genes Immun. 2019 Jul;20(6):509-513. doi: 10.1038/s41435-018-0047-7. Epub 2018 Oct 4.
• [205] Withaferin A modulates AIM2 inflammasome and caspase-1 expression in THP-1 polarized macrophages.Exp Cell Res. 2019 Oct 15;383(2):111564. doi: 10.1016/j.yexcr.2019.111564. Epub 2019 Aug 20.
• [206] Chinese Propolis Exerts Anti-Proliferation Effects in Human Melanoma Cells by Targeting NLRP1 Inflammatory Pathway, Inducing Apoptosis, Cell Cycle Arrest, and Autophagy.Nutrients. 2018 Aug 26;10(9):1170. doi: 10.3390/nu10091170.
• [207] Updated field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma: the MelGene database.J Invest Dermatol. 2015 Apr;135(4):1074-1079. doi: 10.1038/jid.2014.491. Epub 2014 Nov 19.
• [208] A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression.PLoS One. 2018 Apr 4;13(4):e0193461. doi: 10.1371/journal.pone.0193461. eCollection 2018.
• [209] Long noncoding RNA CPS1-IT1 suppresses melanoma cell metastasis through inhibiting Cyr61 via competitively binding to BRG1.J Cell Physiol. 2019 Dec;234(12):22017-22027. doi: 10.1002/jcp.28764. Epub 2019 May 20.
• [210] Cyanidin-3-o-Glucoside Pharmacologically Inhibits Tumorigenesis via Estrogen Receptor in Melanoma Mice.Front Oncol. 2019 Oct 22;9:1110. doi: 10.3389/fonc.2019.01110. eCollection 2019.
• [211] WD repeat and SOCS box containing protein 2 in the proliferation, cycle progression, and migration of melanoma cells.Biomed Pharmacother. 2019 Aug;116:108974. doi: 10.1016/j.biopha.2019.108974. Epub 2019 May 16.
• [212] CCR4 is a determinant of melanoma brain metastasis.Oncotarget. 2017 May 9;8(19):31079-31091. doi: 10.18632/oncotarget.16076.
• [213] High expression of CCR5 in melanoma enhances epithelial-mesenchymal transition and metastasis via TGF1.J Pathol. 2019 Apr;247(4):481-493. doi: 10.1002/path.5207. Epub 2019 Jan 16.
• [214] Accumulation of Circulating CCR7(+) Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.Cancer Immunol Res. 2019 May;7(5):841-852. doi: 10.1158/2326-6066.CIR-18-0651. Epub 2019 Apr 2.
• [215] Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.Cancer Immunol Immunother. 2017 Sep;66(9):1113-1121. doi: 10.1007/s00262-017-2007-x. Epub 2017 May 11.
• [216] The antibody-drug conjugate target landscape across a broad range of tumour types.Ann Oncol. 2017 Dec 1;28(12):3083-3091. doi: 10.1093/annonc/mdx541.
• [217] Identification of CD24 as a marker for tumorigenesis of melanoma.Onco Targets Ther. 2018 Jun 12;11:3401-3406. doi: 10.2147/OTT.S157043. eCollection 2018.
• [218] Tailoring early-phase clinical trial design to address multiple research objectives.Cancer Immunol Immunother. 2020 Jan;69(1):95-102. doi: 10.1007/s00262-019-02442-5. Epub 2019 Dec 5.
• [219] Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients.J Transl Med. 2017 Apr 20;15(1):79. doi: 10.1186/s12967-017-1182-z.
• [220] Utility of CD117 immunoreactivity in differentiating metastatic melanoma from clear cell sarcoma.Arch Pathol Lab Med. 2006 Mar;130(3):343-8. doi: 10.5858/2006-130-343-UOCIID.
• [221] Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.Cancer Sci. 2019 Jul;110(7):2273-2283. doi: 10.1111/cas.14038. Epub 2019 May 29.
• [222] Human Melanoma-Derived Extracellular Vesicles Regulate Dendritic Cell Maturation.Front Immunol. 2017 Mar 29;8:358. doi: 10.3389/fimmu.2017.00358. eCollection 2017.
• [223] Expression and function of CD9 in melanoma cells.Mol Carcinog. 2010 Jan;49(1):85-93. doi: 10.1002/mc.20580.
• [224] Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry.Pigment Cell Melanoma Res. 2012 Sep;25(5):630-8. doi: 10.1111/j.1755-148X.2012.01036.x.
• [225] CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma.Cancer Res. 2018 Dec 1;78(23):6561-6574. doi: 10.1158/0008-5472.CAN-18-0330. Epub 2018 Oct 8.
• [226] Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair.Oncogene. 2019 May;38(19):3616-3635. doi: 10.1038/s41388-018-0661-x. Epub 2019 Jan 16.
• [227] CDKL1 promotes tumor proliferation and invasion in colorectal cancer.Onco Targets Ther. 2017 Mar 16;10:1613-1624. doi: 10.2147/OTT.S133014. eCollection 2017.
• [228] CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter.Acta Biochim Pol. 2004;51(3):723-32.
• [229] Suppression of cFLIPL promotes JNK activation in malignant melanoma cells.Mol Med Rep. 2016 Mar;13(3):2904-8. doi: 10.3892/mmr.2016.4856. Epub 2016 Feb 3.
• [230] Synergistic Effects of Melittin and Plasma Treatment: A Promising Approach for Cancer Therapy.Cancers (Basel). 2019 Aug 3;11(8):1109. doi: 10.3390/cancers11081109.
• [231] The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.Cell Cycle. 2016 Jun 2;15(11):1462-70. doi: 10.1080/15384101.2016.1175258. Epub 2016 Apr 22.
• [232] GNA14 silencing suppresses the proliferation of endometrial carcinoma cells through inducing apoptosis and G(2)/M cell cycle arrest.Biosci Rep. 2018 Sep 7;38(5):BSR20180574. doi: 10.1042/BSR20180574. Print 2018 Oct 31.
• [233] Hexokinase2 controls angiogenesis in melanoma by promoting aerobic glycolysis and activating the p38-MAPK signaling.J Cell Biochem. 2019 Dec;120(12):19721-19729. doi: 10.1002/jcb.29278. Epub 2019 Jul 3.
• [234] Activation of cancer-associated fibroblasts is required for tumor neovascularization in a murine model of melanoma.Matrix Biol. 2018 Dec;74:52-61. doi: 10.1016/j.matbio.2018.06.003. Epub 2018 Jun 7.
• [235] NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.PLoS One. 2016 Apr 5;11(4):e0153181. doi: 10.1371/journal.pone.0153181. eCollection 2016.
• [236] T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.Sci Transl Med. 2018 Apr 11;10(436):eaan3311. doi: 10.1126/scitranslmed.aan3311.
• [237] Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study.Mol Cancer. 2010 Aug 4;9:207. doi: 10.1186/1476-4598-9-207.
• [238] Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir.Int J Cancer. 2018 Mar 1;142(5):988-998. doi: 10.1002/ijc.31111. Epub 2017 Nov 2.
• [239] Cathepsin K expression in melanoma is associated with metastases.Histol Histopathol. 2017 Jul;32(7):711-716. doi: 10.14670/HH-11-833. Epub 2016 Oct 7.
• [240] Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.Oncotarget. 2017 Feb 28;8(9):14428-14442. doi: 10.18632/oncotarget.14803.
• [241] Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model.Oncoimmunology. 2018 Apr 18;7(8):e1450715. doi: 10.1080/2162402X.2018.1450715. eCollection 2018.
• [242] Uveal Melanomas Harbor Recurrent Activating Mutations in CYSLTR2.Cancer Discov. 2016 Jun;6(6):573. doi: 10.1158/2159-8290.CD-RW2016-084. Epub 2016 May 5.
• [243] Directed phenotype switching as an effective antimelanoma strategy.Cancer Cell. 2013 Jul 8;24(1):105-19. doi: 10.1016/j.ccr.2013.05.009. Epub 2013 Jun 20.
• [244] Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.J Cancer. 2017 Sep 5;8(15):3086-3098. doi: 10.7150/jca.14835. eCollection 2017.
• [245] Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype.PLoS One. 2014 Apr 14;9(4):e95157. doi: 10.1371/journal.pone.0095157. eCollection 2014.
• [246] Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice.Oncoimmunology. 2017 Feb 10;6(3):e1290035. doi: 10.1080/2162402X.2017.1290035. eCollection 2017.
• [247] A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.Melanoma Res. 2019 Dec;29(6):582-589. doi: 10.1097/CMR.0000000000000640.
• [248] Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation.Front Biosci. 2008 Jan 1;13:2435-43. doi: 10.2741/2856.
• [249] Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.EBioMedicine. 2016 Aug;10:85-100. doi: 10.1016/j.ebiom.2016.06.023. Epub 2016 Jun 16.
• [250] RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.Cell Signal. 2016 May;28(5):335-347. doi: 10.1016/j.cellsig.2016.01.012. Epub 2016 Jan 29.
• [251] PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.PLoS Genet. 2016 Dec 15;12(12):e1006518. doi: 10.1371/journal.pgen.1006518. eCollection 2016 Dec.
• [252] GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.Sci Immunol. 2019 Dec 13;4(42):eaax8189. doi: 10.1126/sciimmunol.aax8189.
• [253] Hu antigen R (HuR) heterogeneous expression quantification as a prognostic marker of melanoma.J Cutan Pathol. 2018 May;45(5):333-336. doi: 10.1111/cup.13119. Epub 2018 Feb 23.
• [254] Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.Cancer Immunol Res. 2017 May;5(5):417-424. doi: 10.1158/2326-6066.CIR-16-0325. Epub 2017 Apr 14.
• [255] MicroRNA-363-3p/p21(Cip1/Waf1) axis is regulated by HIF-2 in mediating stemness of melanoma cells.Neoplasma. 2019 May 23;66(3):427-436. doi: 10.4149/neo_2018_180828N655.
• [256] Curcumin-loaded nanoemulsion: a new safe and effective formulation to prevent tumor reincidence and metastasis.Nanoscale. 2018 Dec 21;10(47):22612-22622. doi: 10.1039/c8nr06173d. Epub 2018 Nov 28.
• [257] Recombinant human erythropoietin stimulates melanoma tumor growth through activation of initiation factor eIF4E.Oncotarget. 2017 May 2;8(18):30317-30327. doi: 10.18632/oncotarget.16331.
• [258] IRE1 Activation in Bone Marrow-Derived Dendritic Cells Modulates Innate Recognition of Melanoma Cells and Favors CD8(+) T Cell Priming.Front Immunol. 2019 Jan 4;9:3050. doi: 10.3389/fimmu.2018.03050. eCollection 2018.
• [259] ERR Maintains Mitochondrial Oxidative Metabolism and Constitutes an Actionable Target in PGC1-Elevated Melanomas.Mol Cancer Res. 2017 Oct;15(10):1366-1375. doi: 10.1158/1541-7786.MCR-17-0143. Epub 2017 Jun 8.
• [260] Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.Int J Cancer. 2018 Apr 15;142(8):1652-1663. doi: 10.1002/ijc.31196. Epub 2017 Dec 15.
• [261] The epidermal polarity protein Par3 is a non-cell autonomous suppressor of malignant melanoma.J Exp Med. 2017 Feb;214(2):339-358. doi: 10.1084/jem.20160596. Epub 2017 Jan 17.
• [262] Integrated case-control and somatic-germline interaction analyses of melanoma susceptibility genes.Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt B):2247-2254. doi: 10.1016/j.bbadis.2018.01.007. Epub 2018 Jan 6.
• [263] Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.Am J Dermatopathol. 2018 Apr;40(4):259-264. doi: 10.1097/DAD.0000000000000939.
• [264] FBXW7-mediated stability regulation of signal transducer and activator of transcription 2 in melanoma formation.Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):584-594. doi: 10.1073/pnas.1909879116. Epub 2019 Dec 16.
• [265] Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.J Clin Invest. 2017 Jun 1;127(6):2310-2325. doi: 10.1172/JCI91291. Epub 2017 May 2.
• [266] G protein-coupled receptor 40 expression in human melanoma - correlation with tumour thickness, AJCC stage and survival.J Eur Acad Dermatol Venereol. 2020 Feb;34(2):285-292. doi: 10.1111/jdv.15924. Epub 2019 Oct 31.
• [267] Fatty acid receptor GPR120: a novel marker for human melanoma.Melanoma Res. 2018 Aug;28(4):271-276. doi: 10.1097/CMR.0000000000000445.
• [268] BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1.Oncogenesis. 2018 Sep 20;7(9):71. doi: 10.1038/s41389-018-0082-2.
• [269] CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells.Sci Rep. 2018 Aug 8;8(1):11893. doi: 10.1038/s41598-018-30338-4.
• [270] FOXQ1 controls the induced differentiation of melanocytic cells.Cell Death Differ. 2018 Jun;25(6):1040-1049. doi: 10.1038/s41418-018-0066-y. Epub 2018 Feb 20.
• [271] Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.J Exp Clin Cancer Res. 2017 Dec 8;36(1):180. doi: 10.1186/s13046-017-0650-x.
• [272] Fascin induces melanoma tumorigenesis and stemness through regulating the Hippo pathway.Cell Commun Signal. 2018 Jul 3;16(1):37. doi: 10.1186/s12964-018-0250-1.
• [273] MicroRNA-485-5p represses melanoma cell invasion and proliferation by suppressing Frizzled7.Biomed Pharmacother. 2017 Jun;90:303-310. doi: 10.1016/j.biopha.2017.03.064. Epub 2017 Mar 30.
• [274] Growth Hormone Upregulates Melanocyte-Inducing Transcription Factor Expression and Activity via JAK2-STAT5 and SRC Signaling in GH Receptor-Positive Human Melanoma.Cancers (Basel). 2019 Sep 12;11(9):1352. doi: 10.3390/cancers11091352.
• [275] The influence of oral tumor cell proliferation activity and membrane potential on the transfection efficiency of a cationic liposome.Oncol Rep. 2005 Dec;14(6):1487-91.
• [276] Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.Pathol Oncol Res. 2019 Oct;25(4):1319-1325. doi: 10.1007/s12253-017-0371-7. Epub 2017 Dec 5.
• [277] Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.Oncotarget. 2013 Oct;4(10):1721-8. doi: 10.18632/oncotarget.1379.
• [278] miR-9 regulates ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in melanoma.Mol Carcinog. 2018 Nov;57(11):1566-1576. doi: 10.1002/mc.22878. Epub 2018 Aug 14.
• [279] Next-Generation Cancer Immunotherapy Targeting Glypican-3.Front Oncol. 2019 Apr 10;9:248. doi: 10.3389/fonc.2019.00248. eCollection 2019.
• [280] NFATc2 is an intrinsic regulator of melanoma dedifferentiation.Oncogene. 2016 Jun 2;35(22):2862-72. doi: 10.1038/onc.2015.355. Epub 2015 Sep 21.
• [281] Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.J Am Acad Dermatol. 2019 Jan;80(1):149-157.e4. doi: 10.1016/j.jaad.2018.07.028. Epub 2018 Aug 4.
• [282] Gelsolin affects the migratory ability of human colon adenocarcinoma and melanoma cells.Life Sci. 2012 Jun 6;90(21-22):851-61. doi: 10.1016/j.lfs.2012.03.039. Epub 2012 Apr 19.
• [283] Glutathione reductase-mediated thiol oxidative stress suppresses metastasis of murine melanoma cells.Free Radic Biol Med. 2018 Dec;129:256-267. doi: 10.1016/j.freeradbiomed.2018.07.025. Epub 2018 Aug 4.
• [284] Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma.Oncoimmunology. 2018 Sep 25;7(12):e1504727. doi: 10.1080/2162402X.2018.1504727. eCollection 2018.
• [285] Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.Oncotarget. 2012 Apr;3(4):399-413. doi: 10.18632/oncotarget.473.
• [286] Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma.Cancer Discov. 2019 Apr;9(4):469-471. doi: 10.1158/2159-8290.CD-19-0069.
• [287] Real-time RT-PCR analysis of human histidine decarboxylase, a new marker for several types of leukemia and cancer.Oncol Rep. 2006 Jan;15(1):193-7.
• [288] Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma.Mol Cell. 2016 Apr 7;62(1):34-46. doi: 10.1016/j.molcel.2016.03.013.
• [289] HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor.Br J Dermatol. 2006 Feb;154(2):261-6. doi: 10.1111/j.1365-2133.2005.06896.x.
• [290] SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):40-45. doi: 10.1097/PAI.0000000000000500.
• [291] Loss of SR-BI Down-Regulates MITF and Suppresses Extracellular Vesicle Release in Human Melanoma.Int J Mol Sci. 2019 Mar 1;20(5):1063. doi: 10.3390/ijms20051063.
• [292] Characterisation of the cancer-associated glucocorticoid system: key role of 11-hydroxysteroid dehydrogenase type 2.Br J Cancer. 2017 Sep 26;117(7):984-993. doi: 10.1038/bjc.2017.243. Epub 2017 Aug 10.
• [293] Heat Shock Factor 1 Is a Direct Antagonist of AMP-Activated Protein Kinase.Mol Cell. 2019 Nov 21;76(4):546-561.e8. doi: 10.1016/j.molcel.2019.08.021. Epub 2019 Sep 24.
• [294] Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases.Melanoma Res. 2005 Aug;15(4):235-44. doi: 10.1097/00008390-200508000-00002.
• [295] Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in KRAS and BRAF Tumor Cells.Mol Cell Biol. 2017 Aug 28;37(18):e00061-17. doi: 10.1128/MCB.00061-17. Print 2017 Sep 15.
• [296] Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.Mol Oncol. 2017 Jun;11(6):599-611. doi: 10.1002/1878-0261.12042. Epub 2017 May 8.
• [297] Restored expression of the atypical heat shock protein H11/HspB8 inhibits the growth of genetically diverse melanoma tumors through activation of novel TAK1-dependent death pathways.Cell Death Dis. 2012 Aug 16;3(8):e371. doi: 10.1038/cddis.2012.108.
• [298] Cell surface chondroitin sulphate proteoglycan 4 (CSPG4) binds to the basement membrane heparan sulphate proteoglycan, perlecan, and is involved in cell adhesion.J Biochem. 2018 May 1;163(5):399-412. doi: 10.1093/jb/mvy008.
• [299] Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.Clin Cancer Res. 2018 Nov 15;24(22):5685-5696. doi: 10.1158/1078-0432.CCR-18-0554. Epub 2018 Jul 31.
• [300] Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression.Cancer Res. 2011 May 15;71(10):3494-504. doi: 10.1158/0008-5472.CAN-10-3555. Epub 2011 Apr 5.
• [301] Mps1 is associated with the BRAF(V600E) mutation and predicts poor outcome in patients with colorectal cancer.Oncol Lett. 2019 Mar;17(3):2809-2817. doi: 10.3892/ol.2019.9924. Epub 2019 Jan 14.
• [302] Antitumor Activity of BRAF Inhibitor and IFN Combination in BRAF-Mutant Melanoma.J Natl Cancer Inst. 2016 Feb 5;108(7):djv435. doi: 10.1093/jnci/djv435. Print 2016 Jul.
• [303] Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-1 release.Virus Genes. 2017 Jun;53(3):477-482. doi: 10.1007/s11262-017-1434-2. Epub 2017 Feb 10.
• [304] IGFBP-3 inhibits Wnt signaling in metastatic melanoma cells.Mol Carcinog. 2017 Feb;56(2):681-693. doi: 10.1002/mc.22525. Epub 2016 Jul 27.
• [305] Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKK inhibition.Redox Biol. 2017 Apr;11:562-576. doi: 10.1016/j.redox.2017.01.010. Epub 2017 Jan 12.
• [306] Interleukin-13 receptor 2 is a novel marker and potential therapeutic target for human melanoma.Sci Rep. 2019 Feb 4;9(1):1281. doi: 10.1038/s41598-019-39018-3.
• [307] Apoptosis related protein-1 triggers melanoma cell death via interaction with the juxtamembrane region of p75 neurotrophin receptor.J Cell Mol Med. 2012 Feb;16(2):349-61. doi: 10.1111/j.1582-4934.2011.01304.x.
• [308] Interleukin 32 expression in human melanoma.J Transl Med. 2019 Apr 5;17(1):113. doi: 10.1186/s12967-019-1862-y.
• [309] Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma.Biomaterials. 2018 Mar;159:161-173. doi: 10.1016/j.biomaterials.2018.01.013. Epub 2018 Jan 8.
• [310] T(H)9 cells in anti-tumor immunity.Semin Immunopathol. 2017 Jan;39(1):39-46. doi: 10.1007/s00281-016-0599-4. Epub 2016 Nov 10.
• [311] Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.Medchemcomm. 2017 Jan 1;8(1):88-95. doi: 10.1039/C6MD00466K. Epub 2016 Oct 27.
• [312] Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.J Immunother Cancer. 2019 Sep 18;7(1):254. doi: 10.1186/s40425-019-0731-9.
• [313] Agaricus blazei Murill Polysaccharides Protect Against Cadmium-Induced Oxidative Stress and Inflammatory Damage in Chicken Spleens.Biol Trace Elem Res. 2018 Jul;184(1):247-258. doi: 10.1007/s12011-017-1189-6. Epub 2017 Oct 14.
• [314] Integrin VLA-4 enhances sialyl-Lewisx/a-negative melanoma adhesion to and extravasation through the endothelium under low flow conditions.Am J Physiol Cell Physiol. 2008 Sep;295(3):C701-7. doi: 10.1152/ajpcell.00245.2008. Epub 2008 Jul 16.
• [315] Integrin genes and susceptibility to human melanoma.Mutagenesis. 2012 May;27(3):367-73. doi: 10.1093/mutage/ger090. Epub 2011 Dec 20.
• [316] Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.Cancer Res. 2019 Mar 15;79(6):1113-1123. doi: 10.1158/0008-5472.CAN-18-1722. Epub 2019 Jan 23.
• [317] LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro.BMC Cancer. 2012 Oct 5;12:455. doi: 10.1186/1471-2407-12-455.
• [318] Acquired IFN resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.Nat Commun. 2017 May 31;8:15440. doi: 10.1038/ncomms15440.
• [319] The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells.Tumour Biol. 2016 May;37(5):6275-83. doi: 10.1007/s13277-015-4509-5. Epub 2015 Nov 30.
• [320] Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.Melanoma Res. 2018 Oct;28(5):380-389. doi: 10.1097/CMR.0000000000000473.
• [321] H3K27 Demethylase JMJD3 Employs the NF-B and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis.Cancer Res. 2016 Jan 1;76(1):161-70. doi: 10.1158/0008-5472.CAN-15-0536.
• [322] An immunohistochemical study of NFE2L2, KEAP1 and 8-hydroxy-2'-deoxyguanosine and the EMT markers SNAI2, ZEB1 and TWIST1 in metastatic melanoma.Histol Histopathol. 2017 Feb;32(2):129-136. doi: 10.14670/HH-11-778. Epub 2016 May 12.
• [323] p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors.Cancer Cell. 2019 Jan 14;35(1):46-63.e10. doi: 10.1016/j.ccell.2018.11.008. Epub 2018 Dec 20.
• [324] Associations between sun sensitive pigmentary genes and serum prostate specific antigen levels.PLoS One. 2018 Mar 8;13(3):e0193893. doi: 10.1371/journal.pone.0193893. eCollection 2018.
• [325] Kallikrein-related peptidase 7 overexpression in melanoma cells modulates cell adhesion leading to a malignant phenotype.Biol Chem. 2018 Sep 25;399(9):1099-1105. doi: 10.1515/hsz-2017-0339.
• [326] Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAF(V600E) Melanoma Lines with Vemurafenib.Cancer Immunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub 2017 Jun 2.
• [327] Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.J Am Acad Dermatol. 2019 Jul;81(1):219-227. doi: 10.1016/j.jaad.2019.03.012. Epub 2019 Mar 14.
• [328] Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.J Natl Cancer Inst. 2016 Jun 22;108(11):djw144. doi: 10.1093/jnci/djw144. Print 2016 Nov.
• [329] Low-level internalization of cystatin E/M affects legumain activity and migration of melanoma cells.J Biol Chem. 2017 Sep 1;292(35):14413-14424. doi: 10.1074/jbc.M117.776138. Epub 2017 Jun 19.
• [330] Anti-tumor effects of differentiation-inducing factor-1 in malignant melanoma: GSK-3-mediated inhibition of cell proliferation and GSK-3-independent suppression of cell migration and invasion.Biochem Pharmacol. 2017 Aug 15;138:31-48. doi: 10.1016/j.bcp.2017.05.004. Epub 2017 May 10.
• [331] Endothelial Rab7 GTPase mediates tumor growth and metastasis in lysosomal acid lipase-deficient mice.J Biol Chem. 2017 Nov 24;292(47):19198-19208. doi: 10.1074/jbc.M116.773093. Epub 2017 Sep 18.
• [332] miR-122-5p Expression and Secretion in Melanoma Cells Is Amplified by the LPAR3 SH3-Binding Domain to Regulate Wnt1.Mol Cancer Res. 2019 Jan;17(1):299-309. doi: 10.1158/1541-7786.MCR-18-0460. Epub 2018 Sep 28.
• [333] Involvement of LPA receptor-5 in the enhancement of cell motile activity by phorbol ester and anticancer drug treatments in melanoma A375cells.Biochem Biophys Res Commun. 2018 Jan 29;496(1):225-230. doi: 10.1016/j.bbrc.2018.01.030. Epub 2018 Jan 5.
• [334] Interaction of two antitumor peptides with membrane lipids - Influence of phosphatidylserine and cholesterol on specificity for melanoma cells.PLoS One. 2019 Jan 25;14(1):e0211187. doi: 10.1371/journal.pone.0211187. eCollection 2019.
• [335] Antibody response against cancer-testis antigens MAGEA4 and MAGEA10 in patients with melanoma.Oncol Lett. 2018 Jul;16(1):211-218. doi: 10.3892/ol.2018.8684. Epub 2018 May 10.
• [336] MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.Clin Cancer Res. 2003 Mar;9(3):947-54.
• [337] Effects of CT-Xp gene knock down in melanoma cell lines.Oncotarget. 2013 Apr;4(4):531-41. doi: 10.18632/oncotarget.921.
• [338] MALT1 promotes melanoma progression through JNK/c-Jun signaling.Oncogenesis. 2017 Jul 31;6(7):e365. doi: 10.1038/oncsis.2017.68.
• [339] A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.Cancer Res. 2019 May 1;79(9):2352-2366. doi: 10.1158/0008-5472.CAN-18-2711. Epub 2019 Feb 28.
• [340] Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.Anticancer Res. 2018 Nov;38(11):6393-6397. doi: 10.21873/anticanres.12999.
• [341] TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma.Cell Death Differ. 2019 Dec;26(12):2520-2534. doi: 10.1038/s41418-019-0315-8. Epub 2019 Mar 8.
• [342] Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.Nat Med. 2019 Apr;25(4):597-602. doi: 10.1038/s41591-019-0373-y. Epub 2019 Mar 4.
• [343] The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.Oncotarget. 2011 Jan-Feb;2(1-2):8-17. doi: 10.18632/oncotarget.211.
• [344] Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.Mol Cancer Ther. 2019 Feb;18(2):289-300. doi: 10.1158/1535-7163.MCT-17-1141. Epub 2018 Nov 27.
• [345] Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine.Nature. 2017 Jun 28;546(7660):676-680. doi: 10.1038/nature22977.
• [346] MELK Promotes Melanoma Growth by Stimulating the NF-B Pathway.Cell Rep. 2017 Dec 5;21(10):2829-2841. doi: 10.1016/j.celrep.2017.11.033.
• [347] Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.Mol Cancer Ther. 2019 Feb;18(2):278-288. doi: 10.1158/1535-7163.MCT-18-0456. Epub 2018 Nov 27.
• [348] A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
• [349] CD206-positive myeloid cells bind galectin-9 and promote a tumor-supportive microenvironment.J Pathol. 2018 Aug;245(4):468-477. doi: 10.1002/path.5093. Epub 2018 Jun 28.
• [350] RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model.Biol Cell. 2007 Oct;99(10):573-81. doi: 10.1042/bc20060130.
• [351] MicroRNA-331 Inhibits Proliferation and Invasion of Melanoma Cells by Targeting Astrocyte-Elevated Gene-1.Oncol Res. 2018 Oct 17;26(9):1429-1437. doi: 10.3727/096504018X15186047251584. Epub 2018 Feb 17.
• [352] Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment.Cell. 2019 Feb 7;176(4):757-774.e23. doi: 10.1016/j.cell.2018.12.038. Epub 2019 Jan 31.
• [353] Upregulation of LINC00963 facilitates melanoma progression through miR-608/NACC1 pathway and predicts poor prognosis.Biochem Biophys Res Commun. 2018 Sep 26;504(1):34-39. doi: 10.1016/j.bbrc.2018.08.115. Epub 2018 Sep 1.
• [354] Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.Clin Cancer Res. 2017 Nov 15;23(22):6888-6892. doi: 10.1158/1078-0432.CCR-17-1317. Epub 2017 Aug 8.
• [355] A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets.Oncoimmunology. 2018 Aug 15;7(10):e1475875. doi: 10.1080/2162402X.2018.1475875. eCollection 2018.
• [356] Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).Invest New Drugs. 2017 Feb;35(1):11-25. doi: 10.1007/s10637-016-0398-8. Epub 2016 Oct 25.
• [357] Aberrant NEK2 expression might be an independent predictor for poor recurrence-free survival and overall survival of skin cutaneous melanoma.Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3694-3702. doi: 10.26355/eurrev_201806_15248.
• [358] NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.Oncogene. 2016 May;35(21):2735-45. doi: 10.1038/onc.2015.331. Epub 2015 Sep 14.
• [359] Analysis of NOD-like receptor NLRP1 in multiple sclerosis families.Immunogenetics. 2018 Mar;70(3):205-207. doi: 10.1007/s00251-017-1034-2. Epub 2017 Oct 7.
• [360] Notch3 signaling-mediated melanoma-endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis.Lab Invest. 2017 Jun;97(6):725-736. doi: 10.1038/labinvest.2017.1. Epub 2017 Feb 6.
• [361] UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis.Cancer Cell. 2016 Nov 14;30(5):694-707. doi: 10.1016/j.ccell.2016.10.004. Epub 2016 Oct 27.
• [362] ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.Cancer Res. 2015 Sep 1;75(17):3554-67. doi: 10.1158/0008-5472.CAN-14-2959. Epub 2015 Jul 23.
• [363] The neurotrophin Neuritin1 (cpg15) is involved in melanoma migration, attachment independent growth, and vascular mimicry.Oncotarget. 2017 Jan 3;8(1):1117-1131. doi: 10.18632/oncotarget.13585.
• [364] Netrin-1 and Its Receptor DCC Are Causally Implicated in Melanoma Progression.Cancer Res. 2020 Feb 15;80(4):747-756. doi: 10.1158/0008-5472.CAN-18-1590. Epub 2019 Dec 5.
• [365] Cell division cycle-associated protein 1 as a new melanoma-associated antigen.J Dermatol. 2016 Dec;43(12):1399-1405. doi: 10.1111/1346-8138.13436. Epub 2016 May 30.
• [366] Concordant loss of heterozygosity of DNA repair gene, hOGG1, in melanoma in situ and atypical melanocytic hyperplasia.J Cutan Pathol. 2008 Jun;35(6):525-31. doi: 10.1111/j.1600-0560.2007.00865.x. Epub 2008 Feb 28.
• [367] Functional expression of olfactory receptors in human primary melanoma and melanoma metastasis.Exp Dermatol. 2017 Jul;26(7):569-576. doi: 10.1111/exd.13316. Epub 2017 Apr 21.
• [368] Separate roles of IL-6 and oncostatin M in mouse macrophage polarization in vitro and in vivo.Immunol Cell Biol. 2018 Mar;96(3):257-272. doi: 10.1111/imcb.1035. Epub 2017 Dec 26.
• [369] JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component.Mol Cancer. 2017 Nov 29;16(1):175. doi: 10.1186/s12943-017-0744-2.
• [370] PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.Oncogene. 2017 Jun 8;36(23):3252-3262. doi: 10.1038/onc.2016.469. Epub 2017 Jan 16.
• [371] Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1.Oncotarget. 2017 Jun 27;8(40):66833-66848. doi: 10.18632/oncotarget.18706. eCollection 2017 Sep 15.
• [372] Identification of zinc finger protein of the cerebellum 5 as a survival factor of prostate and colorectal cancer cells.Cancer Sci. 2017 Dec;108(12):2405-2412. doi: 10.1111/cas.13419. Epub 2017 Oct 25.
• [373] Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.Br J Cancer. 2017 Mar 14;116(6):802-810. doi: 10.1038/bjc.2017.8. Epub 2017 Feb 7.
• [374] Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.
• [375] (131)I-Traced PLGA-Lipid Nanoparticles as Drug Delivery Carriers for the Targeted Chemotherapeutic Treatment of Melanoma.Nanoscale Res Lett. 2017 Dec;12(1):365. doi: 10.1186/s11671-017-2140-7. Epub 2017 May 19.
• [376] RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma.Cancer Res. 2018 May 1;78(9):2191-2204. doi: 10.1158/0008-5472.CAN-17-2215. Epub 2018 Feb 12.
• [377] Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.Int J Oncol. 2016 Apr;48(4):1581-9. doi: 10.3892/ijo.2016.3362. Epub 2016 Jan 29.
• [378] Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.Cell Metab. 2019 Jun 4;29(6):1410-1421.e4. doi: 10.1016/j.cmet.2019.02.015. Epub 2019 Mar 21.
• [379] Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.Nat Cell Biol. 2019 Jun;21(6):778-790. doi: 10.1038/s41556-019-0328-z. Epub 2019 Jun 3.
• [380] Enhanced Anti-melanoma Efficacy of a Pim-3-Targeting Bifunctional Small Hairpin RNA via Single-Stranded RNA-Mediated Activation of Plasmacytoid Dendritic Cells.Front Immunol. 2019 Nov 26;10:2721. doi: 10.3389/fimmu.2019.02721. eCollection 2019.
• [381] Inhibition of peptidyl-prolyl isomerase (PIN1) and BRAF signaling to target melanoma.Am J Transl Res. 2019 Jul 15;11(7):4425-4437. eCollection 2019.
• [382] Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.Int J Cancer. 2004 May 20;110(1):125-33. doi: 10.1002/ijc.20077.
• [383] Combination therapy of PKC and COX-2 inhibitors synergistically suppress melanoma metastasis.J Exp Clin Cancer Res. 2017 Sep 2;36(1):115. doi: 10.1186/s13046-017-0585-2.
• [384] Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth.Cell Rep. 2016 Mar 22;14(11):2599-610. doi: 10.1016/j.celrep.2016.02.028. Epub 2016 Mar 10.
• [385] PRMT1 regulates tumor growth and metastasis of human melanoma via targeting ALCAM.Mol Med Rep. 2016 Jul;14(1):521-8. doi: 10.3892/mmr.2016.5273. Epub 2016 May 13.
• [386] Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000. doi: 10.1073/pnas.1901323116. Epub 2019 Aug 22.
• [387] SIRT1 regulates Mxd1 during malignant melanoma progression.Oncotarget. 2017 Oct 3;8(70):114540-114553. doi: 10.18632/oncotarget.21457. eCollection 2017 Dec 29.
• [388] Parkinson Disease and Melanoma: Confirming and Reexamining an Association.Mayo Clin Proc. 2017 Jul;92(7):1070-1079. doi: 10.1016/j.mayocp.2017.03.014.
• [389] Systemic Platelet-Activating Factor-Receptor Agonism Enhances Non-Melanoma Skin Cancer Growth.Int J Mol Sci. 2018 Oct 11;19(10):3109. doi: 10.3390/ijms19103109.
• [390] Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis.Oncogene. 2019 May;38(21):4182-4196. doi: 10.1038/s41388-019-0797-3. Epub 2019 Apr 1.
• [391] The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.Clin Cancer Res. 2019 Mar 1;25(5):1650-1663. doi: 10.1158/1078-0432.CCR-18-1163. Epub 2018 Dec 11.
• [392] Electrochemical aptamer-based determination of protein tyrosine kinase-7 using toehold-mediated strand displacement amplification on gold nanoparticles and graphene oxide.Mikrochim Acta. 2019 Oct 26;186(11):720. doi: 10.1007/s00604-019-3849-z.
• [393] Therapeutic silence of pleiotrophin by targeted delivery of siRNA and its effect on the inhibition of tumor growth and metastasis.PLoS One. 2017 May 31;12(5):e0177964. doi: 10.1371/journal.pone.0177964. eCollection 2017.
• [394] PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1.J Invest Dermatol. 2015 Sep;135(9):2273-2282. doi: 10.1038/jid.2015.154. Epub 2015 Apr 10.
• [395] N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.Cell Death Differ. 2018 Feb;25(2):353-367. doi: 10.1038/cdd.2017.165. Epub 2017 Oct 13.
• [396] EPAC-RAP1 Axis-Mediated Switch in the Response of Primary and Metastatic Melanoma to Cyclic AMP.Mol Cancer Res. 2017 Dec;15(12):1792-1802. doi: 10.1158/1541-7786.MCR-17-0067. Epub 2017 Aug 29.
• [397] The alternatively spliced RECK transcript variant 3 is a predictor of poor survival for melanoma patients being upregulated in aggressive cell lines and modulating MMP gene expression in vitro.Melanoma Res. 2020 Jun;30(3):223-234. doi: 10.1097/CMR.0000000000000650.
• [398] Regulator of G protein signaling 4 inhibits human melanoma cells proliferation and invasion through the PI3K/AKT signaling pathway.Oncotarget. 2017 Sep 11;8(45):78530-78544. doi: 10.18632/oncotarget.20825. eCollection 2017 Oct 3.
• [399] Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.Neoplasia. 2018 Dec;20(12):1198-1208. doi: 10.1016/j.neo.2018.10.001. Epub 2018 Nov 4.
• [400] Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.Melanoma Res. 2017 Aug;27(4):309-314. doi: 10.1097/CMR.0000000000000360.
• [401] LncRNA HAND2-AS1 overexpression inhibits cancer cell proliferation in melanoma by downregulating ROCK1.Oncol Lett. 2019 Aug;18(2):1005-1010. doi: 10.3892/ol.2019.10402. Epub 2019 May 27.
• [402] Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination.J Natl Cancer Inst. 2015 Oct 13;108(1):djv289. doi: 10.1093/jnci/djv289. Print 2016 Jan.
• [403] Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.Cancer. 2017 Apr 1;123(7):1194-1201. doi: 10.1002/cncr.30455. Epub 2016 Nov 22.
• [404] p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.J Invest Dermatol. 2017 Oct;137(10):2187-2196. doi: 10.1016/j.jid.2016.12.033. Epub 2017 Jun 7.
• [405] siRNA - Mediated LRP/LR knock-down reduces cellular viability of malignant melanoma cells through the activation of apoptotic caspases.Exp Cell Res. 2018 Jul 1;368(1):1-12. doi: 10.1016/j.yexcr.2018.04.003. Epub 2018 Apr 10.
• [406] Profiles of brain metastases: Prioritization of therapeutic targets.Int J Cancer. 2018 Dec 1;143(11):3019-3026. doi: 10.1002/ijc.31624. Epub 2018 Oct 9.
• [407] The Effect of RGD/NGR Peptide Modification of Melanoma Differentiation-Associated Gene-7/Interleukin-24 on Its Receptor Attachment, an In Silico Analysis.Cancer Biother Radiopharm. 2017 Aug;32(6):205-214. doi: 10.1089/cbr.2017.2195. Epub 2017 Aug 9.
• [408] Runx2 stimulates neoangiogenesis through the Runt domain in melanoma.Sci Rep. 2019 May 29;9(1):8052. doi: 10.1038/s41598-019-44552-1.
• [409] Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.Cancer Lett. 2019 Jun 28;452:178-190. doi: 10.1016/j.canlet.2019.03.023. Epub 2019 Mar 21.
• [410] Enhanced chemosensitization of anoikis-resistant melanoma cells through syndecan-2 upregulation upon anchorage independency.Oncotarget. 2017 Jun 27;8(37):61528-61537. doi: 10.18632/oncotarget.18616. eCollection 2017 Sep 22.
• [411] SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma.PLoS One. 2017 Jun 29;12(6):e0180392. doi: 10.1371/journal.pone.0180392. eCollection 2017.
• [412] Activation of human vascular endothelium in melanoma metastases induces ICAM-1 and E-selectin expression and results in increased infiltration with effector lymphocytes.Exp Dermatol. 2019 Nov;28(11):1258-1269. doi: 10.1111/exd.14023. Epub 2019 Sep 9.
• [413] IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin.Sci Rep. 2016 Jul 14;6:29736. doi: 10.1038/srep29736.
• [414] Sema4D, the ligand for Plexin B1, suppresses c-Met activation and migration and promotes melanocyte survival and growth.J Invest Dermatol. 2012 Apr;132(4):1230-8. doi: 10.1038/jid.2011.414. Epub 2011 Dec 22.
• [415] Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.Nat Genet. 2016 Nov;48(11):1327-1329. doi: 10.1038/ng.3677. Epub 2016 Sep 26.
• [416] Maspin and Mutant p53 expression in malignant melanoma and carcinoma: use of tissue microarray.Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):19-23. doi: 10.1097/PAI.0b013e31815d0fca.
• [417] Analysis of Malignant Melanoma Cell Lines Exposed to Hypoxia Reveals the Importance of PFKFB4 Overexpression for Disease Progression.Anticancer Res. 2018 Dec;38(12):6745-6752. doi: 10.21873/anticanres.13044.
• [418] Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene.Carcinogenesis. 2020 May 14;41(3):284-295. doi: 10.1093/carcin/bgz153.
• [419] miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma.Cell Death Differ. 2018 Aug;25(8):1457-1472. doi: 10.1038/s41418-017-0053-8. Epub 2018 Jan 18.
• [420] Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes.Diabetes Obes Metab. 2018 Dec;20(12):2919-2924. doi: 10.1111/dom.13474. Epub 2018 Aug 23.
• [421] SMAD7 is a novel independent predictor of survival in patients with cutaneous melanoma.Transl Res. 2019 Feb;204:72-81. doi: 10.1016/j.trsl.2018.09.002. Epub 2018 Sep 27.
• [422] SOX5 is involved in balanced MITF regulation in human melanoma cells.BMC Med Genomics. 2016 Feb 29;9:10. doi: 10.1186/s12920-016-0170-0.
• [423] SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development.FASEB J. 2018 Oct;32(10):5647-5660. doi: 10.1096/fj.201700645RRRRR. Epub 2018 May 11.
• [424] Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy.Mol Cancer Res. 2009 Mar;7(3):300-10. doi: 10.1158/1541-7786.MCR-08-0215. Epub 2009 Mar 10.
• [425] Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.J Immunother Cancer. 2017 Sep 19;5(1):72. doi: 10.1186/s40425-017-0276-8.
• [426] Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models.Sci Rep. 2018 Oct 24;8(1):15726. doi: 10.1038/s41598-018-33879-w.
• [427] Molecular analysis of melanoma precursor lesions.Cell Growth Differ. 1996 Dec;7(12):1733-40.
• [428] Toll-like receptors 7 and 8 expression correlates with the expression of immune biomarkers and positively predicts the clinical outcome of patients with melanoma.Onco Targets Ther. 2017 Sep 1;10:4339-4346. doi: 10.2147/OTT.S136194. eCollection 2017.
• [429] Actin-sequestering protein, thymosin beta-4, induces paclitaxel resistance through ROS/HIF-1alpha stabilization in HeLa human cervical tumor cells.Life Sci. 2010 Aug 28;87(9-10):286-93. doi: 10.1016/j.lfs.2010.07.002. Epub 2010 Jul 14.
• [430] TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma.Cancer Immunol Immunother. 2019 Sep;68(9):1493-1500. doi: 10.1007/s00262-019-02382-0. Epub 2019 Sep 9.
• [431] Naringenin Impairs Two-Pore Channel 2 Activity And Inhibits VEGF-Induced Angiogenesis.Sci Rep. 2017 Jul 11;7(1):5121. doi: 10.1038/s41598-017-04974-1.
• [432] TCTP as a therapeutic target in melanoma treatment.Br J Cancer. 2017 Aug 22;117(5):656-665. doi: 10.1038/bjc.2017.230. Epub 2017 Jul 27.
• [433] Identification and analyses of natural compounds as potential inhibitors of TRAF6-Basigin interactions in melanoma using structure-based virtual screening and molecular dynamics simulations.J Mol Graph Model. 2018 Oct;85:281-293. doi: 10.1016/j.jmgm.2018.09.008. Epub 2018 Sep 17.
• [434] The Alzheimer's disease-associated TREM2 gene is regulated by p53 tumor suppressor protein.Neurosci Lett. 2018 Aug 10;681:62-67. doi: 10.1016/j.neulet.2018.05.037. Epub 2018 May 26.
• [435] LncRNA SNHG5 promotes growth and invasion in melanoma by regulating the miR-26a-5p/TRPC3 pathway.Onco Targets Ther. 2018 Dec 24;12:169-179. doi: 10.2147/OTT.S184078. eCollection 2019.
• [436] TRPM8: a potential target for cancer treatment.J Cancer Res Clin Oncol. 2016 Sep;142(9):1871-81. doi: 10.1007/s00432-015-2112-1. Epub 2016 Jan 23.
• [437] Tyro3-mediated phosphorylation of ACTN4 at tyrosines is FAK-dependent and decreases susceptibility to cleavage by m-Calpain.Int J Biochem Cell Biol. 2018 Feb;95:73-84. doi: 10.1016/j.biocel.2017.12.014. Epub 2017 Dec 20.
• [438] UCHL1 Regulates Melanogenesis throughControlling MITF Stability in Human Melanocytes.J Invest Dermatol. 2017 Aug;137(8):1757-1765. doi: 10.1016/j.jid.2017.03.024. Epub 2017 Apr 6.
• [439] Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals.Oncogene. 2017 Mar 23;36(12):1644-1654. doi: 10.1038/onc.2016.330. Epub 2016 Nov 21.
• [440] USP5 promotes tumorigenesis and progression of pancreatic cancer by stabilizing FoxM1 protein.Biochem Biophys Res Commun. 2017 Oct 7;492(1):48-54. doi: 10.1016/j.bbrc.2017.08.040. Epub 2017 Aug 12.
• [441] Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs.Cancer Res. 2018 Sep 15;78(18):5349-5362. doi: 10.1158/0008-5472.CAN-18-0644. Epub 2018 Jul 19.
• [442] USP8 suppresses death receptor-mediated apoptosis by enhancing FLIP(L) stability.Oncogene. 2017 Jan 26;36(4):458-470. doi: 10.1038/onc.2016.215. Epub 2016 Jun 20.
• [443] BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.Cell Death Dis. 2018 Sep 5;9(9):907. doi: 10.1038/s41419-018-0932-z.
• [444] Discrepancy Between Tumor Antigen Distribution and Radiolabeled Antibody Binding in a Nude Mouse Xenograft Model of Human Melanoma.Cancer Biother Radiopharm. 2017 Apr;32(3):83-89. doi: 10.1089/cbr.2016.2115. Epub 2017 Apr 5.
• [445] Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697. doi: 10.1073/pnas.1811067116. Epub 2019 Jan 11.
• [446] Ku80 promotes melanoma growth and regulates antitumor effect of melatonin by targeting HIF1- dependent PDK-1 signaling pathway.Redox Biol. 2019 Jul;25:101197. doi: 10.1016/j.redox.2019.101197. Epub 2019 Apr 20.
• [447] Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors.Cell Oncol (Dordr). 2018 Aug;41(4):379-393. doi: 10.1007/s13402-018-0375-7. Epub 2018 Mar 7.
• [448] Prognostic significance of 2-adrenergic receptor expression in malignant melanoma.Tumour Biol. 2016 May;37(5):5971-8. doi: 10.1007/s13277-015-4420-0. Epub 2015 Nov 23.
• [449] Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.Cancer Discov. 2014 May;4(5):538-45. doi: 10.1158/2159-8290.CD-13-1038. Epub 2014 Mar 3.
• [450] Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.PLoS Genet. 2013 Apr;9(4):e1003464. doi: 10.1371/journal.pgen.1003464. Epub 2013 Apr 25.
• [451] Delivery of PUMA Apoptosis Gene Using Polyethyleneimine-SMCC-TAT/DNA Nanoparticles: Biophysical Characterization and In Vitro Transfection Into Malignant Melanoma Cells.J Biomed Nanotechnol. 2015 Oct;11(10):1776-82. doi: 10.1166/jbn.2015.2151.
• [452] MC1R CpG island regulates MC1R expression and is methylated in a subset of melanoma tumours.Pigment Cell Melanoma Res. 2019 Mar;32(2):320-325. doi: 10.1111/pcmr.12739. Epub 2018 Oct 18.
• [453] Novel antibody probes for the characterization of endosialin/TEM-1.Oncotarget. 2016 Oct 25;7(43):69420-69435. doi: 10.18632/oncotarget.11018.
• [454] Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy.Oncoimmunology. 2019 Oct 11;8(12):e1672494. doi: 10.1080/2162402X.2019.1672494. eCollection 2019.
• [455] Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity.J Exp Med. 2018 Mar 5;215(3):877-893. doi: 10.1084/jem.20171435. Epub 2018 Feb 7.
• [456] Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.J Mol Med (Berl). 2019 Aug;97(8):1139-1153. doi: 10.1007/s00109-019-01797-7. Epub 2019 Jun 3.
• [457] Tumor-suppressive effects of CDK8 in endometrial cancer cells.Cell Cycle. 2013 Mar 15;12(6):987-99. doi: 10.4161/cc.24003. Epub 2013 Mar 1.
• [458] High-throughput sequencing of the melanoma genome.Exp Dermatol. 2013 Jan;22(1):10-7. doi: 10.1111/exd.12054. Epub 2012 Nov 22.
• [459] Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment.Semin Cancer Biol. 2011 Apr;21(2):83-8. doi: 10.1016/j.semcancer.2010.12.007. Epub 2010 Dec 13.
• [460] Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.Immunity. 2019 Jun 18;50(6):1498-1512.e5. doi: 10.1016/j.immuni.2019.04.010. Epub 2019 May 13.
• [461] Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy.Mol Cancer Ther. 2019 Dec;18(12):2343-2356. doi: 10.1158/1535-7163.MCT-18-1262. Epub 2019 Sep 12.
• [462] Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion.Oncogene. 2013 Apr 25;32(17):2131-9. doi: 10.1038/onc.2012.239. Epub 2012 Jun 11.
• [463] Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma.Oncotarget. 2014 May 15;5(9):2450-61. doi: 10.18632/oncotarget.1683.
• [464] Dynamic interactions between cancer cells and the embryonic microenvironment regulate cell invasion and reveal EphB6 as a metastasis suppressor.Mol Cancer Res. 2014 Sep;12(9):1303-13. doi: 10.1158/1541-7786.MCR-13-0673. Epub 2014 May 16.
• [465] Selective Uptake Into Drug Resistant Mammalian Cancer by Cell Penetrating Peptide-Mediated Delivery.Bioconjug Chem. 2018 Oct 17;29(10):3273-3284. doi: 10.1021/acs.bioconjchem.8b00429. Epub 2018 Oct 8.
• [466] MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.Cancer Res. 2019 May 15;79(10):2649-2661. doi: 10.1158/0008-5472.CAN-18-2331. Epub 2019 Mar 25.
• [467] Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression.Int J Oncol. 2015 Apr;46(4):1667-76. doi: 10.3892/ijo.2015.2886. Epub 2015 Feb 10.
• [468] KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis.Immunogenetics. 2013 May;65(5):333-43. doi: 10.1007/s00251-013-0682-0. Epub 2013 Jan 31.
• [469] Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.Cancer Res. 2016 May 15;76(10):3067-77. doi: 10.1158/0008-5472.CAN-15-2680. Epub 2016 Mar 15.
• [470] GRP94/gp96 in Cancer: Biology, Structure, Immunology, and Drug Development.Adv Cancer Res. 2016;129:165-90. doi: 10.1016/bs.acr.2015.09.001. Epub 2015 Sep 28.
• [471] Silencing the KCNK9 potassium channel (TASK-3) gene disturbs mitochondrial function, causes mitochondrial depolarization, and induces apoptosis of human melanoma cells.Arch Dermatol Res. 2014 Dec;306(10):885-902. doi: 10.1007/s00403-014-1511-5. Epub 2014 Oct 16.
• [472] The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis.FASEB J. 2019 Mar;33(3):3465-3480. doi: 10.1096/fj.201801339RRR. Epub 2018 Nov 20.
• [473] Matrix metalloproteinases MMP-1, MMP-2, and MMP-13 are overexpressed in primary nodular melanoma.J Cutan Pathol. 2020 Feb;47(2):139-145. doi: 10.1111/cup.13603. Epub 2019 Nov 27.
• [474] Fluorescence In Situ Hybridization for Melanoma Diagnosis: A Review and a Reappraisal.Am J Dermatopathol. 2016 Apr;38(4):253-69. doi: 10.1097/DAD.0000000000000380.
• [475] Notch4 Signaling Induces a Mesenchymal-Epithelial-like Transition in Melanoma Cells to Suppress Malignant Behaviors.Cancer Res. 2016 Apr 1;76(7):1690-7. doi: 10.1158/0008-5472.CAN-15-1722. Epub 2016 Jan 22.
• [476] NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.Cancer Res. 2015 Jul 1;75(13):2708-15. doi: 10.1158/0008-5472.CAN-13-3209. Epub 2015 Apr 1.
• [477] The effect of fenofibrate, a PPAR activator on toll-like receptor-4 signal transduction in melanoma both in vitro and in vivo.Clin Transl Oncol. 2020 Apr;22(4):486-494. doi: 10.1007/s12094-019-02150-7. Epub 2019 Jun 7.
• [478] Conformation-dependent binding of a Tetrastatin peptide to (v)(3) integrin decreases melanoma progression through FAK/PI(3)K/Akt pathway inhibition.Sci Rep. 2018 Jun 29;8(1):9837. doi: 10.1038/s41598-018-28003-x.
• [479] A potential function of RLIP76 in the ovarian corpus luteum.J Ovarian Res. 2019 Apr 18;12(1):34. doi: 10.1186/s13048-019-0510-8.
• [480] Molecular genetics and targeted therapy of WNT-related human diseases (Review).Int J Mol Med. 2017 Sep;40(3):587-606. doi: 10.3892/ijmm.2017.3071. Epub 2017 Jul 19.
• [481] Anti-tumor effects of resveratrol on malignant melanoma is associated with promoter demethylation of RUNX3 gene.Pharmazie. 2019 Mar 1;74(3):163-167. doi: 10.1691/ph.2019.8838.
• [482] MicroRNA-373 promotes cell migration via targeting salt-inducible kinase 1 expression in melanoma.Exp Ther Med. 2018 Dec;16(6):4759-4764. doi: 10.3892/etm.2018.6784. Epub 2018 Sep 21.
• [483] Combination of chemotherapy and physical plasma elicits melanoma cell death via upregulation of SLC22A16.Cell Death Dis. 2018 Dec 5;9(12):1179. doi: 10.1038/s41419-018-1221-6.
• [484] Role of Acid Sphingomyelinase-Induced Signaling in Melanoma Cells for Hematogenous Tumor Metastasis.Cell Physiol Biochem. 2016;38(1):1-14. doi: 10.1159/000438604. Epub 2016 Jan 8.
• [485] Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism.Am J Emerg Med. 2017 Jul;35(7):1039.e5-1039.e7. doi: 10.1016/j.ajem.2017.02.048. Epub 2017 Feb 27.
• [486] Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.Exp Dermatol. 2019 Jan;28(1):35-44. doi: 10.1111/exd.13805. Epub 2018 Dec 21.
• [487] Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies.Oncotarget. 2016 Oct 11;7(41):66569-66585. doi: 10.18632/oncotarget.11892.
• [488] Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk.Int J Cancer. 2015 Oct 15;137(8):1901-1909. doi: 10.1002/ijc.29570. Epub 2015 May 26.
• [489] Tie2-dependent deletion of 6 integrin subunit in mice reduces tumor growth and angiogenesis.Int J Oncol. 2014 Nov;45(5):2058-64. doi: 10.3892/ijo.2014.2631. Epub 2014 Sep 1.
• [490] Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.ACS Nano. 2019 Nov 26;13(11):12671-12686. doi: 10.1021/acsnano.9b04207. Epub 2019 Oct 11.
• [491] Sensitization of Melanoma Cells for Death Ligand TRAIL Is Based on Cell Cycle Arrest, ROS Production, and Activation of Proapoptotic Bcl-2 Proteins.J Invest Dermatol. 2015 Nov;135(11):2794-2804. doi: 10.1038/jid.2015.250. Epub 2015 Jul 2.
• [492] Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.Clin Cancer Res. 2015 Dec 1;21(23):5338-48. doi: 10.1158/1078-0432.CCR-15-0293. Epub 2015 Jul 7.
• [493] Targeting of TRX2 by miR-330-3p in melanoma inhibits proliferation.Biomed Pharmacother. 2018 Nov;107:1020-1029. doi: 10.1016/j.biopha.2018.08.058. Epub 2018 Aug 24.
• [494] Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis.Clin Chem. 2014 Jun;60(6):873-85. doi: 10.1373/clinchem.2013.213611. Epub 2014 Apr 9.
• [495] Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.Int J Cancer. 2005 Jun 20;115(3):393-402. doi: 10.1002/ijc.20899.
• [496] Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.Cancer Res. 2014 Dec 15;74(24):7250-9. doi: 10.1158/0008-5472.CAN-13-3583. Epub 2014 Nov 6.
• [497] Characterization of the Methylthioadenosine Phosphorylase Polymorphism rs7023954 - Incidence and Effects on Enzymatic Function in Malignant Melanoma.PLoS One. 2016 Aug 1;11(8):e0160348. doi: 10.1371/journal.pone.0160348. eCollection 2016.
• [498] -Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.Tumour Biol. 2014 Dec;35(12):12015-20. doi: 10.1007/s13277-014-2500-1. Epub 2014 Aug 24.
• [499] Basic fibroblast growth factor affects the expression of angiogenin and cell proliferation in A375 human melanoma cells.Tumori. 2011 Jan-Feb;97(1):95-103. doi: 10.1177/030089161109700117.
• [500] Increased caspase-2 activity is associated with induction of apoptosis in IFN-beta sensitive melanoma cell lines.J Interferon Cytokine Res. 2010 May;30(5):349-57. doi: 10.1089/jir.2009.0015.
• [501] Role of the cystathionine lyase/hydrogen sulfide pathway in human melanoma progression.Pigment Cell Melanoma Res. 2015 Jan;28(1):61-72. doi: 10.1111/pcmr.12312. Epub 2014 Oct 6.
• [502] Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma.Retina. 2012 Jul;32(7):1373-84. doi: 10.1097/IAE.0b013e318239e299.
• [503] CCR9 homes metastatic melanoma cells to the small bowel.Clin Cancer Res. 2008 Feb 1;14(3):621-3. doi: 10.1158/1078-0432.CCR-07-2235.
• [504] Human hemokinin-1 promotes migration of melanoma cells and increases MMP-2 and MT1-MMP expression by activating tumor cell NK1 receptors.Peptides. 2016 Sep;83:8-15. doi: 10.1016/j.peptides.2016.07.004. Epub 2016 Jul 22.
• [505] Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200.Cancer Immunol Immunother. 2008 Jul;57(7):987-96. doi: 10.1007/s00262-007-0429-6.
• [506] Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.J Cell Physiol. 2002 Feb;190(2):200-6. doi: 10.1002/jcp.10050.
• [507] Epigenetic disruption of cadherin-11 in human cancer metastasis.J Pathol. 2012 Oct;228(2):230-40. doi: 10.1002/path.4011. Epub 2012 Jul 26.
• [508] A secreted form of P-cadherin is expressed in malignant melanoma.Exp Cell Res. 2005 May 1;305(2):418-26. doi: 10.1016/j.yexcr.2005.01.024.
• [509] The IKK-dependent non-canonical pathway of NF-B activation is constitutively active and modulates progression-related functions in a subset of human melanomas.Arch Dermatol Res. 2016 Dec;308(10):733-742. doi: 10.1007/s00403-016-1696-x. Epub 2016 Oct 15.
• [510] TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.Sci Transl Med. 2013 Jul 31;5(196):196ra98. doi: 10.1126/scitranslmed.3005753.
• [511] CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.Anticancer Res. 2015 Jul;35(7):3787-92.
• [512] Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.Mol Cancer Ther. 2014 Jul;13(7):1894-906. doi: 10.1158/1535-7163.MCT-13-0938. Epub 2014 May 13.
• [513] Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.Oncogene. 2003 May 15;22(19):2869-81. doi: 10.1038/sj.onc.1206427.
• [514] Expression of proteins involved in epigenetic regulation in human cutaneous melanoma and peritumoral skin.Tumour Biol. 2014 Aug;35(8):8225-33. doi: 10.1007/s13277-014-2098-3. Epub 2014 May 22.
• [515] Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion.Br J Cancer. 2014 Jan 21;110(2):399-408. doi: 10.1038/bjc.2013.688. Epub 2013 Oct 31.
• [516] Experimental hypoxia does not influence gene expression and protein synthesis of Eph receptors and ephrin ligands in human melanoma cells in vitro.Melanoma Res. 2013 Apr;23(2):85-95. doi: 10.1097/CMR.0b013e32835e58f3.
• [517] LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues.J Cell Biol. 2014 Oct 27;207(2):299-315. doi: 10.1083/jcb.201404067.
• [518] Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.Endocr Pathol. 2014 Sep;25(3):324-31. doi: 10.1007/s12022-014-9303-1.
• [519] Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton.Carcinogenesis. 2002 Oct;23(10):1593-601. doi: 10.1093/carcin/23.10.1593.
• [520] Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response.Int J Cancer. 2008 Dec 15;123(12):2832-9. doi: 10.1002/ijc.23870.
• [521] Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.J Hepatol. 2009 Jan;50(1):118-27. doi: 10.1016/j.jhep.2008.08.015. Epub 2008 Oct 12.
• [522] Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.Oncotarget. 2015 Jun 10;6(16):14290-9. doi: 10.18632/oncotarget.3742.
• [523] A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors.Epigenetics. 2014 Aug;9(8):1163-71. doi: 10.4161/epi.29628. Epub 2014 Jul 8.
• [524] Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.Cell Cycle. 2014;13(17):2790-7. doi: 10.4161/15384101.2015.945879.
• [525] The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans.Front Neuroendocrinol. 2003 Dec;24(4):279-95. doi: 10.1016/j.yfrne.2003.10.003.
• [526] Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.J Mol Diagn. 2014 Jan;16(1):56-67. doi: 10.1016/j.jmoldx.2013.08.004. Epub 2013 Nov 2.
• [527] Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to PK oncolytic activity in melanoma.Gene Ther. 2014 Apr;21(4):371-8. doi: 10.1038/gt.2014.6. Epub 2014 Feb 20.
• [528] Downregulation of hepatoma-derived growth factor contributes to retarded lung metastasis via inhibition of epithelial-mesenchymal transition by systemic POMC gene delivery in melanoma.Mol Cancer Ther. 2013 Jun;12(6):1016-25. doi: 10.1158/1535-7163.MCT-12-0832. Epub 2013 Mar 6.
• [529] Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma.J Invest Dermatol. 2015 Sep;135(9):2283-2291. doi: 10.1038/jid.2015.160. Epub 2015 Apr 24.
• [530] Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
• [531] Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer.Gynecol Oncol. 2006 Oct;103(1):253-60. doi: 10.1016/j.ygyno.2006.03.006. Epub 2006 May 2.
• [532] Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases.Cancer Res. 2011 Mar 15;71(6):2077-86. doi: 10.1158/0008-5472.CAN-10-3994. Epub 2011 Jan 31.
• [533] PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.Nat Commun. 2013;4:1508. doi: 10.1038/ncomms2489.
• [534] Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.BMC Cancer. 2010 Apr 14;10:142. doi: 10.1186/1471-2407-10-142.
• [535] Retrotransposon hypomethylation in melanoma and expression of a placenta-specific gene.PLoS One. 2014 Apr 23;9(4):e95840. doi: 10.1371/journal.pone.0095840. eCollection 2014.
• [536] Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.Cancer Cell. 2018 Feb 12;33(2):322-336.e8. doi: 10.1016/j.ccell.2018.01.002.
• [537] The kisspeptin (KiSS-1)/GPR54 system in cancer biology.Cancer Treat Rev. 2008 Dec;34(8):682-92. doi: 10.1016/j.ctrv.2008.05.007. Epub 2008 Jun 25.
• [538] LASP1, a Newly Identified Melanocytic Protein with a Possible Role in Melanin Release, but Not in Melanoma Progression.PLoS One. 2015 Jun 10;10(6):e0129219. doi: 10.1371/journal.pone.0129219. eCollection 2015.
• [539] High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.Oncotarget. 2015 Sep 22;6(28):25484-98. doi: 10.18632/oncotarget.4688.
• [540] Investigation of prognostic indicators for human uveal melanoma as biomarkers of canine uveal melanoma metastasis.J Small Anim Pract. 2013 Nov;54(11):584-93. doi: 10.1111/jsap.12141.
• [541] Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma.Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):E3640-9. doi: 10.1073/pnas.1314435110. Epub 2013 Sep 3.
• [542] Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness.Tumour Biol. 2015 Nov;36(11):8593-600. doi: 10.1007/s13277-015-3622-9. Epub 2015 Jun 4.
• [543] Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model.Int Immunopharmacol. 2013 Sep;17(1):9-17. doi: 10.1016/j.intimp.2013.04.015. Epub 2013 Apr 25.
• [544] Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.Melanoma Res. 2011 Aug;21(4):274-84. doi: 10.1097/CMR.0b013e328343a1d6.
• [545] Polymorphisms in base excision DNA repair genes and association with melanoma risk in a pilot study on Central-South Italian population.Clin Chim Acta. 2012 Oct 9;413(19-20):1519-24. doi: 10.1016/j.cca.2012.06.013. Epub 2012 Jun 9.
• [546] N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis.EMBO J. 2001 Mar 15;20(6):1383-93. doi: 10.1093/emboj/20.6.1383.
• [547] Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms.Int J Oncol. 2013 Jul;43(1):297-306. doi: 10.3892/ijo.2013.1948. Epub 2013 May 20.
• [548] The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts.J Cutan Pathol. 2010 Apr;37 Suppl 1(Suppl 1):19-25. doi: 10.1111/j.1600-0560.2010.01503.x.
• [549] Involvement of Nurr-1/Nur77 in corticotropin-releasing factor/urocortin1-induced tyrosinase-related protein 1 gene transcription in human melanoma HMV-II cells.Mol Cell Endocrinol. 2013 May 6;370(1-2):42-51. doi: 10.1016/j.mce.2013.01.022. Epub 2013 Feb 14.
• [550] Variants associated with susceptibility to pancreatic cancer and melanoma do not reciprocally affect risk.Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1121-4. doi: 10.1158/1055-9965.EPI-13-0627. Epub 2014 Mar 18.
• [551] miR?6 functions as a tumor suppressor gene by targeting NUAK1 in pancreatic cancer.Int J Mol Med. 2014 Dec;34(6):1599-605. doi: 10.3892/ijmm.2014.1940. Epub 2014 Sep 19.
• [552] STIM1- and Orai1-mediated Ca(2+) oscillation orchestrates invadopodium formation and melanoma invasion.J Cell Biol. 2014 Nov 24;207(4):535-48. doi: 10.1083/jcb.201407082. Epub 2014 Nov 17.
• [553] Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.Curr Pharm Des. 2013;19(17):3161-72. doi: 10.2174/13816128113199990313.
• [554] Associations between smoking behavior-related alleles and the risk of melanoma.Oncotarget. 2016 Jul 26;7(30):47366-47375. doi: 10.18632/oncotarget.10144.
• [555] Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells.Oncol Rep. 2013 Apr;29(4):1275-84. doi: 10.3892/or.2013.2260. Epub 2013 Jan 31.
• [556] Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes.Int J Cancer. 1994 Oct 1;59(1):78-82. doi: 10.1002/ijc.2910590116.
• [557] Gene expression analysis to identify mRNA markers of cardiac myxoma.J Mol Cell Cardiol. 2004 Sep;37(3):717-33. doi: 10.1016/j.yjmcc.2004.06.006.
• [558] Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor.Cancer Res. 2004 Jan 1;64(1):13-8. doi: 10.1158/0008-5472.can-03-2658.
• [559] Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2.Medicine (Baltimore). 2015 Aug;94(33):e1327. doi: 10.1097/MD.0000000000001327.
• [560] Genetic variants in DNA repair genes and the risk of cutaneous malignant melanoma in melanoma-prone families with/without CDKN2A mutations.Int J Cancer. 2012 May 1;130(9):2062-6. doi: 10.1002/ijc.26231. Epub 2011 Aug 9.
• [561] PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.Mol Cancer Res. 2019 Feb;17(2):583-593. doi: 10.1158/1541-7786.MCR-18-0777. Epub 2018 Oct 24.
• [562] Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.Oncogene. 2004 May 13;23(22):4014-22. doi: 10.1038/sj.onc.1207505.
• [563] Aberrant demethylation of the recoverin gene is involved in the aberrant expression of recoverin in cancer cells.Exp Dermatol. 2010 Nov;19(11):1023-5. doi: 10.1111/j.1600-0625.2010.01126.x. Epub 2010 Aug 31.
• [564] Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.Mol Cancer Res. 2016 Sep;14(9):767-75. doi: 10.1158/1541-7786.MCR-16-0099. Epub 2016 Jun 13.
• [565] Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model.PLoS One. 2012;7(3):e33633. doi: 10.1371/journal.pone.0033633. Epub 2012 Mar 20.
• [566] New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.Biochim Biophys Acta. 2016 Nov;1863(11):2710-2718. doi: 10.1016/j.bbamcr.2016.08.007. Epub 2016 Aug 16.
• [567] Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.Br J Cancer. 2014 Jul 29;111(3):477-85. doi: 10.1038/bjc.2014.342. Epub 2014 Jul 10.
• [568] Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.Peptides. 2014 May;55:1-12. doi: 10.1016/j.peptides.2014.01.030. Epub 2014 Feb 15.
• [569] Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.EMBO Mol Med. 2013 Nov;5(11):1720-39. doi: 10.1002/emmm.201302524. Epub 2013 Oct 11.
• [570] Thrombomodulin modulates cell migration in human melanoma cell lines.Melanoma Res. 2014 Feb;24(1):11-9. doi: 10.1097/CMR.0000000000000035.
• [571] Constitutive RAC activation is not sufficient to initiate melanocyte neoplasia but accelerates malignant progression.J Invest Dermatol. 2013 Jun;133(6):1572-81. doi: 10.1038/jid.2013.23. Epub 2013 Jan 21.
• [572] TWEAK activation of the non-canonical NF-B signaling pathway differentially regulates melanoma and prostate cancer cell invasion.Oncotarget. 2016 Dec 6;7(49):81474-81492. doi: 10.18632/oncotarget.13034.
• [573] Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.Cancer Res. 2014 Jan 1;74(1):130-40. doi: 10.1158/0008-5472.CAN-13-1672.
• [574] Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation.Cytotherapy. 2007;9(4):386-96. doi: 10.1080/14653240701326749.
• [575] C-terminal tensin-like protein is a novel prognostic marker for primary melanoma patients.PLoS One. 2013 Nov 7;8(11):e80492. doi: 10.1371/journal.pone.0080492. eCollection 2013.
• [576] Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells.Apoptosis. 2011 Nov;16(11):1165-76. doi: 10.1007/s10495-011-0635-8.
• [577] Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles.Nucleic Acids Res. 2015 Apr 20;43(7):e44. doi: 10.1093/nar/gku1393. Epub 2015 Jan 8.
• [578] Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.Oncotarget. 2015 Jun 30;6(18):16488-506. doi: 10.18632/oncotarget.4108.
• [579] Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1.Oncotarget. 2015 Nov 3;6(34):36338-53. doi: 10.18632/oncotarget.5537.
• [580] Disorders of nucleotide excision repair.Handb Clin Neurol. 2013;113:1637-50. doi: 10.1016/B978-0-444-59565-2.00032-0.
• [581] Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.PLoS One. 2014 Jul 24;9(7):e102983. doi: 10.1371/journal.pone.0102983. eCollection 2014.
• [582] Overcoming Resistance to Targeted Therapies in Cancer.Semin Oncol. 2015 Dec;42(6):896-908. doi: 10.1053/j.seminoncol.2015.09.028. Epub 2015 Sep 25.
• [583] Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes.PLoS Genet. 2016 Jun 15;12(6):e1006081. doi: 10.1371/journal.pgen.1006081. eCollection 2016 Jun.
• [584] Ousting RAGE in melanoma: A viable therapeutic target?.Semin Cancer Biol. 2018 Apr;49:20-28. doi: 10.1016/j.semcancer.2017.10.008. Epub 2017 Oct 24.
• [585] Novel therapeutic compound acridine-retrotuftsin action on biological forms of melanoma and neuroblastoma.J Cancer Res Clin Oncol. 2019 Jan;145(1):165-179. doi: 10.1007/s00432-018-2776-4. Epub 2018 Oct 26.
• [586] Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin Cancers.Front Med (Lausanne). 2019 Sep 4;6:194. doi: 10.3389/fmed.2019.00194. eCollection 2019.
• [587] SHARPIN Promotes Melanoma Progression viaRap1 Signaling Pathway.J Invest Dermatol. 2020 Feb;140(2):395-403.e6. doi: 10.1016/j.jid.2019.07.696. Epub 2019 Aug 8.
• [588] AKT1(E17K) Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.Mol Cancer Res. 2019 Sep;17(9):1787-1800. doi: 10.1158/1541-7786.MCR-18-1372. Epub 2019 May 28.
• [589] Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study.Pathology. 2018 Jun;50(4):402-410. doi: 10.1016/j.pathol.2017.12.340. Epub 2018 Apr 17.
• [590] Current Treatment Options for Breast Cancer Brain Metastases.Curr Treat Options Oncol. 2019 Feb 15;20(3):19. doi: 10.1007/s11864-019-0618-5.
• [591] Molecular identification, localization and function of platelet-type 12-lipoxygenase in human melanoma progression, under experimental and clinical conditions.Melanoma Res. 2004 Aug;14(4):245-50. doi: 10.1097/01.cmr.0000138479.00897.d8.
• [592] Loss of vascular adhesion protein-1 expression in intratumoral microvessels of human skin melanoma.Melanoma Res. 2004 Apr;14(2):135-40. doi: 10.1097/00008390-200404000-00010.
• [593] Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.Oncotarget. 2014 May 30;5(10):3273-86. doi: 10.18632/oncotarget.1926.
• [594] In vivo modulation of angiogenesis by beta 2 glycoprotein I.J Autoimmun. 2010 Nov;35(3):232-40. doi: 10.1016/j.jaut.2010.06.013. Epub 2010 Jul 24.
• [595] Expression Pattern of Aquaporin 1 and Aquaporin 3 in Melanocytic and Nonmelanocytic Skin Tumors.Am J Clin Pathol. 2019 Sep 9;152(4):446-457. doi: 10.1093/ajcp/aqz066.
• [596] Targeting Angiogenesis by Blocking the ATM-SerRS-VEGFA Pathway for UV-Induced Skin Photodamage and Melanoma Growth.Cancers (Basel). 2019 Nov 22;11(12):1847. doi: 10.3390/cancers11121847.
• [597] Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.Int J Cancer. 1998 Sep 25;78(1):13-5. doi: 10.1002/(sici)1097-0215(19980925)78:1<13::aid-ijc3>3.0.co;2-#.
• [598] MiR-154 inhibits cells proliferation and metastasis in melanoma by targeting AURKA and serves as a novel prognostic indicator.Eur Rev Med Pharmacol Sci. 2019 May;23(10):4275-4284. doi: 10.26355/eurrev_201905_17932.
• [599] Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.J Transl Med. 2015 Jan 27;13:26. doi: 10.1186/s12967-015-0385-4.
• [600] AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.Oncogene. 2018 Jun;37(24):3275-3289. doi: 10.1038/s41388-018-0205-4. Epub 2018 Mar 19.
• [601] Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy.J Invest Dermatol. 2019 Jul;139(7):1490-1496. doi: 10.1016/j.jid.2019.01.007. Epub 2019 Jan 23.
• [602] Two distinct steps of Bak regulation during apoptotic stress signaling: different roles of MEKK1 and JNK1.Exp Cell Res. 2006 May 15;312(9):1581-9. doi: 10.1016/j.yexcr.2006.01.023. Epub 2006 Mar 9.
• [603] Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.ACS Chem Biol. 2006 Sep 19;1(8):525-33. doi: 10.1021/cb600276q.
• [604] Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.Cancer Immunol Immunother. 2012 May;61(5):655-65. doi: 10.1007/s00262-011-1124-1. Epub 2011 Oct 28.
• [605] BMP6-induced modulation of the tumor micro-milieu.Oncogene. 2019 Jan;38(5):609-621. doi: 10.1038/s41388-018-0475-x. Epub 2018 Aug 31.
• [606] FANCJ localization by mismatch repair is vital to maintain genomic integrity after UV irradiation.Cancer Res. 2014 Feb 1;74(3):932-44. doi: 10.1158/0008-5472.CAN-13-2474. Epub 2013 Dec 18.
• [607] Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.Cancer Sci. 2008 Dec;99(12):2461-6. doi: 10.1111/j.1349-7006.2008.00968.x. Epub 2008 Nov 20.
• [608] Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma.PLoS One. 2011;6(6):e20971. doi: 10.1371/journal.pone.0020971. Epub 2011 Jun 15.
• [609] Increased risk of melanoma in C9ORF72 repeat expansion carriers: A case-control study.Muscle Nerve. 2019 Mar;59(3):362-365. doi: 10.1002/mus.26383. Epub 2018 Dec 27.
• [610] Microsatellite analysis of melanoma lesions using (CA)13 oligonucleotides as an internal probe.Int J Oncol. 2000 Oct;17(4):783-7. doi: 10.3892/ijo.17.4.783.
• [611] Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.Clin Cancer Res. 2005 Nov 15;11(22):8201-7. doi: 10.1158/1078-0432.CCR-05-0816.
• [612] Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.Oncotarget. 2019 Feb 12;10(13):1344. doi: 10.18632/oncotarget.26685. eCollection 2019 Feb 12.
• [613] Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma.Hum Mutat. 2008 Dec;29(12):1443-51. doi: 10.1002/humu.20803.
• [614] Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?.J Pathol. 2003 Oct;201(2):278-87. doi: 10.1002/path.1424.
• [615] Cisplatin-induced apoptosis in melanoma cells: role of caspase-3 and caspase-7 in Apaf-1 proteolytic cleavage and in execution of the degradative phases.Ann N Y Acad Sci. 2003 Dec;1010:200-4. doi: 10.1196/annals.1299.034.
• [616] CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus.Oncogene. 2005 Aug 25;24(36):5543-51. doi: 10.1038/sj.onc.1208735.
• [617] Gastrin exerts pleiotropic effects on human melanoma cell biology.Neoplasia. 2005 Oct;7(10):930-43. doi: 10.1593/neo.05379.
• [618] Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner.Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):E9271-E9279. doi: 10.1073/pnas.1703921114. Epub 2017 Oct 16.
• [619] The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.Melanoma Res. 2019 Jun;29(3):237-247. doi: 10.1097/CMR.0000000000000522.
• [620] Downregulation of RNF128 activates Wnt/-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma.J Hematol Oncol. 2019 Mar 4;12(1):21. doi: 10.1186/s13045-019-0711-z.
• [621] Targeting CDC7 sensitizes resistance melanoma cells to BRAF(V600E)-specific inhibitor by blocking the CDC7/MCM2-7 pathway.Sci Rep. 2019 Oct 2;9(1):14197. doi: 10.1038/s41598-019-50732-w.
• [622] Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis.Int J Mol Med. 2019 Jan;43(1):404-412. doi: 10.3892/ijmm.2018.3985. Epub 2018 Nov 7.
• [623] Melanoma Suppressor Functions of the Carcinoma Oncogene FOXQ1. Cell Rep. 2017 Sep 19;20(12):2820-2832.
• [624] Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families.Int J Cancer. 2002 Jun 20;99(6):834-8. doi: 10.1002/ijc.10422.
• [625] Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.Cancer Genet Cytogenet. 1999 Jan 15;108(2):91-9. doi: 10.1016/s0165-4608(98)00122-8.
• [626] The interplay of CDK4 and CDK6 in melanoma.Oncotarget. 2019 Feb 15;10(14):1346-1359. doi: 10.18632/oncotarget.26515. eCollection 2019 Feb 15.
• [627] Associations of properdin factor B with melanoma.Cancer Genet Cytogenet. 1982 Mar;5(3):247-51. doi: 10.1016/0165-4608(82)90031-0.
• [628] Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.J Natl Cancer Inst. 2003 Jun 4;95(11):790-8. doi: 10.1093/jnci/95.11.790.
• [629] Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.Mol Oncol. 2019 Jul;13(7):1503-1518. doi: 10.1002/1878-0261.12497. Epub 2019 Jun 14.
• [630] The CLN3 gene is a novel molecular target for cancer drug discovery.Cancer Res. 2002 Feb 1;62(3):801-8.
• [631] Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol. 2005 Jun;124(6):1300-7. doi: 10.1111/j.0022-202X.2005.23720.x.
• [632] Association study of MIA3 rs17465637 polymorphism with cardiovascular disease in rheumatoid arthritis patients.DNA Cell Biol. 2012 Aug;31(8):1412-7. doi: 10.1089/dna.2012.1672. Epub 2012 May 11.
• [633] Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions.Mod Pathol. 2004 Jul;17(7):811-8. doi: 10.1038/modpathol.3800123.
• [634] T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas.J Invest Dermatol. 1997 Jun;108(6):914-9. doi: 10.1111/1523-1747.ep12292705.
• [635] Altered expression patterns of clock gene mRNAs and clock proteins in human skin tumors.Tumour Biol. 2013 Apr;34(2):811-9. doi: 10.1007/s13277-012-0611-0. Epub 2012 Dec 15.
• [636] Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCR Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.Front Immunol. 2019 Sep 18;10:2213. doi: 10.3389/fimmu.2019.02213. eCollection 2019.
• [637] [Cloning and analysis of coding cDNA sequence of human lymphocyte Csk tyrosine kinase under normal conditions and in choroidal melanoma].Izv Akad Nauk Ser Biol. 2008 Nov-Dec;(6):663-70.
• [638] Differential expression patterns of capping protein, protein phosphatase 1, and casein kinase 1 may serve as diagnostic markers for malignant melanoma.Melanoma Res. 2011 Aug;21(4):335-43. doi: 10.1097/CMR.0b013e328346b715.
• [639] Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles.Cancers (Basel). 2019 Jan 30;11(2):157. doi: 10.3390/cancers11020157.
• [640] The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.Melanoma Res. 2020 Feb;30(1):85-101. doi: 10.1097/CMR.0000000000000620.
• [641] Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.Int J Cancer. 2008 Feb 15;122(4):777-84. doi: 10.1002/ijc.23140.
• [642] High-resolution interrogation of functional elements in the noncoding genome.Science. 2016 Sep 30;353(6307):1545-1549. doi: 10.1126/science.aaf7613.
• [643] Targeting tumor-resident mast cells for effective anti-melanoma immune responses.JCI Insight. 2019 Oct 3;4(19):e125057. doi: 10.1172/jci.insight.125057.
• [644] Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways.J Control Release. 2018 Oct 28;288:148-160. doi: 10.1016/j.jconrel.2018.08.015. Epub 2018 Aug 9.
• [645] Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame.Cancer Res. 2001 Nov 15;61(22):8150-7.
• [646] CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.Melanoma Res. 2020 Feb;30(1):14-25. doi: 10.1097/CMR.0000000000000639.
• [647] RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.Ann Oncol. 2011 Oct;22(10):2208-15. doi: 10.1093/annonc/mdq737. Epub 2011 Feb 16.
• [648] Carbidopa Alters Tryptophan Metabolism in Breast Cancer and Melanoma Cells Leading to the Formation of Indole-3-Acetonitrile, a Pro-Proliferative Metabolite.Biomolecules. 2019 Aug 24;9(9):409. doi: 10.3390/biom9090409.
• [649] Downregulation of discoidin domain receptor 2 in A375 human melanoma cells reduces its experimental liver metastasis ability.Oncol Rep. 2011 Oct;26(4):971-8. doi: 10.3892/or.2011.1356. Epub 2011 Jun 23.
• [650] Diacylglycerol kinase -selective inhibitors induce apoptosis and reduce viability of melanoma and several other cancer cell lines.J Cell Biochem. 2019 Jun;120(6):10043-10056. doi: 10.1002/jcb.28288. Epub 2018 Dec 9.
• [651] DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis.Int J Cancer. 2005 Jun 10;115(2):224-30. doi: 10.1002/ijc.20885.
• [652] Expression of Dickkopf genes is strongly reduced in malignant melanoma.Oncogene. 2006 Aug 17;25(36):5027-36. doi: 10.1038/sj.onc.1209508. Epub 2006 Mar 27.
• [653] Different pattern of T cell receptor delta gene rearrangement in tumour-infiltrating lymphocytes and peripheral blood in patients with solid tumours.Cancer Immunol Immunother. 1994 Oct;39(4):275-8. doi: 10.1007/BF01525992.
• [654] Knockdown of Delta-like 3 restricts lipopolysaccharide-induced inflammation, migration and invasion of A2058 melanoma cells via blocking Twist1-mediated epithelial-mesenchymal transition.Life Sci. 2019 Jun 1;226:149-155. doi: 10.1016/j.lfs.2019.04.024. Epub 2019 Apr 11.
• [655] Triptolide modulates tumour-colonisation and anti-tumour effect of attenuated Salmonella encoding DNase I.Appl Microbiol Biotechnol. 2019 Jan;103(2):929-939. doi: 10.1007/s00253-018-9481-8. Epub 2018 Nov 17.
• [656] Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers.Pathol Oncol Res. 2020 Jul;26(3):1539-1547. doi: 10.1007/s12253-019-00734-w. Epub 2019 Sep 2.
• [657] Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.Mol Cancer. 2009 Aug 11;8:61. doi: 10.1186/1476-4598-8-61.
• [658] E2F1 germline copy number variations and melanoma susceptibility.J Transl Med. 2019 May 29;17(1):181. doi: 10.1186/s12967-019-1933-0.
• [659] AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human melanoma differentiation.J Cell Physiol. 2000 Oct;185(1):36-46. doi: 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V.
• [660] EGFL7 silencing inactivates the Notch signaling pathway; enhancing cell apoptosis and suppressing cell proliferation in human cutaneous melanoma.Neoplasma. 2019 Mar 5;66(2):187-196. doi: 10.4149/neo_2018_180310N167. Epub 2018 Sep 16.
• [661] Overexpression of long non-coding RNA NORAD promotes invasion and migration in malignant melanoma via regulating the MIR-205-EGLN2 pathway.Cancer Med. 2019 Apr;8(4):1744-1754. doi: 10.1002/cam4.2046. Epub 2019 Mar 7.
• [662] Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells.Biochem Biophys Res Commun. 1996 Jan 26;218(3):714-9. doi: 10.1006/bbrc.1996.0127.
• [663] The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.Tumour Biol. 2019 Apr;42(4):1010428319837138. doi: 10.1177/1010428319837138.
• [664] Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma.Int J Cancer. 1997 Jun 11;71(6):1061-5. doi: 10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f.
• [665] Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.Bioorg Chem. 2019 Feb;82:290-305. doi: 10.1016/j.bioorg.2018.10.044. Epub 2018 Oct 23.
• [666] Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.PLoS One. 2014 Jan 29;9(1):e84417. doi: 10.1371/journal.pone.0084417. eCollection 2014.
• [667] Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).Cancer Immunol Immunother. 2019 Aug;68(8):1245-1261. doi: 10.1007/s00262-019-02358-0. Epub 2019 Jun 20.
• [668] Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.Nat Commun. 2017 Feb 15;8:14449. doi: 10.1038/ncomms14449.
• [669] Assembly and regulation of prothrombinase complex on B16F10 melanoma cells.Thromb Res. 2005;115(1-2):123-9. doi: 10.1016/j.thromres.2004.08.001.
• [670] miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells.Pigment Cell Melanoma Res. 2014 May;27(3):431-41. doi: 10.1111/pcmr.12217. Epub 2014 Feb 6.
• [671] Dabrafenib and Trametinibprolong coagulation through the inhibition of tissue factor in BRAF(v600e) mutated melanoma cells in vitro.Cancer Cell Int. 2019 Aug 28;19:223. doi: 10.1186/s12935-019-0938-3. eCollection 2019.
• [672] Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did Not.Invest Ophthalmol Vis Sci. 2012 Jul 9;53(8):4634-43. doi: 10.1167/iovs.11-9019.
• [673] Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.Melanoma Res. 2019 Aug;29(4):401-412. doi: 10.1097/CMR.0000000000000614.
• [674] Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products.J Biol Chem. 2011 Aug 12;286(32):28181-91. doi: 10.1074/jbc.M111.234419. Epub 2011 Jun 16.
• [675] VIT1/FBXO11 knockdown induces morphological alterations and apoptosis in B10BR mouse melanocytes.Int J Mol Med. 2009 May;23(5):673-8. doi: 10.3892/ijmm_00000179.
• [676] Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest. 2012 Oct;122(10):3769-80. doi: 10.1172/JCI64837. Epub 2012 Sep 24.
• [677] Sasanquasaponin from Schima crenata Korth induces autophagy through Akt/mTOR/p70S6K pathway and promotes apoptosis in human melanoma A375 cells.Phytomedicine. 2019 May;58:152769. doi: 10.1016/j.phymed.2018.11.029. Epub 2018 Nov 20.
• [678] Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.J Invest Dermatol. 2011 Oct;131(10):2087-95. doi: 10.1038/jid.2011.177. Epub 2011 Jul 14.
• [679] The prolyl hydroxylase PHD3 identifies proinflammatory macrophages and its expression is regulated by activin A.J Immunol. 2012 Aug 15;189(4):1946-54. doi: 10.4049/jimmunol.1201064. Epub 2012 Jul 9.
• [680] Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis.Sci Signal. 2013 Apr 30;6(273):ra28.1-13, S0-15. doi: 10.1126/scisignal.2003884.
• [681] The FOXC2 Transcription Factor Promotes Melanoma Outgrowth and Regulates Expression of Genes Associated With Drug Resistance and Interferon Responsiveness.Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):491-503. doi: 10.21873/cgp.20152.
• [682] Clinical and Therapeutic Implications of Follistatin in Solid Tumours.Cancer Genomics Proteomics. 2016 11-12;13(6):425-435. doi: 10.21873/cgp.20005.
• [683] Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines.Melanoma Res. 2020 Feb;30(1):26-38. doi: 10.1097/CMR.0000000000000644.
• [684] Increased expression of long noncoding RNA GAS6-AS2 promotes proliferation and inhibits apoptosis of melanoma cells via upregulating GAS6 expression.IUBMB Life. 2019 Oct;71(10):1503-1514. doi: 10.1002/iub.2071. Epub 2019 Jun 4.
• [685] Histamine receptor 2-mediated growth-differentiation factor-15 expression is involved in histamine-induced melanogenesis.Int J Biochem Cell Biol. 2012 Dec;44(12):2124-8. doi: 10.1016/j.biocel.2012.08.020. Epub 2012 Sep 2.
• [686] Redox modulation of NF-kappaB nuclear translocation and DNA binding in metastatic melanoma. The role of endogenous and gamma-glutamyl transferase-dependent oxidative stress.Tumori. 2003 Jul-Aug;89(4):426-33. doi: 10.1177/030089160308900416.
• [687] Exploring Differential Connexin Expression across Melanocytic Tumor Progression Involving the Tumor Microenvironment.Cancers (Basel). 2019 Feb 1;11(2):165. doi: 10.3390/cancers11020165.
• [688] Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.Oncogene. 2017 Mar 30;36(13):1849-1861. doi: 10.1038/onc.2016.348. Epub 2016 Oct 17.
• [689] Transcriptional repression of the tyrosinase-related protein 2 gene by transforming growth factor- and the Kruppel-like transcription factor GLI2.J Dermatol Sci. 2019 Jun;94(3):321-329. doi: 10.1016/j.jdermsci.2019.04.001. Epub 2019 Apr 6.
• [690] miR-137 inhibits melanoma cell proliferation through downregulation of GLO1.Sci China Life Sci. 2018 May;61(5):541-549. doi: 10.1007/s11427-017-9138-9. Epub 2018 Jan 2.
• [691] GPR56 and its related diseases.Prog Mol Biol Transl Sci. 2009;89:1-13. doi: 10.1016/S1877-1173(09)89001-7. Epub 2009 Oct 7.
• [692] Genetic and Functional Analysis of GRIN2A in Tumor Samples.Methods Mol Biol. 2017;1677:93-116. doi: 10.1007/978-1-4939-7321-7_3.
• [693] Melanoma-associated GRM3 variants dysregulate melanosome trafficking and cAMP signaling.Pigment Cell Melanoma Res. 2018 Jan;31(1):115-119. doi: 10.1111/pcmr.12610. Epub 2017 Oct 23.
• [694] MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma.Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15840-5. doi: 10.1073/pnas.1019312108. Epub 2011 Sep 6.
• [695] Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.Clin Chim Acta. 2000 Jun;296(1-2):17-33. doi: 10.1016/s0009-8981(00)00198-4.
• [696] HAX-1, identified by differential display reverse transcription polymerase chain reaction, is overexpressed in lesional psoriasis.J Invest Dermatol. 2003 Jun;120(6):1045-51. doi: 10.1046/j.1523-1747.2003.12247.x.
• [697] Evaluation of [(11)C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma.Nucl Med Biol. 2019 Jul-Aug;74-75:1-11. doi: 10.1016/j.nucmedbio.2019.05.004. Epub 2019 May 29.
• [698] MicroRNA-329 upregulation impairs the HMGB2/-catenin pathway and regulates cell biological behaviors in melanoma.J Cell Physiol. 2019 Dec;234(12):23518-23527. doi: 10.1002/jcp.28920. Epub 2019 Jun 20.
• [699] Altered expressions of HOX genes in human cutaneous malignant melanoma.Int J Cancer. 2005 Apr 10;114(3):436-41. doi: 10.1002/ijc.20706.
• [700] Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid.J Clin Invest. 2009 Apr;119(4):954-63. doi: 10.1172/JCI34015. Epub 2009 Mar 9.
• [701] Histamine elevates the expression of Ets-1, a protooncogen in human melanoma cell lines through H2 receptor.FEBS Lett. 2005 Apr 25;579(11):2475-9. doi: 10.1016/j.febslet.2005.03.053.
• [702] Inhibitors of HSP90 in melanoma.Apoptosis. 2020 Feb;25(1-2):12-28. doi: 10.1007/s10495-019-01577-1.
• [703] High-resolution population structure and runs of homozygosity reveal the genetic architecture of complex traits in the Lipizzan horse.BMC Genomics. 2019 Mar 5;20(1):174. doi: 10.1186/s12864-019-5564-x.
• [704] Antitumor agent 25-epi Ritterostatin GN1N induces endoplasmic reticulum stress and autophagy mediated cell death in melanoma cells.Int J Oncol. 2017 May;50(5):1482-1490. doi: 10.3892/ijo.2017.3944. Epub 2017 Apr 3.
• [705] Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.Cancer Res. 2010 Dec 1;70(23):9581-90. doi: 10.1158/0008-5472.CAN-10-1379. Epub 2010 Nov 23.
• [706] Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.Clin Cancer Res. 2019 Jul 15;25(14):4530-4541. doi: 10.1158/1078-0432.CCR-18-2840. Epub 2019 Apr 2.
• [707] Pegylation and Cell Based Bioassay of Human Interferon-2b Along its Docking Studies and Effect on Plasma Half-Life.Protein Pept Lett. 2020;27(3):219-224. doi: 10.2174/0929866526666191014124026.
• [708] Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.J Clin Oncol. 2006 Jul 1;24(19):3157-63. doi: 10.1200/JCO.2005.04.5344.
• [709] Interferon- sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy.Int J Oncol. 2019 May;54(5):1864-1874. doi: 10.3892/ijo.2019.4743. Epub 2019 Mar 7.
• [710] Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8(+) T Cells.J Invest Dermatol. 2019 Jul;139(7):1535-1544.e1. doi: 10.1016/j.jid.2019.02.016. Epub 2019 Mar 2.
• [711] Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity.J Invest Dermatol. 2008 Aug;128(8):1991-6. doi: 10.1038/jid.2008.10. Epub 2008 Apr 3.
• [712] Adipocytes: A Novel Target for IL-15/IL-15R Cancer Gene Therapy.Mol Ther. 2019 May 8;27(5):922-932. doi: 10.1016/j.ymthe.2019.02.011. Epub 2019 Feb 16.
• [713] IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner.PLoS One. 2013 Oct 14;8(10):e76159. doi: 10.1371/journal.pone.0076159. eCollection 2013.
• [714] IL-19 induced Th2 cytokines and was up-regulated in asthma patients.J Immunol. 2004 Dec 1;173(11):6712-8. doi: 10.4049/jimmunol.173.11.6712.
• [715] Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3100-3105. doi: 10.1073/pnas.1815087116. Epub 2019 Feb 4.
• [716] MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5687-5692. doi: 10.1073/pnas.1819869116. Epub 2019 Mar 6.
• [717] IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo.Cancer Immunol Immunother. 2010 Jun;59(6):805-17. doi: 10.1007/s00262-009-0802-8. Epub 2009 Dec 13.
• [718] A human recombinant IL-7/HGF hybrid cytokine enhances antitumor immunity in mice.Am J Cancer Res. 2017 Aug 1;7(8):1714-1723. eCollection 2017.
• [719] Investigation of IGF2/ApaI and H19/RsaI polymorphisms in patients with cutaneous melanoma.Growth Horm IGF Res. 2010 Aug;20(4):295-7. doi: 10.1016/j.ghir.2010.03.006. Epub 2010 May 18.
• [720] Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization.Gene. 2004 Dec 8;343(1):191-201. doi: 10.1016/j.gene.2004.09.002.
• [721] IFN regulatory factor-8 expression in macrophages governs an antimetastatic program.JCI Insight. 2019 Feb 7;4(3):e124267. doi: 10.1172/jci.insight.124267.
• [722] Insights into Fibroblast Plasticity: Cellular Communication Network 2 Is Required for Activation of Cancer-Associated Fibroblasts in a Murine Model of Melanoma.Am J Pathol. 2020 Jan;190(1):206-221. doi: 10.1016/j.ajpath.2019.09.006. Epub 2019 Oct 11.
• [723] PRL-3/PTP4A3 phosphatase regulates integrin 1 in adhesion structures during migration of human ocular melanoma cells.Exp Cell Res. 2017 Apr 15;353(2):88-99. doi: 10.1016/j.yexcr.2017.03.012. Epub 2017 Mar 8.
• [724] Blockade of integrin 3 signals to reverse the stem-like phenotype and drug resistance in melanoma.Cancer Chemother Pharmacol. 2019 Apr;83(4):615-624. doi: 10.1007/s00280-018-3760-z. Epub 2019 Jan 9.
• [725] Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms.Transl Oncol. 2019 Nov;12(11):1442-1452. doi: 10.1016/j.tranon.2019.07.015. Epub 2019 Aug 14.
• [726] Notch signaling activation induces cell death in MAPKi-resistant melanoma cells.Pigment Cell Melanoma Res. 2019 Jul;32(4):528-539. doi: 10.1111/pcmr.12764. Epub 2019 Feb 3.
• [727] The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One. 2010 Nov 1;5(11):e13779.
• [728] Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.J Invest Dermatol. 2019 Dec;139(12):2506-2516.e10. doi: 10.1016/j.jid.2019.06.124. Epub 2019 Jun 21.
• [729] NKG2D Polymorphism in Melanoma Patients from Southeastern Spain.Cancers (Basel). 2019 Mar 28;11(4):438. doi: 10.3390/cancers11040438.
• [730] ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity. Cell Rep. 2014 Jul 24;8(2):542-56. doi: 10.1016/j.celrep.2014.06.018. Epub 2014 Jul 10.
• [731] Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.Bioorg Med Chem Lett. 2018 Oct 1;28(18):3113-3118. doi: 10.1016/j.bmcl.2018.07.001. Epub 2018 Jul 6.
• [732] The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells.J Biol Chem. 2008 May 30;283(22):15399-408. doi: 10.1074/jbc.M708272200. Epub 2008 Mar 17.
• [733] Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma.Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5962-7.
• [734] BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.Clin Cancer Res. 2019 May 1;25(9):2783-2794. doi: 10.1158/1078-0432.CCR-18-2725. Epub 2019 Feb 14.
• [735] Effect of the transcriptional repressor Mad1 on proliferation of human melanoma cells.Exp Dermatol. 2002 Oct;11(5):439-47. doi: 10.1034/j.1600-0625.2002.110507.x.
• [736] Recognition of human recombinant myelin associated glycoprotein by anti-carbohydrate antibodies of the L2/HNK-1 family.Biochem Biophys Res Commun. 1995 Dec 5;217(1):171-8. doi: 10.1006/bbrc.1995.2760.
• [737] Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma.J Immunother. 2002 Jan-Feb;25(1):16-26. doi: 10.1097/00002371-200201000-00002.
• [738] Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.Nat Genet. 2012 Sep;44(9):1006-14. doi: 10.1038/ng.2359. Epub 2012 Jul 29.
• [739] Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.Ital J Dermatol Venerol. 2021 Oct;156(5):593-598. doi: 10.23736/S2784-8671.19.06516-7. Epub 2019 Dec 4.
• [740] Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin.J Invest Dermatol. 2014 Feb;134(2):452-460. doi: 10.1038/jid.2013.365. Epub 2013 Sep 5.
• [741] Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.Nat Genet. 2011 Dec 25;44(2):165-9. doi: 10.1038/ng.1041.
• [742] Regulation of ERK3/MAPK6 expression by BRAF.Int J Oncol. 2006 Oct;29(4):839-49.
• [743] Apatinib-loaded nanoparticles inhibit tumor growth and angiogenesis in a model of melanoma.Biochem Biophys Res Commun. 2020 Jan 8;521(2):296-302. doi: 10.1016/j.bbrc.2019.10.084. Epub 2019 Oct 23.
• [744] Obesity promotes melanoma tumor growth: role of leptin.Cancer Biol Ther. 2009 Oct;8(19):1871-9. doi: 10.4161/cbt.8.19.9650.
• [745] Endogenous melanin-concentrating hormone receptor SLC-1 in human melanoma SK-MEL-37 cells.Biochem Biophys Res Commun. 2001 Nov 23;289(1):44-50. doi: 10.1006/bbrc.2001.5926.
• [746] Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.J Clin Oncol. 2019 Nov 10;37(32):3000-3008. doi: 10.1200/JCO.18.02306. Epub 2019 Sep 26.
• [747] BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.Cell Death Dis. 2019 Apr 24;10(5):342. doi: 10.1038/s41419-019-1568-3.
• [748] MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1/mTOR signaling pathway.J Cell Biochem. 2020 Feb;121(2):1283-1294. doi: 10.1002/jcb.29361. Epub 2019 Sep 18.
• [749] TRPML1 Promotes Protein Homeostasis in Melanoma Cells by Negatively Regulating MAPK and mTORC1 Signaling.Cell Rep. 2019 Aug 27;28(9):2293-2305.e9. doi: 10.1016/j.celrep.2019.07.086.
• [750] Control of Gene Regulatory Networks Using Bayesian Inverse Reinforcement Learning.IEEE/ACM Trans Comput Biol Bioinform. 2019 Jul-Aug;16(4):1250-1261. doi: 10.1109/TCBB.2018.2830357. Epub 2018 Apr 26.
• [751] Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma.Am J Pathol. 2001 Jun;158(6):2107-15. doi: 10.1016/S0002-9440(10)64682-2.
• [752] Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment.Cancer Res. 2008 Nov 1;68(21):8889-98. doi: 10.1158/0008-5472.CAN-08-2147.
• [753] Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis.J Cell Physiol. 2019 May;234(5):7356-7367. doi: 10.1002/jcp.27495. Epub 2018 Oct 28.
• [754] Expression of stromelysin 3 in the stromal elements of human basal cell carcinoma.Diagn Mol Pathol. 1992 Sep;1(3):200-5.
• [755] Analysis of Enzymatic Activity of Matrix Metalloproteinase (MMP) by Collagen Zymography in Melanoma.Methods Mol Biol. 2018;1731:97-106. doi: 10.1007/978-1-4939-7595-2_10.
• [756] The applications of anti-CD20 antibodies to treat various B cells disorders.Biomed Pharmacother. 2019 Jan;109:2415-2426. doi: 10.1016/j.biopha.2018.11.121. Epub 2018 Nov 30.
• [757] Expression of the Musashi1 gene encoding the RNA-binding protein in human hepatoma cell lines.Biochem Biophys Res Commun. 2002 Apr 26;293(1):150-4. doi: 10.1016/S0006-291X(02)00175-4.
• [758] Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome.Melanoma Res. 2019 Dec;29(6):590-595. doi: 10.1097/CMR.0000000000000578.
• [759] Melatonin receptors in human uveal melanocytes and melanoma cells.J Pineal Res. 2000 Apr;28(3):165-71. doi: 10.1034/j.1600-079x.2001.280306.x.
• [760] Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma.J Exp Clin Cancer Res. 2009 Jun 5;28(1):75. doi: 10.1186/1756-9966-28-75.
• [761] Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice.BMC Cancer. 2010 Jun 24;10:325. doi: 10.1186/1471-2407-10-325.
• [762] NEDD4 Negatively Regulates GITR via Ubiquitination in Immune Microenvironment of Melanoma.Onco Targets Ther. 2019 Dec 4;12:10629-10637. doi: 10.2147/OTT.S212317. eCollection 2019.
• [763] SOX9 is a dose-dependent metastatic fate determinant in melanoma.J Exp Clin Cancer Res. 2019 Jan 14;38(1):17. doi: 10.1186/s13046-018-0998-6.
• [764] Merlin is a negative regulator of human melanoma growth.PLoS One. 2012;7(8):e43295. doi: 10.1371/journal.pone.0043295. Epub 2012 Aug 17.
• [765] Tropomyosin-Related Kinase Receptor and Neurotrophin Expression in Cutaneous Melanoma Is Associated with a Poor Prognosis and Decreased Survival.Oncology. 2019;97(1):26-37. doi: 10.1159/000499384. Epub 2019 May 9.
• [766] Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53.Biochem Biophys Res Commun. 2005 Aug 19;334(1):223-30. doi: 10.1016/j.bbrc.2005.06.073.
• [767] Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System.J Oncol. 2019 Feb 3;2019:5245034. doi: 10.1155/2019/5245034. eCollection 2019.
• [768] Dual-Arm Nanocapsule Targets Neuropilin-1 Receptor and Microtubule: A Potential Nanomedicine Platform.Mol Pharm. 2019 Jun 3;16(6):2522-2531. doi: 10.1021/acs.molpharmaceut.9b00123. Epub 2019 May 3.
• [769] Neurotrophins and their receptors stimulate melanoma cell proliferation and migration.J Invest Dermatol. 2008 Aug;128(8):2031-40. doi: 10.1038/jid.2008.21. Epub 2008 Feb 28.
• [770] TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines.BMC Cancer. 2015 Oct 24;15:777. doi: 10.1186/s12885-015-1791-y.
• [771] Transcriptional gene expression profile of human esophageal squamous cell carcinoma.Genomics. 2003 May;81(5):481-8. doi: 10.1016/s0888-7543(03)00023-5.
• [772] Melanoma-associated cancer-testis antigen 16 (CT16) regulates the expression of apoptotic and antiapoptotic genes and promotes cell survival. PLoS One. 2012;7(9):e45382.
• [773] Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi.J Invest Dermatol. 1985 Jul;85(1):4-8. doi: 10.1111/1523-1747.ep12274479.
• [774] Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.Int J Mol Sci. 2019 Nov 27;20(23):5980. doi: 10.3390/ijms20235980.
• [775] Effective Combined Photodynamic Therapy with Lipid Platinum Chloride Nanoparticles Therapies of Oral Squamous Carcinoma Tumor Inhibition.J Clin Med. 2019 Dec 2;8(12):2112. doi: 10.3390/jcm8122112.
• [776] PRESM: personalized reference editor for somatic mutation discovery in cancer genomics.Bioinformatics. 2019 May 1;35(9):1445-1452. doi: 10.1093/bioinformatics/bty812.
• [777] Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis.Biochim Biophys Acta. 1997 Sep 12;1353(3):287-97. doi: 10.1016/s0167-4781(97)00080-8.
• [778] Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.BMC Cancer. 2019 Mar 25;19(1):266. doi: 10.1186/s12885-019-5489-4.
• [779] Negative trans-acting mechanisms controlling expression of platelet-derived growth factor A and B MRNA in somatic cell hybrids.Exp Cell Res. 1993 Aug;207(2):283-9. doi: 10.1006/excr.1993.1195.
• [780] The role of vascular mimicry as a biomarker in malignant melanoma: a systematic review and meta-analysis.BMC Cancer. 2019 Nov 21;19(1):1134. doi: 10.1186/s12885-019-6350-5.
• [781] Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma.Pharm Res. 2007 Jul;24(7):1290-8. doi: 10.1007/s11095-007-9249-9. Epub 2007 Mar 22.
• [782] Expression and clinical significance of pepsinogen C in uveal melanomas.Int J Biol Markers. 2004 Jul-Sep;19(3):240-4.
• [783] Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.Oncotarget. 2017 Mar 14;8(11):17586-17592. doi: 10.18632/oncotarget.15230.
• [784] Protein kinase C alpha associates with phospholipase D1 and enhances basal phospholipase D activity in a protein phosphorylation-independent manner in human melanoma cells.J Invest Dermatol. 2003 Jul;121(1):69-76. doi: 10.1046/j.1523-1747.2003.12300.x.
• [785] PLEKHA5 regulates tumor growth in metastatic melanoma.Cancer. 2020 Mar 1;126(5):1016-1030. doi: 10.1002/cncr.32611. Epub 2019 Nov 26.
• [786] Analysis of the DNA mismatch repair proteins expression in malignant melanomas.Anticancer Res. 2000 Nov-Dec;20(6B):4499-505.
• [787] Radiochemical and radiopharmacological characterization of a (64) Cu-labeled -MSH analog conjugated with different chelators.J Labelled Comp Radiopharm. 2019 Jun 30;62(8):495-509. doi: 10.1002/jlcr.3728. Epub 2019 Jun 17.
• [788] Periostin Links Skin Inflammation to Melanoma Progression in Humans and Mice.Int J Mol Sci. 2019 Jan 4;20(1):169. doi: 10.3390/ijms20010169.
• [789] A Role for A3/A1-Crystallin in Type 2 EMT of RPE Cells Occurring in Dry Age-Related Macular Degeneration.Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD104-AMD113. doi: 10.1167/iovs.18-24132.
• [790] Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas.Mod Pathol. 2019 Dec;32(12):1727-1733. doi: 10.1038/s41379-019-0335-4. Epub 2019 Aug 2.
• [791] Protein kinase C- is upregulated by IMP1 in melanoma and is linked to poor survival.Melanoma Res. 2019 Oct;29(5):539-543. doi: 10.1097/CMR.0000000000000558.
• [792] Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic.Semin Cancer Biol. 2020 Nov;66:140-154. doi: 10.1016/j.semcancer.2019.07.013. Epub 2019 Jul 26.
• [793] Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events.J Am Acad Dermatol. 2020 Feb;82(2):311-316. doi: 10.1016/j.jaad.2019.06.035. Epub 2019 Jun 21.
• [794] Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis.Mol Cancer Ther. 2005 Apr;4(4):668-76. doi: 10.1158/1535-7163.MCT-04-0332.
• [795] Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage.Melanoma Res. 2002 Jun;12(3):201-9. doi: 10.1097/00008390-200206000-00003.
• [796] High FcR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy.J Immunol. 2018 Dec 15;201(12):3741-3749. doi: 10.4049/jimmunol.1800700. Epub 2018 Nov 5.
• [797] Immunohistochemical detectability of cyclooxygenase-2 expression in cells of human melanocytic skin lesions: A methodological review.J Cutan Pathol. 2020 Apr;47(4):363-380. doi: 10.1111/cup.13606. Epub 2019 Dec 1.
• [798] The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function.J Immunol. 2011 Apr 1;186(7):3934-45. doi: 10.4049/jimmunol.1001675. Epub 2011 Feb 25.
• [799] Mutation analysis of the MEN1 tumour suppressor gene in malignant melanoma.Melanoma Res. 1999 Jun;9(3):249-52. doi: 10.1097/00008390-199906000-00006.
• [800] RAB22A overexpression promotes the tumor growth of melanoma. Oncotarget. 2016 Nov 1;7(44):71744-71753.
• [801] Long noncoding RNA ZFAS1 promotes tumorigenesis through regulation of miR-150-5p/RAB9A in melanoma.Melanoma Res. 2019 Dec;29(6):569-581. doi: 10.1097/CMR.0000000000000595.
• [802] A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression.Cancer Lett. 2019 Aug 10;457:151-167. doi: 10.1016/j.canlet.2019.05.009. Epub 2019 May 17.
• [803] MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.Curr Top Microbiol Immunol. 2017;407:117-151. doi: 10.1007/82_2017_4.
• [804] Pancreatitis associated protein I (PAP-I) alters adhesion and motility of human melanocytes and melanoma cells.J Invest Dermatol. 2001 Mar;116(3):426-33. doi: 10.1046/j.1523-1747.2001.01278.x.
• [805] The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion.Curr Cancer Drug Targets. 2008 Aug;8(5):404-13. doi: 10.2174/156800908785133141.
• [806] Photoreceptor proteins as cancer-retina antigens.Int J Cancer. 2007 Mar 15;120(6):1268-76. doi: 10.1002/ijc.22458.
• [807] Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.Oncogene. 2003 Feb 27;22(8):1124-34. doi: 10.1038/sj.onc.1206181.
• [808] Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity.Cancer Cell. 2003 Jul;4(1):19-29. doi: 10.1016/s1535-6108(03)00164-8.
• [809] CX-F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy.Biochem Pharmacol. 2019 Oct;168:14-25. doi: 10.1016/j.bcp.2019.06.014. Epub 2019 Jun 14.
• [810] Rsf? regulates malignant melanoma cell viability and chemoresistance via NFB/Bcl? signaling.Mol Med Rep. 2019 Oct;20(4):3487-3498. doi: 10.3892/mmr.2019.10610. Epub 2019 Aug 23.
• [811] Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.J Immunother Cancer. 2019 Dec 5;7(1):343. doi: 10.1186/s40425-019-0828-1.
• [812] The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes.PLoS One. 2011;6(7):e22560. doi: 10.1371/journal.pone.0022560. Epub 2011 Jul 28.
• [813] Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.Neoplasia. 2014 Jun;16(6):529-42. doi: 10.1016/j.neo.2014.06.001. Epub 2014 Jul 13.
• [814] The mutational landscape of mucosal melanoma.Semin Cancer Biol. 2020 Apr;61:139-148. doi: 10.1016/j.semcancer.2019.09.013. Epub 2019 Oct 23.
• [815] Sirt5 is dispensable for Braf(V600E) -mediated cutaneous melanoma development and growth in vivo.Exp Dermatol. 2019 Jan;28(1):83-85. doi: 10.1111/exd.13845.
• [816] The sirtuin 6: An overture in skin cancer.Exp Dermatol. 2020 Feb;29(2):124-135. doi: 10.1111/exd.14057. Epub 2019 Dec 29.
• [817] Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress.Cancer Res. 2017 Nov 15;77(22):6226-6239. doi: 10.1158/0008-5472.CAN-17-1965. Epub 2017 Sep 25.
• [818] Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma.Cancer Chemother Pharmacol. 2010 May;66(1):79-87. doi: 10.1007/s00280-009-1136-0. Epub 2009 Sep 22.
• [819] Evaluation of SAT-1, SAT-2 and GalNAcT-1 mRNA in colon cancer by real-time PCR.Mol Cell Biochem. 2007 Apr;298(1-2):59-68. doi: 10.1007/s11010-006-9350-0. Epub 2006 Nov 21.
• [820] SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000.
• [821] Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics.Front Pharmacol. 2019 Feb 6;10:79. doi: 10.3389/fphar.2019.00079. eCollection 2019.
• [822] Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter.Cancer Gene Ther. 2011 Feb;18(2):144-52. doi: 10.1038/cgt.2010.66. Epub 2010 Oct 29.
• [823] Exome sequencing identifies GRIN2A as frequently mutated in melanoma.Nat Genet. 2011 May;43(5):442-6. doi: 10.1038/ng.810. Epub 2011 Apr 15.
• [824] High SLC7A11 expression in normal skin of melanoma patients.Cancer Epidemiol. 2019 Oct;62:101582. doi: 10.1016/j.canep.2019.101582. Epub 2019 Aug 13.
• [825] Cutaneous pH landscape as a facilitator of melanoma initiation and progression.Acta Physiol (Oxf). 2019 Jan;225(1):e13105. doi: 10.1111/apha.13105. Epub 2018 Jun 17.
• [826] SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression.Sci Rep. 2017 Jan 12;7:40585. doi: 10.1038/srep40585.
• [827] Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nat Commun. 2018 Jun 27;9(1):2500. doi: 10.1038/s41467-018-04664-0.
• [828] Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.Cancer Res. 2009 Apr 1;69(7):2748-56. doi: 10.1158/0008-5472.CAN-08-2690. Epub 2009 Mar 17.
• [829] Thymine DNA glycosylase as a novel target for melanoma.Oncogene. 2019 May;38(19):3710-3728. doi: 10.1038/s41388-018-0640-2. Epub 2019 Jan 23.
• [830] Expression and functional role of CRIPTO-1 in cutaneous melanoma.Br J Cancer. 2011 Sep 27;105(7):1030-8. doi: 10.1038/bjc.2011.324. Epub 2011 Aug 23.
• [831] Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.Am J Dermatopathol. 2019 Apr;41(4):264-272. doi: 10.1097/DAD.0000000000001259.
• [832] Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence.Proc Natl Acad Sci U S A. 1986 Mar;83(5):1261-5. doi: 10.1073/pnas.83.5.1261.
• [833] Loss of heterozygosity of the thyroid hormone receptor B in posterior uveal melanoma.Melanoma Res. 1993 Dec;3(6):457-61. doi: 10.1097/00008390-199311000-00009.
• [834] Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.Front Immunol. 2019 Apr 5;10:650. doi: 10.3389/fimmu.2019.00650. eCollection 2019.
• [835] Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells invivo and enhance potent cytotoxic T-lymphocyte response against melanoma.Biomaterials. 2018 Mar;159:119-129. doi: 10.1016/j.biomaterials.2018.01.004. Epub 2018 Jan 3.
• [836] Tissue Rebuilding During Spontaneous Regression of Melanoma in the Melanoma-bearing Libechov Minipig.Anticancer Res. 2018 Aug;38(8):4629-4636. doi: 10.21873/anticanres.12767.
• [837] Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.J Hematol Oncol. 2018 Jan 3;11(1):1. doi: 10.1186/s13045-017-0548-2.
• [838] Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion.J Pathol. 2006 Oct;210(2):181-91. doi: 10.1002/path.2045.
• [839] Expression of thyrotropin-releasing hormone by human melanoma and nevi.Clin Cancer Res. 2004 Aug 15;10(16):5531-6. doi: 10.1158/1078-0432.CCR-03-0368.
• [840] TRIM59 loss in M2 macrophages promotes melanoma migration and invasion by upregulating MMP-9 and Madcam1.Aging (Albany NY). 2019 Oct 10;11(19):8623-8641. doi: 10.18632/aging.102351. Epub 2019 Oct 10.
• [841] Role of TRPM in melanocytes and melanoma.Exp Dermatol. 2012 Sep;21(9):650-4. doi: 10.1111/j.1600-0625.2012.01565.x.
• [842] Mechanism for Regulation of Melanoma Cell Death via Activation of Thermo-TRPV4 and TRPV2.J Oncol. 2019 Feb 7;2019:7362875. doi: 10.1155/2019/7362875. eCollection 2019.
• [843] Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.Exp Dermatol. 2008 Nov;17(11):908-15. doi: 10.1111/j.1600-0625.2008.00718.x. Epub 2008 Mar 12.
• [844] TYRP1 mRNA level is stable and MITF-M-independent in drug-nave, vemurafenib- and trametinib-resistant BRAF(V600E) melanoma cells.Arch Dermatol Res. 2020 Jul;312(5):385-392. doi: 10.1007/s00403-019-01995-w. Epub 2019 Oct 17.
• [845] Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression.Onco Targets Ther. 2019 Jun 13;12:4643-4654. doi: 10.2147/OTT.S205160. eCollection 2019.
• [846] Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.Anat Rec (Hoboken). 2008 Oct;291(10):1227-35. doi: 10.1002/ar.20736.
• [847] Loss of miR-155 upregulates WEE1 in metastatic melanoma.Melanoma Res. 2019 Apr;29(2):216-219. doi: 10.1097/CMR.0000000000000545.
• [848] Excess of rare cancers in Werner syndrome (adult progeria).Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):239-46.
• [849] The X-linked inhibitor of apoptosis protein (XIAP) is involved in melanoma invasion by regulating cell migration and survival.Cell Oncol (Dordr). 2019 Jun;42(3):319-329. doi: 10.1007/s13402-019-00427-1. Epub 2019 Feb 18.
• [850] Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma.Mol Cancer Res. 2019 Jul;17(7):1435-1449. doi: 10.1158/1541-7786.MCR-18-0407. Epub 2019 Mar 4.
• [851] The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.PLoS One. 2013 Oct 3;8(10):e76550. doi: 10.1371/journal.pone.0076550. eCollection 2013.
• [852] A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels.Medicine (Baltimore). 2019 Mar;98(13):e15003. doi: 10.1097/MD.0000000000015003.
• [853] Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma.Eur Radiol. 2018 Apr;28(4):1456-1464. doi: 10.1007/s00330-017-5099-y. Epub 2017 Nov 9.
• [854] The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention.Oncogene. 2019 Mar;38(13):2320-2336. doi: 10.1038/s41388-018-0563-y. Epub 2018 Nov 26.
• [855] Bacitracin is a non-competitive inhibitor of porcine M1 family neutral and glutamyl aminopeptidases.Nat Prod Res. 2021 Sep;35(17):2958-2962. doi: 10.1080/14786419.2019.1678611. Epub 2019 Oct 25.
• [856] Frequent adaptive immune responses against arginase-1.Oncoimmunology. 2017 Dec 26;7(3):e1404215. doi: 10.1080/2162402X.2017.1404215. eCollection 2018.
• [857] Genetic alterations in primary melanoma in Taiwan.Br J Dermatol. 2020 May;182(5):1205-1213. doi: 10.1111/bjd.18425. Epub 2019 Oct 15.
• [858] Co-inhibition of BMI1 and Mel18 enhances chemosensitivity of esophageal squamous cell carcinoma in vitro and in vivo.Oncol Lett. 2019 Jun;17(6):5012-5022. doi: 10.3892/ol.2019.10160. Epub 2019 Mar 19.
• [859] C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma.FASEB J. 2019 Oct;33(10):11060-11071. doi: 10.1096/fj.201800980RR. Epub 2019 Jul 12.
• [860] Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.J Cutan Pathol. 2018 Jul;45(7):539-544. doi: 10.1111/cup.13262. Epub 2018 May 16.
• [861] Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma.Front Med (Lausanne). 2019 Apr 26;6:86. doi: 10.3389/fmed.2019.00086. eCollection 2019.
• [862] B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.Nat Commun. 2019 Sep 13;10(1):4186. doi: 10.1038/s41467-019-12160-2.
• [863] Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.Oncoimmunology. 2019 Sep 6;8(11):e1660121. doi: 10.1080/2162402X.2019.1660121. eCollection 2019.
• [864] Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.Mol Oncol. 2018 Mar;12(3):287-304. doi: 10.1002/1878-0261.12148. Epub 2018 Jan 28.
• [865] Unconventional myosin VIIA promotes melanoma progression.J Cell Sci. 2018 Feb 22;131(4):jcs209924. doi: 10.1242/jcs.209924.
• [866] Chemerin partly mediates tumor-inhibitory effect of all-trans retinoic acid via CMKLR1-dependent natural killer cell recruitment.Immunology. 2019 Jul;157(3):248-256. doi: 10.1111/imm.13065. Epub 2019 May 29.
• [867] A Mixture of Polyunsaturated Fatty Acids -3 and -6 Reduces Melanoma Growth by Inhibiting Inflammatory Mediators in the Murine Tumor Microenvironment.Int J Mol Sci. 2019 Aug 1;20(15):3765. doi: 10.3390/ijms20153765.
• [868] DEK oncogene is overexpressed during melanoma progression.Pigment Cell Melanoma Res. 2017 Mar;30(2):194-202. doi: 10.1111/pcmr.12563. Epub 2017 Mar 7.
• [869] LINC00459 sponging miR-218 to elevate DKK3 inhibits proliferation and invasion in melanoma.Sci Rep. 2019 Dec 16;9(1):19139. doi: 10.1038/s41598-019-55701-x.
• [870] Evaluation of the Active Targeting of Melanin Granules after Intravenous Injection of Dendronized Nanoparticles.Mol Pharm. 2018 Feb 5;15(2):536-547. doi: 10.1021/acs.molpharmaceut.7b00904. Epub 2018 Jan 17.
• [871] lncRNA NEAT1 facilitates melanoma cell proliferation, migration, and invasion via regulating miR-495-3p and E2F3.J Cell Physiol. 2019 Nov;234(11):19592-19601. doi: 10.1002/jcp.28559. Epub 2019 Jun 7.
• [872] Loss of Phd2 cooperates with BRAF(V600E) to drive melanomagenesis.Nat Commun. 2018 Dec 21;9(1):5426. doi: 10.1038/s41467-018-07126-9.
• [873] ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.Mol Cancer Ther. 2018 Jan;17(1):222-231. doi: 10.1158/1535-7163.MCT-17-0472. Epub 2017 Oct 20.
• [874] Electrotransfer of plasmid DNA radiosensitizes B16F10 tumors through activation of immune response.Radiol Oncol. 2017 Feb 22;51(1):30-39. doi: 10.1515/raon-2017-0011. eCollection 2017 Mar 1.
• [875] Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.J Med Chem. 2018 Mar 8;61(5):2052-2061. doi: 10.1021/acs.jmedchem.7b01837. Epub 2018 Feb 27.
• [876] Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.Molecules. 2018 Feb 17;23(2):444. doi: 10.3390/molecules23020444.
• [877] Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF (V600E)-Mutant Melanoma.Clin Cancer Res. 2018 Nov 15;24(22):5516-5524. doi: 10.1158/1078-0432.CCR-18-0565. Epub 2018 Apr 19.
• [878] HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation.Mol Cancer Ther. 2018 Feb;17(2):407-418. doi: 10.1158/1535-7163.MCT-17-0288. Epub 2017 Oct 13.
• [879] TRAF2 and FKBP51 as possible markers for identification of suitable melanoma tumors for tumor necrosis factor- inhibition.Melanoma Res. 2019 Apr;29(2):145-150. doi: 10.1097/CMR.0000000000000553.
• [880] Intratumoral administration of carboplatin bearing poly (-caprolactone) nanoparticles amalgamated with in situ gel tendered augmented drug delivery, cytotoxicity, and apoptosis in melanoma tumor.Colloids Surf B Biointerfaces. 2018 Jun 1;166:339-348. doi: 10.1016/j.colsurfb.2018.03.009. Epub 2018 Mar 31.
• [881] Frizzled-10 and cancer progression: Is it a new prognostic marker?.Oncotarget. 2017 Dec 12;9(1):824-830. doi: 10.18632/oncotarget.23159. eCollection 2018 Jan 2.
• [882] Prioritization and comprehensive analysis of genes associated with melanoma.Oncol Lett. 2019 Jul;18(1):127-136. doi: 10.3892/ol.2019.10284. Epub 2019 Apr 25.
• [883] High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes.Cell Immunol. 2017 Oct;320:29-37. doi: 10.1016/j.cellimm.2017.08.007. Epub 2017 Aug 30.
• [884] Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.BMC Cancer. 2018 Oct 30;18(1):1054. doi: 10.1186/s12885-018-4977-2.
• [885] Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression.Int J Oncol. 2018 Dec;53(6):2397-2408. doi: 10.3892/ijo.2018.4579. Epub 2018 Oct 1.
• [886] Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.Clin Cancer Res. 2012 Oct 1;18(19):5329-40. doi: 10.1158/1078-0432.CCR-12-1632. Epub 2012 Jul 31.
• [887] Interleukin 4-Induced Gene 1 as an Emerging Regulator of B-Cell Biology and its Role in Cutaneous Melanoma.Crit Rev Immunol. 2019;39(1):39-57. doi: 10.1615/CritRevImmunol.2019030020.
• [888] Protein kinase C (PKC) regulates p53 localization and melanoma cell survival downstream of integrin v in three-dimensional collagen and in vivo.J Biol Chem. 2012 Aug 24;287(35):29336-47. doi: 10.1074/jbc.M112.341917. Epub 2012 Jul 6.
• [889] miR-146a Exerts Differential Effects on Melanoma Growth and Metastatization.Mol Cancer Res. 2016 Jun;14(6):548-62. doi: 10.1158/1541-7786.MCR-15-0425-T.
• [890] Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis.Oncotarget. 2018 Feb 3;9(17):13407-13422. doi: 10.18632/oncotarget.24388. eCollection 2018 Mar 2.
• [891] KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy invitro.Cancer Lett. 2018 Mar 28;417:75-88. doi: 10.1016/j.canlet.2017.12.024. Epub 2017 Dec 18.
• [892] Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.Nat Commun. 2018 Nov 14;9(1):4774. doi: 10.1038/s41467-018-06649-5.
• [893] Regulation of the adaptation to ER stress by KLF4 facilitates melanoma cell metastasis via upregulating NUCB2 expression.J Exp Clin Cancer Res. 2018 Jul 28;37(1):176. doi: 10.1186/s13046-018-0842-z.
• [894] Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma.Cancers (Basel). 2019 Mar 29;11(4):450. doi: 10.3390/cancers11040450.
• [895] Increased Expression of GARP in Papillary Thyroid Carcinoma.Endocr Pathol. 2019 Mar;30(1):1-7. doi: 10.1007/s12022-018-9557-0.
• [896] ERK5 is activated by oncogenic BRAF and promotes melanoma growth.Oncogene. 2018 May;37(19):2601-2614. doi: 10.1038/s41388-018-0164-9. Epub 2018 Feb 27.
• [897] JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells.ACS Chem Biol. 2019 Jul 19;14(7):1426-1435. doi: 10.1021/acschembio.9b00083. Epub 2019 May 17.
• [898] Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.Pharmacogenet Genomics. 2009 Oct;19(10):760-9. doi: 10.1097/FPC.0b013e3283307cd9.
• [899] NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.Int J Cancer. 2019 Jan 1;144(1):136-149. doi: 10.1002/ijc.31808. Epub 2018 Oct 30.
• [900] Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.Mol Oncol. 2018 Jan;12(1):74-88. doi: 10.1002/1878-0261.12152. Epub 2017 Nov 23.
• [901] A promising redox cycle-based strategy for designing a catechol-type diphenylbutadiene as a potent prooxidative anti-melanoma agent.Free Radic Biol Med. 2019 Jan;130:489-498. doi: 10.1016/j.freeradbiomed.2018.11.018. Epub 2018 Nov 17.
• [902] Nuclear Receptor Nur77 Facilitates Melanoma Cell Survival under Metabolic Stress by Protecting Fatty Acid Oxidation.Mol Cell. 2018 Feb 1;69(3):480-492.e7. doi: 10.1016/j.molcel.2018.01.001. Epub 2018 Jan 27.
• [903] Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions.Melanoma Res. 2018 Feb;28(1):71-75. doi: 10.1097/CMR.0000000000000416.
• [904] Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations.Pigment Cell Melanoma Res. 2018 Jul;31(4):529-533. doi: 10.1111/pcmr.12695. Epub 2018 Mar 12.
• [905] A novel penicillin derivative induces antitumor effect in melanoma cells.Anticancer Drugs. 2018 Jun;29(5):416-428. doi: 10.1097/CAD.0000000000000611.
• [906] JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.Hum Pathol. 2019 Jun;88:87-91. doi: 10.1016/j.humpath.2018.08.032. Epub 2018 Sep 18.
• [907] MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.BMC Cancer. 2017 Nov 10;17(1):750. doi: 10.1186/s12885-017-3721-7.
• [908] miR-625-5p/PKM2 negatively regulates melanoma glycolysis state.J Cell Biochem. 2019 Mar;120(3):2964-2972. doi: 10.1002/jcb.26917. Epub 2018 Nov 30.
• [909] In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.Mol Cancer Ther. 2019 Sep;18(9):1637-1648. doi: 10.1158/1535-7163.MCT-18-1056. Epub 2019 Jul 3.
• [910] Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma.Mol Cancer Res. 2018 Mar;16(3):517-527. doi: 10.1158/1541-7786.MCR-17-0197. Epub 2018 Jan 12.
• [911] All-trans retinoic acid-encapsulated, CD20 antibody-conjugated poly(lactic-co-glycolic acid) nanoparticles effectively target and eliminate melanoma-initiating cells in vitro.Onco Targets Ther. 2018 Sep 25;11:6177-6187. doi: 10.2147/OTT.S169957. eCollection 2018.
• [912] Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.Br J Cancer. 2018 Feb 20;118(4):495-508. doi: 10.1038/bjc.2017.433. Epub 2017 Dec 12.
• [913] CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis.Cancers (Basel). 2019 Oct 3;11(10):1490. doi: 10.3390/cancers11101490.
• [914] RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.Cancer Cell. 2019 Jul 8;36(1):68-83.e9. doi: 10.1016/j.ccell.2019.05.015. Epub 2019 Jun 27.
• [915] Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.PLoS Genet. 2018 Sep 6;14(9):e1007589. doi: 10.1371/journal.pgen.1007589. eCollection 2018 Sep.
• [916] Critical role for nonGAP function of Gs in RGS1mediated promotion of melanoma progression through AKT and ERK phosphorylation.Oncol Rep. 2018 Jun;39(6):2673-2680. doi: 10.3892/or.2018.6341. Epub 2018 Mar 30.
• [917] On the relationship between VDR, ROR and ROR receptors expression and HIF1- levels in human melanomas.Exp Dermatol. 2019 Sep;28(9):1036-1043. doi: 10.1111/exd.14002. Epub 2019 Aug 8.
• [918] Ablation of epidermal RXR in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas.BMC Cancer. 2017 Nov 9;17(1):736. doi: 10.1186/s12885-017-3714-6.
• [919] Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation.Mol Cancer Res. 2018 Jan;16(1):135-146. doi: 10.1158/1541-7786.MCR-17-0292. Epub 2017 Oct 3.
• [920] SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib.Cancers (Basel). 2019 May 14;11(5):673. doi: 10.3390/cancers11050673.
• [921] Soluble SLAMF6 Receptor Induces Strong CD8(+) T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.Cancer Immunol Res. 2018 Feb;6(2):127-138. doi: 10.1158/2326-6066.CIR-17-0383. Epub 2018 Jan 5.
• [922] Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors.Cell Death Dis. 2018 Feb 27;9(3):325. doi: 10.1038/s41419-018-0340-4.
• [923] SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression.Virchows Arch. 2014 Sep;465(3):331-8. doi: 10.1007/s00428-014-1616-4. Epub 2014 Jul 4.
• [924] Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity.Cell Rep. 2019 Aug 13;28(7):1879-1893.e7. doi: 10.1016/j.celrep.2019.07.044.
• [925] Key candidate genes of STAT1 and CXCL10 in melanoma identified by integrated bioinformatical analysis.IUBMB Life. 2019 Oct;71(10):1634-1644. doi: 10.1002/iub.2103. Epub 2019 Jun 19.
• [926] Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.Melanoma Res. 2019 Apr;29(2):157-162. doi: 10.1097/CMR.0000000000000550.
• [927] Sentinel Lymph Node Genes to Predict Prognosis in Node-Positive Melanoma Patients.Ann Surg Oncol. 2017 Jan;24(1):108-116. doi: 10.1245/s10434-016-5575-7. Epub 2016 Sep 23.
• [928] uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.Int J Cancer. 2017 Sep 15;141(6):1190-1200. doi: 10.1002/ijc.30817. Epub 2017 Jun 21.
• [929] Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators.Nat Nanotechnol. 2019 Sep;14(9):891-901. doi: 10.1038/s41565-019-0512-0. Epub 2019 Aug 5.
• [930] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.Melanoma Res. 2018 Aug;28(4):341-347. doi: 10.1097/CMR.0000000000000459.
• [931] Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.Mol Cancer Ther. 2018 Jul;17(7):1416-1429. doi: 10.1158/1535-7163.MCT-17-0919. Epub 2018 Apr 27.
• [932] Specific Targeting of Melanotic Cells with Peptide Ligated Photosensitizers for Photodynamic Therapy.Sci Rep. 2017 Nov 16;7(1):15750. doi: 10.1038/s41598-017-15142-w.
• [933] A functional approach to understanding the role of NCKX5 in Xenopus pigmentation.PLoS One. 2017 Jul 10;12(7):e0180465. doi: 10.1371/journal.pone.0180465. eCollection 2017.
• [934] Mithramycin A suppresses expression of the human melanoma-associated gene ABCB8. Mol Genet Genomics. 2011 Jan;285(1):57-65.
• [935] FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential.Cell Death Dis. 2013 Apr 4;4(4):e578. doi: 10.1038/cddis.2013.109.
• [936] Microarray analysis of phosphatase gene expression in human melanoma.Br J Dermatol. 2005 May;152(5):925-30. doi: 10.1111/j.1365-2133.2005.06454.x.
• [937] Novel ABCA12 mutations identified in two cases of non-bullous congenital ichthyosiform erythroderma associated with multiple skin malignant neoplasia.J Invest Dermatol. 2007 Nov;127(11):2669-73. doi: 10.1038/sj.jid.5700885. Epub 2007 May 17.
• [938] Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer Discov. 2018 Aug;8(8):1006-1025.
• [939] Diagnostic and prognostic value of glucose transporters in melanocytic lesions.Melanoma Res. 2019 Dec;29(6):603-611. doi: 10.1097/CMR.0000000000000626.
• [940] The combined action of mast cell chymase, tryptase and carboxypeptidase A3 protects against melanoma colonization of the lung.Oncotarget. 2017 Apr 11;8(15):25066-25079. doi: 10.18632/oncotarget.15339.
• [941] On the role of classical and novel forms of vitamin D in melanoma progression and management.J Steroid Biochem Mol Biol. 2018 Mar;177:159-170. doi: 10.1016/j.jsbmb.2017.06.013. Epub 2017 Jul 1.
• [942] A polymorphic GGC repeat in the NPAS2 gene and its association with melanoma.Exp Biol Med (Maywood). 2017 Sep;242(15):1553-1558. doi: 10.1177/1535370217724093. Epub 2017 Aug 11.
• [943] Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1(+) Melanoma.Cancer Res. 2019 Apr 15;79(8):1799-1809. doi: 10.1158/0008-5472.CAN-18-1500. Epub 2019 Apr 15.
• [944] Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells.Oncogene. 2017 Aug 17;36(33):4732-4738. doi: 10.1038/onc.2017.81. Epub 2017 Apr 10.
• [945] Lentivirus-mediated downregulation of MAT2B inhibits cell proliferation and induces apoptosis in melanoma.Int J Oncol. 2016 Sep;49(3):981-90. doi: 10.3892/ijo.2016.3603. Epub 2016 Jul 5.
• [946] Silencing of metallothionein 1A gene in melanoma.J Dermatol Sci. 2017 Nov;88(2):232-237. doi: 10.1016/j.jdermsci.2017.07.009. Epub 2017 Jul 21.
• [947] Inhibition of NAT10 Suppresses Melanogenesis and Melanoma Growth by Attenuating Microphthalmia-Associated Transcription Factor (MITF) Expression.Int J Mol Sci. 2017 Sep 7;18(9):1924. doi: 10.3390/ijms18091924.
• [948] Analysis of nicotinamide N-methyltransferase in oral malignant melanoma and potential prognostic significance.Melanoma Res. 2019 Apr;29(2):151-156. doi: 10.1097/CMR.0000000000000548.
• [949] Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.Cancers (Basel). 2019 Aug 16;11(8):1198. doi: 10.3390/cancers11081198.
• [950] In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells.J Immunol Methods. 2011 Feb 28;365(1-2):76-86. doi: 10.1016/j.jim.2010.12.007. Epub 2010 Dec 21.
• [951] Proinvasion metastasis drivers in early-stage melanoma are oncogenes.Cancer Cell. 2011 Jul 12;20(1):92-103. doi: 10.1016/j.ccr.2011.05.025.
• [952] Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes.Chem Biol Interact. 2019 Dec 1;314:108822. doi: 10.1016/j.cbi.2019.108822. Epub 2019 Sep 30.
• [953] Expression of a catalytically inactive H118Y mutant of nm23-H2 suppresses the metastatic potential of line IV Cl 1 human melanoma cells.Int J Cancer. 2000 Nov 15;88(4):547-53. doi: 10.1002/1097-0215(20001115)88:4<547::aid-ijc5>3.0.co;2-l.
• [954] Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro.J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):375-9. doi: 10.1016/j.jsbmb.2004.03.002.
• [955] Genetic variants in ELOVL2 and HSD17B12 predict melanoma-specific survival.Int J Cancer. 2019 Nov 15;145(10):2619-2628. doi: 10.1002/ijc.32194. Epub 2019 Feb 20.
• [956] Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK.J Med Genet. 2011 Apr;48(4):266-72. doi: 10.1136/jmg.2010.086538. Epub 2011 Feb 15.
• [957] The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer.Br J Cancer. 2009 May 19;100(10):1687-96. doi: 10.1038/sj.bjc.6605042.
• [958] Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma.J Invest Dermatol. 2019 May;139(5):1118-1126. doi: 10.1016/j.jid.2018.10.038. Epub 2018 Nov 16.
• [959] The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker.Int J Cancer. 2006 Sep 1;119(5):1014-22. doi: 10.1002/ijc.21942.
• [960] SCL gene in human tumors.Leukemia. 1992 Jul;6(7):623-5.
• [961] Lipocalin-type prostaglandin D synthase-derived PGD(2) attenuates malignant properties of tumor endothelial cells.J Pathol. 2018 Jan;244(1):84-96. doi: 10.1002/path.4993. Epub 2017 Nov 10.
• [962] Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma.J Invest Dermatol. 2017 Jan;137(1):159-169. doi: 10.1016/j.jid.2016.08.024. Epub 2016 Sep 10.
• [963] An Ancient, Unified Mechanism for Metformin Growth Inhibition in C.elegans and Cancer.Cell. 2016 Dec 15;167(7):1705-1718.e13. doi: 10.1016/j.cell.2016.11.055.
• [964] Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.PLoS One. 2016 May 12;11(5):e0155660. doi: 10.1371/journal.pone.0155660. eCollection 2016.
• [965] Glucose-independent Acetate Metabolism Promotes Melanoma Cell Survival and Tumor Growth.J Biol Chem. 2016 Oct 14;291(42):21869-21879. doi: 10.1074/jbc.M115.712166. Epub 2016 Aug 18.
• [966] Biological properties of melanoma and endothelial cells after plasmid AMEP gene electrotransfer depend on integrin quantity on cells.J Membr Biol. 2013 Nov;246(11):803-19. doi: 10.1007/s00232-013-9550-y. Epub 2013 May 7.
• [967] ADAR1-mediated regulation of melanoma invasion.Nat Commun. 2018 May 31;9(1):2154. doi: 10.1038/s41467-018-04600-2.
• [968] BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAF(V600E) Mutant Melanoma.Clin Cancer Res. 2017 Sep 15;23(18):5631-5638. doi: 10.1158/1078-0432.CCR-16-0758. Epub 2017 May 24.
• [969] AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1.Melanoma Res. 2016 Apr;26(2):108-16. doi: 10.1097/CMR.0000000000000228.
• [970] Inflammation-related induction of absent in melanoma 2 (AIM2) in vascular cells and atherosclerotic lesions suggests a role in vascular pathogenesis.J Vasc Surg. 2014 Mar;59(3):794-803. doi: 10.1016/j.jvs.2013.03.048. Epub 2013 Jun 21.
• [971] Targeting protein kinase-b3 (akt3) signaling in melanoma.Expert Opin Ther Targets. 2017 Mar;21(3):273-290. doi: 10.1080/14728222.2017.1279147. Epub 2017 Jan 16.
• [972] Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.Mol Cell. 2017 Nov 16;68(4):731-744.e9. doi: 10.1016/j.molcel.2017.11.004.
• [973] Development of an HTS-Compatible Assay for Discovery of Melanoma-Related Microphthalmia Transcription Factor Disruptors Using AlphaScreen Technology.SLAS Discov. 2017 Jan;22(1):58-66. doi: 10.1177/1087057116675274. Epub 2016 Nov 11.
• [974] Multiple pro-tumorigenic functions of the human minor Histocompatibility Antigen-1 (HA-1) in melanoma progression.J Dermatol Sci. 2017 Nov;88(2):216-224. doi: 10.1016/j.jdermsci.2017.07.004. Epub 2017 Jul 8.
• [975] TIM-4 Identifies IFN--Expressing Proinflammatory B Effector 1 Cells That Promote Tumor and Allograft Rejection.J Immunol. 2017 Oct 1;199(7):2585-2595. doi: 10.4049/jimmunol.1602107. Epub 2017 Aug 28.
• [976] Patient with anomalous skin pigmentation expands the phenotype of ARID2 loss-of-function disorder, a SWI/SNF-related intellectual disability.Am J Med Genet A. 2019 May;179(5):808-812. doi: 10.1002/ajmg.a.61075. Epub 2019 Mar 5.
• [977] Targeted silencing of the ADP-ribosyltransferase 3 gene inhibits the migration ability of melanoma cells.Oncol Lett. 2018 May;15(5):7053-7059. doi: 10.3892/ol.2018.8252. Epub 2018 Mar 13.
• [978] Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells.Oncogene. 2019 Feb;38(8):1282-1295. doi: 10.1038/s41388-018-0500-0. Epub 2018 Sep 25.
• [979] Identification of key candidate genes involved in melanoma metastasis.Mol Med Rep. 2019 Aug;20(2):903-914. doi: 10.3892/mmr.2019.10314. Epub 2019 May 30.
• [980] Variants in autophagy-related genes and clinical characteristics in melanoma: a population-based study.Cancer Med. 2016 Nov;5(11):3336-3345. doi: 10.1002/cam4.929. Epub 2016 Oct 17.
• [981] Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.Clin Cancer Res. 2019 Apr 15;25(8):2610-2620. doi: 10.1158/1078-0432.CCR-18-1527. Epub 2019 Jan 15.
• [982] ATP13A2/PARK9 regulates endo-/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2-mediated scaffolding function.Hum Mol Genet. 2017 May 1;26(9):1656-1669. doi: 10.1093/hmg/ddx070.
• [983] The plasma membrane Ca(2+) pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.Int J Cancer. 2017 Jun 15;140(12):2758-2770. doi: 10.1002/ijc.30503. Epub 2016 Nov 17.
• [984] UVB-irradiated keratinocytes induce melanoma-associated ganglioside GD3 synthase gene in melanocytes via secretion of tumor necrosis factor and interleukin 6.Biochem Biophys Res Commun. 2014 Mar 7;445(2):504-10. doi: 10.1016/j.bbrc.2014.02.038. Epub 2014 Feb 15.
• [985] The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis.Clin Cancer Res. 2016 Jul 1;22(13):3268-80. doi: 10.1158/1078-0432.CCR-15-2066. Epub 2016 Jan 5.
• [986] A therapeutic trial of human melanomas with combined small interfering RNAs targeting adaptor molecules p130Cas and paxillin activated under expression of ganglioside GD3.Biochim Biophys Acta. 2016 Aug;1860(8):1753-63. doi: 10.1016/j.bbagen.2016.04.005. Epub 2016 Apr 9.
• [987] Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.Oncogene. 2012 May 10;31(19):2461-70. doi: 10.1038/onc.2011.425. Epub 2011 Sep 26.
• [988] BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.Cancer Lett. 2017 Sep 28;404:70-78. doi: 10.1016/j.canlet.2017.07.005. Epub 2017 Jul 15.
• [989] BNIP3 contributes to the glutamine-driven aggressive behavior of melanoma cells.Biol Chem. 2019 Jan 28;400(2):187-193. doi: 10.1515/hsz-2018-0208.
• [990] BPTF transduces MITF-driven prosurvival signals in melanoma cells.Proc Natl Acad Sci U S A. 2016 May 31;113(22):6254-8. doi: 10.1073/pnas.1606027113. Epub 2016 May 16.
• [991] Expression of breast cancer metastasis suppressor-1, BRMS-1, in human breast cancer and the biological impact of BRMS-1 on the migration of breast cancer cells.Anticancer Res. 2014 Mar;34(3):1417-26.
• [992] Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.J Invest Dermatol. 2017 Aug;137(8):1749-1756. doi: 10.1016/j.jid.2017.04.023. Epub 2017 May 10.
• [993] Cul1 promotes melanoma cell proliferation by promoting DEPTOR degradation and enhancing cap-dependent translation.Oncol Rep. 2016 Feb;35(2):1049-56. doi: 10.3892/or.2015.4442. Epub 2015 Nov 23.
• [994] CAP2 is a Valuable Biomarker for Diagnosis and Prognostic in Patients with Gastric Cancer.Pathol Oncol Res. 2020 Jan;26(1):273-279. doi: 10.1007/s12253-018-0450-4. Epub 2018 Jul 26.
• [995] Type 1 diabetes mellitus caused by treatment with low-dose interferon- in a melanoma patient.Melanoma Res. 2017 Oct;27(5):516-518. doi: 10.1097/CMR.0000000000000381.
• [996] Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model.Front Pharmacol. 2017 Jul 7;8:319. doi: 10.3389/fphar.2017.00319. eCollection 2017.
• [997] High CCL27 immunoreactivity in 'supratumoral' epidermis correlates with better prognosis in patients with cutaneous malignant melanoma.J Clin Pathol. 2017 Jan;70(1):15-19. doi: 10.1136/jclinpath-2015-203537. Epub 2016 Jun 20.
• [998] WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial-mesenchymal transition.J Biol Chem. 2019 Apr 5;294(14):5261-5280. doi: 10.1074/jbc.RA118.006122. Epub 2019 Feb 5.
• [999] Potential role of cyclin F mRNA expression in the survival of skin melanoma patients: Comprehensive analysis of the pathways altered due to cyclin F upregulation.Oncol Rep. 2018 Jul;40(1):123-144. doi: 10.3892/or.2018.6435. Epub 2018 May 16.
• [1000] Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.Theranostics. 2019 Aug 12;9(20):5797-5809. doi: 10.7150/thno.35059. eCollection 2019.
• [1001] Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.Theranostics. 2017 Aug 22;7(14):3585-3594. doi: 10.7150/thno.21471. eCollection 2017.
• [1002] CDC5L drives FAH expression to promote metabolic reprogramming in melanoma.Oncotarget. 2017 Dec 7;8(69):114328-114343. doi: 10.18632/oncotarget.23107. eCollection 2017 Dec 26.
• [1003] The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.Sci Transl Med. 2016 Dec 14;8(369):369ra177. doi: 10.1126/scitranslmed.aai9188.
• [1004] MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene.Tumour Biol. 2016 Oct;37(10):13941-13950. doi: 10.1007/s13277-016-5271-z. Epub 2016 Aug 4.
• [1005] Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RAR signaling.Mol Cancer Res. 2013 Oct;11(10):1166-78. doi: 10.1158/1541-7786.MCR-13-0006. Epub 2013 Jul 12.
• [1006] Vitamin D receptor polymorphisms and melanoma.Oncol Lett. 2019 May;17(5):4162-4169. doi: 10.3892/ol.2018.9733. Epub 2018 Nov 19.
• [1007] Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1.Nat Commun. 2017 Dec 21;8(1):2249. doi: 10.1038/s41467-017-02353-y.
• [1008] Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.Nat Genet. 2015 May;47(5):486-95. doi: 10.1038/ng.3275. Epub 2015 Apr 13.
• [1009] Silencing of CerS6 increases the invasion and glycolysis of melanoma WM35, WM451 and SK28 cell lines via increased GLUT1-induced downregulation of WNT5A.Oncol Rep. 2016 May;35(5):2907-15. doi: 10.3892/or.2016.4646. Epub 2016 Mar 2.
• [1010] MicroRNA-dependent regulation of cKit in cutaneous melanoma.Biochem Biophys Res Commun. 2009 Feb 13;379(3):790-4. doi: 10.1016/j.bbrc.2008.12.152. Epub 2009 Jan 4.
• [1011] Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, aCandidate Melanoma Suppressor Function.J Invest Dermatol. 2017 Oct;137(10):2197-2207. doi: 10.1016/j.jid.2017.05.030. Epub 2017 Jun 22.
• [1012] Melanocyte-specific gene 1 promotes melanoma progression by enhancing the expression of Bcl-2.Oncol Lett. 2018 Feb;15(2):2413-2418. doi: 10.3892/ol.2017.7592. Epub 2017 Dec 12.
• [1013] CKS1 expression in melanocytic nevi and melanoma.Oncotarget. 2017 Dec 23;9(3):4173-4187. doi: 10.18632/oncotarget.23648. eCollection 2018 Jan 9.
• [1014] MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.J Invest Dermatol. 2016 Feb;136(2):453-463. doi: 10.1016/j.jid.2015.11.012. Epub 2015 Nov 20.
• [1015] The dysfunction of BP180/collagen XVII in keratinocytes promotes melanoma progression.Oncogene. 2019 Dec;38(50):7491-7503. doi: 10.1038/s41388-019-0961-9. Epub 2019 Aug 21.
• [1016] An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.BMB Rep. 2018 Nov;51(11):572-577. doi: 10.5483/BMBRep.2018.51.11.076.
• [1017] Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers.Nat Commun. 2016 Nov 18;7:13418. doi: 10.1038/ncomms13418.
• [1018] Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation.Int J Biochem Cell Biol. 2016 Dec;81(Pt A):76-81. doi: 10.1016/j.biocel.2016.10.019. Epub 2016 Oct 25.
• [1019] Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.Eur J Cancer. 2012 Jan;48(1):94-100. doi: 10.1016/j.ejca.2011.06.056. Epub 2011 Jul 23.
• [1020] Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients.Br J Dermatol. 2003 Aug;149(2):282-8. doi: 10.1046/j.1365-2133.2003.05410.x.
• [1021] CtBP1 is expressed in melanoma and represses the transcription of p16INK4a and Brca1.J Invest Dermatol. 2013 May;133(5):1294-301. doi: 10.1038/jid.2012.487. Epub 2013 Jan 10.
• [1022] Functional Mutations Form at CTCF-Cohesin Binding Sites in Melanoma Due to Uneven Nucleotide Excision Repair across the Motif.Cell Rep. 2016 Dec 13;17(11):2865-2872. doi: 10.1016/j.celrep.2016.11.055.
• [1023] Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.Oncotarget. 2016 Mar 22;7(12):15065-92. doi: 10.18632/oncotarget.7604.
• [1024] Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion.Mol Cell Proteomics. 2020 Jan;19(1):50-64. doi: 10.1074/mcp.RA119.001811. Epub 2019 Nov 2.
• [1025] The Chemokine Receptor CXCR6 Evokes Reverse Signaling via the Transmembrane Chemokine CXCL16.Int J Mol Sci. 2017 Jul 8;18(7):1468. doi: 10.3390/ijms18071468.
• [1026] Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants.Int J Cancer. 2004 May 20;110(1):15-21. doi: 10.1002/ijc.20078.
• [1027] Overexpression of mRNA-decapping enzyme 1a predicts disease-specific survival in malignant melanoma.Melanoma Res. 2018 Feb;28(1):30-36. doi: 10.1097/CMR.0000000000000406.
• [1028] Prognostic Value of Dynactin mRNA Expression in Cutaneous Melanoma.Med Sci Monit. 2018 Jun 4;24:3752-3763. doi: 10.12659/MSM.910566.
• [1029] Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair.Oncotarget. 2016 Sep 20;7(38):60940-60953. doi: 10.18632/oncotarget.10902.
• [1030] Polymorphisms in the p27kip-1 and prohibitin genes denote novel genes associated with melanoma risk in Brazil, a high ultraviolet index region.Melanoma Res. 2013 Jun;23(3):231-6. doi: 10.1097/CMR.0b013e3283612483.
• [1031] The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma.Cell Rep. 2019 Jun 18;27(12):3573-3586.e7. doi: 10.1016/j.celrep.2019.05.069.
• [1032] DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2.Mol Cells. 2017 May 31;40(5):322-330. doi: 10.14348/molcells.2017.0001. Epub 2017 May 2.
• [1033] Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.Oncogene. 2017 Jun 8;36(23):3334-3345. doi: 10.1038/onc.2016.486. Epub 2017 Jan 16.
• [1034] Pulmonary administration of curcumin inhibits B16F10 melanoma lung metastasis and invasion in mice.Cancer Chemother Pharmacol. 2018 Aug;82(2):265-273. doi: 10.1007/s00280-018-3616-6. Epub 2018 Jun 4.
• [1035] Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.Oncotarget. 2016 Jul 19;7(29):46492-46508. doi: 10.18632/oncotarget.10216.
• [1036] The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.Ann Surg. 2019 Oct;270(4):712-722. doi: 10.1097/SLA.0000000000003522.
• [1037] ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.Cancers (Basel). 2018 Dec 20;11(1):3. doi: 10.3390/cancers11010003.
• [1038] Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes.J Invest Dermatol. 2015 Sep;135(9):2266-2272. doi: 10.1038/jid.2015.138. Epub 2015 Apr 7.
• [1039] Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.Oncotarget. 2017 Jan 24;8(4):6085-6101. doi: 10.18632/oncotarget.14042.
• [1040] Profiling Optimal Conditions for Capturing EDEM Proteins Complexes in Melanoma Using Mass Spectrometry.Adv Exp Med Biol. 2019;1140:155-167. doi: 10.1007/978-3-030-15950-4_9.
• [1041] Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma.J Invest Dermatol. 2020 Apr;140(4):878-890.e5. doi: 10.1016/j.jid.2019.08.451. Epub 2019 Oct 14.
• [1042] Endothelin-3 is produced by metastatic melanoma cells and promotes melanoma cell survival.J Cutan Med Surg. 2008 Mar-Apr;12(2):64-70. doi: 10.2310/7750.2008.06164.
• [1043] SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas.Acta Neuropathol Commun. 2016 Jan 15;4:5. doi: 10.1186/s40478-016-0272-0.
• [1044] Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.Genes Dev. 2017 Jan 1;31(1):18-33. doi: 10.1101/gad.290940.116. Epub 2017 Jan 17.
• [1045] Knockdown of EIF3D suppresses proliferation of human melanoma cells through G2/M phase arrest.Biotechnol Appl Biochem. 2015 Sep-Oct;62(5):615-20. doi: 10.1002/bab.1305. Epub 2015 Jan 12.
• [1046] Cancer Targeted Gene Therapy for Inhibition of Melanoma Lung Metastasis with eIF3i shRNA Loaded Liposomes.Mol Pharm. 2020 Jan 6;17(1):229-238. doi: 10.1021/acs.molpharmaceut.9b00943. Epub 2019 Dec 10.
• [1047] Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.Nat Med. 2018 Dec;24(12):1877-1886. doi: 10.1038/s41591-018-0217-1. Epub 2018 Oct 29.
• [1048] Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway.Oncogene. 2016 Mar 3;35(9):1170-9. doi: 10.1038/onc.2015.175. Epub 2015 Jun 1.
• [1049] XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma.Tumour Biol. 2016 Mar;37(3):3163-71. doi: 10.1007/s13277-015-4123-6. Epub 2015 Oct 2.
• [1050] Current evidences on the XPG Asp1104His polymorphism and melanoma susceptibility: a meta-analysis based on case-control studies.Mol Genet Genomics. 2015 Feb;290(1):273-9. doi: 10.1007/s00438-014-0917-2. Epub 2014 Sep 18.
• [1051] Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.Cancer Immunol Res. 2016 Jun;4(6):552-61. doi: 10.1158/2326-6066.CIR-15-0255. Epub 2016 Apr 4.
• [1052] Ipilimumab in melanoma.Expert Rev Anticancer Ther. 2016 Aug;16(8):811-26. doi: 10.1080/14737140.2016.1211936. Epub 2016 Jul 25.
• [1053] miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1.Oncotarget. 2015 Aug 7;6(22):19006-16. doi: 10.18632/oncotarget.4147.
• [1054] Exonuclease 1 (EXO1) gene variation and melanoma risk.DNA Repair (Amst). 2012 Mar 1;11(3):304-9. doi: 10.1016/j.dnarep.2011.12.005. Epub 2012 Jan 9.
• [1055] Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma.Oncotarget. 2017 Sep 27;8(62):105081-105092. doi: 10.18632/oncotarget.21352. eCollection 2017 Dec 1.
• [1056] Interleukin-like EMT inducer (ILEI) promotes melanoma invasiveness and is transcriptionally up-regulated by upstream stimulatory factor-1 (USF-1).J Biol Chem. 2018 Jul 20;293(29):11401-11414. doi: 10.1074/jbc.RA118.003616. Epub 2018 Jun 5.
• [1057] Expression of kindlin-3 in melanoma cells impedes cell migration and metastasis.Cell Adh Migr. 2017 Sep 3;11(5-6):419-433. doi: 10.1080/19336918.2016.1243645. Epub 2016 Nov 2.
• [1058] FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.Oncotarget. 2017 Sep 23;8(50):87750-87762. doi: 10.18632/oncotarget.21184. eCollection 2017 Oct 20.
• [1059] FHOD1 formin is upregulated in melanomas and modifies proliferation and tumor growth.Exp Cell Res. 2017 Jan 1;350(1):267-278. doi: 10.1016/j.yexcr.2016.12.004. Epub 2016 Dec 2.
• [1060] Expression of mitochondrial dynamics markers during melanoma progression: Comparative study of head and neck cutaneous and mucosal melanomas.J Oral Pathol Med. 2019 May;48(5):373-381. doi: 10.1111/jop.12855. Epub 2019 Apr 10.
• [1061] Aberrant expression of FLI-1 in melanoma.J Cutan Pathol. 2017 Sep;44(9):790-793. doi: 10.1111/cup.12979. Epub 2017 Jul 10.
• [1062] The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells.Cell Death Dis. 2017 Nov 16;8(11):e3169. doi: 10.1038/cddis.2017.521.
• [1063] FAD104, a Regulator of Adipogenesis and Osteogenesis, Interacts with the C-Terminal Region of STAT3 and Represses Malignant Transformation of Melanoma Cells.Biol Pharm Bull. 2016 May 1;39(5):849-55. doi: 10.1248/bpb.b15-01026. Epub 2016 Mar 4.
• [1064] Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents.Cancer Res. 2004 Oct 15;64(20):7386-94. doi: 10.1158/0008-5472.CAN-04-1640.
• [1065] Regulation of Cancer Stem Cell Self-Renewal by HOXB9 Antagonizes Endoplasmic Reticulum Stress-Induced Melanoma Cell Apoptosis via the miR-765-FOXA2 Axis.J Invest Dermatol. 2018 Jul;138(7):1609-1619. doi: 10.1016/j.jid.2018.01.023. Epub 2018 Feb 3.
• [1066] FOXD3 Promotes PAX3 Expression in Melanoma Cells.J Cell Biochem. 2016 Feb;117(2):533-41. doi: 10.1002/jcb.25306. Epub 2015 Sep 1.
• [1067] The fucose salvage pathway inhibits invadopodia formation and extracellular matrix degradation in melanoma cells.PLoS One. 2018 Jun 20;13(6):e0199128. doi: 10.1371/journal.pone.0199128. eCollection 2018.
• [1068] A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis.Cancer Cell. 2017 Jun 12;31(6):804-819.e7. doi: 10.1016/j.ccell.2017.05.007.
• [1069] Immunohistochemical Expression of FXR1 in Canine Normal Tissues and Melanomas.J Histochem Cytochem. 2018 Aug;66(8):585-593. doi: 10.1369/0022155418766292. Epub 2018 Apr 2.
• [1070] Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.Oncotarget. 2017 Oct 30;8(65):108786-108801. doi: 10.18632/oncotarget.22150. eCollection 2017 Dec 12.
• [1071] Distinct prognostic value of mRNA expression of guanylate-binding protein genes in skin cutaneous melanoma.Oncol Lett. 2018 May;15(5):7914-7922. doi: 10.3892/ol.2018.8306. Epub 2018 Mar 20.
• [1072] Genetic variants in the vitamin D pathway genes VDBP and RXRA modulate cutaneous melanoma disease-specific survival.Pigment Cell Melanoma Res. 2016 Mar;29(2):176-85. doi: 10.1111/pcmr.12437. Epub 2016 Jan 29.
• [1073] GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative Breast cancer.Biomed Pharmacother. 2016 Dec;84:1568-1574. doi: 10.1016/j.biopha.2016.10.032. Epub 2016 Nov 6.
• [1074] Identifying and targeting determinants of melanoma cellular invasion.Oncotarget. 2016 Jul 5;7(27):41186-41202. doi: 10.18632/oncotarget.9227.
• [1075] Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.Oncogene. 2017 Jan 5;36(1):84-96. doi: 10.1038/onc.2016.178. Epub 2016 May 16.
• [1076] A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma.J Natl Cancer Inst. 2018 Dec 1;110(12):1380-1385. doi: 10.1093/jnci/djy058.
• [1077] Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma.PLoS One. 2019 Jun 14;14(6):e0218067. doi: 10.1371/journal.pone.0218067. eCollection 2019.
• [1078] Glutathione S-transferase M1/T1 genotype and melanoma in a Southern Italian population: a case-control study.G Ital Dermatol Venereol. 2016 Apr;151(2):140-4. Epub 2015 Jan 14.
• [1079] Validation of the Chowdhury overall survival score in patients with melanoma brain metastasis treated with Gamma Knife Radiosurgery.J Neurooncol. 2018 Jun;138(2):391-399. doi: 10.1007/s11060-018-2808-6. Epub 2018 Feb 22.
• [1080] Oncogenic potential of histone-variant H2A.Z.1 and its regulatory role in cell cycle and epithelial-mesenchymal transition in liver cancer.Oncotarget. 2016 Mar 8;7(10):11412-23. doi: 10.18632/oncotarget.7194.
• [1081] Immunotherapy in mucosal melanoma: a case report and review of the literature.Oncotarget. 2018 Apr 3;9(25):17971-17977. doi: 10.18632/oncotarget.24727. eCollection 2018 Apr 3.
• [1082] HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.Immunogenetics. 2006 Jan;57(12):926-33. doi: 10.1007/s00251-005-0065-2. Epub 2005 Dec 20.
• [1083] Melanoma Cell Adhesion and Migration Is Modulated by the Uronyl 2-O Sulfotransferase.PLoS One. 2017 Jan 20;12(1):e0170054. doi: 10.1371/journal.pone.0170054. eCollection 2017.
• [1084] HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res. 2016 May 1;76(9):2720-30. doi: 10.1158/0008-5472.CAN-15-2137. Epub 2016 Mar 16.
• [1085] HSP105 recruits protein phosphatase 2A to dephosphorylate -catenin.Mol Cell Biol. 2015 Apr;35(8):1390-400. doi: 10.1128/MCB.01307-14. Epub 2015 Feb 2.
• [1086] Inhibitor of DNA Binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cells.PLoS One. 2015 Feb 2;10(2):e0116839. doi: 10.1371/journal.pone.0116839. eCollection 2015.
• [1087] High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.J Immunol. 2019 Nov 15;203(10):2577-2587. doi: 10.4049/jimmunol.1900476. Epub 2019 Oct 7.
• [1088] Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.J Cutan Pathol. 2007 Jun;34(6):448-55. doi: 10.1111/j.1600-0560.2006.00646.x.
• [1089] EWI-2 negatively regulates TGF- signaling leading to altered melanoma growth and metastasis.Cell Res. 2015 Mar;25(3):370-85. doi: 10.1038/cr.2015.17. Epub 2015 Feb 6.
• [1090] MEK inhibition and immune responses in advanced melanoma.Oncoimmunology. 2017 Aug 10;6(8):e1335843. doi: 10.1080/2162402X.2017.1335843. eCollection 2017.
• [1091] The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.JCI Insight. 2018 Jul 26;3(14):e120422. doi: 10.1172/jci.insight.120422. eCollection 2018 Jul 26.
• [1092] The positive feedback loop between ILF3 and lncRNA ILF3-AS1 promotes melanoma proliferation, migration, and invasion.Cancer Manag Res. 2018 Dec 11;10:6791-6802. doi: 10.2147/CMAR.S186777. eCollection 2018.
• [1093] Phosphorylation of the tumor suppressor p33(ING1b) at Ser-126 influences its protein stability and proliferation of melanoma cells.FASEB J. 2007 Nov;21(13):3705-16. doi: 10.1096/fj.07-8069com. Epub 2007 Jun 21.
• [1094] INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma.Genes Dev. 2016 Jun 15;30(12):1440-53. doi: 10.1101/gad.277178.115.
• [1095] Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.Biosci Rep. 2017 Feb 10;37(1):BSR20160432. doi: 10.1042/BSR20160432. Print 2017 Feb 28.
• [1096] The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma.Sci Rep. 2018 Jul 19;8(1):10902. doi: 10.1038/s41598-018-27643-3.
• [1097] Combination of Asiatic Acid and Naringenin Modulates NK Cell Anti-cancer Immunity by Rebalancing Smad3/Smad7 Signaling.Mol Ther. 2018 Sep 5;26(9):2255-2266. doi: 10.1016/j.ymthe.2018.06.016. Epub 2018 Jun 22.
• [1098] Silencing of interferon regulatory factor gene 6 in melanoma.PLoS One. 2017 Sep 6;12(9):e0184444. doi: 10.1371/journal.pone.0184444. eCollection 2017.
• [1099] Oncostatin M induces RIG-I and MDA5 expression and enhances the double-stranded RNA response in fibroblasts.J Cell Mol Med. 2017 Nov;21(11):3087-3099. doi: 10.1111/jcmm.13221. Epub 2017 May 30.
• [1100] Downregulation of miR-493 promoted melanoma proliferation by suppressing IRS4 expression.Tumour Biol. 2017 May;39(5):1010428317701640. doi: 10.1177/1010428317701640.
• [1101] MicroRNA-125b suppresses the epithelial-mesenchymal transition and cell invasion by targeting ITGA9 in melanoma.Tumour Biol. 2016 May;37(5):5941-9. doi: 10.1007/s13277-015-4409-8. Epub 2015 Nov 23.
• [1102] KSRP modulates melanoma growth and efficacy of vemurafenib.Biochim Biophys Acta Gene Regul Mech. 2019 Aug;1862(8):759-770. doi: 10.1016/j.bbagrm.2019.06.005. Epub 2019 Jun 30.
• [1103] Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma Cells.J Nat Prod. 2017 Jul 28;80(7):1981-1991. doi: 10.1021/acs.jnatprod.6b01129. Epub 2017 Jun 15.
• [1104] LIMD2 targeted by miR?4a promotes the proliferation and invasion of nonsmall cell lung cancer cells.Mol Med Rep. 2018 Nov;18(5):4760-4766. doi: 10.3892/mmr.2018.9464. Epub 2018 Sep 6.
• [1105] Identification of cis-regulatory mutations generating de novo edges in personalized cancer gene regulatory networks.Genome Med. 2017 Aug 30;9(1):80. doi: 10.1186/s13073-017-0464-7.
• [1106] LOXL3 Function Beyond Amino Oxidase and Role in Pathologies, Including Cancer.Int J Mol Sci. 2019 Jul 23;20(14):3587. doi: 10.3390/ijms20143587.
• [1107] Multifocal gastric adenocarcinoma in a patient with LRBA deficiency.Orphanet J Rare Dis. 2017 Jul 18;12(1):131. doi: 10.1186/s13023-017-0682-5.
• [1108] Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling.J Exp Clin Cancer Res. 2018 Aug 6;37(1):184. doi: 10.1186/s13046-018-0844-x.
• [1109] Melanoma LAMP-2C Modulates Tumor Growth and Autophagy.Front Cell Dev Biol. 2018 Aug 29;6:101. doi: 10.3389/fcell.2018.00101. eCollection 2018.
• [1110] Wnt5a signaling induced phosphorylation increases APT1 activity and promotes melanoma metastatic behavior.Elife. 2018 Apr 12;7:e34362. doi: 10.7554/eLife.34362.
• [1111] MicroRNA-338-3p suppresses cell proliferation, migration and invasion in human malignant melanoma by targeting MACC1.Exp Ther Med. 2019 Aug;18(2):997-1004. doi: 10.3892/etm.2019.7644. Epub 2019 Jun 4.
• [1112] Giant Pediatric Rhabdoid Meningioma Associated with a Germline BAP1 Pathogenic Variation: A Rare Clinical Case.World Neurosurg. 2018 Nov;119:402-415. doi: 10.1016/j.wneu.2018.06.227. Epub 2018 Jul 6.
• [1113] Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1.J Biol Chem. 2010 Jan 1;285(1):242-54. doi: 10.1074/jbc.M109.068668. Epub 2009 Oct 30.
• [1114] Pro-necrotic molecules impact local immunosurveillance in human breast cancer.Oncoimmunology. 2017 Apr 17;6(4):e1299302. doi: 10.1080/2162402X.2017.1299302. eCollection 2017.
• [1115] The atypical MAPK ERK3 potently suppresses melanoma cell growth and invasiveness.J Cell Physiol. 2019 Aug;234(8):13220-13232. doi: 10.1002/jcp.27994. Epub 2018 Dec 19.
• [1116] Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients.Melanoma Res. 2017 Jun;27(3):277-280. doi: 10.1097/CMR.0000000000000348.
• [1117] Myoglobin does not predict local toxicity in isolated limb perfusion.Int J Hyperthermia. 2017 Sep;33(6):679-683. doi: 10.1080/02656736.2017.1309082. Epub 2017 Apr 10.
• [1118] A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion.Oncogene. 2017 Jan 26;36(4):446-457. doi: 10.1038/onc.2016.219. Epub 2016 Jul 4.
• [1119] MED27 promotes melanoma growth by targeting AKT/MAPK and NF-B/iNOS signaling pathways.Cancer Lett. 2016 Apr 1;373(1):77-87. doi: 10.1016/j.canlet.2016.01.005. Epub 2016 Jan 18.
• [1120] Multiple endocrine neoplasia type 1 associated with a new germline Men1 mutation in a family with atypical tumor phenotype.Hormones (Athens). 2016 Jan-Mar;15(1):113-7. doi: 10.14310/horm.2002.1626.
• [1121] The importance of melanoma inhibitory activity gene family in the tumor progression of oral cancer.Pathol Int. 2018 May;68(5):278-286. doi: 10.1111/pin.12672. Epub 2018 Apr 14.
• [1122] A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion.Oncogene. 2006 Nov 9;25(53):7059-69. doi: 10.1038/sj.onc.1209688. Epub 2006 May 22.
• [1123] MMP7 sensitivity of mutant ECM proteins: An indicator of melanoma survival rates and T-cell infiltration.Clin Biochem. 2019 Jan;63:85-91. doi: 10.1016/j.clinbiochem.2018.11.004. Epub 2018 Nov 8.
• [1124] C-Terminal Binding Protein 1 Modulates Cellular Redox via Feedback Regulation of MPC1 and MPC2 in Melanoma Cells.Med Sci Monit. 2018 Oct 25;24:7614-7624. doi: 10.12659/MSM.912735.
• [1125] Differential chemokine receptor expression and usage by pre-cDC1 and pre-cDC2.Immunol Cell Biol. 2018 Nov;96(10):1131-1139. doi: 10.1111/imcb.12186. Epub 2018 Jul 20.
• [1126] Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.Mol Cancer Ther. 2017 Jan;16(1):193-204. doi: 10.1158/1535-7163.MCT-16-0482. Epub 2016 Nov 11.
• [1127] Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF- signaling.J Clin Invest. 2017 Apr 3;127(4):1321-1337. doi: 10.1172/JCI89281. Epub 2017 Mar 13.
• [1128] MSX1-Induced Neural Crest-Like Reprogramming Promotes MelanomaProgression.J Invest Dermatol. 2018 Jan;138(1):141-149. doi: 10.1016/j.jid.2017.05.038. Epub 2017 Sep 18.
• [1129] Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases.Clin Chem Lab Med. 2018 Oct 25;56(11):1945-1953. doi: 10.1515/cclm-2018-0139.
• [1130] Myosin X is required for efficient melanoblast migration and melanoma initiation and metastasis.Sci Rep. 2018 Jul 11;8(1):10449. doi: 10.1038/s41598-018-28717-y.
• [1131] Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.Neoplasia. 2013 Jul;15(7):826-39. doi: 10.1593/neo.13320.
• [1132] Myoferlin silencing inhibits VEGFR2-mediated proliferation of metastatic clear cell renal cell carcinoma.Sci Rep. 2019 Sep 2;9(1):12656. doi: 10.1038/s41598-019-48968-7.
• [1133] MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth.Oncotarget. 2017 Jun 27;8(40):67287-67299. doi: 10.18632/oncotarget.18617. eCollection 2017 Sep 15.
• [1134] DNA hypermethylation is associated with invasive phenotype of malignant melanoma.Exp Dermatol. 2020 Jan;29(1):39-50. doi: 10.1111/exd.14047. Epub 2019 Nov 14.
• [1135] Neogenin, Defined as a GD3-associated Molecule by Enzyme-mediated Activation of Radical Sources, Confers Malignant Properties via Intracytoplasmic Domain in Melanoma Cells.J Biol Chem. 2016 Aug 5;291(32):16630-43. doi: 10.1074/jbc.M115.708834. Epub 2016 Jun 10.
• [1136] NFAT5 promotes invivo development of murine melanoma metastasis.Biochem Biophys Res Commun. 2018 Nov 2;505(3):748-754. doi: 10.1016/j.bbrc.2018.09.171. Epub 2018 Oct 5.
• [1137] Stress and interferon signalling-mediated apoptosis contributes to pleiotropic anticancer responses induced by targeting NGLY1.Br J Cancer. 2018 Dec;119(12):1538-1551. doi: 10.1038/s41416-018-0265-9. Epub 2018 Nov 2.
• [1138] Lymphoscintigraphy mapping of truncal malignant melanoma: A study of 212 patients at the Christie NHS Foundation Trust.J Plast Reconstr Aesthet Surg. 2017 Jan;70(1):37-39. doi: 10.1016/j.bjps.2016.08.017. Epub 2016 Sep 10.
• [1139] Streptococcus mutans activates the AIM2, NLRP3 and NLRC4 inflammasomes in human THP-1 macrophages.Int J Oral Sci. 2018 Aug 6;10(3):23. doi: 10.1038/s41368-018-0024-z.
• [1140] Cationic folate-mediated liposomal delivery of bis-arylidene oxindole induces efficient melanoma tumor regression.Biomater Sci. 2017 Aug 22;5(9):1898-1909. doi: 10.1039/c7bm00405b.
• [1141] Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation.Oncogene. 2017 Jun 29;36(26):3789-3795. doi: 10.1038/onc.2016.511. Epub 2017 Feb 13.
• [1142] NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1 and p27(Kip1) expression in malignant melanoma and other human tumors.Mol Carcinog. 2017 Dec;56(12):2643-2662. doi: 10.1002/mc.22708. Epub 2017 Aug 30.
• [1143] The emerging role of NPNT in tissue injury repair and bone homeostasis.J Cell Physiol. 2018 Mar;233(3):1887-1894. doi: 10.1002/jcp.26013. Epub 2017 Jun 16.
• [1144] The shed ectodomain of Nr-CAM stimulates cell proliferation and motility, and confers cell transformation.Cancer Res. 2005 Dec 15;65(24):11605-12. doi: 10.1158/0008-5472.CAN-05-2647.
• [1145] NRF1 and NRF2 mRNA and Protein Expression Decrease Early during Melanoma Carcinogenesis: An Insight into Survival and MicroRNAs.Oxid Med Cell Longev. 2019 Sep 4;2019:2647068. doi: 10.1155/2019/2647068. eCollection 2019.
• [1146] Systemic therapy in non-conventional cancers of the larynx.Oral Oncol. 2018 Jul;82:61-68. doi: 10.1016/j.oraloncology.2018.05.005. Epub 2018 May 26.
• [1147] The effect of dielectrophoresis on living cells: crossover frequencies and deregulation in gene expression.Analyst. 2019 Jun 21;144(12):3853-3860. doi: 10.1039/c9an00320g. Epub 2019 May 17.
• [1148] OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1.Cancer Res. 2005 Aug 15;65(16):7151-8. doi: 10.1158/0008-5472.CAN-05-1400.
• [1149] A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity.Cell Death Dis. 2015 Feb 12;6(2):e1634. doi: 10.1038/cddis.2015.17.
• [1150] Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery.Small. 2017 Mar;13(10):10.1002/smll.201603121. doi: 10.1002/smll.201603121. Epub 2016 Dec 27.
• [1151] Inhibition of Pannexin 1 Reduces the Tumorigenic Properties of Human Melanoma Cells.Cancers (Basel). 2019 Jan 16;11(1):102. doi: 10.3390/cancers11010102.
• [1152] Downregulation of PCK2 remodels tricarboxylic acid cycle in tumor-repopulating cells of melanoma.Oncogene. 2017 Jun 22;36(25):3609-3617. doi: 10.1038/onc.2016.520. Epub 2017 Feb 6.
• [1153] MiR-370 functions as oncogene in melanoma by direct targeting pyruvate dehydrogenase B.Biomed Pharmacother. 2017 Jun;90:278-286. doi: 10.1016/j.biopha.2017.03.068. Epub 2017 Mar 30.
• [1154] Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.BMC Cancer. 2019 Jun 17;19(1):599. doi: 10.1186/s12885-019-5808-9.
• [1155] Declination of long noncoding RNA paternally expressed gene 10 inhibits A375 cells proliferation, migration, and invasion via mediating microRNA-33a.J Cell Biochem. 2019 Dec;120(12):19868-19877. doi: 10.1002/jcb.29292. Epub 2019 Jul 18.
• [1156] PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer.Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5766-E5775. doi: 10.1073/pnas.1804779115. Epub 2018 Jun 4.
• [1157] PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.Oncogene. 2018 Apr;37(17):2225-2236. doi: 10.1038/s41388-017-0061-7. Epub 2018 Feb 2.
• [1158] Ensemble Modeling Approach Targeting Heterogeneous RNA-Seq data: Application to Melanoma Pseudogenes.Sci Rep. 2017 Dec 11;7(1):17344. doi: 10.1038/s41598-017-17337-7.
• [1159] Clinicopathological features and pituitary homeobox 1 gene expression in the progression and prognosis of cutaneous malignant melanoma.Kaohsiung J Med Sci. 2016 Oct;32(10):494-500. doi: 10.1016/j.kjms.2016.08.001. Epub 2016 Aug 27.
• [1160] An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin.Angew Chem Int Ed Engl. 2017 Jul 3;56(28):8267-8271. doi: 10.1002/anie.201702242. Epub 2017 May 26.
• [1161] Adipophilin expression in cutaneous malignant melanoma.J Cutan Pathol. 2017 Mar;44(3):228-236. doi: 10.1111/cup.12868. Epub 2016 Dec 22.
• [1162] p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.Eur J Cancer. 2016 Mar;55:98-110. doi: 10.1016/j.ejca.2015.12.002. Epub 2016 Jan 17.
• [1163] Identification of genes potentially regulated by human polynucleotide phosphorylase (hPNPase old-35) using melanoma as a model.PLoS One. 2013 Oct 15;8(10):e76284. doi: 10.1371/journal.pone.0076284. eCollection 2013.
• [1164] Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy.Adv Healthc Mater. 2019 Jan;8(1):e1800837. doi: 10.1002/adhm.201800837. Epub 2018 Dec 3.
• [1165] FBXW7 regulates a mitochondrial transcription program by modulating MITF.Pigment Cell Melanoma Res. 2018 Sep;31(5):636-640. doi: 10.1111/pcmr.12704. Epub 2018 Apr 29.
• [1166] CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins.Oncotarget. 2016 Nov 29;7(48):78242-78254. doi: 10.18632/oncotarget.12919.
• [1167] CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.Oncotarget. 2018 Jul 27;9(58):31264-31277. doi: 10.18632/oncotarget.25805. eCollection 2018 Jul 27.
• [1168] In vitro and in vivo cytotoxic activity of human lactoferricin derived antitumor peptide R-DIM-P-LF11-334 on human malignant melanoma.Oncotarget. 2017 May 11;8(42):71817-71832. doi: 10.18632/oncotarget.17823. eCollection 2017 Sep 22.
• [1169] P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.Cancer Lett. 2017 Oct 28;407:66-75. doi: 10.1016/j.canlet.2017.08.001. Epub 2017 Aug 10.
• [1170] REG accelerates melanoma formation by regulating Wnt/-catenin signalling pathway.Exp Dermatol. 2017 Nov;26(11):1118-1124. doi: 10.1111/exd.13394. Epub 2017 Aug 30.
• [1171] Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-B signaling pathway.Oncogene. 2019 Jul;38(30):5873-5889. doi: 10.1038/s41388-019-0848-9. Epub 2019 Jun 28.
• [1172] A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies.Cancer Immunol Res. 2017 Sep;5(9):790-803. doi: 10.1158/2326-6066.CIR-17-0009. Epub 2017 Aug 3.
• [1173] Downregulation of pyrroline-5-carboxylate reductase-2 induces the autophagy of melanoma cells via AMPK/mTOR pathway.Tumour Biol. 2016 May;37(5):6485-91. doi: 10.1007/s13277-015-3927-8. Epub 2015 Dec 3.
• [1174] A Targeted Quantitative Proteomic Approach Assesses the Reprogramming of Small GTPases during Melanoma Metastasis.Cancer Res. 2018 Sep 15;78(18):5431-5445. doi: 10.1158/0008-5472.CAN-17-3811. Epub 2018 Aug 2.
• [1175] AT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells.Cancers (Basel). 2019 Sep 3;11(9):1299. doi: 10.3390/cancers11091299.
• [1176] The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells.Oncogenesis. 2017 Jan 23;6(1):e291. doi: 10.1038/oncsis.2016.88.
• [1177] RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export.J Invest Dermatol. 2016 Jan;136(1):264-74. doi: 10.1038/JID.2015.401.
• [1178] Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma.Oncotarget. 2012 Sep;3(9):1011-25. doi: 10.18632/oncotarget.622.
• [1179] Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis.Front Oncol. 2019 Nov 15;9:1253. doi: 10.3389/fonc.2019.01253. eCollection 2019.
• [1180] GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.Cell Rep. 2018 Feb 27;22(9):2455-2468. doi: 10.1016/j.celrep.2018.01.081.
• [1181] RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.J Invest Dermatol. 2012 Mar;132(3 Pt 1):687-94. doi: 10.1038/jid.2011.380. Epub 2011 Nov 24.
• [1182] Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma.Epigenetics. 2013 Oct;8(10):1043-52. doi: 10.4161/epi.25810. Epub 2013 Jul 31.
• [1183] Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment.Cell Mol Life Sci. 2012 Apr;69(7):1167-78. doi: 10.1007/s00018-011-0862-8. Epub 2011 Dec 1.
• [1184] Palmitoylation-dependent activation of MC1R prevents melanomagenesis.Nature. 2017 Sep 21;549(7672):399-403. doi: 10.1038/nature23887. Epub 2017 Sep 6.
• [1185] Nuclear envelope-distributed CD147 interacts with and inhibits the transcriptional function of RING1 and promotes melanoma cell motility.PLoS One. 2017 Aug 23;12(8):e0183689. doi: 10.1371/journal.pone.0183689. eCollection 2017.
• [1186] Macrophage inhibitory cytokine-1 regulates melanoma vascular development.Am J Pathol. 2010 Jun;176(6):2948-57. doi: 10.2353/ajpath.2010.090963. Epub 2010 Apr 29.
• [1187] Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-B Pathway in Melanoma.Clin Cancer Res. 2017 Aug 15;23(16):4831-4842. doi: 10.1158/1078-0432.CCR-17-0146. Epub 2017 Apr 7.
• [1188] Degradation of AMPK-1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation.Mol Oncol. 2017 Dec;11(12):1806-1825. doi: 10.1002/1878-0261.12151. Epub 2017 Nov 16.
• [1189] The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types.Oncotarget. 2017 Feb 28;8(9):14462-14478. doi: 10.18632/oncotarget.14895.
• [1190] Palladium based nanoparticles for the treatment of advanced melanoma.Sci Rep. 2019 Mar 1;9(1):3255. doi: 10.1038/s41598-019-40258-6.
• [1191] Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.Acta Pharmacol Sin. 2019 Feb;40(2):268-278. doi: 10.1038/s41401-018-0020-z. Epub 2018 May 18.
• [1192] Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.Oncotarget. 2016 Apr 26;7(17):23885-96. doi: 10.18632/oncotarget.8127.
• [1193] A one-pot laccase-catalysed synthesis of coumestan derivatives and their anticancer activity.Bioorg Med Chem. 2017 Feb 1;25(3):1172-1182. doi: 10.1016/j.bmc.2016.12.025. Epub 2016 Dec 21.
• [1194] A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants.Int J Cancer. 2016 Nov 1;139(9):2012-20. doi: 10.1002/ijc.30245. Epub 2016 Jul 23.
• [1195] Prevalence and Correlates of Skin Cancer Screening Among Indoor Tanners and Nontanners.JAMA Dermatol. 2018 May 1;154(5):554-560. doi: 10.1001/jamadermatol.2018.0163.
• [1196] Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma.Nat Commun. 2016 Jul 18;7:12048. doi: 10.1038/ncomms12048.
• [1197] Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression.EBioMedicine. 2018 Nov;37:47-55. doi: 10.1016/j.ebiom.2018.10.002. Epub 2018 Oct 6.
• [1198] DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients.Hum Pathol. 2017 Feb;60:137-146. doi: 10.1016/j.humpath.2016.10.018. Epub 2016 Nov 4.
• [1199] Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb.J Exp Clin Cancer Res. 2018 Nov 19;37(1):278. doi: 10.1186/s13046-018-0933-x.
• [1200] MicroRNA-199a-5p inhibits tumor proliferation in melanoma by mediating HIF-1.Mol Med Rep. 2016 Jun;13(6):5241-7. doi: 10.3892/mmr.2016.5202. Epub 2016 Apr 28.
• [1201] Melanotic Translocation Renal Cell Carcinoma With a Novel ARID1B-TFE3 Gene Fusion.Am J Surg Pathol. 2017 Nov;41(11):1576-1580. doi: 10.1097/PAS.0000000000000927.
• [1202] sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. Epub 2016 Apr 4.
• [1203] The role of Tks adaptor proteins in invadopodia formation, growth and metastasis of melanoma.Oncotarget. 2016 Nov 29;7(48):78473-78486. doi: 10.18632/oncotarget.12954.
• [1204] Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.Cancer Lett. 2019 May 1;449:145-162. doi: 10.1016/j.canlet.2019.02.012. Epub 2019 Feb 14.
• [1205] Activation of CD8?T Cell Responses after Melanoma Antigen Targeting to CD169?Antigen Presenting Cells in Mice and Humans.Cancers (Basel). 2019 Feb 5;11(2):183. doi: 10.3390/cancers11020183.
• [1206] Gene expression and promoter methylation of angiogenic and lymphangiogenic factors as prognostic markers in melanoma.Mol Oncol. 2019 Jun;13(6):1433-1449. doi: 10.1002/1878-0261.12501. Epub 2019 May 25.
• [1207] Efficient TGF-/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression.Mol Cancer. 2011 Jan 6;10(1):2. doi: 10.1186/1476-4598-10-2.
• [1208] Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1296-305. doi: 10.1073/pnas.1513801113. Epub 2016 Feb 16.
• [1209] Copper Chelation Inhibits BRAF(V600E)-Driven Melanomagenesis and Counters Resistance to BRAF(V600E) and MEK1/2 Inhibitors.Cancer Res. 2017 Nov 15;77(22):6240-6252. doi: 10.1158/0008-5472.CAN-16-1190. Epub 2017 Oct 6.
• [1210] Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma.Clin Cancer Res. 2019 Dec 15;25(24):7585-7593. doi: 10.1158/1078-0432.CCR-19-1194. Epub 2019 Sep 30.
• [1211] SLURP-1 is mutated in Mal de Meleda, a potential molecular signature for melanoma and a putative squamous lineage tumor suppressor gene.Int J Dermatol. 2018 Feb;57(2):162-170. doi: 10.1111/ijd.13850. Epub 2017 Dec 12.
• [1212] MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells.PLoS One. 2013;8(1):e54110. doi: 10.1371/journal.pone.0054110. Epub 2013 Jan 17.
• [1213] High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.Cell Rep. 2017 Oct 17;21(3):773-783. doi: 10.1016/j.celrep.2017.09.085.
• [1214] Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases.J Neurooncol. 2017 May;132(3):455-462. doi: 10.1007/s11060-017-2394-z. Epub 2017 Mar 4.
• [1215] Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells.Stem Cells. 2016 Apr;34(4):832-46. doi: 10.1002/stem.2284. Epub 2016 Jan 19.
• [1216] IFN-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment.Cell. 2017 Jun 29;170(1):127-141.e15. doi: 10.1016/j.cell.2017.06.016.
• [1217] The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.
• [1218] Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-nave and vemurafenib-resistant melanomas.Oncotarget. 2018 Dec 11;9(97):36945-36965. doi: 10.18632/oncotarget.26421. eCollection 2018 Dec 11.
• [1219] Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma.Science. 2018 Nov 30;362(6418):1055-1060. doi: 10.1126/science.aau6509. Epub 2018 Nov 1.
• [1220] The lncRNA SLNCR1 Mediates Melanoma Invasion through a Conserved SRA1-like Region.Cell Rep. 2016 May 31;15(9):2025-37. doi: 10.1016/j.celrep.2016.04.018. Epub 2016 May 19.
• [1221] Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma.J Clin Invest. 2018 Jan 2;128(1):294-308. doi: 10.1172/JCI92513. Epub 2017 Dec 4.
• [1222] Signal Sequence Receptor 2 is required for survival of human melanoma cells as part of an unfolded protein response to endoplasmic reticulum stress.Mutagenesis. 2016 Sep;31(5):573-82. doi: 10.1093/mutage/gew023. Epub 2016 May 14.
• [1223] Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.Nat Med. 2016 Sep;22(9):1056-61. doi: 10.1038/nm.4155. Epub 2016 Aug 8.
• [1224] STAP-2 protein promotes prostate cancer growth by enhancing epidermal growth factor receptor stabilization.J Biol Chem. 2017 Nov 24;292(47):19392-19399. doi: 10.1074/jbc.M117.802884. Epub 2017 Oct 6.
• [1225] Liver kinase B1/adenosine monophosphate-activated protein kinase signaling axis induces p21/WAF1 expression in a p53-dependent manner.Oncol Lett. 2018 Jul;16(1):1291-1297. doi: 10.3892/ol.2018.8741. Epub 2018 May 18.
• [1226] Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.Cell. 2019 Feb 21;176(5):1113-1127.e16. doi: 10.1016/j.cell.2019.01.002. Epub 2019 Jan 31.
• [1227] MAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma.Oncol Rep. 2017 Aug;38(2):1199-1205. doi: 10.3892/or.2017.5774. Epub 2017 Jun 30.
• [1228] Human sulfatase 1 exerts anti-tumor activity by inhibiting the AKT/ CDK4 signaling pathway in melanoma.Oncotarget. 2016 Dec 20;7(51):84486-84495. doi: 10.18632/oncotarget.12996.
• [1229] Precise control of apoptosis via gold nanostars for dose dependent photothermal therapy of melanoma.J Mater Chem B. 2019 Nov 28;7(44):6934-6944. doi: 10.1039/c9tb01956a. Epub 2019 Nov 1.
• [1230] Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types.Clin Epigenetics. 2019 Aug 5;11(1):114. doi: 10.1186/s13148-019-0710-5.
• [1231] Characterization of the typical multidrug resistance profile in human uveal melanoma cell lines and in mouse liver metastasis derivatives.Melanoma Res. 2005 Aug;15(4):257-66. doi: 10.1097/00008390-200508000-00005.
• [1232] Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.Mol Pharm. 2018 Mar 5;15(3):955-961. doi: 10.1021/acs.molpharmaceut.7b00894. Epub 2018 Feb 15.
• [1233] Controlled Secretion of the Anticancer Protein MDA-7 from Engineered Mesenchymal Stem Cells.Biol Pharm Bull. 2017;40(1):113-117. doi: 10.1248/bpb.b16-00658.
• [1234] Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival.Int J Cancer. 2015 Aug 1;137(3):638-45. doi: 10.1002/ijc.29429. Epub 2015 Jan 28.
• [1235] Transcription factor LSF (TFCP2) inhibits melanoma growth.Oncotarget. 2016 Jan 19;7(3):2379-90. doi: 10.18632/oncotarget.6230.
• [1236] MITF has a central role in regulating starvation-induced autophagy in melanoma.Sci Rep. 2019 Jan 31;9(1):1055. doi: 10.1038/s41598-018-37522-6.
• [1237] Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene.Genes Chromosomes Cancer. 2012 May;51(5):452-61. doi: 10.1002/gcc.21932. Epub 2012 Jan 17.
• [1238] Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells.Am J Pathol. 2012 Apr;180(4):1663-74. doi: 10.1016/j.ajpath.2011.12.035. Epub 2012 Feb 9.
• [1239] Downregulation of reversion-inducing cysteine-rich protein with Kazal motifs in malignant melanoma: inverse correlation with membrane-type 1-matrix metalloproteinase and tissue inhibitor of metalloproteinase 2.Melanoma Res. 2014 Feb;24(1):32-9. doi: 10.1097/CMR.0000000000000039.
• [1240] In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma.Mol Immunol. 2019 Aug;112:93-102. doi: 10.1016/j.molimm.2019.04.030. Epub 2019 May 9.
• [1241] Identification of a gene signature for discriminating metastatic from primary melanoma using a molecular interaction network approach.Sci Rep. 2017 Dec 11;7(1):17314. doi: 10.1038/s41598-017-17330-0.
• [1242] Transcriptome and Proteome Analyses of TNFAIP8 Knockdown Cancer Cells Reveal New Insights into Molecular Determinants of Cell Survival and Tumor Progression.Methods Mol Biol. 2017;1513:83-100. doi: 10.1007/978-1-4939-6539-7_7.
• [1243] Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.Methods Mol Biol. 2020;2058:133-154. doi: 10.1007/978-1-4939-9794-7_9.
• [1244] miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy.Oncotarget. 2015 Feb 20;6(5):2966-80. doi: 10.18632/oncotarget.3070.
• [1245] Metformin reduces TRIB3 expression and restores autophagy flux: an alternative antitumor action.Autophagy. 2018;14(7):1278-1279. doi: 10.1080/15548627.2018.1460022. Epub 2018 Jul 20.
• [1246] Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis.J Cancer Res Clin Oncol. 2019 Sep;145(9):2241-2250. doi: 10.1007/s00432-019-02981-5. Epub 2019 Jul 24.
• [1247] Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells.Sci Rep. 2016 Jul 28;6:30405. doi: 10.1038/srep30405.
• [1248] AP2 controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression.Oncogene. 2016 Jun 9;35(23):3016-26. doi: 10.1038/onc.2015.357. Epub 2015 Oct 5.
• [1249] BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.Clin Cancer Res. 2017 Oct 15;23(20):6203-6214. doi: 10.1158/1078-0432.CCR-17-0098. Epub 2017 Jul 19.
• [1250] miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells.Int J Oncol. 2013 Apr;42(4):1443-51. doi: 10.3892/ijo.2013.1823. Epub 2013 Feb 12.
• [1251] Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma.Sci Rep. 2018 Dec 21;8(1):18036. doi: 10.1038/s41598-018-36173-x.
• [1252] The long non-coding RNA CRNDE competed endogenously with miR-205 to promote proliferation and metastasis of melanoma cells by targeting CCL18.Cell Cycle. 2018;17(18):2296-2308. doi: 10.1080/15384101.2018.1526602. Epub 2018 Oct 9.
• [1253] Targeting Rac and Cdc42 GTPases in Cancer.Cancer Res. 2018 Jun 15;78(12):3101-3111. doi: 10.1158/0008-5472.CAN-18-0619. Epub 2018 Jun 1.
• [1254] Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma.Mol Carcinog. 2014 Aug;53(8):635-47. doi: 10.1002/mc.22018. Epub 2013 Apr 26.
• [1255] Review of the medical literature and assessment of current utilization patterns regarding the use of two common fluorescence in situ hybridization assays in the diagnosis of dermatofibrosarcoma protuberans and clear cell sarcoma.J Cutan Pathol. 2018 Dec;45(12):905-913. doi: 10.1111/cup.13345. Epub 2018 Sep 27.
• [1256] Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.Clin Exp Metastasis. 2016 Oct;33(7):637-49. doi: 10.1007/s10585-016-9803-0. Epub 2016 Jun 27.
• [1257] The Structure in Solution of Fibronectin Type III Domain 14 Reveals Its Synergistic Heparin Binding Site.Biochemistry. 2018 Oct 23;57(42):6045-6049. doi: 10.1021/acs.biochem.8b00771. Epub 2018 Oct 11.
• [1258] Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation.Int J Cancer. 2018 Dec 1;143(11):2962-2972. doi: 10.1002/ijc.31799. Epub 2018 Sep 29.
• [1259] Down-regulation of GADD45A enhances chemosensitivity in melanoma.Sci Rep. 2018 Mar 7;8(1):4111. doi: 10.1038/s41598-018-22484-6.
• [1260] Loss of GCNT2/I-branched glycans enhances melanoma growth and survival.Nat Commun. 2018 Aug 22;9(1):3368. doi: 10.1038/s41467-018-05795-0.
• [1261] Differential UBE2C and HOXA1 expression in melanocytic nevi and melanoma.J Cutan Pathol. 2017 Oct;44(10):843-850. doi: 10.1111/cup.12997. Epub 2017 Jul 21.
• [1262] Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis.Oncotarget. 2015 Sep 8;6(26):23026-35. doi: 10.18632/oncotarget.4854.
• [1263] Inhibition of tumor-associated v3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo.Angiogenesis. 2015 Jan;18(1):31-46. doi: 10.1007/s10456-014-9445-2. Epub 2014 Sep 24.
• [1264] Role of inhibitor of growth 4 in the suppression of human melanoma cells through the Fas/FasL-mediated apoptosis pathway.Int J Mol Med. 2018 Feb;41(2):1055-1061. doi: 10.3892/ijmm.2017.3274. Epub 2017 Nov 20.
• [1265] Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.Oncotarget. 2017 Jul 18;8(29):47440-47453. doi: 10.18632/oncotarget.17663.
• [1266] Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway.Pathol Oncol Res. 2019 Jan;25(1):377-389. doi: 10.1007/s12253-017-0334-z. Epub 2017 Nov 14.
• [1267] Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide.Sci Rep. 2017 Aug 9;7(1):7700. doi: 10.1038/s41598-017-07043-9.
• [1268] A targeted therapy for melanoma by graphene oxide composite with microRNA carrier.Drug Des Devel Ther. 2018 Sep 21;12:3095-3106. doi: 10.2147/DDDT.S160088. eCollection 2018.
• [1269] NOP14 inhibits melanoma proliferation and metastasis by regulating Wnt/-catenin signaling pathway.Braz J Med Biol Res. 2018 Nov 23;52(1):e7952. doi: 10.1590/1414-431X20187952.
• [1270] Trial watch: Peptide-based vaccines in anticancer therapy.Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018.
• [1271] WIPI1, BAG1, and PEX3 Autophagy-Related Genes Are Relevant Melanoma Markers.Oxid Med Cell Longev. 2018 Dec 2;2018:1471682. doi: 10.1155/2018/1471682. eCollection 2018.
• [1272] Mechanism of miR-137 regulating migration and invasion of melanoma cells by targeting PIK3R3 gene.J Cell Biochem. 2019 May;120(5):8393-8400. doi: 10.1002/jcb.28124. Epub 2018 Nov 28.
• [1273] Panduratin A induces protective autophagy in melanoma via the AMPK and mTOR pathway.Phytomedicine. 2018 Mar 15;42:144-151. doi: 10.1016/j.phymed.2018.03.027. Epub 2018 Mar 15.
• [1274] 67-kDa laminin receptor-dependent protein phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance.J Biol Chem. 2014 Nov 21;289(47):32671-81. doi: 10.1074/jbc.M114.604983. Epub 2014 Oct 7.
• [1275] Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.Hum Mutat. 2014 Nov;35(11):1301-10. doi: 10.1002/humu.22630. Epub 2014 Sep 10.
• [1276] Pyrroline-5-carboxylate reductase 1 promotes cell proliferation via inhibiting apoptosis in human malignant melanoma.Cancer Manag Res. 2018 Nov 27;10:6399-6407. doi: 10.2147/CMAR.S166711. eCollection 2018.
• [1277] RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes.Int J Cancer. 2019 Jun 15;144(12):3070-3085. doi: 10.1002/ijc.32064. Epub 2019 Jan 3.
• [1278] High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer.J Breast Cancer. 2018 Sep;21(3):288-296. doi: 10.4048/jbc.2018.21.e34. Epub 2018 Aug 28.
• [1279] Tip110/SART3 regulates IL-8 expression and predicts the clinical outcomes in melanoma.Mol Cancer. 2018 Aug 17;17(1):124. doi: 10.1186/s12943-018-0868-z.
• [1280] SFRP5 inhibits the migration and invasion of melanoma cells through Wnt signaling pathway.Onco Targets Ther. 2018 Dec 6;11:8761-8772. doi: 10.2147/OTT.S181146. eCollection 2018.
• [1281] MicroRNA-605 functions as a tumor suppressor by targeting INPP4B in melanoma.Oncol Rep. 2017 Aug;38(2):1276-1286. doi: 10.3892/or.2017.5740. Epub 2017 Jun 22.
• [1282] The novel immunoglobulin super family receptor SLAMF9 identified in TAM of murine and human melanoma influences pro-inflammatory cytokine secretion and migration.Cell Death Dis. 2018 Sep 19;9(10):939. doi: 10.1038/s41419-018-1011-1.
• [1283] Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway.Oncotarget. 2014 Aug 15;5(15):6387-403. doi: 10.18632/oncotarget.2201.
• [1284] miR?0a?p inhibits the proliferation, migration and invasion of melanoma cells by targeting SOX4.Mol Med Rep. 2018 Aug;18(2):2492-2498. doi: 10.3892/mmr.2018.9166. Epub 2018 Jun 14.
• [1285] STAM-binding protein regulates melanoma metastasis through SLUG stabilization.Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):484-488. doi: 10.1016/j.bbrc.2018.11.068. Epub 2018 Nov 16.
• [1286] Targeting MC1R depalmitoylation to prevent melanomagenesis in redheads.Nat Commun. 2019 Feb 20;10(1):877. doi: 10.1038/s41467-019-08691-3.
• [1287] TBX2 expression is regulated by PAX3 in the melanocyte lineage.Pigment Cell Melanoma Res. 2013 Jan;26(1):67-77. doi: 10.1111/pcmr.12029. Epub 2012 Nov 21.
• [1288] Mitochondrial transcription factor A (TFAM) shapes metabolic and invasion gene signatures in melanoma.Sci Rep. 2018 Sep 21;8(1):14190. doi: 10.1038/s41598-018-31170-6.
• [1289] MiR-21 enhances melanoma invasiveness via inhibition of tissue inhibitor of metalloproteinases 3 expression: in vivo effects of MiR-21 inhibitor.PLoS One. 2015 Jan 14;10(1):e0115919. doi: 10.1371/journal.pone.0115919. eCollection 2015.
• [1290] Constitutional promoter methylation and risk of familial melanoma.Epigenetics. 2014 May;9(5):685-92. doi: 10.4161/epi.28151. Epub 2014 Feb 13.
• [1291] Association of TNFRSF10D DNA-methylation with the survival of melanoma patients.Int J Mol Sci. 2014 Jul 7;15(7):11984-95. doi: 10.3390/ijms150711984.
• [1292] A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice.Melanoma Res. 2012 Jun;22(3):225-35. doi: 10.1097/CMR.0b013e32835312fd.
• [1293] Running for time: circadian rhythms and melanoma.Tumour Biol. 2014 Sep;35(9):8359-68. doi: 10.1007/s13277-014-1904-2. Epub 2014 Apr 14.
• [1294] Apoptosis-associated tyrosine kinase 1 inhibits growth and migration and promotes apoptosis in melanoma.Lab Invest. 2014 Apr;94(4):430-8. doi: 10.1038/labinvest.2014.13. Epub 2014 Mar 3.
• [1295] AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis.Cancer Res. 2015 Sep 1;75(17):3492-504. doi: 10.1158/0008-5472.CAN-15-0088. Epub 2015 Jul 2.
• [1296] Molecular profiling of ADAM12 and ADAM17 genes in human malignant melanoma.Pathol Oncol Res. 2013 Oct;19(4):755-62. doi: 10.1007/s12253-013-9639-8. Epub 2013 May 6.
• [1297] AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.Cell Death Dis. 2013 Nov 7;4(11):e914. doi: 10.1038/cddis.2013.441.
• [1298] Argonaute Family Protein Expression in Normal Tissue and Cancer Entities.PLoS One. 2016 Aug 12;11(8):e0161165. doi: 10.1371/journal.pone.0161165. eCollection 2016.
• [1299] Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.Microvasc Res. 2000 Jul;60(1):70-80. doi: 10.1006/mvre.2000.2249.
• [1300] AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma.Oncotarget. 2016 Sep 20;7(38):60872-60884. doi: 10.18632/oncotarget.11506.
• [1301] Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway.Mol Cancer Res. 2015 Oct;13(10):1408-20. doi: 10.1158/1541-7786.MCR-15-0048. Epub 2015 Jun 16.
• [1302] A pilot study of genetic variants in dopamine regulators with indoor tanning and melanoma.Exp Dermatol. 2013 Sep;22(9):576-81. doi: 10.1111/exd.12200.
• [1303] TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types.Cancer Cell. 2012 Feb 14;21(2):212-26. doi: 10.1016/j.ccr.2012.01.004.
• [1304] Melanoma's high C>T mutation rate: is deamination playing a role?.Exp Dermatol. 2014 Aug;23(8):551-2. doi: 10.1111/exd.12436. Epub 2014 Aug 1.
• [1305] Functional and cancer genomics of ASXL family members.Br J Cancer. 2013 Jul 23;109(2):299-306. doi: 10.1038/bjc.2013.281. Epub 2013 Jun 4.
• [1306] Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress.Cell Signal. 2014 Feb;26(2):287-94. doi: 10.1016/j.cellsig.2013.11.008. Epub 2013 Nov 12.
• [1307] Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.Blood. 2010 Apr 15;115(15):3025-32. doi: 10.1182/blood-2009-11-253641. Epub 2010 Feb 3.
• [1308] Wnt/-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.Sci Signal. 2012 Jan 10;5(206):ra3. doi: 10.1126/scisignal.2002274.
• [1309] MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD).J Invest Dermatol. 2013 May;133(5):1286-93. doi: 10.1038/jid.2012.400. Epub 2012 Nov 29.
• [1310] BAP31, a promising target for the immunotherapy of malignant melanomas.J Exp Clin Cancer Res. 2015 Apr 18;34(1):36. doi: 10.1186/s13046-015-0153-6.
• [1311] Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity.Int J Oncol. 2012 Jul;41(1):53-60. doi: 10.3892/ijo.2012.1424. Epub 2012 Apr 2.
• [1312] Anti-metastatic and anti-angiogenic activities of sulfated polysaccharide of Sepiella maindroni ink.Carbohydr Polym. 2013 Jan 2;91(1):403-9. doi: 10.1016/j.carbpol.2012.08.050. Epub 2012 Aug 22.
• [1313] A novel interaction between calcium-modulating cyclophilin ligand and Basigin regulates calcium signaling and matrix metalloproteinase activities in human melanoma cells.Cancer Lett. 2013 Oct 1;339(1):93-101. doi: 10.1016/j.canlet.2013.07.019. Epub 2013 Jul 20.
• [1314] Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness.Oncol Rep. 2013 Dec;30(6):2887-96. doi: 10.3892/or.2013.2791. Epub 2013 Oct 10.
• [1315] The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma.Oncotarget. 2015 Oct 6;6(30):29111-28. doi: 10.18632/oncotarget.5059.
• [1316] Downregulation of CCN3 expression as a potential mechanism for melanoma progression.Oncogene. 2008 Apr 17;27(18):2552-60. doi: 10.1038/sj.onc.1210896. Epub 2007 Oct 29.
• [1317] MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.Pigment Cell Melanoma Res. 2014 Mar;27(2):275-86. doi: 10.1111/pcmr.12200. Epub 2014 Jan 17.
• [1318] DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.Cancer Immunol Immunother. 2015 Apr;64(4):409-18. doi: 10.1007/s00262-014-1648-2. Epub 2014 Dec 31.
• [1319] Cadherin-7 interacts with melanoma inhibitory activity protein and negatively modulates melanoma cell migration.Cancer Sci. 2009 Feb;100(2):261-8. doi: 10.1111/j.1349-7006.2008.01048.x.
• [1320] Death-signal-induced relocalization of cyclin-dependent kinase 11 to mitochondria.Biochem J. 2005 Nov 15;392(Pt 1):65-73. doi: 10.1042/BJ20050195.
• [1321] MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations.Am J Hum Genet. 2001 Oct;69(4):765-73. doi: 10.1086/323412. Epub 2001 Aug 8.
• [1322] Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors.Cancer Invest. 2014 Aug;32(7):363-7. doi: 10.3109/07357907.2014.919304. Epub 2014 Jun 4.
• [1323] Discovering biological connections between experimental conditions based on common patterns of differential gene expression.BMC Bioinformatics. 2011 Sep 27;12:381. doi: 10.1186/1471-2105-12-381.
• [1324] Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk.Eur J Cancer. 2014 Dec;50(18):3168-77. doi: 10.1016/j.ejca.2014.09.017. Epub 2014 Oct 31.
• [1325] Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.Fam Cancer. 2019 Oct;18(4):439-444. doi: 10.1007/s10689-019-00137-5.
• [1326] Single nucleotide polymorphism array analysis of uveal melanomas reveals that amplification of CNKSR3 is correlated with improved patient survival.Am J Pathol. 2013 Mar;182(3):678-87. doi: 10.1016/j.ajpath.2012.11.036. Epub 2013 Jan 26.
• [1327] Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.Oncotarget. 2015 Jan 20;6(2):1115-27. doi: 10.18632/oncotarget.2747.
• [1328] TNF-receptor-1 adaptor protein FAN mediates TNF-induced B16 melanoma motility and invasion.Br J Cancer. 2013 Jul 23;109(2):422-32. doi: 10.1038/bjc.2013.242. Epub 2013 May 14.
• [1329] A novel conditionally replicating adenoviral vector with dual expression of IL-24 and arresten inserted in E1 and the region between E4 and fiber for improved melanoma therapy.Cancer Gene Ther. 2012 Apr;19(4):247-54. doi: 10.1038/cgt.2011.84. Epub 2011 Dec 23.
• [1330] Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas.Br J Cancer. 2013 Jul 23;109(2):444-51. doi: 10.1038/bjc.2013.326. Epub 2013 Jun 25.
• [1331] Inherited variation at MC1R and ASIP and association with melanoma-specific survival.Int J Cancer. 2015 Jun 1;136(11):2659-67. doi: 10.1002/ijc.29317. Epub 2014 Nov 26.
• [1332] Non-hepatic tumors change the activity of genes encoding copper trafficking proteins in the liver.Cancer Biol Ther. 2013 Jul;14(7):614-24. doi: 10.4161/cbt.24594. Epub 2013 May 10.
• [1333] Ras-induced melanoma transformation is associated with the proteasomal degradation of the transcriptional repressor ICER.Mol Carcinog. 2013 Sep;52(9):692-704. doi: 10.1002/mc.21908. Epub 2012 Apr 4.
• [1334] CTC1 increases the radioresistance of human melanoma cells by inhibiting telomere shortening and apoptosis.Int J Mol Med. 2014 Jun;33(6):1484-90. doi: 10.3892/ijmm.2014.1721. Epub 2014 Apr 2.
• [1335] Alpha-catulin contributes to drug-resistance of melanoma by activating NF-B and AP-1.PLoS One. 2015 Mar 20;10(3):e0119402. doi: 10.1371/journal.pone.0119402. eCollection 2015.
• [1336] Nucleus accumbens-associated 1 contributes to cortactin deacetylation and augments the migration of melanoma cells.J Invest Dermatol. 2011 Aug;131(8):1710-9. doi: 10.1038/jid.2011.110. Epub 2011 May 12.
• [1337] TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25.
• [1338] Transcriptional regulation of ASK/Dbf4 in cutaneous melanoma is dependent on E2F1.Exp Dermatol. 2008 Dec;17(12):986-91. doi: 10.1111/j.1600-0625.2008.00730.x. Epub 2008 May 21.
• [1339] The helicase HAGE prevents interferon--induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.Cell Death Dis. 2014 Feb 13;5(2):e1061. doi: 10.1038/cddis.2014.29.
• [1340] Nucleoside Analog Activity in Malignant Melanoma Cell Lines.Nucleosides Nucleotides Nucleic Acids. 2015;34(9):639-49. doi: 10.1080/15257770.2015.1047029.
• [1341] Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression.Oncogene. 2013 Feb 14;32(7):837-48. doi: 10.1038/onc.2012.115. Epub 2012 Apr 2.
• [1342] The metastasis gene NEDD9 product acts through integrin 3 and Src to promote mesenchymal motility and inhibit amoeboid motility.J Cell Sci. 2012 Apr 1;125(Pt 7):1814-26. doi: 10.1242/jcs.101444. Epub 2012 Feb 10.
• [1343] Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells.PLoS One. 2015 May 20;10(5):e0124094. doi: 10.1371/journal.pone.0124094. eCollection 2015.
• [1344] Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk.Carcinogenesis. 2013 Apr;34(4):885-92. doi: 10.1093/carcin/bgs407. Epub 2013 Jan 4.
• [1345] Human Melanoma cells over-express extracellular matrix 1 (ECM1) which is regulated by TFAP2C.PLoS One. 2013 Sep 2;8(9):e73953. doi: 10.1371/journal.pone.0073953. eCollection 2013.
• [1346] Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.Ann Oncol. 2014 Jan;25(1):246-50. doi: 10.1093/annonc/mdt411. Epub 2013 Nov 24.
• [1347] Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.Cell Cycle. 2016 Sep 16;15(18):2405-9. doi: 10.1080/15384101.2016.1208862. Epub 2016 Aug 11.
• [1348] Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.Hum Gene Ther. 2015 Apr;26(4):220-31. doi: 10.1089/hum.2014.112. Epub 2015 Apr 13.
• [1349] Abnormal hypermethylation and clinicopathological significance of FBLN1 gene in cutaneous melanoma.Tumour Biol. 2014 Jan;35(1):123-7. doi: 10.1007/s13277-013-1015-5. Epub 2013 Aug 2.
• [1350] DNA repair variants, indoor tanning, and risk of melanoma.Pigment Cell Melanoma Res. 2013 Sep;26(5):677-84. doi: 10.1111/pcmr.12117. Epub 2013 Jun 3.
• [1351] Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.Cell Cycle. 2012 Sep 1;11(17):3250-9. doi: 10.4161/cc.21611. Epub 2012 Aug 16.
• [1352] Characterization of the GAGE genes that are expressed in various human cancers and in normal testis.Cancer Res. 1999 Jul 1;59(13):3157-65.
• [1353] Functional proteomics, human genetics and cancer biology of GIPC family members.Exp Mol Med. 2013 Jun 7;45(6):e26. doi: 10.1038/emm.2013.49.
• [1354] G-protein-coupled receptor-2-interacting protein-1 is required for endothelial cell directional migration and tumor angiogenesis via cortactin-dependent lamellipodia formation.Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):419-26. doi: 10.1161/ATVBAHA.113.302689. Epub 2013 Nov 21.
• [1355] G13 mediates human cytomegalovirus-encoded chemokine receptor US28-induced cell death in melanoma.Int J Cancer. 2015 Sep 15;137(6):1503-8. doi: 10.1002/ijc.29506. Epub 2015 Mar 16.
• [1356] Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.J Invest Dermatol. 2014 Dec;134(12):2957-2966. doi: 10.1038/jid.2014.270. Epub 2014 Jul 7.
• [1357] Glycerol-3-phosphate acyltranferase-2 behaves as a cancer testis gene and promotes growth and tumorigenicity of the breast cancer MDA-MB-231 cell line.PLoS One. 2014 Jun 26;9(6):e100896. doi: 10.1371/journal.pone.0100896. eCollection 2014.
• [1358] Melanoma cells control HA synthesis in peritumoral fibroblasts via PDGF-AA and PDGF-CC: impact on melanoma cell proliferation.J Invest Dermatol. 2012 Feb;132(2):385-93. doi: 10.1038/jid.2011.325. Epub 2011 Oct 13.
• [1359] Hyaluronan synthase 3 (HAS3) overexpression downregulates MV3 melanoma cell proliferation, migration and adhesion.Exp Cell Res. 2015 Sep 10;337(1):1-15. doi: 10.1016/j.yexcr.2015.07.026. Epub 2015 Jul 26.
• [1360] Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells.J Immunol. 2006 Sep 1;177(5):3100-7. doi: 10.4049/jimmunol.177.5.3100.
• [1361] Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.Mol Cell. 2015 Aug 6;59(3):345-358. doi: 10.1016/j.molcel.2015.05.037. Epub 2015 Jul 2.
• [1362] Oncogenic HoxB7 requires TALE cofactors and is inactivated by a dominant-negative Pbx1 mutant in a cell-specific manner.Cancer Lett. 2008 Aug 8;266(2):144-55. doi: 10.1016/j.canlet.2008.02.042. Epub 2008 Apr 2.
• [1363] Combination of adenoviruses expressing melanoma differentiation-associated gene-7 and chemotherapeutic agents produces enhanced cytotoxicity on esophageal carcinoma.Cancer Gene Ther. 2014 Jan;21(1):31-7. doi: 10.1038/cgt.2013.79. Epub 2014 Jan 17.
• [1364] IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive Tcells.Eur J Immunol. 2016 Jul;46(7):1770-82. doi: 10.1002/eji.201546061. Epub 2016 May 6.
• [1365] Involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma.PLoS One. 2014 Apr 17;9(4):e95522. doi: 10.1371/journal.pone.0095522. eCollection 2014.
• [1366] Nuclear ING2 expression is reduced in human cutaneous melanomas.Br J Cancer. 2006 Jul 3;95(1):80-6. doi: 10.1038/sj.bjc.6603205. Epub 2006 Jun 6.
• [1367] MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project.Int J Cancer. 2015 Feb 1;136(3):618-31. doi: 10.1002/ijc.29018. Epub 2014 Jun 18.
• [1368] Role of Tip60 in human melanoma cell migration, metastasis, and patient survival.J Invest Dermatol. 2012 Nov;132(11):2632-41. doi: 10.1038/jid.2012.193. Epub 2012 Jun 7.
• [1369] Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling.PLoS One. 2013 May 21;8(5):e63597. doi: 10.1371/journal.pone.0063597. Print 2013.
• [1370] MicroRNA-203 regulates melanosome transport and tyrosinase expression in melanoma cells by targeting kinesin superfamily protein 5b.J Invest Dermatol. 2014 Feb;134(2):461-469. doi: 10.1038/jid.2013.310. Epub 2013 Jul 22.
• [1371] Expression and functions of galectin-7 in human and murine melanomas.PLoS One. 2013 May 3;8(5):e63307. doi: 10.1371/journal.pone.0063307. Print 2013.
• [1372] Loss of Hugl-1 expression associates with lymph node metastasis in endometrial cancer.Oncol Res. 2007;16(9):431-5. doi: 10.3727/000000007783980855.
• [1373] Knockdown of lecithin retinol acyltransferase increases all-trans retinoic acid levels and restores retinoid sensitivity in malignant melanoma cells.Exp Dermatol. 2014 Nov;23(11):832-7. doi: 10.1111/exd.12548. Epub 2014 Oct 10.
• [1374] NRAGE suppresses metastasis of melanoma and pancreatic cancer in vitro and in vivo.Cancer Lett. 2007 Jun 8;250(2):268-75. doi: 10.1016/j.canlet.2006.10.020. Epub 2006 Nov 30.
• [1375] The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells.Carcinogenesis. 2012 Oct;33(10):1871-81. doi: 10.1093/carcin/bgs236. Epub 2012 Jul 12.
• [1376] A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response.Cancer Immunol Immunother. 2013 Jan;62(1):183-90. doi: 10.1007/s00262-012-1318-1. Epub 2012 Aug 5.
• [1377] Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma.Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1101-10. doi: 10.1158/1055-9965.EPI-14-1380-T. Epub 2015 May 7.
• [1378] MDA-9/syntenin is essential for factor VIIa-induced signaling, migration, and metastasis in melanoma cells.J Biol Chem. 2015 Feb 6;290(6):3333-48. doi: 10.1074/jbc.M114.606913. Epub 2014 Dec 10.
• [1379] Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.J Am Acad Dermatol. 2008 May;58(5):750-4. doi: 10.1016/j.jaad.2007.12.026. Epub 2008 Feb 4.
• [1380] Expression of integrins 31 and 51 and GlcNAc 1,6 glycan branching influences metastatic melanoma cell migration on fibronectin.Eur J Cell Biol. 2013 Dec;92(12):355-62. doi: 10.1016/j.ejcb.2013.10.007. Epub 2013 Nov 1.
• [1381] Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.Oncotarget. 2015 Feb 20;6(5):2779-93. doi: 10.18632/oncotarget.2995.
• [1382] RPS3 regulates melanoma cell growth and apoptosis by targeting Cyto C/Ca2+/MICU1 dependent mitochondrial signaling.Oncotarget. 2015 Oct 6;6(30):29614-25. doi: 10.18632/oncotarget.4868.
• [1383] Absence of RIPK3 predicts necroptosis resistance in malignant melanoma.Cell Death Dis. 2015 Sep 10;6(9):e1884. doi: 10.1038/cddis.2015.240.
• [1384] Keratinocyte-derived laminin-332 protein promotes melanin synthesis via regulation of tyrosine uptake.J Biol Chem. 2014 Aug 1;289(31):21751-9. doi: 10.1074/jbc.M113.541177. Epub 2014 Jun 20.
• [1385] MTSS1 is a metastasis driver in a subset of human melanomas.Nat Commun. 2014 Mar 17;5:3465. doi: 10.1038/ncomms4465.
• [1386] MX 2 is a novel regulator of cell cycle in melanoma cells.Pigment Cell Melanoma Res. 2020 May;33(3):446-457. doi: 10.1111/pcmr.12837. Epub 2019 Nov 13.
• [1387] Knockdown of myosin VI by lentivirus-mediated short hairpin RNA suppresses proliferation of melanoma.Mol Med Rep. 2015 Nov;12(5):6801-6. doi: 10.3892/mmr.2015.4261. Epub 2015 Aug 28.
• [1388] HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.Br J Cancer. 2011 Jun 28;105(1):118-23. doi: 10.1038/bjc.2011.193. Epub 2011 Jun 7.
• [1389] Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.Cancer Res. 2014 Jul 1;74(13):3429-40. doi: 10.1158/0008-5472.CAN-13-3017. Epub 2014 Apr 29.
• [1390] Neural stem cell-like gene expression in a mouse ependymoma cell line transformed by human BK polyomavirus.Cancer Sci. 2011 Jan;102(1):122-9. doi: 10.1111/j.1349-7006.2010.01775.x. Epub 2010 Nov 12.
• [1391] CD147 interacts with NDUFS6 in regulating mitochondrial complex I activity and the mitochondrial apoptotic pathway in human malignant melanoma cells.Curr Mol Med. 2014;14(10):1252-64. doi: 10.2174/1566524014666141202144601.
• [1392] Pathobiological properties of the ubiquitin ligase Nedd4L in melanoma.Int J Exp Pathol. 2014 Feb;95(1):24-8. doi: 10.1111/iep.12051. Epub 2013 Oct 31.
• [1393] Targeting NEU Protein in Melanoma Cells with Non-Thermal Atmospheric Pressure Plasma and Gold Nanoparticles.J Biomed Nanotechnol. 2015 May;11(5):900-5. doi: 10.1166/jbn.2015.1999.
• [1394] Amplified lipid rafts of malignant cells constitute a target for inhibition of aberrantly active NFAT and melanoma tumor growth by the aminobisphosphonate zoledronic acid.Carcinogenesis. 2014 Nov;35(11):2555-66. doi: 10.1093/carcin/bgu178. Epub 2014 Aug 20.
• [1395] Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.Nat Genet. 2015 Oct;47(10):1194-9. doi: 10.1038/ng.3382. Epub 2015 Sep 7.
• [1396] Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis.Am J Med Sci. 2007 Nov;334(5):342-9. doi: 10.1097/MAJ.0b013e318068b627.
• [1397] Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling.BMC Cancer. 2013 May 7;13:227. doi: 10.1186/1471-2407-13-227.
• [1398] Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.Oncotarget. 2015 Jun 30;6(18):15953-65. doi: 10.18632/oncotarget.3643.
• [1399] Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites.PLoS One. 2012;7(5):e36054. doi: 10.1371/journal.pone.0036054. Epub 2012 May 2.
• [1400] The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway.Int J Cancer. 2013 Aug 15;133(4):879-92. doi: 10.1002/ijc.28097. Epub 2013 Mar 13.
• [1401] Protein Kinase CK2 Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2 Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.J Biol Chem. 2016 Aug 19;291(34):17804-15. doi: 10.1074/jbc.M115.712885. Epub 2016 May 17.
• [1402] PHF19 and Akt control the switch between proliferative and invasive states in melanoma.Cell Cycle. 2012 Apr 15;11(8):1634-45. doi: 10.4161/cc.20095. Epub 2012 Apr 15.
• [1403] TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.BMC Cancer. 2008 Jul 2;8:189. doi: 10.1186/1471-2407-8-189.
• [1404] Impaired PIASy-Tip60 signaling weakens activation of p53 in melanoma.Melanoma Res. 2013 Jun;23(3):213-7. doi: 10.1097/CMR.0b013e328361056d.
• [1405] Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. Br J Dermatol. 2019 Feb;180(2):346-356. doi: 10.1111/bjd.17333. Epub 2018 Nov 25.
• [1406] Cloning of the human phospholipase A2 activating protein (hPLAP) gene on the chromosome 9p21 melanoma deleted region.Gene. 1999 Oct 18;239(1):155-61. doi: 10.1016/s0378-1119(99)00354-6.
• [1407] Oncogenic suppression of PHLPP1 in human melanoma.Oncogene. 2014 Sep 25;33(39):4756-66. doi: 10.1038/onc.2013.420. Epub 2013 Oct 14.
• [1408] Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies.BMC Cancer. 2009 Aug 25;9:297. doi: 10.1186/1471-2407-9-297.
• [1409] POLE mutations in families predisposed to cutaneous melanoma.Fam Cancer. 2015 Dec;14(4):621-8. doi: 10.1007/s10689-015-9826-8.
• [1410] hShroom1 links a membrane bound protein to the actin cytoskeleton.Cell Mol Life Sci. 2009 Feb;66(4):681-96. doi: 10.1007/s00018-009-8645-1.
• [1411] Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.J Immunol. 2013 Jun 15;190(12):6034-42. doi: 10.4049/jimmunol.1202830. Epub 2013 May 20.
• [1412] RacGAP1-driven focal adhesion formation promotes melanoma transendothelial migration through mediating adherens junction disassembly.Biochem Biophys Res Commun. 2015 Mar 27;459(1):1-9. doi: 10.1016/j.bbrc.2014.11.088. Epub 2014 Dec 2.
• [1413] Germline RAD51B truncating mutation in a family with cutaneous melanoma.Fam Cancer. 2015 Jun;14(2):337-40. doi: 10.1007/s10689-015-9781-4.
• [1414] Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.Pigment Cell Melanoma Res. 2014 Jul;27(4):640-52. doi: 10.1111/pcmr.12248. Epub 2014 May 14.
• [1415] RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.Epigenetics. 2014 Nov;9(11):1496-503. doi: 10.4161/15592294.2014.983361.
• [1416] RASSF8 regulates progression of cutaneous melanoma through nuclear factor-b.Oncotarget. 2015 Oct 6;6(30):30165-77. doi: 10.18632/oncotarget.5030.
• [1417] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [1418] Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.J Immunol. 2014 Nov 15;193(10):4803-13. doi: 10.4049/jimmunol.1400800. Epub 2014 Oct 13.
• [1419] REST negatively and ISGF3 positively regulate the human STAT1 gene in melanoma.Mol Cancer Ther. 2013 Jul;12(7):1288-98. doi: 10.1158/1535-7163.MCT-12-0923. Epub 2013 Apr 18.
• [1420] Autophagic UVRAG Promotes UV-Induced Photolesion Repair by Activation of the CRL4(DDB2) E3 Ligase.Mol Cell. 2016 May 19;62(4):507-19. doi: 10.1016/j.molcel.2016.04.014.
• [1421] JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma.Carcinogenesis. 2013 Dec;34(12):2778-88. doi: 10.1093/carcin/bgt318. Epub 2013 Sep 24.
• [1422] A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition.Mol Cancer. 2011 Sep 14;10:114. doi: 10.1186/1476-4598-10-114.
• [1423] Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.Cell Rep. 2015 Jun 9;11(9):1458-73. doi: 10.1016/j.celrep.2015.04.049. Epub 2015 May 28.
• [1424] Ribonuclease inhibitor up-regulation inhibits the growth and induces apoptosis in murine melanoma cells through repression of angiogenin and ILK/PI3K/AKT signaling pathway.Biochimie. 2014 Aug;103:89-100. doi: 10.1016/j.biochi.2014.04.007. Epub 2014 Apr 24.
• [1425] p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells.J Dermatol Sci. 2012 Oct;68(1):19-24. doi: 10.1016/j.jdermsci.2012.07.005. Epub 2012 Aug 2.
• [1426] YY1 regulates melanoma tumorigenesis through a miR-9~RYBP axis.J Exp Clin Cancer Res. 2015 Jun 24;34(1):66. doi: 10.1186/s13046-015-0177-y.
• [1427] Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.Br J Cancer. 2014 May 13;110(10):2489-95. doi: 10.1038/bjc.2014.169. Epub 2014 Apr 10.
• [1428] Regulation of S100A2 expression by TGF--induced MEK/ERK signalling and its role in cell migration/invasion.Biochem J. 2012 Oct 1;447(1):81-91. doi: 10.1042/BJ20120014.
• [1429] SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas.Oncogene. 2007 Jun 21;26(29):4216-25. doi: 10.1038/sj.onc.1210216. Epub 2007 Feb 12.
• [1430] Cancer-linked satellite 2 DNA hypomethylation does not regulate Sat2 non-coding RNA expression and is initiated by heat shock pathway activation.Epigenetics. 2012 Aug;7(8):903-13. doi: 10.4161/epi.21107. Epub 2012 Jun 22.
• [1431] SBF-1, a synthetic steroidal glycoside, inhibits melanoma growth and metastasis through blocking interaction between PDK1 and AKT3.Biochem Pharmacol. 2012 Jul 15;84(2):172-81. doi: 10.1016/j.bcp.2012.04.006. Epub 2012 Apr 13.
• [1432] Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells.PLoS One. 2014 Feb 18;9(2):e89491. doi: 10.1371/journal.pone.0089491. eCollection 2014.
• [1433] Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.J Immunol. 2014 Apr 15;192(8):3981-9. doi: 10.4049/jimmunol.1302532. Epub 2014 Mar 17.
• [1434] Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling.Oncotarget. 2015 Oct 20;6(32):33091-105. doi: 10.18632/oncotarget.5173.
• [1435] Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy.Cancer Res. 2013 Apr 1;73(7):2247-58. doi: 10.1158/0008-5472.CAN-12-2501. Epub 2013 Jan 28.
• [1436] Increased expression of sex determining region Y-box 11 (SOX11) in cutaneous malignant melanoma.J Int Med Res. 2013 Aug;41(4):1221-7. doi: 10.1177/0300060513476592. Epub 2013 Jul 18.
• [1437] SPANX-B and SPANX-C (Xq27 region) gene dosage analysis in Sicilian patients with melanoma.Melanoma Res. 2008 Aug;18(4):295-9. doi: 10.1097/CMR.0b013e32830aaa90.
• [1438] Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening.Pigment Cell Melanoma Res. 2013 Jan;26(1):97-112. doi: 10.1111/pcmr.12031. Epub 2012 Nov 6.
• [1439] Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential.J Invest Dermatol. 2015 Jul;135(7):1849-1862. doi: 10.1038/jid.2015.95. Epub 2015 Mar 10.
• [1440] Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry.Pigment Cell Melanoma Res. 2014 May;27(3):442-53. doi: 10.1111/pcmr.12222. Epub 2014 Mar 7.
• [1441] STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice.Cancer Immunol Immunother. 2015 Aug;64(8):1057-66. doi: 10.1007/s00262-015-1713-5. Epub 2015 May 19.
• [1442] PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014 Oct 9;514(7521):247-51.
• [1443] MicroRNA-143 targets Syndecan-1 to repress cell growth in melanoma.PLoS One. 2014 Apr 10;9(4):e94855. doi: 10.1371/journal.pone.0094855. eCollection 2014.
• [1444] MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma.Aging (Albany NY). 2016 May;8(5):933-44. doi: 10.18632/aging.100951.
• [1445] Proteolytic cleavage of Livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase.J Dermatol Sci. 2006 Sep;43(3):189-200. doi: 10.1016/j.jdermsci.2006.05.007. Epub 2006 Jun 27.
• [1446] Prognostic relevance of the expressions of CAV1 and TES genes on 7q31 in melanoma.Front Biosci (Elite Ed). 2012 Jan 1;4(5):1802-12. doi: 10.2741/501.
• [1447] Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium.Oncogene. 2005 Jul 7;24(29):4710-20. doi: 10.1038/sj.onc.1208559.
• [1448] TRIB2 as a biomarker for diagnosis and progression of melanoma.Carcinogenesis. 2015 Apr;36(4):469-77. doi: 10.1093/carcin/bgv002. Epub 2015 Jan 13.
• [1449] The human TPR protein TTC4 is a putative Hsp90 co-chaperone which interacts with CDC6 and shows alterations in transformed cells.PLoS One. 2008 Mar 5;3(3):e0001737. doi: 10.1371/journal.pone.0001737.
• [1450] Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.J Natl Cancer Inst. 2014 Dec 13;107(2):dju408. doi: 10.1093/jnci/dju408. Print 2015 Feb.
• [1451] Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.Mol Cancer Res. 2010 Nov;8(11):1513-25. doi: 10.1158/1541-7786.MCR-10-0262. Epub 2010 Oct 13.
• [1452] A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in the SLC45A2 gene.PLoS One. 2011 Apr 29;6(4):e19271. doi: 10.1371/journal.pone.0019271.
• [1453] Vulvar malignant melanoma associated with human papillomavirus DNA: report of two cases and review of literature.Am J Dermatopathol. 2002 Jun;24(3):230-40. doi: 10.1097/00000372-200206000-00008.
• [1454] Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations.Clin Cancer Res. 2019 Jun 15;25(12):3548-3560. doi: 10.1158/1078-0432.CCR-18-3442. Epub 2019 Feb 19.
• [1455] Differential modulatory effects of GSK-3 and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.Mol Cancer. 2011 Sep 19;10:115. doi: 10.1186/1476-4598-10-115.
• [1456] ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output.Cancers (Basel). 2019 Dec 6;11(12):1963. doi: 10.3390/cancers11121963.
• [1457] Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.Cancer Res. 2011 Apr 1;71(7):2561-71. doi: 10.1158/0008-5472.CAN-10-2958. Epub 2011 Feb 22.
• [1458] Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.Br J Cancer. 2003 Apr 22;88(8):1292-300. doi: 10.1038/sj.bjc.6600888.
• [1459] Knockdown of aristaless-like homeobox1 inhibits epithelial-mesenchymal transition through Wnt/-catenin signaling pathway in melanoma cells.Biochem Biophys Res Commun. 2019 Mar 26;511(1):105-110. doi: 10.1016/j.bbrc.2019.02.050. Epub 2019 Feb 14.
• [1460] Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas.Br J Dermatol. 2020 Jan;182(1):156-165. doi: 10.1111/bjd.18086. Epub 2019 Jun 19.
• [1461] Expression and function of the AMF receptor by human melanoma in experimental and clinical systems.Clin Exp Metastasis. 2002;19(3):225-32. doi: 10.1023/a:1015595708241.
• [1462] AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway.Lasers Med Sci. 2019 Apr;34(3):473-478. doi: 10.1007/s10103-018-2616-4. Epub 2018 Aug 24.
• [1463] Recombinant angioarrestin secreted from mouse melanoma cells inhibits growth of primary tumours.Acta Biochim Pol. 2005;52(4):875-9. Epub 2005 Jun 6.
• [1464] Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity.Genes Dev. 2019 Dec 1;33(23-24):1641-1656. doi: 10.1101/gad.329417.119. Epub 2019 Nov 14.
• [1465] Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression.Cancer Res. 1996 Sep 1;56(17):3855-8.
• [1466] Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.Hum Mol Genet. 2011 Dec 15;20(24):5012-23. doi: 10.1093/hmg/ddr415. Epub 2011 Sep 17.
• [1467] Rap1-GTP-interacting adaptor molecule (RIAM) protein controls invasion and growth of melanoma cells.J Biol Chem. 2011 May 27;286(21):18492-504. doi: 10.1074/jbc.M110.189811. Epub 2011 Mar 26.
• [1468] Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells.Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7200-4. doi: 10.1073/pnas.90.15.7200.
• [1469] Activated G(alpha)13 impairs cell invasiveness through p190RhoGAP-mediated inhibition of RhoA activity.Cancer Res. 2008 Oct 15;68(20):8221-30. doi: 10.1158/0008-5472.CAN-08-0561.
• [1470] Identification of ARHGEF17, DENND2D, FGFR3, and RB1 mutations in melanoma by inhibition of nonsense-mediated mRNA decay.Genes Chromosomes Cancer. 2008 Dec;47(12):1076-85. doi: 10.1002/gcc.20598.
• [1471] Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.Melanoma Res. 2009 Aug;19(4):226-37. doi: 10.1097/CMR.0b013e32832e0bc3.
• [1472] ARLTS1 variants and melanoma risk.Int J Cancer. 2006 Oct 1;119(7):1736-7. doi: 10.1002/ijc.22008.
• [1473] Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.Cancer Res. 2001 Nov 1;61(21):7900-7.
• [1474] Systems analysis of barrier molecule and ARNT-related gene expression regulation in melanoma.Oncoimmunology. 2019 Sep 24;8(12):e1665978. doi: 10.1080/2162402X.2019.1665978. eCollection 2019.
• [1475] Arpc1b gene is a candidate prediction marker for choroidal malignant melanomas sensitive to radiotherapy.Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2300-4. doi: 10.1167/iovs.05-0810.
• [1476] DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma.Clin Cancer Res. 2005 May 15;11(10):3609-13. doi: 10.1158/1078-0432.CCR-04-1941.
• [1477] Scleral Thinning Documented by Ultrasound Biomicroscopy after Plaque Therapy for Anterior Ciliary Melanoma.Semin Ophthalmol. 2018;33(4):571-575. doi: 10.1080/08820538.2017.1346131. Epub 2017 Jul 13.
• [1478] Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.Mol Cancer Ther. 2013 Nov;12(11):2581-90. doi: 10.1158/1535-7163.MCT-13-0302. Epub 2013 Aug 26.
• [1479] miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.Cell Signal. 2018 Jan;42:30-43. doi: 10.1016/j.cellsig.2017.09.024. Epub 2017 Oct 2.
• [1480] Elevated expression of the V-ATPase D2 subunit triggers increased energy metabolite levels in Kras(G12D) -driven cancer cells.J Cell Biochem. 2019 Jul;120(7):11690-11701. doi: 10.1002/jcb.28448. Epub 2019 Feb 11.
• [1481] Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma.Genes Chromosomes Cancer. 2008 Jul;47(7):614-24. doi: 10.1002/gcc.20567.
• [1482] Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice.Int J Cancer. 2003 Feb 20;103(5):606-15. doi: 10.1002/ijc.10881.
• [1483] Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction.Cancer Res. 2014 Jan 15;74(2):563-74. doi: 10.1158/0008-5472.CAN-13-1062. Epub 2013 Nov 26.
• [1484] Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts.FEBS Lett. 2003 Oct 23;553(3):250-6. doi: 10.1016/s0014-5793(03)01017-2.
• [1485] Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.Clin Cancer Res. 2012 Jun 15;18(12):3316-27. doi: 10.1158/1078-0432.CCR-11-2232. Epub 2012 May 2.
• [1486] Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4583-4591. doi: 10.1073/pnas.1821889116. Epub 2019 Feb 19.
• [1487] Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent.Toxicol Appl Pharmacol. 2008 Aug 15;231(1):61-7. doi: 10.1016/j.taap.2008.03.020. Epub 2008 Apr 9.
• [1488] Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts.BMC Med Genet. 2019 May 3;20(1):69. doi: 10.1186/s12881-019-0808-9.
• [1489] Comparison of calmodulin gene expression in human neonatal melanocytes and metastatic melanoma cell lines.J Invest Dermatol. 1992 Dec;99(6):764-73. doi: 10.1111/1523-1747.ep12614725.
• [1490] Preventing Calpain Externalization by Reducing ABCA1 Activity with Probenecid Limits Melanoma Angiogenesis and Development.J Invest Dermatol. 2020 Feb;140(2):445-454. doi: 10.1016/j.jid.2019.06.148. Epub 2019 Aug 16.
• [1491] Laminin-421 produced by lymphatic endothelial cells induces chemotaxis for human melanoma cells.Pigment Cell Melanoma Res. 2009 Oct;22(5):601-10. doi: 10.1111/j.1755-148X.2009.00590.x. Epub 2009 Jun 5.
• [1492] Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.Clin Cancer Res. 2008 Feb 1;14(3):638-45. doi: 10.1158/1078-0432.CCR-07-2025.
• [1493] Homophilic interactions of Tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways.J Biol Chem. 2006 Aug 25;281(34):24279-92. doi: 10.1074/jbc.M601209200. Epub 2006 Jun 23.
• [1494] Increased cytoplasmatic expression of cancer immune surveillance receptor CD1d in anaplastic thyroid carcinomas.Cancer Med. 2019 Nov;8(16):7065-7073. doi: 10.1002/cam4.2573. Epub 2019 Sep 27.
• [1495] The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes.Int J Cancer. 1994 May 15;57(4):612-9. doi: 10.1002/ijc.2910570428.
• [1496] Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression.PLoS One. 2007 Jul 4;2(7):e594. doi: 10.1371/journal.pone.0000594.
• [1497] CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1379-84. doi: 10.1073/pnas.1017228108. Epub 2011 Jan 10.
• [1498] CDK5RAP1 targeting NF-B signaling pathway in human malignant melanoma A375 cell apoptosis.Oncol Lett. 2018 Apr;15(4):4767-4774. doi: 10.3892/ol.2018.7920. Epub 2018 Feb 1.
• [1499] Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.Cancer Res. 1998 Jun 1;58(11):2298-303.
• [1500] Expression of APITD1 is not related to copy number changes of chromosomal region 1p36 or the prognosis of uveal melanoma.Invest Ophthalmol Vis Sci. 2007 Nov;48(11):4919-23. doi: 10.1167/iovs.07-0061.
• [1501] The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma.J Biol Chem. 2010 Aug 27;285(35):27487-27498. doi: 10.1074/jbc.M110.155382. Epub 2010 Jun 29.
• [1502] An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.Cancer Cell. 2019 Jan 14;35(1):33-45.e6. doi: 10.1016/j.ccell.2018.12.001.
• [1503] Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma.Br J Dermatol. 2011 May;164(5):1010-6. doi: 10.1111/j.1365-2133.2011.10223.x.
• [1504] Decreased Lung Tumor Development in SwAPP Mice through the Downregulation of CHI3L1 and STAT 3 Activity via the Upregulation of miRNA342-3p.Mol Ther Nucleic Acids. 2019 Jun 7;16:63-72. doi: 10.1016/j.omtn.2019.02.007. Epub 2019 Feb 20.
• [1505] Mechanism of regulation and suppression of melanoma invasiveness by novel retinoic acid receptor-gamma target gene carbohydrate sulfotransferase 10.Cancer Res. 2009 Jun 15;69(12):5218-25. doi: 10.1158/0008-5472.CAN-09-0705. Epub 2009 May 26.
• [1506] Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma.Epigenetics. 2011 Mar;6(3):388-94. doi: 10.4161/epi.6.3.14056. Epub 2011 Mar 1.
• [1507] Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.Cancer Res. 2006 Jun 15;66(12):6080-6. doi: 10.1158/0008-5472.CAN-06-0157.
• [1508] Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma.Front Pharmacol. 2019 Feb 8;10:66. doi: 10.3389/fphar.2019.00066. eCollection 2019.
• [1509] Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma.J Extracell Vesicles. 2019 Aug 27;8(1):1635420. doi: 10.1080/20013078.2019.1635420. eCollection 2019.
• [1510] ER-aminopeptidase 1 determines the processing and presentation of an immunotherapy-relevant melanoma epitope.Eur J Immunol. 2020 Feb;50(2):270-283. doi: 10.1002/eji.201948116. Epub 2019 Nov 27.
• [1511] Vitamin A metabolism and mRNA expression of retinoid-binding protein and receptor genes in human epidermal melanocytes and melanoma cells.Melanoma Res. 1997 Aug;7(4):267-74. doi: 10.1097/00008390-199708000-00001.
• [1512] Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.Hum Gene Ther. 2004 Jul;15(7):637-47. doi: 10.1089/1043034041361181.
• [1513] AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome.J Invest Dermatol. 2012 Jun;132(6):1689-97. doi: 10.1038/jid.2012.36. Epub 2012 Mar 8.
• [1514] Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes.Cancer Biol Ther. 2004 Jan;3(1):110-20. doi: 10.4161/cbt.3.1.662. Epub 2004 Jan 24.
• [1515] Contact of high-invasive, but not low-invasive, melanoma cells to native collagen I induces the release of mature cathepsin B.Int J Cancer. 2006 Jun 1;118(11):2735-43. doi: 10.1002/ijc.21700.
• [1516] cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing.J Invest Dermatol. 2003 Jul;121(1):198-206. doi: 10.1046/j.1523-1747.2003.12318.x.
• [1517] Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC.Int J Cancer. 2002 Aug 10;100(5):549-56. doi: 10.1002/ijc.10512.
• [1518] The transcription factor CUTL1 is associated with proliferation and prognosis in malignant melanoma.Melanoma Res. 2014 Jun;24(3):198-206. doi: 10.1097/CMR.0000000000000064.
• [1519] Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis.Cancer Lett. 2011 Mar 1;302(1):54-62. doi: 10.1016/j.canlet.2010.12.013. Epub 2011 Jan 13.
• [1520] CD4+ T-cell response to mitochondrial cytochrome B in human melanoma.Cancer Res. 2006 Jun 1;66(11):5919-26. doi: 10.1158/0008-5472.CAN-05-4574.
• [1521] Genome-wide screening identifies novel genes implicated in cellular sensitivity to BRAF(V600E) expression.Oncogene. 2020 Jan;39(4):723-738. doi: 10.1038/s41388-019-1022-0. Epub 2019 Sep 23.
• [1522] Clone 10d/BM28 (CDCL1), an early S-phase protein, is an important growth regulator of melanoma.Cancer Res. 1997 Nov 15;57(22):5122-8.
• [1523] mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties.Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):637-42. doi: 10.1073/pnas.022637199.
• [1524] DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis.Exp Cell Res. 2019 Jun 1;379(1):48-54. doi: 10.1016/j.yexcr.2019.03.021. Epub 2019 Mar 14.
• [1525] Establishment and characterization of a cell line (DEOC-1) originating from a human malignant melanoma of the skin.Hum Cell. 2007 May;20(2):23-38. doi: 10.1111/j.1749-0774.2007.00028.x.
• [1526] Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.Genes Dev. 2006 Dec 15;20(24):3426-39. doi: 10.1101/gad.406406.
• [1527] MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells.Cancer Res. 2006 Aug 15;66(16):7939-47. doi: 10.1158/0008-5472.CAN-06-1888.
• [1528] Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas.FEBS Lett. 1998 Jul 3;430(3):227-30. doi: 10.1016/s0014-5793(98)00603-6.
• [1529] Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.Breast Cancer Res. 2008;10(2):R22. doi: 10.1186/bcr1874. Epub 2008 Mar 7.
• [1530] Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia.Int J Cancer. 2003 Aug 20;106(2):224-31. doi: 10.1002/ijc.11200.
• [1531] Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways.Metallomics. 2019 Oct 16;11(10):1687-1699. doi: 10.1039/c9mt00174c.
• [1532] DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells.Curr Biol. 2008 Oct 14;18(19):1456-65. doi: 10.1016/j.cub.2008.08.053. Epub 2008 Oct 2.
• [1533] Silencing of diphthamide synthesis 3 (Dph3) reduces metastasis of murine melanoma.PLoS One. 2012;7(11):e49988. doi: 10.1371/journal.pone.0049988. Epub 2012 Nov 20.
• [1534] DRG2 supports the growth of primary tumors and metastases of melanoma by enhancing VEGF-A expression.FEBS J. 2020 May;287(10):2070-2086. doi: 10.1111/febs.15125. Epub 2019 Dec 1.
• [1535] Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.Nat Genet. 2011 Dec 25;44(2):133-9. doi: 10.1038/ng.1026.
• [1536] Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development.Oncogene. 2001 Dec 6;20(56):8125-35. doi: 10.1038/sj.onc.1205034.
• [1537] Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression.Mol Cancer Res. 2007 Aug;5(8):761-71. doi: 10.1158/1541-7786.MCR-07-0088.
• [1538] Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.Br J Cancer. 2020 Feb;122(4):506-516. doi: 10.1038/s41416-019-0673-5. Epub 2019 Dec 16.
• [1539] The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death.Cell Death Differ. 2019 Mar;26(3):443-454. doi: 10.1038/s41418-018-0128-1. Epub 2018 May 31.
• [1540] Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display.Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6778-82. doi: 10.1073/pnas.92.15.6778.
• [1541] Up-regulation of ephrin-A1 during melanoma progression.Int J Cancer. 1999 Oct 22;84(5):494-501. doi: 10.1002/(sici)1097-0215(19991022)84:5<494::aid-ijc8>3.0.co;2-o.
• [1542] Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3.Blood. 2010 Mar 25;115(12):2520-32. doi: 10.1182/blood-2009-07-233478. Epub 2009 Nov 23.
• [1543] Loss of the eukaryotic initiation factor 3f in melanoma.Mol Carcinog. 2008 Oct;47(10):806-13. doi: 10.1002/mc.20436.
• [1544] DERP6 (ELP5) and C3ORF75 (ELP6) regulate tumorigenicity and migration of melanoma cells as subunits of Elongator.J Biol Chem. 2012 Sep 21;287(39):32535-45. doi: 10.1074/jbc.M112.402727. Epub 2012 Aug 1.
• [1545] ERK/p90(RSK)/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capica.Biochem J. 2011 Feb 1;433(3):515-25. doi: 10.1042/BJ20101562.
• [1546] Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN- and valproic acid.Cancer Res. 2011 Jun 15;71(12):4150-60. doi: 10.1158/0008-5472.CAN-10-3498. Epub 2011 Apr 14.
• [1547] Oxidative stress and antioxidants in the pathophysiology of malignant melanoma.Biol Chem. 2019 Apr 24;400(5):589-612. doi: 10.1515/hsz-2018-0327.
• [1548] FARP1 Facilitates Cell Proliferation Through Modulating MAPK Signaling Pathway in Cutaneous Melanoma.Am J Dermatopathol. 2019 Dec;41(12):908-913. doi: 10.1097/DAD.0000000000001426.
• [1549] Inhibitory mechanism of FAT4 gene expression in response to actin dynamics during Src-induced carcinogenesis.PLoS One. 2015 Feb 13;10(2):e0118336. doi: 10.1371/journal.pone.0118336. eCollection 2015.
• [1550] Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1/VEGF pathway.Invest New Drugs. 2020 Feb;38(1):20-28. doi: 10.1007/s10637-019-00761-z. Epub 2019 Mar 18.
• [1551] Novel melanoma antigen, FCRL/FREB, identified by cDNA profile comparison using DNA chip are immunogenic in multiple melanoma patients.Int J Cancer. 2005 Mar 20;114(2):283-90. doi: 10.1002/ijc.20735.
• [1552] Identifying FL11 subtype by characterizing tumor immune microenvironment in prostate adenocarcinoma via Chou's 5-steps rule.Genomics. 2020 Mar;112(2):1500-1515. doi: 10.1016/j.ygeno.2019.08.021. Epub 2019 Aug 28.
• [1553] FLOT2 overexpression is associated with the progression and prognosis of human colorectal cancer.Oncol Lett. 2019 Mar;17(3):2802-2808. doi: 10.3892/ol.2019.9882. Epub 2019 Jan 2.
• [1554] Recent Advances in Understanding FOXN3 in Breast Cancer, and Other Malignancies.Front Oncol. 2019 May 31;9:234. doi: 10.3389/fonc.2019.00234. eCollection 2019.
• [1555] NOVA1 acts as an oncogene in melanoma via regulating FOXO3a expression.J Cell Mol Med. 2018 May;22(5):2622-2630. doi: 10.1111/jcmm.13527. Epub 2018 Mar 2.
• [1556] Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence.Cancer Res. 2010 Nov 1;70(21):8526-36. doi: 10.1158/0008-5472.CAN-10-1563. Epub 2010 Oct 19.
• [1557] Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma.PLoS One. 2011 Apr 8;6(4):e18369. doi: 10.1371/journal.pone.0018369.
• [1558] Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.Epigenetics. 2018;13(3):214-227. doi: 10.1080/15592294.2016.1229730. Epub 2018 Apr 18.
• [1559] Ferritin light chain down-modulation generates depigmentation in human metastatic melanoma cells by influencing tyrosinase maturation.J Cell Physiol. 2006 Mar;206(3):843-8. doi: 10.1002/jcp.20543.
• [1560] Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.Cancer. 2005 Apr 15;103(8):1693-700. doi: 10.1002/cncr.20984.
• [1561] Down-regulation of FZD3 receptor suppresses growth and metastasis of human melanoma independently of canonical WNT signaling.Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4548-4557. doi: 10.1073/pnas.1813802116. Epub 2019 Feb 21.
• [1562] Protein kinase C-betaII represses hepatocyte growth factor-induced invasion by preventing the association of adapter protein Gab1 and phosphatidylinositol 3-kinase in melanoma cells.J Invest Dermatol. 2008 Jan;128(1):188-95. doi: 10.1038/sj.jid.5700961. Epub 2007 Jul 12.
• [1563] GAB2 induces tumor angiogenesis in NRAS-driven melanoma.Oncogene. 2013 Aug 1;32(31):3627-37. doi: 10.1038/onc.2012.367. Epub 2012 Aug 27.
• [1564] A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.J Exp Med. 1995 Sep 1;182(3):689-98. doi: 10.1084/jem.182.3.689.
• [1565] Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.Nat Med. 2007 Sep;13(9):1070-7. doi: 10.1038/nm1627. Epub 2007 Sep 2.
• [1566] Sperm-specific glyceraldehyde-3-phosphate dehydrogenase is expressed in melanoma cells.Biochem Biophys Res Commun. 2012 Oct 26;427(3):649-53. doi: 10.1016/j.bbrc.2012.09.115. Epub 2012 Sep 28.
• [1567] A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene.Genes Dev. 2008 Nov 1;22(21):2932-40. doi: 10.1101/gad.1714608.
• [1568] GBP-5 splicing variants: New guanylate-binding proteins with tumor-associated expression and antigenicity.J Invest Dermatol. 2004 Jun;122(6):1510-7. doi: 10.1111/j.0022-202X.2004.22613.x.
• [1569] c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines.PLoS One. 2010 Apr 21;5(4):e10279. doi: 10.1371/journal.pone.0010279.
• [1570] Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.J Clin Invest. 2019 May 1;129(5):1940-1945. doi: 10.1172/JCI123089. Epub 2019 Mar 5.
• [1571] PLD-repair in human melanoma xenografts following single dose and fractionated irradiation.Br J Cancer. 1990 Jun;61(6):856-60. doi: 10.1038/bjc.1990.191.
• [1572] Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.J Immunol. 2003 Feb 1;170(3):1579-85. doi: 10.4049/jimmunol.170.3.1579.
• [1573] Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation.Nat Commun. 2019 Apr 11;10(1):1689. doi: 10.1038/s41467-019-09397-2.
• [1574] Long noncoding RNA HCP5 suppresses skin cutaneous melanoma development by regulating RARRES3 gene expression via sponging miR-12.Onco Targets Ther. 2019 Aug 12;12:6323-6335. doi: 10.2147/OTT.S195796. eCollection 2019.
• [1575] Natural and orthogonal model for estimating gene-gene interactions applied to cutaneous melanoma.Hum Genet. 2014 May;133(5):559-74. doi: 10.1007/s00439-013-1392-2. Epub 2013 Nov 17.
• [1576] Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.J Exp Med. 2000 Feb 21;191(4):625-30. doi: 10.1084/jem.191.4.625.
• [1577] Linkage analysis in familial melanoma kindreds to markers on chromosome 6p.Int J Cancer. 1994 Dec 15;59(6):771-5. doi: 10.1002/ijc.2910590611.
• [1578] Increased interleukin-10 mRNA stability in melanoma cells is associated with decreased levels of A + U-rich element binding factor AUF1.J Interferon Cytokine Res. 2003 Oct;23(10):553-64. doi: 10.1089/107999003322485053.
• [1579] Higher expression of the heterogeneous nuclear ribonucleoprotein k in melanoma.Ann Surg Oncol. 2010 Oct;17(10):2619-27. doi: 10.1245/s10434-010-1121-1. Epub 2010 May 25.
• [1580] Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.Med Sci Monit. 2019 Feb 16;25:1275-1282. doi: 10.12659/MSM.912632.
• [1581] Transduction of HOXD3-antisense into human melanoma cells results in decreased invasive and motile activities.Clin Exp Metastasis. 2002;19(6):503-11. doi: 10.1023/a:1020346211686.
• [1582] Inhibitory effects of N-(4-hydrophenyl) retinamide on liver cancer and malignant melanoma cells. World J Gastroenterol. 2005 Oct 7;11(37):5763-9. doi: 10.3748/wjg.v11.i37.5763.
• [1583] Human chromosome 3 mediates growth arrest and suppression of apoptosis in microcell hybrids.Mol Cell Biol. 1996 May;16(5):2214-25. doi: 10.1128/MCB.16.5.2214.
• [1584] Isocordoin analogues promote apoptosis in human melanoma cells via Hsp70.Phytother Res. 2019 Dec;33(12):3242-3250. doi: 10.1002/ptr.6498. Epub 2019 Sep 5.
• [1585] Evaluation of apoptosis imaging biomarkers in a genetic model of cell death.EJNMMI Res. 2019 Feb 19;9(1):18. doi: 10.1186/s13550-019-0487-8.
• [1586] Oxalomalate reduces tumor progression in melanoma via ROS-dependent proapoptotic and antiangiogenic effects.Biochimie. 2019 Mar;158:165-171. doi: 10.1016/j.biochi.2019.01.004. Epub 2019 Jan 9.
• [1587] Interferon-alpha induces reversible DNA demethylation of the interferon-induced transmembrane protein-3 core promoter in human melanoma cells.J Interferon Cytokine Res. 2011 Aug;31(8):601-8. doi: 10.1089/jir.2010.0134. Epub 2011 Mar 17.
• [1588] Non-coding RNAs: the cancer genome dark matter that matters!.Clin Chem Lab Med. 2017 May 1;55(5):705-714. doi: 10.1515/cclm-2016-0740.
• [1589] Antiproliferative activity of IL-27 on melanoma.J Immunol. 2008 May 15;180(10):6527-35. doi: 10.4049/jimmunol.180.10.6527.
• [1590] Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.Nature. 2010 Jul 1;466(7302):133-7. doi: 10.1038/nature09161.
• [1591] ING3 is required for ATM signaling and DNA repair in response to DNA double strand breaks.Cell Death Differ. 2019 Nov;26(11):2344-2357. doi: 10.1038/s41418-019-0305-x. Epub 2019 Feb 25.
• [1592] IRF5 gene polymorphisms in melanoma.J Transl Med. 2012 Aug 21;10:170. doi: 10.1186/1479-5876-10-170.
• [1593] Parallel expression of alphaIIbbeta3 and alphavbeta3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype.Int J Cancer. 2005 Aug 10;116(1):27-35. doi: 10.1002/ijc.20991.
• [1594] Expression of integrin alpha10 is induced in malignant melanoma.Cell Oncol. 2007;29(5):373-86. doi: 10.1155/2007/601497.
• [1595] Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression.Front Genet. 2018 Dec 18;9:675. doi: 10.3389/fgene.2018.00675. eCollection 2018.
• [1596] Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.Clin Cancer Res. 1996 Apr;2(4):679-86.
• [1597] Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.Future Oncol. 2019 Nov;15(32):3665-3674. doi: 10.2217/fon-2019-0433. Epub 2019 Sep 20.
• [1598] Downregulation of KCTD12 contributes to melanoma stemness by modulating CD271.Cancer Biol Med. 2019 Aug;16(3):498-513. doi: 10.20892/j.issn.2095-3941.2019.0073.
• [1599] ARMS depletion facilitates UV irradiation induced apoptotic cell death in melanoma.Cancer Res. 2007 Dec 15;67(24):11547-56. doi: 10.1158/0008-5472.CAN-07-1930.
• [1600] KIF15 plays a role in promoting the tumorigenicity of melanoma.Exp Eye Res. 2019 Aug;185:107598. doi: 10.1016/j.exer.2019.02.014. Epub 2019 Feb 21.
• [1601] Kinesin family member 18B: A contributor and facilitator in the proliferation and metastasis of cutaneous melanoma.J Biochem Mol Toxicol. 2019 Dec;33(12):e22409. doi: 10.1002/jbt.22409. Epub 2019 Oct 16.
• [1602] Kinesin family member 20A is a novel melanoma-associated antigen.Acta Derm Venereol. 2012 Nov;92(6):593-7. doi: 10.2340/00015555-1416.
• [1603] Characterization of KIF7 gene in silico.Int J Oncol. 2004 Dec;25(6):1881-6.
• [1604] MHC class I-independent recognition of NK-activating receptor KIR2DS4.J Immunol. 2004 Aug 1;173(3):1819-25. doi: 10.4049/jimmunol.173.3.1819.
• [1605] NEAT1/miR-23a-3p/KLF3: a novel regulatory axis in melanoma cancer progression.Cancer Cell Int. 2019 Aug 22;19:217. doi: 10.1186/s12935-019-0927-6. eCollection 2019.
• [1606] KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment.J Natl Cancer Inst. 2010 Aug 4;102(15):1131-47. doi: 10.1093/jnci/djq218. Epub 2010 Jul 21.
• [1607] KLF9-dependent ROS regulate melanoma progression in stage-specific manner.Oncogene. 2019 May;38(19):3585-3597. doi: 10.1038/s41388-019-0689-6. Epub 2019 Jan 21.
• [1608] Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients.Clin Exp Metastasis. 2007;24(1):1-11. doi: 10.1007/s10585-006-9043-9. Epub 2007 Feb 13.
• [1609] Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14).Oncogene. 2003 Mar 6;22(9):1418-24. doi: 10.1038/sj.onc.1206272.
• [1610] Lichen planus: molecular pathway and clinical implications in oral disorders.J Biol Regul Homeost Agents. 2018 Jan-Feb;32(2 Suppl. 1):135-138.
• [1611] Cross-species application of cDNA microarrays to profile gene expression using UV-induced melanoma in Monodelphis domestica as the model system.Genomics. 2004 Apr;83(4):588-99. doi: 10.1016/j.ygeno.2003.10.007.
• [1612] Melanoma cells produce multiple laminin isoforms and strongly migrate on 5 laminin(s) via several integrin receptors.Exp Cell Res. 2011 May 1;317(8):1119-33. doi: 10.1016/j.yexcr.2010.12.019. Epub 2010 Dec 31.
• [1613] Phosphorylation of ectopically expressed L-plastin enhances invasiveness of human melanoma cells.Int J Cancer. 2007 Jun 15;120(12):2590-9. doi: 10.1002/ijc.22589.
• [1614] ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma.J Invest Dermatol. 2011 Jun;131(6):1280-90. doi: 10.1038/jid.2011.35. Epub 2011 Mar 10.
• [1615] Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis.Cell. 2012 Nov 21;151(5):1068-82. doi: 10.1016/j.cell.2012.10.028. Epub 2012 Nov 8.
• [1616] Lymphocyte-specific protein 1 expression in eukaryotic cells reproduces the morphologic and motile abnormality of NAD 47/89 neutrophils.Blood. 1998 Jun 15;91(12):4786-95.
• [1617] Latent transforming growth factor-beta-binding protein 2 is an adhesion protein for melanoma cells.J Biol Chem. 2003 Jul 4;278(27):24705-13. doi: 10.1074/jbc.M212953200. Epub 2003 Apr 25.
• [1618] Sequence and expression of a novel member (LTBP-4) of the family of latent transforming growth factor-beta binding proteins.FEBS Lett. 1997 Jul 14;411(2-3):164-8. doi: 10.1016/s0014-5793(97)00685-6.
• [1619] Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma.Virchows Arch. 2001 Nov;439(5):628-35. doi: 10.1007/s004280100451.
• [1620] A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis.Clin Cancer Res. 2008 Jun 15;14(12):3737-45. doi: 10.1158/1078-0432.CCR-07-5144.
• [1621] A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.J Immunol. 2000 Apr 15;164(8):4382-92. doi: 10.4049/jimmunol.164.8.4382.
• [1622] Hypertonicity induction of melanoma antigen, a tumor-associated antigen.Mol Cells. 2002 Apr 30;13(2):288-95.
• [1623] Antitumor activity of an adenovirus harboring human IL-24 in colon cancer.Mol Biol Rep. 2011 Jan;38(1):395-401. doi: 10.1007/s11033-010-0121-3. Epub 2010 Mar 31.
• [1624] Expression of the human CMP-NeuAc:GM3 alpha2,8-sialyltransferase (GD3 synthase) gene through the NF-kappaB activation in human melanoma SK-MEL-2 cells.Biochim Biophys Acta. 2007 Nov-Dec;1769(11-12):622-30. doi: 10.1016/j.bbaexp.2007.08.001. Epub 2007 Aug 25.
• [1625] Histamine inhibits the production of interferon-induced protein of 10 kDa in human squamous cell carcinoma and melanoma.J Invest Dermatol. 2002 Dec;119(6):1411-9. doi: 10.1046/j.1523-1747.2002.19627.x.
• [1626] Malignant blue nevus: a case report and molecular analysis.Am J Dermatopathol. 2003 Feb;25(1):21-7. doi: 10.1097/00000372-200302000-00005.
• [1627] Cancer-associated expression of minichromosome maintenance 3 gene in several human cancers and its involvement in tumorigenesis.Clin Cancer Res. 2004 Dec 15;10(24):8386-95. doi: 10.1158/1078-0432.CCR-04-1029.
• [1628] Linkage group V of platyfishes and Swordtails of the genus Xiphophorus (Poeciliidae): linkage of loci for malate dehydrogenase-2 and esterase-1 and esterase-4 with a gene controlling the severity of hybrid melanomas.J Natl Cancer Inst. 1983 Oct;71(4):809-13.
• [1629] Altered HOX gene expression in human skin and breast cancer cells.Cancer Biol Ther. 2003 Sep-Oct;2(5):518-23. doi: 10.4161/cbt.2.5.441.
• [1630] RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2.Melanoma Res. 2019 Aug;29(4):382-389. doi: 10.1097/CMR.0000000000000580.
• [1631] Dissecting the role of RNA modification regulatory proteins in melanoma.Oncotarget. 2019 Jun 4;10(38):3745-3759. eCollection 2019 Jun 4.
• [1632] Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma.Oncogene. 2019 Mar;38(11):1876-1891. doi: 10.1038/s41388-018-0531-6. Epub 2018 Nov 1.
• [1633] Mahogunin ring finger-1 (MGRN1) E3 ubiquitin ligase inhibits signaling from melanocortin receptor by competition with Galphas.J Biol Chem. 2009 Nov 13;284(46):31714-25. doi: 10.1074/jbc.M109.028100. Epub 2009 Sep 8.
• [1634] Natural killer cell-based immunotherapy: a new fighter against melanoma?.Melanoma Res. 2019 Apr;29(2):208-211. doi: 10.1097/CMR.0000000000000552.
• [1635] Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor.J Biol Chem. 2000 Jul 7;275(27):20540-4. doi: 10.1074/jbc.M002349200.
• [1636] Cytologic characterization of two distinct alpha satellite DNA domains on human chromosome 7, using double-labeling hybridizations in fluorescence and electron microscopy on a melanoma cell line.Cancer Genet Cytogenet. 1997 Jul 1;96(1):17-22. doi: 10.1016/s0165-4608(96)00282-8.
• [1637] Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses.J Exp Med. 1986 Nov 1;164(5):1710-22. doi: 10.1084/jem.164.5.1710.
• [1638] Identification of URIM, a novel gene up-regulated in metastasis.Anticancer Res. 1999 Jan-Feb;19(1A):525-30.
• [1639] Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma.Br J Cancer. 2011 Aug 9;105(4):565-74. doi: 10.1038/bjc.2011.249. Epub 2011 Jul 5.
• [1640] Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis.Melanoma Res. 2010 Oct;20(5):392-400.
• [1641] Characterization of morphological changes of B16 melanoma cells under natural killer cell attack.Int Immunopharmacol. 2019 Feb;67:366-371. doi: 10.1016/j.intimp.2018.12.037. Epub 2018 Dec 21.
• [1642] Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. Cancer Lett. 2017 Sep 10;403:144-151.
• [1643] Sensitivity of human melanoma cells to oestrogens, tamoxifen and quercetin: is there any relationship with type I and II oestrogen binding site expression?.Melanoma Res. 1998 Aug;8(4):313-22. doi: 10.1097/00008390-199808000-00004.
• [1644] Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes.Hum Mutat. 2009 Feb;30(2):E451-9. doi: 10.1002/humu.20927.
• [1645] Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library.Cancer Res. 2000 Jul 1;60(13):3584-91.
• [1646] Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth in vivo.BMC Cancer. 2011 Oct 12;11:443. doi: 10.1186/1471-2407-11-443.
• [1647] Hypoxic Gene Signature of Primary and Metastatic Melanoma Cell Lines: Focusing on HIF-1 and NDRG-1.Balkan Med J. 2019 Dec 20;37(1):15-23. doi: 10.4274/balkanmedj.galenos.2019.2019.3.145. Epub 2019 Oct 9.
• [1648] Membrane sialidase NEU3 is highly expressed in human melanoma cells promoting cell growth with minimal changes in the composition of gangliosides.Cancer Sci. 2011 Dec;102(12):2139-49. doi: 10.1111/j.1349-7006.2011.02086.x. Epub 2011 Oct 17.
• [1649] Decreased expression of nemo-like kinase in melanoma is correlated with increased vascularity and metastasis.Melanoma Res. 2019 Aug;29(4):376-381. doi: 10.1097/CMR.0000000000000576.
• [1650] Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth.Int J Cancer. 2009 Aug 1;125(3):556-64. doi: 10.1002/ijc.24276.
• [1651] p54nrb is a new regulator of progression of malignant melanoma.Carcinogenesis. 2011 Aug;32(8):1176-82. doi: 10.1093/carcin/bgr103. Epub 2011 Jun 3.
• [1652] Melanosome maturation proteins Oca2, Mitfa and Vps11 are differentially required for cisplatin resistance in zebrafish melanocytes.Exp Dermatol. 2019 Jul;28(7):795-800. doi: 10.1111/exd.13937. Epub 2019 May 15.
• [1653] Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma.Cancer Immun. 2002 Jul 19;2:9.
• [1654] The role of the OVOL1-OVOL2 axis in normal and diseased human skin.J Dermatol Sci. 2018 Jun;90(3):227-231. doi: 10.1016/j.jdermsci.2018.02.005. Epub 2018 Feb 12.
• [1655] Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22.
• [1656] RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.Carcinogenesis. 2008 Jun;29(6):1157-63. doi: 10.1093/carcin/bgn119. Epub 2008 May 29.
• [1657] PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells.PLoS One. 2011;6(8):e22312. doi: 10.1371/journal.pone.0022312. Epub 2011 Aug 18.
• [1658] Ca2+ binding to EF hands 1 and 3 is essential for the interaction of apoptosis-linked gene-2 with Alix/AIP1 in ocular melanoma.Biochemistry. 2004 Sep 7;43(35):11175-86. doi: 10.1021/bi048848d.
• [1659] Role of ERp57 in the signaling and transcriptional activity of STAT3 in a melanoma cell line.Arch Biochem Biophys. 2010 Feb 15;494(2):178-83. doi: 10.1016/j.abb.2009.12.004. Epub 2009 Dec 6.
• [1660] Identification and characterization of a novel melanoma tumor suppressor gene on human chromosome 6q21.Clin Cancer Res. 2009 Feb 1;15(3):797-803. doi: 10.1158/1078-0432.CCR-08-1472.
• [1661] Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression.Nat Med. 2011 Jan;17(1):123-9. doi: 10.1038/nm.2269. Epub 2010 Dec 12.
• [1662] Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.Exp Eye Res. 2006 Oct;83(4):911-9. doi: 10.1016/j.exer.2006.04.016. Epub 2006 Jun 19.
• [1663] Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors.Ann Oncol. 2005 Jan;16(1):162-8. doi: 10.1093/annonc/mdi028.
• [1664] Epigenetic regulation of the transcription factor Foxa2 directs differential elafin expression in melanocytes and melanoma cells.Biochem Biophys Res Commun. 2011 Apr 29;408(1):160-6. doi: 10.1016/j.bbrc.2011.04.001. Epub 2011 Apr 3.
• [1665] Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.Int J Cancer. 2004 Jan 10;108(2):307-13. doi: 10.1002/ijc.11537.
• [1666] A small-molecule inhibitor shows that pirin regulates migration of melanoma cells.Nat Chem Biol. 2010 Sep;6(9):667-73. doi: 10.1038/nchembio.423. Epub 2010 Aug 15.
• [1667] Coexpression network analysis identified that plakophilin 1 is associated with the metastasis in human melanoma.Biomed Pharmacother. 2019 Mar;111:1234-1242. doi: 10.1016/j.biopha.2018.12.135. Epub 2019 Jan 15.
• [1668] PKP3 interactions with MAPK-JNK-ERK1/2-mTOR pathway regulates autophagy and invasion in ovarian cancer.Biochem Biophys Res Commun. 2019 Jan 8;508(2):646-653. doi: 10.1016/j.bbrc.2018.11.163. Epub 2018 Dec 4.
• [1669] Knockdown of PLCB2 expression reduces melanoma cell viability and promotes melanoma cell apoptosis by altering Ras/Raf/MAPK signals.Mol Med Rep. 2020 Jan;21(1):420-428. doi: 10.3892/mmr.2019.10798. Epub 2019 Nov 6.
• [1670] Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.Mod Pathol. 2017 Mar;30(3):350-356. doi: 10.1038/modpathol.2016.201. Epub 2016 Dec 9.
• [1671] The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion.Pigment Cell Melanoma Res. 2019 May;32(3):424-434. doi: 10.1111/pcmr.12760. Epub 2018 Dec 21.
• [1672] A distinct octamer-binding protein present in malignant melanoma cells.Nucleic Acids Res. 1988 Dec 9;16(23):11047-56. doi: 10.1093/nar/16.23.11047.
• [1673] BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.Genes Dev. 2019 Mar 1;33(5-6):310-332. doi: 10.1101/gad.314633.118. Epub 2019 Feb 25.
• [1674] GADD153 is an independent prognostic factor in melanoma: immunohistochemical and molecular genetic analysis.Histol Histopathol. 2002;17(3):805-11. doi: 10.14670/HH-17.805.
• [1675] Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms.Oncogene. 2000 Feb 24;19(9):1191-5. doi: 10.1038/sj.onc.1203389.
• [1676] Phosphorylation of eIF2 triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma.Sci Signal. 2015 Mar 10;8(367):ra27. doi: 10.1126/scisignal.aaa0899.
• [1677] Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36.Oncogene. 2002 May 2;21(19):3038-42. doi: 10.1038/sj.onc.1205457.
• [1678] Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.Cancer Res. 2011 Jun 15;71(12):4280-91. doi: 10.1158/0008-5472.CAN-10-3761. Epub 2011 Apr 28.
• [1679] Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells.Stem Cells. 2012 Sep;30(9):1808-18. doi: 10.1002/stem.1160.
• [1680] Expression of co-factors (SMRT and Trip-1) for retinoic acid receptors in human neuroectodermal cell lines.Biochem Biophys Res Commun. 1997 May 8;234(1):278-82. doi: 10.1006/bbrc.1997.6626.
• [1681] RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas.Cancer Res. 2007 Apr 1;67(7):3064-73. doi: 10.1158/0008-5472.CAN-06-2301.
• [1682] Qualitative and quantitative changes in nuclear DNA and phenotypic gene expression in human malignant skin tumors during their progression.Eur J Histochem. 1992;36(3):289-302.
• [1683] Cyclopalladated compounds containing 2,6-lutidine: Synthesis, spectral and biological studies.J Inorg Biochem. 2020 Feb;203:110944. doi: 10.1016/j.jinorgbio.2019.110944. Epub 2019 Nov 22.
• [1684] Overexpression of Ras-Related C3 Botulinum Toxin Substrate 2 Radiosensitizes Melanoma Cells In Vitro and In Vivo.Oxid Med Cell Longev. 2019 Jun 2;2019:5254798. doi: 10.1155/2019/5254798. eCollection 2019.
• [1685] Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.Nat Med. 2012 Aug;18(8):1248-53. doi: 10.1038/nm.2856. Epub 2012 Jul 8.
• [1686] No evidence of RALGDS mutations in cutaneous melanoma.Melanoma Res. 2007 Dec;17(6):410-2. doi: 10.1097/CMR.0b013e3282ef4178.
• [1687] Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma.Cancer Res. 2005 Oct 1;65(19):8869-77. doi: 10.1158/0008-5472.CAN-05-1387.
• [1688] Decreased tissue plasminogen activator and increased plasminogen activator inhibitors and increased activator protein-1 and specific promoter 1 are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine.Int J Oncol. 2001 Apr;18(4):877-83. doi: 10.3892/ijo.18.4.877.
• [1689] Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis.Cancer Res. 2006 Aug 15;66(16):7880-8. doi: 10.1158/0008-5472.CAN-06-0254.
• [1690] HRAS1 proto-oncogene polymorphisms in human malignant melanoma: TaqI defined alleles significantly associated with the disease.Oncogene. 1987;2(1):91-5.
• [1691] Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals.Cancer Immunol Immunother. 2005 Feb;54(2):172-8. doi: 10.1007/s00262-004-0575-z. Epub 2004 Jul 10.
• [1692] Human melanomas of fibroblast and epithelial morphology differ widely in their ability to synthesize retinyl esters.Carcinogenesis. 2002 Nov;23(11):1821-30. doi: 10.1093/carcin/23.11.1821.
• [1693] Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis.J Biol Chem. 2004 Nov 26;279(48):50537-54. doi: 10.1074/jbc.M406454200. Epub 2004 Sep 23.
• [1694] On the interplay of telomeres, nevi and the risk of melanoma.PLoS One. 2012;7(12):e52466. doi: 10.1371/journal.pone.0052466. Epub 2012 Dec 27.
• [1695] mTOR is activated in the majority of malignant melanomas.J Invest Dermatol. 2008 Apr;128(4):980-7. doi: 10.1038/sj.jid.5701074. Epub 2007 Oct 4.
• [1696] Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets.BMC Cancer. 2008 Jan 22;8:19. doi: 10.1186/1471-2407-8-19.
• [1697] RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma.Tumour Biol. 2012 Oct;33(5):1511-8. doi: 10.1007/s13277-012-0402-7. Epub 2012 May 25.
• [1698] Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma.Cancer Lett. 2007 Dec 8;258(1):38-44. doi: 10.1016/j.canlet.2007.08.005. Epub 2007 Sep 27.
• [1699] Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma.BMC Cancer. 2019 Mar 7;19(1):207. doi: 10.1186/s12885-019-5384-z.
• [1700] Weighted correlation network and differential expression analyses identify candidate genes associated with BRAF gene in melanoma.BMC Med Genet. 2019 Mar 29;20(1):54. doi: 10.1186/s12881-019-0791-1.
• [1701] RNASET2 as a tumor antagonizing gene in a melanoma cancer model.Oncol Res. 2008;17(2):69-74. doi: 10.3727/096504008784523658.
• [1702] Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer.Cancer Res. 2007 Sep 1;67(17):8172-9. doi: 10.1158/0008-5472.CAN-07-0045.
• [1703] Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display.Cancer Res. 2007 Apr 15;67(8):3555-9. doi: 10.1158/0008-5472.CAN-06-2763.
• [1704] BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.Cell Death Differ. 2012 Dec;19(12):2029-39. doi: 10.1038/cdd.2012.94. Epub 2012 Aug 3.
• [1705] Functional genomics of calcium channels in human melanoma cells.Int J Cancer. 2007 Jul 1;121(1):55-65. doi: 10.1002/ijc.22621.
• [1706] Expression patterns of S100 proteins in melanocytes and melanocytic lesions.Melanoma Res. 2009 Aug;19(4):215-25. doi: 10.1097/CMR.0b013e32832c6358.
• [1707] Prediction and Analysis of Skin Cancer Progression using Genomics Profiles of Patients.Sci Rep. 2019 Oct 31;9(1):15790. doi: 10.1038/s41598-019-52134-4.
• [1708] Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression.Cancers (Basel). 2019 Feb 11;11(2):209. doi: 10.3390/cancers11020209.
• [1709] Expression analysis of the epithelial Na+ channel delta subunit in human melanoma G-361 cells.Biochem Biophys Res Commun. 2008 Feb 8;366(2):489-92. doi: 10.1016/j.bbrc.2007.11.177. Epub 2007 Dec 10.
• [1710] The SNAIL family member SCRATCH1 is not expressed in human tumors.Oncol Rep. 2010 Feb;23(2):523-9.
• [1711] Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism.Int J Biochem Cell Biol. 2009 Jun;41(6):1323-31. doi: 10.1016/j.biocel.2008.11.008. Epub 2008 Dec 6.
• [1712] A PDZ Protein MDA-9/Syntenin: As a Target for Cancer Therapy.Comput Struct Biotechnol J. 2019 Jan 8;17:136-141. doi: 10.1016/j.csbj.2019.01.002. eCollection 2019.
• [1713] Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression.Am J Pathol. 2008 Dec;173(6):1873-81. doi: 10.2353/ajpath.2008.080136. Epub 2008 Oct 30.
• [1714] Plexin C1, a receptor for semaphorin 7a, inactivates cofilin and is a potential tumor suppressor for melanoma progression.J Invest Dermatol. 2009 Apr;129(4):954-63. doi: 10.1038/jid.2008.329. Epub 2008 Nov 6.
• [1715] Knockdown of STAT3 targets a subpopulation of invasive melanoma stem-like cells.Cell Biol Int. 2019 Jun;43(6):613-622. doi: 10.1002/cbin.11134. Epub 2019 Apr 30.
• [1716] Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.Clin Cancer Res. 2005 Sep 1;11(17):6400-7. doi: 10.1158/1078-0432.CCR-05-0306.
• [1717] Metastatic Melanoma Cells Rely on Sestrin2 to Acquire Anoikis Resistance via Detoxifying Intracellular ROS.J Invest Dermatol. 2020 Mar;140(3):666-675.e2. doi: 10.1016/j.jid.2019.07.720. Epub 2019 Aug 31.
• [1718] Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.Clin Epigenetics. 2019 Mar 8;11(1):43. doi: 10.1186/s13148-019-0644-y.
• [1719] Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.Front Pharmacol. 2019 Apr 30;10:443. doi: 10.3389/fphar.2019.00443. eCollection 2019.
• [1720] Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.Pigment Cell Melanoma Res. 2020 Mar;33(2):345-357. doi: 10.1111/pcmr.12824. Epub 2019 Sep 25.
• [1721] The Cdh5-CreERT2 transgene causes conditional Shb gene deletion in hematopoietic cells with consequences for immune cell responses to tumors.Sci Rep. 2019 May 17;9(1):7548. doi: 10.1038/s41598-019-44039-z.
• [1722] Siglec-9 Regulates an Effector Memory CD8(+) T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.Cancer Immunol Res. 2019 May;7(5):707-718. doi: 10.1158/2326-6066.CIR-18-0505. Epub 2019 Apr 15.
• [1723] Inhibition of the prohormone convertase subtilisin-kexin isoenzyme-1 induces apoptosis in human melanoma cells.J Invest Dermatol. 2014 Jan;134(1):168-175. doi: 10.1038/jid.2013.282. Epub 2013 Jun 27.
• [1724] Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells.J Biol Chem. 2010 Dec 17;285(51):40333-41. doi: 10.1074/jbc.M110.151076. Epub 2010 Oct 18.
• [1725] Slit3 inhibits activator protein 1-mediated migration of malignant melanoma cells.Int J Mol Med. 2011 Nov;28(5):721-6. doi: 10.3892/ijmm.2011.742. Epub 2011 Jul 8.
• [1726] SMAD signaling promotes melanoma metastasis independently of phenotype switching.J Clin Invest. 2019 Apr 30;129(7):2702-2716. doi: 10.1172/JCI94295.
• [1727] Development of a yeast-based system to identify new hBRAFV600E functional interactors.Oncogene. 2019 Feb;38(8):1355-1366. doi: 10.1038/s41388-018-0496-5. Epub 2018 Sep 20.
• [1728] Recurrent vulvar melanoma in a patient with neurofibromatosis and gastrointestinal stromal tumour.BMJ Case Rep. 2019 Jan 20;12(1):e224744. doi: 10.1136/bcr-2018-224744.
• [1729] The role of microRNA-30a and downstream snail1 on the growth and metastasis of melanoma tumor.Iran J Basic Med Sci. 2019 May;22(5):534-540. doi: 10.22038/IJBMS.2019.32317.7745.
• [1730] Impact of NAD(P)H:quinone oxidoreductase-1 on pigmentation.J Invest Dermatol. 2010 Mar;130(3):784-92. doi: 10.1038/jid.2009.280. Epub 2009 Sep 17.
• [1731] Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature.J Cutan Pathol. 2020 Jan;47(1):36-46. doi: 10.1111/cup.13551. Epub 2019 Aug 11.
• [1732] Effect of disrupted SOX18 transcription factor function on tumor growth, vascularization, and endothelial development.J Natl Cancer Inst. 2006 Aug 2;98(15):1060-7. doi: 10.1093/jnci/djj299.
• [1733] Overlapping genetic architecture between Parkinson disease and melanoma.Acta Neuropathol. 2020 Feb;139(2):347-364. doi: 10.1007/s00401-019-02110-z. Epub 2019 Dec 16.
• [1734] Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.Mol Ther. 2010 Jul;18(7):1275-83. doi: 10.1038/mt.2010.79. Epub 2010 May 4.
• [1735] Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.J Exp Clin Cancer Res. 2019 Sep 13;38(1):405. doi: 10.1186/s13046-019-1389-3.
• [1736] Association between the expression of secreted phosphoprotein - related genes and prognosis of human cancer.BMC Cancer. 2019 Dec 18;19(1):1230. doi: 10.1186/s12885-019-6441-3.
• [1737] SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.Cancer Res. 2004 Aug 15;64(16):5556-9. doi: 10.1158/0008-5472.CAN-04-1669.
• [1738] FNBP2 gene on human chromosome 1q32.1 encodes ARHGAP family protein with FCH, FBH, RhoGAP and SH3 domains.Int J Mol Med. 2003 Jun;11(6):791-7.
• [1739] Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells.PLoS One. 2014 Apr 30;9(4):e95136. doi: 10.1371/journal.pone.0095136. eCollection 2014.
• [1740] Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines.Cancer Res. 2000 Mar 15;60(6):1654-62.
• [1741] Characterization of two glycolipid: alpha 2-3sialyltransferases, SAT-3 (CMP-NeuAc:nLcOse4Cer alpha 2-3sialyltransferase) and SAT-4 (CMP-NeuAc:GgOse4Cer alpha 2-3sialyltransferase), from human colon carcinoma (Colo 205) cell line.Biochemistry. 1996 Apr 23;35(16):5166-74. doi: 10.1021/bi960239l.
• [1742] RETRACTED: Stress induced phosphoprotein 1 promotes tumor growth and metastasis of melanoma via modulating JAK2/STAT3 pathway.Biomed Pharmacother. 2019 Aug;116:108962. doi: 10.1016/j.biopha.2019.108962. Epub 2019 May 16.
• [1743] Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro.J Virol. 1994 May;68(5):3317-23. doi: 10.1128/JVI.68.5.3317-3323.1994.
• [1744] Synaptotagmin-4 promotes dendrite extension and melanogenesis in alpaca melanocytes by regulating Ca(2+) influx via TRPM1 channels.Cell Biochem Funct. 2020 Apr;38(3):275-282. doi: 10.1002/cbf.3465. Epub 2019 Nov 19.
• [1745] The special stemness functions of Tbx3 in stem cells and cancer development.Semin Cancer Biol. 2019 Aug;57:105-110. doi: 10.1016/j.semcancer.2018.09.010. Epub 2018 Sep 27.
• [1746] Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma.Carcinogenesis. 2011 Oct;32(10):1467-73. doi: 10.1093/carcin/bgr138. Epub 2011 Jul 18.
• [1747] TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression.Cancer Res. 2019 Feb 1;79(3):482-494. doi: 10.1158/0008-5472.CAN-18-1214. Epub 2018 Dec 11.
• [1748] Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.J Invest Dermatol. 2013 May;133(5):1278-85. doi: 10.1038/jid.2012.493. Epub 2013 Feb 14.
• [1749] Knockdown THOC2 suppresses the proliferation and invasion of melanoma.Bioengineered. 2019 Dec;10(1):635-645. doi: 10.1080/21655979.2019.1685727.
• [1750] Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines.ACS Chem Biol. 2010 Mar 19;5(3):333-42. doi: 10.1021/cb900267j.
• [1751] Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion.Am J Pathol. 2005 May;166(5):1541-54. doi: 10.1016/S0002-9440(10)62370-X.
• [1752] Frequent TLE1 Expression in Cutaneous Neoplasms.Am J Dermatopathol. 2019 Jan;41(1):1-6. doi: 10.1097/DAD.0000000000001186.
• [1753] Transducin-like enhancer of split 3 regulates proliferation of melanoma cells via histone deacetylase activity.Oncotarget. 2019 Jan 8;10(3):404-414. doi: 10.18632/oncotarget.26552. eCollection 2019 Jan 8.
• [1754] Thymosin beta-10 expression in melanoma cell lines and melanocytic lesions: a new progression marker for human cutaneous melanoma.Int J Cancer. 1993 Jan 21;53(2):278-84. doi: 10.1002/ijc.2910530218.
• [1755] Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target.Int J Cancer. 2007 Mar 15;120(6):1304-10. doi: 10.1002/ijc.22367.
• [1756] Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study.BMC Cancer. 2009 May 11;9:140. doi: 10.1186/1471-2407-9-140.
• [1757] Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.Pigment Cell Melanoma Res. 2008 Oct;21(5):545-58. doi: 10.1111/j.1755-148X.2008.00484.x. Epub 2007 Jun 28.
• [1758] Decreased expression of a single tropomyosin isoform, TM5/TM30nm, results in reduction in motility of highly metastatic B16-F10 mouse melanoma cells.Biochem Biophys Res Commun. 1996 Aug 14;225(2):427-35. doi: 10.1006/bbrc.1996.1190.
• [1759] Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNFalpha and suppression of NF-kappaB activities.Oncogene. 2001 Apr 26;20(18):2243-53. doi: 10.1038/sj.onc.1204314.
• [1760] TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4.J Exp Clin Cancer Res. 2019 Mar 28;38(1):137. doi: 10.1186/s13046-019-1138-7.
• [1761] Growth-regulated oncogene-1 expression is associated with angiogenesis and lymph node metastasis in human oral cancer.Oncology. 2004;66(4):316-22. doi: 10.1159/000078333.
• [1762] Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity.Microbiol Immunol. 2004;48(4):339-45. doi: 10.1111/j.1348-0421.2004.tb03515.x.
• [1763] Tspan8 is expressed in breast cancer and regulates E-cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesicles.J Pathol. 2019 Aug;248(4):421-437. doi: 10.1002/path.5281. Epub 2019 Jun 18.
• [1764] Identification and characterization of TPARM gene in silico.Int J Oncol. 2003 Oct;23(4):1213-7.
• [1765] ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity.Nat Commun. 2018 Feb 14;9(1):676. doi: 10.1038/s41467-018-03080-8.
• [1766] Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy.Cancer Med. 2018 May;7(5):1933-1943. doi: 10.1002/cam4.1435. Epub 2018 Mar 24.
• [1767] ACTN4 regulates the stability of RIPK1 in melanoma.Oncogene. 2018 Jul;37(29):4033-4045. doi: 10.1038/s41388-018-0260-x. Epub 2018 Apr 30.
• [1768] Expression of orphan GPR56 correlates with tumor progression in human epithelial ovarian cancer.Neoplasma. 2017;64(1):32-39. doi: 10.4149/neo_2017_104.
• [1769] Long non-coding RNA H19 promotes glucose metabolism and cell growth in malignant melanoma via miR-106a-5p/E2F3 axis.J Cancer Res Clin Oncol. 2018 Mar;144(3):531-542. doi: 10.1007/s00432-018-2582-z. Epub 2018 Jan 19.
• [1770] Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors.Virchows Arch. 2018 Mar;472(3):469-476. doi: 10.1007/s00428-017-2290-0. Epub 2018 Feb 21.
• [1771] A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.Hum Genet. 2012 Jan;131(1):77-85. doi: 10.1007/s00439-011-1048-z. Epub 2011 Jun 26.
• [1772] Recombinant DNA technology for melanoma immunotherapy: anti-Id DNA vaccines targeting high molecular weight melanoma-associated antigen.Mol Biotechnol. 2014 Nov;56(11):1032-9. doi: 10.1007/s12033-014-9782-9.
• [1773] The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.Cancer Res. 2019 Jun 1;79(11):2892-2908. doi: 10.1158/0008-5472.CAN-18-3026. Epub 2019 May 2.
• [1774] JWA suppresses the invasion of human breast carcinoma cells by downregulating the expression of CXCR4.Mol Med Rep. 2018 Jun;17(6):8137-8144. doi: 10.3892/mmr.2018.8866. Epub 2018 Apr 11.
• [1775] PKC phosphorylation regulates the mitochondrial translocation of ATF2 in ischemia-induced neurodegeneration.BMC Neurosci. 2018 Nov 29;19(1):76. doi: 10.1186/s12868-018-0479-z.
• [1776] Copper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma.Metallomics. 2019 Aug 1;11(8):1430-1440. doi: 10.1039/c9mt00042a. Epub 2019 Jul 18.
• [1777] EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.J Control Release. 2018 May 10;277:48-56. doi: 10.1016/j.jconrel.2018.03.016. Epub 2018 Mar 14.
• [1778] A commensal strain of Staphylococcus epidermidis protects against skin neoplasia.Sci Adv. 2018 Feb 28;4(2):eaao4502. doi: 10.1126/sciadv.aao4502. eCollection 2018 Feb.
• [1779] Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Ann Oncol. 2017 Mar 1;28(3):634-641. doi: 10.1093/annonc/mdw641.
• [1780] Genome-wide association study identifies three new melanoma susceptibility loci.Nat Genet. 2011 Oct 9;43(11):1108-13. doi: 10.1038/ng.959.
• [1781] CADM1 is a TWIST1-regulated suppressor of invasion and survival.Cell Death Dis. 2019 Mar 25;10(4):281. doi: 10.1038/s41419-019-1515-3.
• [1782] The function of FAK/CCDC80/E-cadherin pathway in the regulation of B16F10 cell migration.Oncol Lett. 2018 Oct;16(4):4761-4767. doi: 10.3892/ol.2018.9159. Epub 2018 Jul 17.
• [1783] CD63 tetraspanin is a negative driver of epithelial-to-mesenchymal transition in human melanoma cells.J Invest Dermatol. 2014 Dec;134(12):2947-2956. doi: 10.1038/jid.2014.258. Epub 2014 Jun 18.
• [1784] CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation.Oncogene. 2016 Sep 22;35(38):5056-5069. doi: 10.1038/onc.2016.67. Epub 2016 Apr 4.
• [1785] Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma.Hum Pathol. 2018 May;75:137-145. doi: 10.1016/j.humpath.2018.02.009. Epub 2018 Feb 13.
• [1786] Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis.Clin Cancer Res. 2018 Jan 15;24(2):433-444. doi: 10.1158/1078-0432.CCR-17-1444. Epub 2017 Sep 15.
• [1787] Potential predictive value of cofilin-1 for metastasis occurrence in a small cohort of Argentinian patients with mid-low Breslow thickness melanoma.Pathol Res Pract. 2019 Oct;215(10):152582. doi: 10.1016/j.prp.2019.152582. Epub 2019 Aug 8.
• [1788] The Concomitant Expression of Human Endogenous Retroviruses and Embryonic Genes in Cancer Cells under Microenvironmental Changes is a Potential Target for Antiretroviral Drugs.Cancer Microenviron. 2019 Dec;12(2-3):105-118. doi: 10.1007/s12307-019-00231-3. Epub 2019 Nov 5.
• [1789] FT-IR Spectroscopy Study in Early Diagnosis of Skin Cancer.In Vivo. 2017 Nov-Dec;31(6):1131-1137. doi: 10.21873/invivo.11179.
• [1790] CXCL5 as Regulator of Neutrophil Function inCutaneous Melanoma.J Invest Dermatol. 2019 Jan;139(1):186-194. doi: 10.1016/j.jid.2018.07.006. Epub 2018 Oct 4.
• [1791] Cytotoxicity of Nubein6.8 peptide isolated from the snake venom of Naja nubiae on melanoma and ovarian carcinoma cell lines.Toxicon. 2019 Oct;168:22-31. doi: 10.1016/j.toxicon.2019.06.220. Epub 2019 Jun 21.
• [1792] Prognostic genes of melanoma identified by weighted gene co-expression network analysis and drug repositioning using a network-based method.Oncol Lett. 2019 Dec;18(6):6066-6078. doi: 10.3892/ol.2019.10961. Epub 2019 Oct 4.
• [1793] EMP2 acts as a suppressor of melanoma and is negatively regulated by mTOR-mediated autophagy.J Cancer. 2019 Jun 9;10(16):3582-3592. doi: 10.7150/jca.30342. eCollection 2019.
• [1794] Overexpression of microRNA-612 Restrains the Growth, Invasion, and Tumorigenesis of Melanoma Cells by Targeting Espin.Mol Cells. 2018 Feb 28;41(2):119-126. doi: 10.14348/molcells.2018.2235. Epub 2018 Jan 29.
• [1795] IL-12/23p40 overproduction by dendritic cells leads to an increased Th1 and Th17 polarization in a model of Yersinia enterocolitica-induced reactive arthritis in TNFRp55-/- mice.PLoS One. 2018 Mar 1;13(3):e0193573. doi: 10.1371/journal.pone.0193573. eCollection 2018.
• [1796] MicroRNA-22 targets FMNL2 to inhibit melanoma progression via the regulation of the Wnt/-catenin signaling pathway and epithelial-mesenchymal transition.Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5332-5342. doi: 10.26355/eurrev_201906_18200.
• [1797] Novel circular RNA, hsa_circ_0025039 promotes cell growth, invasion and glucose metabolism in malignant melanoma via the miR-198/CDK4 axis.Biomed Pharmacother. 2018 Dec;108:165-176. doi: 10.1016/j.biopha.2018.08.152. Epub 2018 Sep 13.
• [1798] -1,3-Galactosyl-O-Glycosyl-Glycoprotein -1,6-N-Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer Motility.Oncol Res. 2018 Apr 10;26(3):431-444. doi: 10.3727/096504017X15031557924123. Epub 2017 Sep 18.
• [1799] GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma.Melanoma Res. 2019 Dec;29(6):612-620. doi: 10.1097/CMR.0000000000000631.
• [1800] Nuclear pseudoinclusions in melanoma cells: prognostic fact or artifact? The possible role of Golgi phosphoprotein 3 overexpression in nuclear pseudoinclusions generation.Pathol Int. 2018 Feb;68(2):117-122. doi: 10.1111/pin.12629. Epub 2018 Jan 29.
• [1801] ABCB5 promotes melanoma metastasis through enhancing NF-B p65 protein stability.Biochem Biophys Res Commun. 2017 Oct 7;492(1):18-26. doi: 10.1016/j.bbrc.2017.08.052. Epub 2017 Aug 15.
• [1802] Glutathione peroxidase 3 (GPX3) suppresses the growth of melanoma cells through reactive oxygen species (ROS)-dependent stabilization of hypoxia-inducible factor 1- and 2-.J Cell Biochem. 2019 Nov;120(11):19124-19136. doi: 10.1002/jcb.29240. Epub 2019 Jul 16.
• [1803] High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis.Cancer Sci. 2018 Jun;109(6):1787-1798. doi: 10.1111/cas.13607. Epub 2018 May 11.
• [1804] Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.Cell Death Differ. 2018 Nov;25(11):2010-2022. doi: 10.1038/s41418-018-0090-y. Epub 2018 Mar 7.
• [1805] Immune-Checkpoint Blockade Opposes CD8(+) T-cell Suppression in Human and Murine Cancer.Cancer Immunol Res. 2019 Mar;7(3):510-525. doi: 10.1158/2326-6066.CIR-18-0054. Epub 2019 Feb 6.
• [1806] Identification of Catechol-Type Diphenylbutadiene as a Tyrosinase-Activated Pro-oxidative Chemosensitizer against Melanoma A375 Cells via Glutathione S-Transferase Inhibition.J Agric Food Chem. 2019 Aug 14;67(32):9060-9069. doi: 10.1021/acs.jafc.9b02875. Epub 2019 Aug 1.
• [1807] Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Nat Med. 2019 Dec;25(12):1916-1927. doi: 10.1038/s41591-019-0654-5. Epub 2019 Dec 2.
• [1808] Melanoma induced immunosuppression is mediated by hematopoietic dysregulation.Oncoimmunology. 2017 Dec 14;7(3):e1408750. doi: 10.1080/2162402X.2017.1408750. eCollection 2018.
• [1809] Genetic variation in IRF4 expression modulates growth characteristics, tyrosinase expression and interferon-gamma response in melanocytic cells.Pigment Cell Melanoma Res. 2018 Jan;31(1):51-63. doi: 10.1111/pcmr.12620. Epub 2017 Oct 23.
• [1810] Catalase-like metal-organic framework nanoparticles to enhance radiotherapy in hypoxic cancer and prevent cancer recurrence.Chem Sci. 2019 Apr 25;10(22):5773-5778. doi: 10.1039/c9sc00747d. eCollection 2019 Jun 14.
• [1811] Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.Clin Cancer Res. 2017 Jun 15;23(12):3181-3190. doi: 10.1158/1078-0432.CCR-17-0201. Epub 2017 Feb 23.
• [1812] BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma.Cancer Immunol Immunother. 2018 Feb;67(2):299-310. doi: 10.1007/s00262-017-2079-7. Epub 2017 Nov 1.
• [1813] Carbon ion irradiation abrogates Lin28B-induced X-ray resistance in melanoma cells.J Radiat Res. 2017 Nov 1;58(6):765-771. doi: 10.1093/jrr/rrx022.
• [1814] Overexpression of microRNA?1 inhibits the growth and metastasis of melanoma cells by targeting MKK3.Mol Med Rep. 2019 Aug;20(2):1797-1807. doi: 10.3892/mmr.2019.10408. Epub 2019 Jun 20.
• [1815] Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.JAMA Dermatol. 2019 Jun 1;155(6):673-678. doi: 10.1001/jamadermatol.2019.0425.
• [1816] Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.Front Med (Lausanne). 2017 Mar 17;4:30. doi: 10.3389/fmed.2017.00030. eCollection 2017.
• [1817] Elevated cyclic AMP levels promote BRAF(CA)/Pten(-/-) mouse melanoma growth but pCREB is negatively correlated with human melanoma progression.Cancer Lett. 2018 Feb 1;414:268-277. doi: 10.1016/j.canlet.2017.11.027. Epub 2017 Nov 24.
• [1818] New MSC: MSCs as pericytes are Sentinels and gatekeepers.J Orthop Res. 2017 Jun;35(6):1151-1159. doi: 10.1002/jor.23560. Epub 2017 Apr 11.
• [1819] Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation.Oncogene. 2019 May;38(19):3763-3764. doi: 10.1038/s41388-019-0679-8.
• [1820] Higher Nevus Count Exhibits a Distinct DNA Methylation Signature in Healthy Human Skin: Implications for Melanoma.J Invest Dermatol. 2017 Apr;137(4):910-920. doi: 10.1016/j.jid.2016.11.029. Epub 2016 Dec 18.
• [1821] Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma.J Med Virol. 2019 Sep;91(9):1702-1706. doi: 10.1002/jmv.25501. Epub 2019 Jun 24.
• [1822] Gene Expression and Methylation Analysis in Melanomas and Melanocytes From the Same Patient: Loss of NPM2 Expression Is a Potential Immunohistochemical Marker for Melanoma.Front Oncol. 2019 Jan 21;8:675. doi: 10.3389/fonc.2018.00675. eCollection 2018.
• [1823] Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma.J Control Release. 2019 Jul 28;306:15-28. doi: 10.1016/j.jconrel.2019.05.036. Epub 2019 May 25.
• [1824] A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.Nat Commun. 2018 Jan 31;9(1):461. doi: 10.1038/s41467-018-02851-7.
• [1825] miR-495 inhibits proliferation, migration, and invasion and induces apoptosis via inhibiting PBX3 in melanoma cells.Onco Targets Ther. 2018 Apr 5;11:1909-1920. doi: 10.2147/OTT.S152362. eCollection 2018.
• [1826] Peli1 Modulates the Subcellular Localization and Activity of Mdmx.Cancer Res. 2018 Jun 1;78(11):2897-2910. doi: 10.1158/0008-5472.CAN-17-3531. Epub 2018 Mar 9.
• [1827] Common sequence variants on 20q11.22 confer melanoma susceptibility.Nat Genet. 2008 Jul;40(7):838-40. doi: 10.1038/ng.163. Epub 2008 May 18.
• [1828] Association between serum autotaxin or phosphatidylserine-specific phospholipase A1 levels and melanoma.J Dermatol. 2018 May;45(5):571-579. doi: 10.1111/1346-8138.14278. Epub 2018 Mar 3.
• [1829] Long non-coding RNA CASC2 inhibits tumorigenesis via the miR-181a/PLXNC1 axis in melanoma.Acta Biochim Biophys Sin (Shanghai). 2018 Mar 1;50(3):263-272. doi: 10.1093/abbs/gmx148.
• [1830] BRAF inhibition sensitizes melanoma cells to -amanitin via decreased RNA polymerase II assembly.Sci Rep. 2019 May 23;9(1):7779. doi: 10.1038/s41598-019-44112-7.
• [1831] Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma.Sci Rep. 2019 Feb 22;9(1):2552. doi: 10.1038/s41598-018-36810-5.
• [1832] Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.Oncotarget. 2017 Dec 9;8(69):113472-113493. doi: 10.18632/oncotarget.23052. eCollection 2017 Dec 26.
• [1833] RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.Sci Rep. 2018 Jan 12;8(1):653. doi: 10.1038/s41598-017-18851-4.
• [1834] Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?.Oncotarget. 2018 Apr 3;9(25):17656-17663. doi: 10.18632/oncotarget.24825. eCollection 2018 Apr 3.
• [1835] Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance).Oncologist. 2018 Aug;23(8):887-e94. doi: 10.1634/theoncologist.2018-0100. Epub 2018 Apr 17.
• [1836] SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma.Oncotarget. 2018 Jan 9;9(7):7567-7581. doi: 10.18632/oncotarget.24085. eCollection 2018 Jan 26.
• [1837] Pathogenic Germline Variants in 10,389 Adult Cancers.Cell. 2018 Apr 5;173(2):355-370.e14. doi: 10.1016/j.cell.2018.03.039.
• [1838] Molecular Mechanisms by Which Selenoprotein K Regulates Immunity and Cancer.Biol Trace Elem Res. 2019 Nov;192(1):60-68. doi: 10.1007/s12011-019-01774-8. Epub 2019 Jun 11.
• [1839] Eradication of melanoma in vitro and in vivo via targeting with a Killer-Red-containing telomerase-dependent adenovirus.Cell Cycle. 2017 Aug 18;16(16):1502-1508. doi: 10.1080/15384101.2016.1249548. Epub 2017 Jan 5.
• [1840] Identification of a gene expression signature associated with the metastasis suppressor function of NME1: prognostic value in human melanoma.Lab Invest. 2018 Mar;98(3):327-338. doi: 10.1038/labinvest.2017.108. Epub 2017 Oct 23.
• [1841] TNF-signal and cAMP-mediated signals oppositely regulate melanoma- associated ganglioside GD3 synthase gene in human melanocytes.Sci Rep. 2019 Oct 14;9(1):14740. doi: 10.1038/s41598-019-51333-3.
• [1842] STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases.Cancers (Basel). 2019 Sep 27;11(10):1448. doi: 10.3390/cancers11101448.
• [1843] The Construction and Comprehensive Analysis of ceRNA Networks and Tumor-Infiltrating Immune Cells in Bone Metastatic Melanoma.Front Genet. 2019 Sep 25;10:828. doi: 10.3389/fgene.2019.00828. eCollection 2019.
• [1844] Effects of nano-encapsulated curcumin-chrysin on telomerase, MMPs and TIMPs gene expression in mouse B16F10 melanoma tumour model.Artif Cells Nanomed Biotechnol. 2018;46(sup2):75-86. doi: 10.1080/21691401.2018.1452021. Epub 2018 Apr 1.
• [1845] Design, synthesis and evaluation of novel sulfonamides as potential anticancer agents.Comput Biol Chem. 2018 Jun;74:294-303. doi: 10.1016/j.compbiolchem.2018.04.006. Epub 2018 Apr 10.
• [1846] Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma.Genes Chromosomes Cancer. 2018 Jun;57(6):294-303. doi: 10.1002/gcc.22528. Epub 2018 Feb 21.
• [1847] TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma.Melanoma Res. 2018 Jun;28(3):185-194. doi: 10.1097/CMR.0000000000000440.
• [1848] The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.J Invest Dermatol. 2018 Jan;138(1):159-170. doi: 10.1016/j.jid.2017.07.850. Epub 2017 Sep 9.